IPCM-2015.6.30-10Q

0001410471-15-000080.txt : 20150730 0001410471-15-000080.hdr.sgml : 20150730 20150730170505 ACCESSION NUMBER: 0001410471-15-000080 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20150630 FILED AS OF DATE: 20150730 DATE AS OF CHANGE: 20150730 FILER: COMPANY DATA: COMPANY CONFORMED NAME: IPC Healthcare, Inc. CENTRAL INDEX KEY: 0001410471 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 954562058 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33930 FILM NUMBER: 151017000 BUSINESS ADDRESS: STREET 1: 4605 LANKERSHIM BLVD., SUITE 617 CITY: NORTH HOLLYWOOD STATE: CA ZIP: 91602 BUSINESS PHONE: 818-766-3502 MAIL ADDRESS: STREET 1: 4605 LANKERSHIM BLVD., SUITE 617 CITY: NORTH HOLLYWOOD STATE: CA ZIP: 91602 FORMER COMPANY: FORMER CONFORMED NAME: IPC The Hospitalist Company, Inc. DATE OF NAME CHANGE: 20070822 10-Q 1 ipcm-2015630x10q.htm 10-Q IPCM-2015.6.30-10Q

Table Of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark one)

ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2015.

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________ to __________

Commission file number: 001-33930

IPC HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)



Delaware	95-4562058
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

4605 Lankershim Boulevard, Suite 617 North Hollywood, California	91602
(Address of principal executive offices)	(Zip code)

Registrant’s telephone number, including area code: (888) 447-2362

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ý No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer	ý	Accelerated filer	¨

Non-accelerated filer	¨ (Do not check if a smaller reporting company)	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ¨ No ý

As of July 23, 2015, there were 17,415,207 shares of the registrant’s common stock, $0.001 par value, outstanding.

Table Of Contents

IPC HEALTHCARE, INC.

FORM 10-Q

QUARTERLY REPORT

TABLE OF CONTENTS



		Page
	PART I

Item 1	Financial Statements (unaudited)	3
	Consolidated Balance Sheets – June 30, 2015 and December 31, 2014	3
	Consolidated Statements of Income – Three and six months ended June 30, 2015 and 2014	4
	Consolidated Statements of Cash Flows – Six months ended June 30, 2015 and 2014	5
	Notes to the Consolidated Financial Statements	6
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3	Quantitative and Qualitative Disclosures about Market Risk	20
Item 4	Controls and Procedures	20

	PART II

Item 1	Legal Proceedings	21
Item 6	Exhibits	22
Signatures		23
Exhibit Index		24

Note: Items 1A, 2, 3, 4 and 5 of Part II are omitted because they are not applicable.

Table Of Contents

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

IPC Healthcare, Inc.

Consolidated Balance Sheets

(dollars in thousands, except for share data)



	June 30, 2015		December 31, 2014
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	11,565	$	14,913
Accounts receivable, net	121,699		122,092
Insurance receivable for malpractice claims, current portion	12,322		12,564
Prepaid expenses and other current assets	14,121		20,876
Total current assets	159,707		170,445
Property and equipment, net	8,960		8,798
Goodwill	458,494		408,988
Other intangible assets, net	4,924		4,957
Insurance receivable for malpractice claims, less current portion	22,999		21,574
Total assets	$	655,084	$	614,762
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued liabilities	$	7,829	$	8,388
Accrued compensation	37,544		40,907
Payable for practice acquisitions, current portion	49,611		35,411
Medical malpractice and self-insurance reserves, current portion	12,889		13,079
Deferred tax liabilities, current portion	584		584
Total current liabilities	108,457		98,369
Long-term debt	90,000		80,000
Medical malpractice and self-insurance reserves, less current portion	49,129		47,239
Payable for practice acquisitions, less current portion	4,496		9,500
Deferred tax liabilities, less current portion	13,622		11,737
Total liabilities	265,704		246,845
Stockholders’ equity:
Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued	—		—
Common stock. $0.001 par value, 50,000,000 shares authorized, 17,414,907 and 17,242,209 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively	17		17
Additional paid-in capital	188,144		181,841
Retained earnings	201,219		186,059
Total stockholders’ equity	389,380		367,917
Total liabilities and stockholders’ equity	$	655,084	$	614,762

The accompanying notes are an integral part of these consolidated financial statements.

Table Of Contents

IPC Healthcare, Inc.

Consolidated Statements of Income

(dollars in thousands, except for per share data)

(unaudited)



	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
Net revenue	$	184,026		$	172,268		$	364,797		$	344,994
Operating expenses:
Cost of services—physician practice salaries, benefits and other	135,677			125,687			269,844			252,960
General and administrative	31,317			28,334			61,109			55,941
Net change in fair value of contingent consideration	1,174			(695		)	5,858			(1,078		)
Depreciation and amortization	1,461			1,366			2,976			2,631
Total operating expenses	169,629			154,692			339,787			310,454
Income from operations	14,397			17,576			25,010			34,540
Investment income	—			1			1			2
Interest expense	(283		)	(382		)	(560		)	(696		)
Income before income taxes	14,114			17,195			24,451			33,846
Income tax provision	5,364			6,586			9,291			12,963
Net income	$	8,750		$	10,609		$	15,160		$	20,883
Net income per share:
Basic	$	0.50		$	0.62		$	0.87		$	1.22
Diluted	$	0.49		$	0.61		$	0.85		$	1.19

The accompanying notes are an integral part of these consolidated financial statements.

Table Of Contents

IPC Healthcare, Inc.

Consolidated Statements of Cash Flows

(dollars in thousands)

(unaudited)



	Six Months Ended June 30,
	2015			2014
Operating activities
Net income	$	15,160		$	20,883
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,976			2,631
Stock-based compensation expense	3,688			4,024
Changes in assets and liabilities:
Accounts receivable	393			(9,710		)
Prepaid expenses and other current assets	6,755			7,452
Accounts payable and accrued liabilities	1,667			3,400
Accrued compensation	(3,363		)	(1,199		)
Medical malpractice and self-insurance reserves, net	517			1,937
Accrued contingent consideration	4,884			(3,304		)
Net cash provided by operating activities	32,677			26,114
Investing activities
Acquisitions of physician practices	(45,831		)	(21,575		)
Purchase of property and equipment	(2,931		)	(2,485		)
Net cash used in investing activities	(48,762		)	(24,060		)
Financing activities
Proceeds from long-term debt	35,000			—
Repayments of long-term debt	(25,000		)	(5,000		)
Net proceeds from issuance of common stock	2,526			3,648
Excess tax benefits from stock-based compensation	211			585
Net cash provided by (used in) financing activities	12,737			(767		)
Net (decrease) increase in cash and cash equivalents	(3,348		)	1,287
Cash and cash equivalents, beginning of period	14,913			25,010
Cash and cash equivalents, end of period	$	11,565		$	26,297
Supplemental disclosure of cash flow information
Cash paid for:
Interest	$	548		$	693
Income taxes	$	7,809		$	8,448

The accompanying notes are an integral part of these consolidated financial statements.

Table Of Contents

IPC Healthcare, Inc.

Notes to the Consolidated Financial Statements

(Unaudited)

June 30, 2015

Note 1. Basis of Presentation and Significant Accounting Policies

Basis of Presentation

IPC Healthcare, Inc. and its wholly-owned subsidiaries (the “Company,” “IPC,” “we,” “us,” and “our”) is a national physician group practice company that operates and manages full-time acute hospitalist and post-acute physician practices. We prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) on the same basis as our audited annual financial statements. The consolidated financial statements include all accounts of IPC Healthcare, Inc. and its wholly owned subsidiaries and consolidated professional medical corporations (Professional Medical Corporations) managed under long-term management agreements.

Through the management agreements and our relationship with the stockholders of the Professional Medical Corporations, we have exclusive authority over all non-medical decision making related to the ongoing business operations of the Professional Medical Corporations. Further, our rights under the management agreements are unilaterally salable or transferable. Based on the provisions of the agreements, we have determined that the Professional Medical Corporations are variable interest entities (VIE’s), and that we are the primary beneficiary because we have control over the operations of these VIE’s, provide full financial and management support to them, and take all residual benefits and bear all residual losses from their operations. Consequently, we consolidate the revenue and expenses of the Professional Medical Corporations from the date of execution of the agreements. All intercompany balances and transactions have been eliminated in consolidation.

In our opinion, these consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial information set forth therein. Certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to GAAP and SEC rules and regulations, which are applicable to interim financial statements. As a result, the following disclosures should be read in conjunction with our audited consolidated financial statements and notes thereto as of December 31, 2014 included in our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on February 23, 2015.

Revenue

Net revenue consists of fees for medical services provided by our affiliated hospitalists under fee-for-service, case rate and other professional fee arrangements with various payors including Medicare, Medicaid, managed care organizations, insurance companies and hospitals. Net revenue is reported in the period in which services are provided at amounts expected to be collected, which excludes contractual discounts and an estimate of uncollectible accounts.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions of the fair value of certain reported amounts of assets, liabilities, revenues and expenses at the date and for the periods that the financial statements are prepared. Significant estimates include the estimated net realizable value of accounts receivable, medical malpractice insurance receivable and payable for known claims, liabilities for claims incurred but not reported (IBNR) related to medical malpractice, fair value of contingent consideration related to business combinations and the analysis of goodwill for impairment. The process of estimating these assets and liabilities involves judgment, which is subject to an inherent degree of uncertainty. Actual results could differ from those estimates. The results of operations for the current interim period are not necessarily indicative of the results for the entire year ending December 31, 2015.

Fair Value of Financial Instruments

Our consolidated balance sheets as of June 30, 2015 and December 31, 2014 included the following financial instruments: cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, payable for practice acquisitions and long-term debt. We consider the carrying amounts of cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amount of our long-term debt borrowed from our line of credit approximated its fair value at June 30, 2015 and December 31, 2014. Pursuant to GAAP, we determine the

Table Of Contents

fair value of our long-term borrowing using observable inputs, which are defined as Level 2 inputs under GAAP on fair value measures. See Note 3 for the definition of Level 2 inputs under GAAP.

Our payable for practice acquisitions consisted of accrued contingent consideration for practice acquisitions. The accrued contingent consideration is carried at fair value largely determined using the income approach with unobservable inputs defined as Level 3 inputs under GAAP. See Note 3 for the definition of Level 3 inputs under GAAP and more information.

Goodwill

The changes in the carrying amount of goodwill for the six months ended June 30, 2015 are as follows (in thousands):



Goodwill - beginning balance at January 1, 2015	$	408,988
Goodwill acquired during 2015	49,789
Adjustment for prior year transactions	(283		)
Goodwill - ending balance at June 30, 2015	$	458,494

The valuation studies related to the practice acquisitions that occurred in the fourth quarter of 2014 were completed in early 2015, and as a result, the value of contingent consideration liability related to these acquisitions as of the acquisition dates was decreased by $283,000, along with a corresponding decrease in our goodwill.

Medical Malpractice Liability Insurance

We record our medical malpractice reserves, on an undiscounted basis, for claims incurred and reported and claims incurred but not reported (IBNR) during the policy period, based on actuarial loss projections using historical loss patterns. For claims incurred and reported, an insurance receivable from our carrier has been recorded pursuant to GAAP. Total accrued medical malpractice reserves and related insurance receivables were as follows (in thousands):



	June 30, 2015								December 31, 2014
	Assets		Liabilities						Assets		Liabilities
	Insurance Receivable		Claims Reserve		IBNR Reserve		Total Liabilities		Insurance Receivable		Claims Reserve		IBNR Reserve		Total Liabilities
Current Portion	$	12,322	$	12,322	$	567	$	12,889	$	12,564	$	12,564	$	515	$	13,079
Long-term Portion	22,999		22,999		26,130		49,129		21,574		21,574		25,665		47,239
Total	$	35,321	$	35,321	$	26,697	$	62,018	$	34,138	$	34,138	$	26,180	$	60,318

New Accounting Principles

In May 2014, the Financial Accounting Standards Board issued a GAAP update "Revenue from Contracts with Customers". This GAAP update requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. This GAAP update also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The GAAP update is effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2016, which is extended to December 15, 2017. We are currently evaluating the impact of the GAAP update on our consolidated financial position, results of operations and cash flows.

Note 2. Business Acquisitions

For practice acquisitions, we recognize all of the assets acquired, liabilities assumed and any contingent consideration at the acquisition-date fair value and expense all transaction related costs.

During the six months ended June 30, 2015, we completed the acquisition of thirteen hospitalist physician practices. In connection with these acquisitions, we recorded goodwill and other identifiable intangible assets consisting of physician and hospital agreements.

Goodwill represents the potential business synergy from the combined operations of our existing and acquired practices through an expanded national network of providers, improved managed care contracting, improved collections, identification of growth initiatives and cost savings based upon the significant infrastructure we have developed. Amounts recorded as goodwill

Table Of Contents

and identifiable intangible assets with indefinite lives are not amortizable for GAAP financial reporting purposes but are amortized for tax purposes over 15 years.

In addition to the initial consideration paid at the close of each transaction, the asset purchase agreements for ten out of the thirteen acquisitions completed during the six months ended June 30, 2015 provide for contingent consideration to be paid, which is generally based upon the achievement of certain operating results of the acquired practices as of certain measurement dates. These additional payments are not contingent upon the future employment of the sellers. The contingent consideration for four acquisitions completed during the three months ended June 30, 2015 was recorded on a provisional basis pending completion of the valuation studies as of the acquisition dates.

We estimate the fair value of contingent consideration to be paid based on discounted projected earnings of the acquired practices as of certain measurement dates. The discount rate that we use consists of a risk-free U.S. Treasury bond yield plus a Company specific credit spread which we believe is acceptable by willing market participants.

The following table summarizes the total amounts recorded during the six months ended June 30, 2015 related to the acquisition of hospitalist practices (in thousands):



Acquired assets, net of assumed liabilities – paid and accrued:
Goodwill - current year transactions	$	49,789
Other intangible assets	630
Fixed assets	7
Total acquired assets - current year	50,426
Goodwill - adjustment for prior year transactions	(283		)
	50,143
Cash paid for acquisitions:
Current year transactions	(41,125		)
Contingent consideration	(4,706		)
Total cash paid for acquisitions	(45,831		)

Change in accrued contingent consideration	4,884
Net change in payable for practice acquisitions	9,196
Payable for practice acquisitions, beginning of period	44,911
Payable for practice acquisitions, end of period	$	54,107

Note 3. Fair Value Measurement

Some of our liabilities are measured and recorded at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The established fair value hierarchy distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (Levels 1 and 2) and the reporting entity’s own assumptions about market participant assumptions (Level 3). This hierarchy is used to measure fair value as follows:


•	Level 1 inputs utilize quoted prices in active markets for identical assets or liabilities.


•	Level 2 inputs include quoted prices for similar assets and liabilities in active markets; quoted prices in markets that are not active; and other inputs that are observable or can be corroborated by observable market data for the asset or liability.


•	Level 3 inputs are unobservable inputs for the asset or liability that are supported by little or no market activity.

Table Of Contents

The following table presents our liabilities measured at fair value on a recurring basis as of June 30, 2015 (in thousands):



	Quoted Price In Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Balance
Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)	$	—	$	—	$	54,107	$	54,107

The following table presents a rollforward of our liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three and six months ended June 30, 2015 (in thousands):



	Three Months Ended June 30, 2015			Six Months Ended June 30, 2015
Accrued contingent consideration for practice acquisitions
Beginning balance	$	56,308		$	44,911
Addition through acquisition transactions	1,262			9,301
Adjustment for prior year transactions	—			(283		)
Change in accrued contingent consideration	505			4,884
Payments	(3,968		)	(4,706		)
Ending balance	$	54,107		$	54,107

The fair value of our accrued contingent consideration is determined using widely accepted valuation techniques, which include the income approach for estimating future consideration to be paid based on projected earnings of our acquired practices as of specified measurement dates. The income approach involves the use of a probability-weighted discounted cash flow model based on significant inputs not observable in the market. The significant inputs include discount rates of 1.27% to 1.90%, 100% probability of achieving the estimated projected earnings, and 10% to 80% probability of achieving certain other objectives.

Because our accrued contingent consideration is generally based on a certain multiple of earnings of the acquired practices during a specified measurement period, a moderate change in such projected earnings may result in a material change to the fair value of such contingent consideration liability with a corresponding adjustment to income from operations. We reassess our projected earnings and the related fair value of our accrued contingent consideration for practice acquisitions on a quarterly basis.

Note 4. Debt

Our secured revolving credit agreement (Credit Facility) provides a revolving line of credit of $125.0 million and contains an “accordion” feature that allows an increase of up to $25.0 million to the Credit Facility with lender approval. The Credit Facility has a maturity date of August 4, 2016 and is available for working capital, practice acquisitions, capital expenditures and general business expenses. As of June 30, 2015, we had borrowings of $90.0 million and letters of credit of $0.3 million outstanding, and $34.7 million available under the Credit Facility.

The revolving line of credit is limited by a formula based on a certain multiple times the trailing twelve months of earnings before interest, taxes, depreciation, amortization and certain non-cash items. Interest rate options for each borrowing under the Credit Facility, to be selected by us at the time of each borrowing, include either LIBOR plus 0.75% to 1.75%, or the lender’s prime rate plus 0% to 0.75%, both based on a leverage ratio. We pay an unused commitment fee equal to 0.25% per annum on the difference between the revolving line capacity and the average balance outstanding during the year. Outstanding amounts advanced to us under the revolving line of credit are repayable on or before the maturity date. The interest rate for our borrowings under the Credit Facility at June 30, 2015 was 0.9375% per annum.

The Credit Facility is guaranteed by our subsidiaries and affiliated Professional Medical Corporations and limited liability companies, and is secured by substantially all of our and our guarantors’ tangible and intangible assets. The Credit Facility includes various customary financial covenants and restrictions, as well as customary remedies for our lenders following an event of default. As of June 30, 2015, we were in compliance with such financial covenants and restrictions.

Table Of Contents

Note 5. Income Taxes

The following table sets forth our income tax provisions and effective tax rates for the three and six months ended June 30, 2015 and 2014 (dollars in thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
Income tax provision	$	5,364		$	6,586		$	9,291		$	12,963
Effective tax rate	38.0		%	38.3		%	38.0		%	38.3		%

The effective tax rates differ from the statutory U.S. federal income tax rate of 35.0% due primarily to state income taxes.

Our accounting policy is to include interest and penalties related to income tax liabilities in income tax expense. As of June 30, 2015, we did not have any estimated interest and penalties related to uncertain tax positions.

The tax years 2009 to 2013 remain open to examination by the major taxing jurisdictions to which we are subject. The statute of limitations for tax years 1999 to 2008 has expired, except that the tax year 1999 is subject to adjustment of net operating losses by the Internal Revenue Service. We are subject to taxation in the United States and various state jurisdictions. We are currently subject to one state tax examination for the tax year of 2009 and two federal tax examinations for the tax year of 2013. The outcome of the examinations cannot be predicted with certainty; however, we believe that the ultimate resolution will not have a material effect on our consolidated financial position, results of operations, or cash flows.

We make our best estimate of the tax rate expected to be applicable for the full fiscal year. The rate so determined is used to compute our income tax expense for an interim period.

Note 6. Stock-Based Compensation

At June 30, 2015, we had a stock-based employee compensation program, for which we had reserved a total of 4,943,170 common shares for issuance. Under our 2012 Equity Participation Plan (Equity Plan), which was approved by our stockholders on June 7, 2012, a total of 1,422,130 shares of our common stock were available for issuance and no new awards will be issued under any previous equity participation plans. As of June 30, 2015, there were 529,851 shares of our common stock available for future grants under our Equity Plan, which included the canceled and forfeited shares issued under previous equity participation plans.

All option awards previously granted were issued with exercise prices equal to the closing price of our common stock on the NASDAQ Global Select Market on the dates of the grant. The options under the Equity Plan generally vest over a four-year period from date of grant, and options terminate on the 10th anniversary of the agreement date for all grants issued before January 1, 2013 and on the 7th anniversary of the agreement date for all grants issued after December 31, 2012. Restricted stock awards generally vest over a four-year period from date of the award. Performance stock units granted prior to 2015 generally vest over two to three years from date of the award based on the expected level of achievement of certain operational goals that will be obtained and adjusted as appropriate to reflect actual shares issued. Performance stock units granted in 2015 generally vest over three to four years from date of the award based on the expected level of achievement of certain market conditions that will be obtained and adjusted as appropriate to reflect actual shares issued.

Stock-based compensation expense is recognized over the period when the options, restricted stock awards, performance stock awards and our employee stock purchase plan shares vest, which is included in total general and administrative expenses as follows (in thousands):



	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
Total stock-based compensation expense	$	1,784		$	2,059		$	3,688		$	4,024
Tax benefit from stock-based compensation expense	(678		)	(789		)	(1,401		)	(1,541		)
Total stock-based compensation expense, net of tax	$	1,106		$	1,270		$	2,287		$	2,483

Table Of Contents

As of June 30, 2015, total unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under our Equity Plan and previous equity participation plans and the weighted-average period of years expected to recognize those costs are as follows (dollars in thousands):



	Total Unrecognized Compensation Cost		Weighted -average Remaining Recognition Period
			(Years)
Stock option	$	903	1.47
Restricted/Performance stock	$	11,916	2.47

The grant date fair value of each restricted stock award or performance stock units with operational goals is based on the closing stock price on the grant date of the award as reported by NASDAQ Global Select Market. The grant date fair value of performance stock units with market conditions is determined using a Monte-Carlo simulation model. Key assumptions in the Monte-Carlo simulation model are the risk-free interest rate, expected volatility and correlation coefficient.

The following table summarizes the stock option activities in our Equity Plan during the six months ended June 30, 2015:



	Shares		Weighted- Average Exercise Price		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value		Weighted- Average Fair Value
					(Years)	(in 000s)
Options outstanding as of December 31, 2014	1,234,530		$	31.10				$	12.75
Changes during period:
Exercised	(46,980	)	33.07					13.90
Canceled	(2,574	)	34.61					14.14
Options outstanding as of June 30, 2015	1,184,976		$	31.01	4.69	$	28,946	$	12.70
Options exercisable as of June 30, 2015	1,120,916		$	30.40	4.61	$	28,068	$	12.55

The following table summarizes the restricted stock award and performance stock award activities in our Equity Plan during the six months ended June 30, 2015:



	Shares		Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value		Weighted- Average Fair Value
			(Years)	(in 000s)
Restricted/performance stock awards outstanding as of December 31, 2014	265,219					$	45.69
Changes during period:
Granted	198,893					44.43
Vested	(105,444	)				41.89
Forfeited	(4,959	)				46.10
Restricted/performance stock awards outstanding as of June 30, 2015	353,709		1.80	$	19,225	$	46.11

Note 7. Earnings Per Share

Basic net income per share is calculated by dividing net income for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing net income for the period by the weighted average number of shares outstanding during the period plus the dilutive effect of our outstanding stock awards and shares issuable under our employee stock purchase plan using the treasury stock method.

Table Of Contents

The calculations of basic and diluted net income per share for the three and six months ended June 30, 2015 and 2014 are as follows (dollars in thousands, except for per share data):



	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Basic:
Net income attributable to common stockholders	$	8,750	$	10,609	$	15,160	$	20,883
Weighted average number of common shares outstanding	17,388,646		17,123,840		17,345,822		17,089,410
Basic net income per share attributable to common stockholders	$	0.50	$	0.62	$	0.87	$	1.22
Diluted:
Net income attributable to common stockholders	$	8,750	$	10,609	$	15,160	$	20,883
Weighted average number of common shares outstanding	17,388,646		17,123,840		17,345,822		17,089,410
Weighted average number of dilutive common share equivalents from options to purchase common stock	487,076		392,098		476,568		467,535
Common shares and common share equivalents	17,875,722		17,515,938		17,822,390		17,556,945
Diluted net income per share	$	0.49	$	0.61	$	0.85	$	1.19

Outstanding stock options and performance stock units that have an above-market exercise price or that are anti-dilutive under the treasury stock method, are excluded from our diluted computation. As of June 30, 2015, the total number of excluded stock options and performance stock units was 51,349.

Note 8. Commitments and Contingencies

Legal

In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated clinicians. We may also become subject to other lawsuits, which could involve significant claims and/or significant defense costs.

We believe, based upon our review of pending actions and proceedings that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, consolidated financial position, results of operations, or cash flows. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, consolidated financial position, results of operations, or cash flows in a future period.

Government Claim

On June 7, 2010, we received a civil investigative demand (CID) issued by the Department of Justice (DOJ), U.S. Attorney’s Office for the Northern District of Illinois. The CID requested information concerning claims that we have submitted to Medicare and Medicaid. The CID covered the period from January 1, 2003, through June 4, 2010, and requested production of a range of documents relating to our Medicare and Medicaid participation, physician arrangements, operations, billings and compliance programs. We believe we have a strong compliance focus, and that we operate with appropriate billing policies, procedures, provider training, and compliance programs and controls. We produced responsive documents and were in contact with representatives of the DOJ who informed us that the inquiry related to a qui tam whistleblower action filed under court seal in the U.S. District Court for the Northern District of Illinois (Chicago). We also were informed that several state attorneys general were examining our Medicaid claims in coordination with the DOJ.

Table Of Contents

healthcare programs from January 1, 2003 to the present, seeks to recover treble damages and civil penalties under the civil False Claims Act, and seeks to recover damages under the common law theories of payment by mistake and unjust enrichment. On August 13, 2014, IPC and the IPC subsidiary defendants filed a joint motion to dismiss the Complaint in Intervention or, in the alternative, to sever claims against the defendants. The federal government filed its response on September 18, 2014, to which the defendants replied on September 25, 2014. The court’s decision, which was filed on February 17, 2015, granted the motion to dismiss in part and denied it in part. The Court’s Opinion and Order dismissed the 29 IPC subsidiary and affiliate defendants without prejudice, but the Court denied the request to dismiss IPC, which remains the sole defendant in the lawsuit. The parties are engaged in active discovery.

It is not possible to predict when this matter may be resolved, the time or resources that we will need to devote to this litigation, or what impact, if any, the outcome of this matter might have on our business, consolidated financial position, results of operations, or cash flows.

Derivative Lawsuit

Although the underlying government lawsuit is still in an early stage and no liability has been found by a court, on October 20 and 24, 2014, shareholder derivative lawsuits were filed in the Court of Chancery of the State of Delaware against certain of our current and former directors and officers. We are named as a nominal defendant in both suits. The actions both assert alleged breaches of fiduciary duties related to our billing practices, and incorporate allegations from the False Claims Act case. The lawsuits seek a variety of relief, including monetary damages and injunctive relief. On December 4, 2014, the derivative lawsuits were consolidated into one lawsuit. On April 15, 2015, we filed a motion to stay the consolidated derivative lawsuit, pending the resolution of the False Claims Act case. That motion remains pending. The litigation is in an early stage and it is not possible to predict when this matter may be resolved, the time or resources that we will need to devote to this litigation, or what impact, if any, the outcome of this matter might have on our business, consolidated financial position, results of operations, or cash flows.

Table Of Contents


ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following management’s discussion and analysis should be read in conjunction with the unaudited consolidated financial statements and the notes thereto included in this Quarterly Report. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our most recent Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission (SEC) on February 23, 2015.

The following discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding future events and the future results of IPC that are based on management’s current expectations, estimates, projections, and assumptions about our business. Words such as “may,” “will,” “could,” “should,” “target,” “potential,” “project,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “sees,” “estimates” and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including, but not limited to, those discussed in our most recent Annual Report on Form 10-K, including the section entitled “Risk Factors,” as well as those discussed from time to time in the Company’s other SEC filings and reports. In addition, such statements could be affected by general industry and market conditions. Such forward-looking statements speak only as of the date of this Quarterly Report or, in the case of any document incorporated by reference, the date of that document, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this Quarterly Report, or for changes made to this document by wire services or internet service providers. If we update or correct one or more forward-looking statements, investors and others should not conclude that we will make additional updates or corrections with respect to other forward-looking statements.

Company Overview and Recent Developments

We are a leading national acute hospitalist and post-acute care provider group practice in the United States. Hospitalist medicine is organized around inpatient care, primarily delivered in hospitals, and our services in post-acute care are primarily delivered in skilled nursing facilities. Our services are focused on providing, managing and coordinating the care of patients at inpatient facilities. We believe we are the largest dedicated provider of these clinical services in the United States based on revenues, patient encounters and number of affiliated clinicians. Our early entry into the emerging hospitalist industry has permitted us to establish a reputation and leadership position that we believe is closely identified with hospitalist medicine.

Business Acquisitions

During the six months ended June 30, 2015, we acquired thirteen hospitalist physician practices for a total estimated purchase price of $50,426,000. In connection with these acquisitions, we recorded goodwill of $49,789,000, identifiable intangible assets of $630,000 and fixed assets of $7,000. Total transaction costs of $105,000 for our acquisition activities during the six months ended June 30, 2015 were expensed as incurred.

In connection with ten out of the thirteen acquisitions, we recorded liabilities of $9,301,000 representing the fair value of future contingent consideration to be paid based upon the estimated achievement of certain operating results of the acquired practices as of certain measurement dates. The contingent consideration for four acquisitions completed during the three months ended June 30, 2015 was recorded on a provisional basis pending completion of the valuation studies as of the acquisition dates. The finalized fair value of contingent considerations is re-evaluated on a quarterly basis based on changes in our estimate of the operating results of future periods. The changes in fair value, if any, are recognized in our results of operations. Because the fair value of contingent consideration is generally based on a certain multiple of operating results of the acquired practices during a measurement period, a moderate change in projected operating results can result in a large change to the fair value of such contingent consideration.

The net change in fair value of contingent consideration (“net change in fair value”) for acquisitions was an increase to expense of $1,174,000 and a reduction to expense of $695,000 for the three months ended June 30, 2015 and 2014, respectively. The net change in fair value for acquisitions was an increase to expense of $5,858,000 and a reduction to expense of $1,078,000 for the six months ended June 30, 2015 and 2014, respectively.

Diluted earnings per share for the three months ended June 30, 2015, which includes the net change in fair value, was $0.49 diluted earnings per share, compared with $0.61 diluted earnings per share for the same period in the prior year.

Table Of Contents

Excluding the net change in fair value, diluted earnings per share for the three months ended June 30, 2015 was $0.53 diluted earnings per share, compared with $0.58 diluted earnings per share for the same period in the prior year. This $0.05 decrease in diluted earnings per share is primarily related to Medicaid Parity, which largely expired at the end of 2014.

Diluted earnings per share for the six months ended June 30, 2015, which includes the net change in fair value, was $0.85 diluted earnings per share, compared with $1.19 diluted earnings per share for the same period in the prior year. Excluding the net change in fair value, diluted earnings per share for the six months ended June 30, 2015 was $1.05 diluted earnings per share, compared with $1.15 diluted earnings per share for the same period in the prior year. This $0.10 decrease in diluted earnings per share is primarily related to Medicaid Parity, which largely expired at the end of 2014.

Rate Changes by Government Sponsored Programs

The Medicare program reimburses for our services based upon the rates set forth in the annually updated Medicare Physician Fee Schedule. Many private payors use the Medicare Physician Fee Schedule to determine their own reimbursement rates. Effective January 1, 2015, the Medicare update resulted in a slight increase in our net patient revenue per encounter.

On April 14, 2015, Congress passed the Medicare Access and CHIP Reauthorization Act of 2015, which was signed into law by President Obama on April 16, 2015. This law repeals the Sustainable Growth Rate methodology from the physician payment formula, institutes a 0% update to the Medicare Physician Fee Schedule for the January 1 to July 1, 2015 period, a 0.5% payment update for July 2015 through the end of 2019, and a 0% payment update for 2020 through 2025. For 2026 and subsequent years, the payment update will be either 0.75% or 0.25%, depending on the Alternate Payment Model (APM) in which the physician participates. Given that the payment updates for APMs have yet to take effect, we cannot determine the impact of such payments models on our business at this time.

Another provision that affects physician payments is an adjustment under the Medicare statute to reflect the geographic variation in the cost of delivering physician services, by comparing those costs to the national average. This concerns the “work” component of the Geographic Practice Cost Indices (GPCI). If Congress does not block this adjustment, payments would be decreased to any geographic area with an index of less than 1.0. Although Congress has delayed the GPCI payment adjustment several times, most recently in the Medicare Access and CHIP Reauthorization Act of 2015, which blocks the GPCI payment adjustment until January 1, 2018, there is no guarantee that Congress will block the adjustment in the future, which could result in a decrease in the payments we receive for physician services.

In addition, in recent years, Congress has enacted various laws seeking to reduce the federal debt level and contain healthcare expenditures. For example, the Budget Control Act of 2011 (BCA) called for the establishment of a Joint Select Committee on Deficit Reduction, tasked with reducing the federal debt level. However, because the Committee did not draft a proposal by the BCA’s deadline, President Obama issued an initial sequestration order on March 1, 2013 that imposed automatic spending cuts on various federal programs. Under the Bipartisan Budget Act of 2013 and a bill signed by the President on February 15, 2014, sequestration has been extended through fiscal year 2024. Medicare payments to providers are subject to such cuts, although the BCA generally limited the Medicare cuts to two percent. For fiscal year 2024, however, Medicare sequestration amounts will be realigned such that there will be a 4.0 percent sequester for the first six months and a zero percent sequester for the second six months. Thus far, this 2.0 percent net reduction in Medicare reimbursement rates for the codes applicable to the services performed by our affiliated clinicians reduced our net patient revenue per encounter by approximately 1.0 percent.

Moreover, the instability of the federal budget may lead to legislation that could result in further cuts in Medicare and Medicaid payments to providers. In recent years, the government has enacted a patchwork of appropriations legislation to temporarily suspend the debt ceiling and continue government operations. Most recently, on December 9, 2014, Congress passed the Consolidated and Further Continuing Appropriations Act of 2015, which funds the government through September 30, 2015. However, this new law is a temporary measure that does not resolve the debt ceiling issue. Many members of Congress have made public statements indicating that some or all of these budget-related deadlines should be used as leverage to negotiate additional cuts in federal spending. The Medicare program is frequently mentioned as a target for spending cuts.

Healthcare Reform

In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively the Affordable Care Act or ACA) was enacted. The ACA includes a number of provisions that may affect our Company, although the impact of many of the changes will be unknown until they are fully implemented, which in some cases will not occur for a couple of years. The impact of some of these provisions have already proven to be positive, such as the Primary Care Incentive Payment Program, which makes a ten percent Medicare bonus

Table Of Contents

payment for primary care services (including outpatient and nursing home visits) furnished on or after January 1, 2011 and before January 1, 2016 to primary care practitioners for whom primary care services represented a minimum of 60 percent of Medicare allowed charges in a prior period, and the increase in Medicaid rates up to the level of Medicare rates (Medicaid parity) in 2013 and 2014 for primary care services. Another positive provision is the expansion in the number of individuals with health insurance, which increased in January 2014 with the expansion of Medicaid eligibility and the initiation of health coverage through plans purchased on the health exchanges.

The impact of other provisions is unknown at this time, such as the establishment of an Independent Payment Advisory Board (the IPA Board)-a fifteen-member board which is tasked with making proposals to Congress and the U.S. Department of Health and Human Services (HHS) to reduce the per capita rate of growth in Medicare spending in years when that growth exceeds established targets. HHS generally will be required to implement these proposals unless Congress enacts superseding legislation. Pursuant to statute, the IPA Board’s first set of recommendations were due on January 15, 2014. However, as of mid 2015, the President had yet to nominate anyone to serve on the IPA Board. Additionally, the U.S. legislature is currently considering a repeal of the IPA Board. On June 23, 2015, the House voted to repeal the IPA Board, and the Senate has referred the bill to the Committee on Finance. At this time, it is unclear when, if at all, the bill would be passed or what impact it might have on our business.

Fraud and abuse penalty increases and the expansion in the scope of the reach of the federal False Claims Act and other government enforcement tools may adversely impact entities in the healthcare industry, including our Company.

The impact of certain ACA provisions will depend upon the ultimate method of implementation. For example, the ACA requires HHS to develop a budget neutral, value-based payment modifier that provides for differential payment under the Medicare Physician Fee Schedule for physicians or groups of physicians that is linked to quality of care furnished compared to cost. CMS has continued to implement the modifier through the Medicare Physician Fee Schedule rulemaking for 2014, by, among other things, finalizing its proposal to apply the value-based payment modifier to groups of physicians with 10 or more eligible professionals in calendar year 2016 and to expand the modifier to all physicians in calendar year 2017. In the 2015 Physician Fee Schedule final rule, CMS continued to expand the impact of value-based payment methodologies, for example, effective calendar year 2017, the amount of payment at risk under the value-based payment modifier will increase from 2.0 percent to 4.0 percent. The impact of this payment modifier, if any, cannot be determined at this time.

In addition, certain provisions of the ACA authorize voluntary demonstration projects, which include the development of bundling payments for acute, inpatient hospital services, physician services, and post-acute care services for episodes of hospital care. The Medicare Bundled Payments for Care Improvement Initiative is currently underway and assesses four models of care linking payments for multiple services provided to beneficiaries during an episode of care. Although we have entered into an agreement to participate in this initiative, effective July 1, 2015, the impact of these projects on our consolidated financial position, results of operations, or cash flows cannot be determined at this time.

Seasonality and Quarterly Fluctuations

We have historically experienced and expect to continue to experience quarterly fluctuations in net revenue and income from operations. Absent the impact and timing of acquisitions, our net revenue has historically been higher in the first and fourth quarters of the year primarily due to the following factors:


•	the number of physicians we have on staff during the quarter, which may fluctuate based upon the timing of hires due to the end of the academic year for graduating resident physicians, the schedule of the Internal Medicine Board exams and terminations in our existing practices; and


•	fluctuations in patient encounters, which are impacted by hospital census, which can be volatile, and physician productivity and often reflect seasonality due to the higher occurrence of illnesses such as flu and pneumonia in patient populations in the first quarter.

We have significant fixed operating costs, including physician practice salaries and benefits and, as a result, are highly dependent on patient encounters and the productivity of our affiliated hospitalists to sustain profitability. Additionally, quarterly results may be affected by the timing of practice acquisitions and the hiring and termination of our affiliated hospitalists.

Results of Operations and Operating Data

The following table sets forth operating data and selected consolidated statement of income information stated as a percentage of net revenue:

Table Of Contents



	Three Months Ended June 30,				Six Months Ended June 30,
	2015		2014		2015		2014
Operating data – patient encounters	1,964,000		1,727,000		3,927,000		3,491,000

Net revenue	100.0	%	100.0	%	100.0	%	100.0	%
Operating expenses:
Cost of services—physician practice salaries, benefits and other	73.7	%	73.0	%	74.0	%	73.3	%
General and administrative	17.0	%	16.4	%	16.8	%	16.2	%
Net change in fair value of contingent consideration	0.6	%	(0.4	)%	1.6	%	(0.3	)%
Depreciation and amortization	0.9	%	0.8	%	0.7	%	0.8	%
Total operating expenses	92.2	%	89.8	%	93.1	%	90.0	%
Income from operations	7.8	%	10.2	%	6.9	%	10.0	%
Investment income	–		—	%	–		—	%
Interest expense	(0.1	)%	(0.2	)%	(0.2%)		(0.2	)%
Income before income taxes	7.7	%	10.0	%	6.7	%	9.8	%
Income tax provision	2.9	%	3.8	%	2.5	%	3.7	%
Net income	4.8	%	6.2	%	4.2	%	6.1	%

Three months ended June 30, 2015 compared with three months ended June 30, 2014

Our patient encounters for the three months ended June 30, 2015 increased by 237,000 encounters or 13.7% to 1,964,000, compared with 1,727,000 for the same period in the prior year. Net revenue for the three months ended June 30, 2015 was $184.0 million, an increase of $11.7 million, or 6.8%, from $172.3 million for the same period in the prior year. The difference between revenue growth and encounter growth is principally related to Medicaid Parity, which largely expired at the end of 2014, and the exiting of a few facility contracts during 2014. Of this $11.7 million increase, 52.3% was attributable to same-market area growth, including new hires and tuck-in acquisitions, and 47.7% was attributable to revenue generated from operations in new markets. Same-market encounters increased 9.8% and same-market net revenue increased 3.6%. Adjusting for Medicaid Parity and the exiting of certain contracted facilities in 2014 and the six months ended June 30, 2015, same-market encounter growth and net revenue growth would have been approximately 10.8% and 9.9%, respectively. Same-market areas are those geographic areas in which we have had operations for the entire current period and the entire comparable prior period. Because in-market area acquisitions are often small practice groups which become subsumed within our existing practice groups and are managed by our existing regional management staff, we consider these as part of our same-market area growth.

Physician practice salaries, benefits and other expenses increased by $10.0 million or 7.9% to $135.7 million, or 73.7% of net revenue, for the three months ended June 30, 2015, as compared with $125.7 million, or 73.0% of net revenue, for the same period in the prior year. The 70 basis point increase in costs as a percentage of revenue is primarily due to the acquisition of certain practices that are operating below the Company’s average gross margin. The dollar increase in cost of services is largely related to the increase in the number of hospitalists added through hiring and acquisitions during the period. Same-market area physician costs increased a total of $5.4 million, which was primarily the result of increased costs related to our new hires or acquired physician practices. In addition, $4.6 million of the $10.0 million overall cost increase is attributable to physician costs associated with our entrance into new markets.

General and administrative expenses include all salaries, benefits and operating expenses not specifically related to the day-to-day operations of our physician group practices, including billing and collections functions, our regional and market-area administrative offices and our corporate management and overhead. General and administrative expenses increased $3.0 million, or 10.5%, to $31.3 million, or 17.0% of net revenue, for the three months ended June 30, 2015, as compared with $28.3 million, or 16.4% of net revenue, for the same period in the prior year. Adjusting for the cessation of Medicaid Parity, general and administrative expenses would have been 16.4% of net revenue for the three months ended June 30, 2015. The dollar increase in expense was primarily the result of increased costs to support the continuing growth of our operations. Excluding stock based compensation and the cessation of Medicaid Parity, general and administrative expenses were 15.5% of net revenue for the three months ended June 30, 2015, as compared with 15.3% of net revenue for the same period in the prior year.

Table Of Contents

The net change in fair value of contingent consideration (“net change in fair value”) for acquisitions was an increase to expense of $1.2 million and a decrease to expense of $0.7 million for the three months ended June 30, 2015 and 2014, respectively. The $1.2 million increase to expense was largely associated with a practice acquired in 2013 in the post-acute setting in New York. Because the fair value of contingent consideration for this practice is based on a certain multiple of operating results, the recent moderate improvement in projected earnings resulted in a large increase to expense.

Income from operations for the three months ended June 30, 2015 decreased $3.2 million, or 18.1%, to $14.4 million from $17.6 million for the same period in the prior year. Our operating margin was 7.8% and 10.2% for the three months ended June 30, 2015 and 2014, respectively. Excluding the net change in fair value, income from operations for the three months ended June 30, 2015 decreased 7.8% to $15.6 million, or an operating margin of 8.5%, compared with income from operations of $16.9 million, or an operating margin of 9.8% for the same period in the prior year.

Our effective tax rate for the three months ended June 30, 2015 and 2014 was 38.0% and 38.3%, respectively. The effective tax rate differs from the statutory U.S. federal rate of 35.0% due primarily to state income taxes.

Net income for the three months ended June 30, 2015 was $8.8 million, as compared with $10.6 million for the same period in the prior year, and our net income margin was 4.8% for the three months ended June 30, 2015, as compared with 6.2% for the same period in the prior year. Diluted earnings per share for the three months ended June 30, 2015 was $0.49, as compared with $0.61 for the same period in the prior year. Excluding the net change in fair value, net income for the three months ended June 30, 2015 was $9.5 million, or $0.53 diluted earnings per share, as compared with net income of $10.2 million, or $0.58 diluted earnings per share for the same period in the prior year.

Six months ended June 30, 2015 compared with six months ended June 30, 2014

Our patient encounters for the six months ended June 30, 2015 increased by 436,000 encounters or 12.5% to 3,927,000, compared with 3,491,000 for the same period in the prior year. Net revenue for the six months ended June 30, 2015 was $364.8 million, an increase of $19.8 million, or 5.7%, from $345.0 million for the same period in the prior year. The difference between revenue growth and encounter growth is principally related to Medicaid Parity, which largely expired at the end of 2014, and the exiting of a few facility contracts during 2014. Of this $19.8 million increase, 53.6% was attributable to same-market area growth, including new hires and tuck-in acquisitions, and 46.4% was attributable to revenue generated from operations in new markets. Same-market encounters increased 9.3% and same-market net revenue increased 3.1%. Adjusting for Medicaid Parity and the exiting of certain contracted facilities in 2014 and the six months ended June 30, 2015, same-market encounter growth and net revenue growth would have been approximately 10.1% and 9.8%, respectively.

Physician practice salaries, benefits and other expenses increased by $16.8 million or 6.7% to $269.8 million, or 74.0% of net revenue, for the six months ended June 30, 2015, as compared with $253.0 million, or 73.3% of net revenue, for the same period in the prior year. The 70 basis point increase in costs as a percentage of revenue is primarily due to the acquisition of certain practices that are operating below the Company’s average gross margin. The dollar increase in cost of services is largely related to the increase in the number of hospitalists added through hiring and acquisitions during the period. Same-market area physician costs increased a total of $9.4 million, which was primarily the result of increased costs related to our new hires or acquired physician practices. In addition, $7.4 million of the $16.8 million overall cost increase is attributable to physician costs associated with our entrance into new markets.

General and administrative expenses increased $5.2 million, or 9.2%, to $61.1 million, or 16.8% of net revenue, for the six months ended June 30, 2015, as compared with $55.9 million, or 16.2% of net revenue, for the same period in the prior year. Adjusting for the cessation of Medicaid Parity, general and administrative expenses would have been 16.1% of net revenue for the six months ended June 30, 2015. The dollar increase in expense was primarily the result of increased costs to support the continuing growth of our operations. Excluding stock based compensation and the cessation of Medicaid Parity, general and administrative expenses were 15.2% of net revenue for the six months ended June 30, 2015, as compared with 15.0% of net revenue for the same period in the prior year.

The net change in fair value of contingent consideration (“net change in fair value”) for acquisitions was an increase to expense of $5.9 million and a decrease to expense of $1.1 million for the six months ended June 30, 2015 and 2014, respectively. The $5.9 million increase to expense was largely associated with a practice acquired in 2013 in the post-acute setting in New York. Because the fair value of contingent consideration for this practice is based on a certain multiple of operating results, the recent moderate improvement in projected earnings resulted in a large increase to expense.

Income from operations for the six months ended June 30, 2015 decreased $9.5 million, or 27.6%, to $25.0 million from $34.5 million for the same period in the prior year. Our operating margin was 6.9% and 10.0% for the six months ended June

Table Of Contents

30, 2015 and 2014, respectively. Excluding the net change in fair value, income from operations for the six months ended June 30, 2015 decreased 7.8% to $30.9 million, or an operating margin of 8.5%, compared with income from operations of $33.5 million, or an operating margin of 9.7% for the same period in the prior year.

Our effective tax rate for the six months ended June 30, 2015 and 2014 was 38.0% and 38.3%, respectively. The effective tax rate differs from the statutory U.S. federal rate of 35.0% due primarily to state income taxes.

Net income for the six months ended June 30, 2015 was $15.2 million, as compared with $20.9 million for the same period in the prior year, and our net income margin was 4.2% for the six months ended June 30, 2015, as compared with 6.1% for the same period in the prior year. Diluted earnings per share for the six months ended June 30, 2015 was $0.85, as compared with $1.19 for the same period in the prior year. Excluding the net change in fair value, net income for the six months ended June 30, 2015 was $18.8 million, or $1.05 diluted earnings per share, as compared with net income of $20.2 million, or $1.15 diluted earnings per share for the same period in the prior year.

Liquidity and Capital Resources

As of June 30, 2015, we had approximately $46.3 million in liquidity, which is composed of $11.6 million in cash and cash equivalents and an available line of credit of $34.7 million. We had borrowings of $90.0 million from our revolving line of credit outstanding at June 30, 2015, which was used to fund our practice acquisitions.

Net cash provided by operating activities was $32.7 million and $26.1 million for the six months ended June 30, 2015 and 2014, respectively. The changes in working capital during the six months ended June 30, 2015 was largely related to a decrease in prepaid expenses and other current assets of $6.8 million, an increase in accounts payable and accrued liabilities of $1.7 million and a decrease in accrued compensation of $3.4 million primarily related to timing of payrolls and physician bonus payments.

Our days sales outstanding (DSO), which we use to measure the effectiveness of our collections, was 58 DSO and 60 DSO as of June 30, 2015 and December 31, 2014, respectively. We calculate our DSO using a three-month rolling average of net revenues.

Net cash used in investing activities was $48.8 million for the six months ended June 30, 2015, as compared with $24.1 million for the same period in the prior year. Cash of $45.8 million was used in the six months ended June 30, 2015 for physician practice acquisitions and contingent consideration payments on prior acquisitions, as compared with $21.6 million for the same period in the prior year. The remainder of cash used in investing activities was for purchases of computer hardware and software, and office furnishings.

For the six months ended June 30, 2015, net cash provided by financing activities was $12.7 million, as compared with net cash used in financing activities of $0.8 million for the same period in the prior year. During the six months ended June 30, 2015, we repaid $25.0 million of our outstanding revolving line of credit and borrowed $35.0 million under our revolving line of credit to fund our practice acquisitions. During the six months ended June 30, 2014, we repaid $5.0 million of our outstanding revolving line of credit.

Credit Facility and Liquidity

Table Of Contents

We anticipate that funds generated from operations, together with our current cash on hand and funds available under our Credit Facility will be sufficient to finance our working capital requirements and fund anticipated acquisitions, contingent acquisition consideration and capital expenditures.

Off Balance Sheet Arrangements

As of June 30, 2015, we had no off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to changes in interest rate as a result of our Credit Facility. At our option, the interest rate on outstanding borrowings under our Credit Facility is either LIBOR plus 0.75% to 1.75% or the lender’s prime rate plus 0% to 0.75%, both based on a leverage ratio. The lender’s prime rate is a daily floating rate most recently announced by our lender, whether or not such announced rate is the lowest rate available from our lender. LIBOR is either the 30, 60, 90 or 180 day LIBOR. Historically, we have chosen not to use interest rate derivatives to manage our exposure to changes in interest rates. We had long-term borrowings of $90.0 million bearing an annual interest of 0.9375% under our Credit Facility at June 30, 2015. A 1.0% change in interest rate on our borrowings of $90.0 million would result in an impact to income before income taxes of approximately $900,000 on an annual basis.

Investments in both fixed rate and floating rate interest earning instruments carry a degree of interest rate risk. Fixed rate securities may have their fair market value adversely impacted due to a rise in interest rates, while floating rate securities with shorter maturities may produce less income if interest rates fall. As of June 30, 2015, all of our short-term investments were invested in money market funds with less than 90-day maturities and are classified as cash equivalents.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain controls and procedures designed to ensure that we are able to collect the information we are required to disclose in the reports we file with the SEC, and to process, summarize and disclose this information within the time periods specified in the rules of the SEC. Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has conducted an evaluation of the design and operation of our “disclosure controls and procedures” as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective as of the end of the period covered by this report to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting during the three months ended June 30, 2015 that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

Table Of Contents

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Legal

In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated hospitalists. We may also become subject to other lawsuits, which could involve significant claims and/or significant defense costs.

Government Claim

Though we cooperated with the government’s investigation and would welcome a resolution to this matter, we are now in active litigation with the federal government regarding this matter and intend to contest the case vigorously. On December 6, 2013, the U.S. District Court partially lifted the seal on the civil False Claims Act case related to this investigation. The unsealed portions of the Court docket at that time included the whistleblower’s Complaint, which contains allegations of improper billing to Medicare and Medicaid, a Notice of Election to Intervene filed by the federal government and a Notice of Election to Decline Intervention filed by the State of Illinois and 12 other states that participated in the investigation. On June 16, 2014, the federal government filed its Complaint in Intervention against IPC and several of its subsidiaries in the U.S. District Court. The Complaint in Intervention contains allegations of improper billing to Medicare, Medicaid and other federal healthcare programs from January 1, 2003 to the present, seeks to recover treble damages and civil penalties under the civil False Claims Act, and seeks to recover damages under the common law theories of payment by mistake and unjust enrichment. On August 13, 2014, IPC and the IPC subsidiary defendants filed a joint motion to dismiss the Complaint in Intervention or, in the alternative, to sever claims against the defendants. The federal government filed its response on September 18, 2014, to which the defendants replied on September 25, 2014. The court’s decision, which was filed on February 17, 2015, granted the motion to dismiss in part and denied it in part. The Court’s Opinion and Order dismissed the 29 IPC subsidiary and affiliate defendants without prejudice, but the Court denied the request to dismiss IPC, which remains the sole defendant in the lawsuit. The parties are engaged in active discovery.

Derivative Lawsuit

Table Of Contents

litigation, or what impact, if any, the outcome of this matter might have on our business, consolidated financial position, results of operations, or cash flows.

ITEMS 1A, 2, 3, 4 AND 5 ARE NOT APPLICABLE

ITEM 6. EXHIBITS

(a) Exhibits

Exhibits required by Item 601 of Regulation S-K are listed in the Exhibit Index on page 24 of this report.

Table Of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on July 30, 2015.




IPC HEALTHCARE, INC.

By:		/s/ ADAM D. SINGER, M.D.
		Adam D. Singer, M.D. Chief Executive Officer

By:		/s/ RICK KLINE
		Rick Kline Chief Financial Officer

Table Of Contents

EXHIBIT INDEX




Exhibit Number		Description of Document

31.1		Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes Oxley Act.

31.2		Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes Oxley Act.

32.1		Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act.

32.2		Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

EX-31.1 2 ipcm-2015630xex311.htm EXHIBIT 31.1 IPCM-2015.6.30-Ex31.1

Exhibit 31.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13A-14(A)

OR RULE 15D-14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AS ADOPTED

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT

I, Adam D. Singer, M.D., certify that:


1.	I have reviewed this quarterly report on Form 10-Q of IPC Healthcare, Inc.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: July 30, 2015



	/s/ ADAM D. SINGER, M.D.
	Adam D. Singer, M.D.
	Chief Executive Officer

EX-31.2 3 ipcm-2015630xex312.htm EXHIBIT 31.2 IPCM-2015.6.30-Ex31.2

Exhibit 31.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13A-14(A)

OR RULE 15D-14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AS ADOPTED

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT

I, Rick Kline, certify that:


1.	I have reviewed this quarterly report on Form 10-Q of IPC Healthcare, Inc.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: July 30, 2015



	/s/ RICK KLINE
	Rick Kline
	Chief Financial Officer

EX-32.1 4 ipcm-2015630xex321.htm EXHIBIT 32.1 IPCM-2015.6.30-Ex32.1

Exhibit 32.1

CERTIFICATE PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of IPC Healthcare, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, as Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:


(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



	/s/ ADAM D. SINGER, M.D.
	Adam D. Singer, M.D. Chief Executive Officer

Date: July 30, 2015

EX-32.2 5 ipcm-2015630xex322.htm EXHIBIT 32.2 IPCM-2015.6.30-Ex32.2

Exhibit 32.2

CERTIFICATE PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of IPC Healthcare, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:


(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



	/s/ RICK KLINE
	Rick Kline Chief Financial Officer

Date: July 30, 2015

EX-101.INS 6 ipcm-20150630.xml XBRL INSTANCE DOCUMENT 0001410471 2015-01-01 2015-06-30 0001410471 2015-07-23 0001410471 2014-12-31 0001410471 2015-06-30 0001410471 2014-01-01 2014-06-30 0001410471 2015-04-01 2015-06-30 0001410471 2014-04-01 2014-06-30 0001410471 2013-12-31 0001410471 2014-06-30 0001410471 ipcm:ClaimsIncurredButNotReportedIBNRMember 2014-12-31 0001410471 ipcm:ClaimsIncurredandReportedMember 2015-06-30 0001410471 ipcm:ClaimsIncurredandReportedMember 2014-12-31 0001410471 ipcm:ClaimsIncurredButNotReportedIBNRMember 2015-06-30 0001410471 ipcm:AchievementOfCertainOperatingResultsMember 2015-01-01 2015-06-30 0001410471 us-gaap:FairValueInputsLevel3Member us-gaap:MaximumMember 2015-01-01 2015-06-30 0001410471 us-gaap:FairValueInputsLevel3Member 2015-01-01 2015-06-30 0001410471 us-gaap:FairValueInputsLevel3Member us-gaap:MinimumMember 2015-01-01 2015-06-30 0001410471 ipcm:BusinessCombinationAccruedContingentConsiderationMember 2015-03-31 0001410471 ipcm:BusinessCombinationAccruedContingentConsiderationMember 2015-06-30 0001410471 ipcm:BusinessCombinationAccruedContingentConsiderationMember 2015-01-01 2015-06-30 0001410471 ipcm:BusinessCombinationAccruedContingentConsiderationMember 2015-04-01 2015-06-30 0001410471 ipcm:BusinessCombinationAccruedContingentConsiderationMember 2014-12-31 0001410471 us-gaap:FairValueInputsLevel3Member 2015-06-30 0001410471 us-gaap:FairValueInputsLevel2Member 2015-06-30 0001410471 us-gaap:FairValueInputsLevel1Member 2015-06-30 0001410471 us-gaap:RevolvingCreditFacilityMember 2015-01-01 2015-06-30 0001410471 us-gaap:RevolvingCreditFacilityMember 2015-06-30 0001410471 us-gaap:LetterOfCreditMember 2015-06-30 0001410471 us-gaap:RevolvingCreditFacilityMember us-gaap:MinimumMember us-gaap:PrimeRateMember 2015-01-01 2015-06-30 0001410471 us-gaap:RevolvingCreditFacilityMember us-gaap:MaximumMember us-gaap:PrimeRateMember 2015-01-01 2015-06-30 0001410471 us-gaap:RevolvingCreditFacilityMember us-gaap:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-01-01 2015-06-30 0001410471 us-gaap:RevolvingCreditFacilityMember us-gaap:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-01-01 2015-06-30 0001410471 us-gaap:RestrictedStockMember 2015-01-01 2015-06-30 0001410471 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-06-30 0001410471 us-gaap:PerformanceSharesMember us-gaap:MaximumMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2015-01-01 2015-06-30 0001410471 us-gaap:PerformanceSharesMember us-gaap:MaximumMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2015-01-01 2015-06-30 0001410471 2012-06-07 0001410471 us-gaap:PerformanceSharesMember us-gaap:MinimumMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2015-01-01 2015-06-30 0001410471 us-gaap:PerformanceSharesMember us-gaap:MinimumMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2015-01-01 2015-06-30 0001410471 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-06-30 0001410471 us-gaap:GeneralAndAdministrativeExpenseMember 2015-04-01 2015-06-30 0001410471 us-gaap:GeneralAndAdministrativeExpenseMember 2014-04-01 2014-06-30 0001410471 us-gaap:GeneralAndAdministrativeExpenseMember 2015-01-01 2015-06-30 0001410471 ipcm:RestrictedStockAndPerformanceSharesMember 2015-06-30 0001410471 us-gaap:EmployeeStockOptionMember 2015-06-30 0001410471 ipcm:RestrictedStockAndPerformanceSharesMember 2015-01-01 2015-06-30 0001410471 ipcm:RestrictedStockAndPerformanceSharesMember 2014-12-31 0001410471 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-06-30 ipcm:defendant xbrli:pure iso4217:USD xbrli:shares iso4217:USD ipcm:Hospitalist xbrli:shares false --12-31 Q2 2015 2015-06-30 10-Q 0001410471 17415207 Large Accelerated Filer IPC Healthcare, Inc. 3304000 -4884000 695000 1078000 -1174000 -5858000 1.00 0.80 0.10 -505000 -4884000 0 283000 P15Y 25000000.0 12.55 13.90 14.14 12.75 12.70

8388000

7829000

122092000

121699000

181841000

188144000

2059000

4024000

1784000

3688000

1270000

2483000

1106000

2287000

51349

614762000

655084000

170445000

159707000

41125000

9196000

44911000

54107000

35411000

49611000

9500000

4496000

50426000

630000

50143000

7000

25010000

26297000

14913000

11565000

1287000

-3348000

0.001

50000000

17242209

17414907

17242209

17414907

17000

125687000

252960000

135677000

269844000

0.0175

0.0075

584000

11737000

13622000

1366000

2631000

1461000

2976000

2631000

2976000

0.62

1.22

0.50

0.87

0.61

1.19

0.49

0.85

0.383

0.380

0.350

40907000

37544000

11916000

903000

P2Y5M19D

P1Y5M19D

789000

1541000

678000

1401000

585000

211000

0.0190

0.0127

1262000

9301000

3968000

4706000

44911000

56308000

54107000

28334000

55941000

31317000

61109000

408988000

458494000

49789000

-283000

17195000

33846000

14114000

24451000

6586000

12963000

5364000

9291000

8448000

7809000

3400000

1667000

9710000

-393000

-1199000

-3363000

1937000

517000

-7452000

-6755000

34138000

35321000

12564000

12322000

21574000

22999000

4957000

4924000

382000

696000

283000

560000

693000

548000

1000

2000

1000

246845000

265704000

614762000

655084000

98369000

108457000

54107000

300000

90000000

0.0025

0.009375

125000000.0

34700000

80000000

90000000

60318000

26180000

34138000

62018000

26697000

35321000

13079000

515000

12564000

12889000

567000

12322000

47239000

25665000

21574000

49129000

26130000

22999000

-767000

12737000

-24060000

-48762000

26114000

32677000

10609000

20883000

8750000

15160000

10609000

20883000

8750000

15160000

10609000

20883000

8750000

15160000

154692000

310454000

169629000

339787000

17576000

34540000

14397000

25010000

45831000

21575000

45831000

2485000

2931000

0.001

15000000

20876000

14121000

3648000

2526000

35000000

8798000

8960000

5000000

25000000

186059000

201219000

172268000

344994000

184026000

364797000

4024000

3688000

P4Y

P3Y

P4Y

P2Y

P3Y

P4Y

4959

46.10

198893

44.43

265219

353709

45.69

46.11

P1Y9M20D

105444

41.89

4943170

529851

1422130

1120916

30.40

2574

28946000

1234530

1184976

31.10

31.01

33.07

34.61

19225000

28068000

P4Y7M9D

P4Y8M10D

46980

367917000

389380000

392098

467535

487076

476568

17515938

17556945

17875722

17822390

17123840

17089410

17388646

17345822

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPC Healthcare, Inc. and its wholly-owned subsidiaries (the “Company,” “IPC,” “we,” “us,” and “our”) is a national physician group practice company that operates and manages full-time acute hospitalist and post-acute physician practices. We prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) on the same basis as our audited annual financial statements. The consolidated financial statements include all accounts of IPC Healthcare, Inc. and its wholly owned subsidiaries and consolidated professional medical corporations (Professional Medical Corporations) managed under long-term management agreements.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through the management agreements and our relationship with the stockholders of the Professional Medical Corporations, we have exclusive authority over all non-medical decision making related to the ongoing business operations of the Professional Medical Corporations. Further, our rights under the management agreements are unilaterally salable or transferable. Based on the provisions of the agreements, we have determined that the Professional Medical Corporations are variable interest entities (VIE’s), and that we are the primary beneficiary because we have control over the operations of these VIE’s, provide full financial and management support to them, and take all residual benefits and bear all residual losses from their operations. Consequently, we consolidate the revenue and expenses of the Professional Medical Corporations from the date of execution of the agreements. All intercompany balances and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our opinion, these consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial information set forth therein. Certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to GAAP and SEC rules and regulations, which are applicable to interim financial statements. As a result, the following disclosures should be read in conjunction with our audited consolidated financial statements and notes thereto as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> filed with the SEC on February 23, 2015.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation and Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IPC Healthcare, Inc. and its wholly-owned subsidiaries (the “Company,” “IPC,” “we,” “us,” and “our”) is a national physician group practice company that operates and manages full-time acute hospitalist and post-acute physician practices. We prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) on the same basis as our audited annual financial statements. The consolidated financial statements include all accounts of IPC Healthcare, Inc. and its wholly owned subsidiaries and consolidated professional medical corporations (Professional Medical Corporations) managed under long-term management agreements.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through the management agreements and our relationship with the stockholders of the Professional Medical Corporations, we have exclusive authority over all non-medical decision making related to the ongoing business operations of the Professional Medical Corporations. Further, our rights under the management agreements are unilaterally salable or transferable. Based on the provisions of the agreements, we have determined that the Professional Medical Corporations are variable interest entities (VIE’s), and that we are the primary beneficiary because we have control over the operations of these VIE’s, provide full financial and management support to them, and take all residual benefits and bear all residual losses from their operations. Consequently, we consolidate the revenue and expenses of the Professional Medical Corporations from the date of execution of the agreements. All intercompany balances and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In our opinion, these consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial information set forth therein. Certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to GAAP and SEC rules and regulations, which are applicable to interim financial statements. As a result, the following disclosures should be read in conjunction with our audited consolidated financial statements and notes thereto as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> filed with the SEC on February 23, 2015.</font></div><div style="line-height:120%;padding-top:16px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net revenue consists of fees for medical services provided by our affiliated hospitalists under fee-for-service, case rate and other professional fee arrangements with various payors including Medicare, Medicaid, managed care organizations, insurance companies and hospitals. Net revenue is reported in the period in which services are provided at amounts expected to be collected, which excludes contractual discounts and an estimate of uncollectible accounts.</font></div><div style="line-height:120%;padding-top:16px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions of the fair value of certain reported amounts of assets, liabilities, revenues and expenses at the date and for the periods that the financial statements are prepared. Significant estimates include the estimated net realizable value of accounts receivable, medical malpractice insurance receivable and payable for known claims, liabilities for claims incurred but not reported (IBNR) related to medical malpractice, fair value of contingent consideration related to business combinations and the analysis of goodwill for impairment. The process of estimating these assets and liabilities involves judgment, which is subject to an inherent degree of uncertainty. Actual results could differ from those estimates. The results of operations for the current interim period are not necessarily indicative of the results for the entire year ending </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our consolidated balance sheets as of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> included the following financial instruments: cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, payable for practice acquisitions and long-term debt. We consider the carrying amounts of cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amount of our long-term debt borrowed from our line of credit approximated its fair value at </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">. Pursuant to GAAP, we determine the fair value of our long-term borrowing using observable inputs, which are defined as Level 2 inputs under GAAP on fair value measures. See Note 3 for the definition of Level 2 inputs under GAAP.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our payable for practice acquisitions consisted of accrued contingent consideration for practice acquisitions. The accrued contingent consideration is carried at fair value largely determined using the income approach with unobservable inputs defined as Level 3 inputs under GAAP. See Note 3 for the definition of Level 3 inputs under GAAP and more information.</font></div><div style="line-height:120%;padding-top:16px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The changes in the carrying amount of goodwill for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="82%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill - beginning balance at January 1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">408,988</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill acquired during 2015</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,789</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment for prior year transactions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(283</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill - ending balance at June 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">458,494</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The valuation studies related to the practice acquisitions that occurred in the fourth quarter of 2014 were completed in early 2015, and as a result, the value of contingent consideration liability related to these acquisitions as of the acquisition dates was decreased by </font><font style="font-family:inherit;font-size:10pt;">$283,000</font><font style="font-family:inherit;font-size:10pt;">, along with a corresponding decrease in our goodwill.</font></div><div style="line-height:120%;padding-top:16px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Medical Malpractice Liability Insurance</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record our medical malpractice reserves, on an undiscounted basis, for claims incurred and reported and claims incurred but not reported (IBNR) during the policy period, based on actuarial loss projections using historical loss patterns. For claims incurred and reported, an insurance receivable from our carrier has been recorded pursuant to GAAP. Total accrued medical malpractice reserves and related insurance receivables were as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32" rowspan="1"></td></tr><tr><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Liabilities</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Insurance</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Claims</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Reserve</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">IBNR</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Reserve</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Insurance</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Claims</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Reserve</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">IBNR</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Reserve</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Liabilities</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current Portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,079</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term Portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,999</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,999</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,130</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,129</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,574</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,574</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,665</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,239</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,321</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,321</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,697</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,138</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,138</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,180</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,318</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New Accounting Principles</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board issued a GAAP update "Revenue from Contracts with Customers". This GAAP update requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. This GAAP update also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The GAAP update is effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2016, which is extended to December 15, 2017. We are currently evaluating the impact of the GAAP update on our consolidated financial position, results of operations and cash flows.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, we had a stock-based employee compensation program, for which we had reserved a total of </font><font style="font-family:inherit;font-size:10pt;">4,943,170</font><font style="font-family:inherit;font-size:10pt;"> common shares for issuance. Under our 2012 Equity Participation Plan (Equity Plan), which was approved by our stockholders on June 7, 2012, a total of </font><font style="font-family:inherit;font-size:10pt;">1,422,130</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock were available for issuance and no new awards will be issued under any previous equity participation plans. As of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">529,851</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock available for future grants under our Equity Plan, which included the canceled and forfeited shares issued under previous equity participation plans.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All option awards previously granted were issued with exercise prices equal to the closing price of our common stock on the NASDAQ Global Select Market on the dates of the grant. The options under the Equity Plan generally vest over a </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year period from date of grant, and options terminate on the 10th anniversary of the agreement date for all grants issued before January 1, 2013 and on the 7th anniversary of the agreement date for all grants issued after December 31, 2012. Restricted stock awards generally vest over a </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-year period from date of the award. Performance stock units granted prior to 2015 generally vest over </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years from date of the award based on the expected level of achievement of certain operational goals that will be obtained and adjusted as appropriate to reflect actual shares issued. Performance stock units granted in 2015 generally vest over </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> years from date of the award based on the expected level of achievement of certain market conditions that will be obtained and adjusted as appropriate to reflect actual shares issued.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense is recognized over the period when the options, restricted stock awards, performance stock awards and our employee stock purchase plan shares vest, which is included in total general and administrative expenses as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,784</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax benefit from stock-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(678</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(789</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,401</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense, net of tax</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,106</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,270</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,287</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,483</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, total unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under our Equity Plan and previous equity participation plans and the weighted-average period of years expected to recognize those costs are as follows (dollars in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="18%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="20%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Unrecognized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Compensation</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted -average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining Recognition</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock option</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">903</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.47</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted/Performance stock</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,916</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.47</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The grant date fair value of each restricted stock award or performance stock units with operational goals is based on the closing stock price on the grant date of the award as reported by NASDAQ Global Select Market. The grant date fair value of performance stock units with market conditions is determined using a Monte-Carlo simulation model. Key assumptions in the Monte-Carlo simulation model are the risk-free interest rate, expected volatility and correlation coefficient.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the stock option activities in our Equity Plan during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="39%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in 000s)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding as of December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,234,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes during period:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,574</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding as of June 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,184,976</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.70</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable as of June 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,120,916</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30.40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.61</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,068</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.55</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the restricted stock award and performance stock award activities in our Equity Plan during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="61%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in 000s)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted/performance stock awards outstanding as of December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes during period:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">198,893</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(105,444</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41.89</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,959</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted/performance stock awards outstanding as of June 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.80</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,225</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents our liabilities measured at fair value on a recurring basis as of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="36%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="17%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Price In</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Markets for</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Identical Instruments</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total Balance</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,107</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,107</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents a rollforward of our liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td width="68%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="14%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/> June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended <br clear="none"/> June 30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accrued contingent consideration for practice acquisitions</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,308</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,911</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Addition through acquisition transactions</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,262</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,301</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment for prior year transactions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(283</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in accrued contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">505</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,968</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,706</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,107</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54,107</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our consolidated balance sheets as of </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;"> included the following financial instruments: cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, payable for practice acquisitions and long-term debt. We consider the carrying amounts of cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amount of our long-term debt borrowed from our line of credit approximated its fair value at </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">. Pursuant to GAAP, we determine the fair value of our long-term borrowing using observable inputs, which are defined as Level 2 inputs under GAAP on fair value measures. See Note 3 for the definition of Level 2 inputs under GAAP.</font></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our payable for practice acquisitions consisted of accrued contingent consideration for practice acquisitions. The accrued contingent consideration is carried at fair value largely determined using the income approach with unobservable inputs defined as Level 3 inputs under GAAP. See Note 3 for the definition of Level 3 inputs under GAAP and more information.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">New Accounting Principles</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board issued a GAAP update "Revenue from Contracts with Customers". This GAAP update requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. This GAAP update also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The GAAP update is effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2016, which is extended to December 15, 2017. We are currently evaluating the impact of the GAAP update on our consolidated financial position, results of operations and cash flows.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense is recognized over the period when the options, restricted stock awards, performance stock awards and our employee stock purchase plan shares vest, which is included in total general and administrative expenses as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,784</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,059</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax benefit from stock-based compensation expense</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(678</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(789</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,401</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense, net of tax</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,106</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,270</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,287</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,483</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The calculations of basic and diluted net income per share for the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> are as follows (dollars in thousands, except for per share data):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="49%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended <br clear="none"/> June 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended <br clear="none"/> June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income attributable to common stockholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,609</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,388,646</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,123,840</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,345,822</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,089,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net income per share attributable to common stockholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.50</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.62</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.87</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.22</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income attributable to common stockholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,750</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,609</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,388,646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,123,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,345,822</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,089,410</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of dilutive common share equivalents from options to purchase common stock</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">487,076</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">392,098</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">476,568</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">467,535</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares and common share equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,875,722</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,515,938</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,822,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,556,945</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted net income per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.49</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.61</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.85</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth our income tax provisions and effective tax rates for the </font><font style="font-family:inherit;font-size:10pt;">three and six</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;"> (dollars in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td width="43%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax provision</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,364</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,586</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,291</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective tax rate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The changes in the carrying amount of goodwill for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td width="82%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill - beginning balance at January 1, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">408,988</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill acquired during 2015</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,789</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment for prior year transactions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(283</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill - ending balance at June 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">458,494</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accrued medical malpractice reserves and related insurance receivables were as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32" rowspan="1"></td></tr><tr><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="6%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Liabilities</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Insurance</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Claims</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Reserve</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">IBNR</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Reserve</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Insurance</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Claims</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Reserve</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">IBNR</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Reserve</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Liabilities</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current Portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,564</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">515</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,079</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term Portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,999</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,999</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,130</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,129</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,574</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,574</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,665</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,239</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,321</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,321</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,697</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,138</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,138</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,180</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,318</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the restricted stock award and performance stock award activities in our Equity Plan during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="61%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in 000s)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted/performance stock awards outstanding as of December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes during period:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">198,893</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(105,444</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41.89</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,959</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted/performance stock awards outstanding as of June 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">353,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.80</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,225</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the stock option activities in our Equity Plan during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="39%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in 000s)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding as of December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,234,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes during period:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46,980</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.07</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Canceled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,574</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options outstanding as of June 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,184,976</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,946</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.70</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercisable as of June 30, 2015</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,120,916</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30.40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.61</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,068</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.55</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions of the fair value of certain reported amounts of assets, liabilities, revenues and expenses at the date and for the periods that the financial statements are prepared. Significant estimates include the estimated net realizable value of accounts receivable, medical malpractice insurance receivable and payable for known claims, liabilities for claims incurred but not reported (IBNR) related to medical malpractice, fair value of contingent consideration related to business combinations and the analysis of goodwill for impairment. The process of estimating these assets and liabilities involves judgment, which is subject to an inherent degree of uncertainty. Actual results could differ from those estimates. The results of operations for the current interim period are not necessarily indicative of the results for the entire year ending </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>

EX-101.SCH 7 ipcm-20150630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2101100 - Disclosure - Basis of Presentation and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Changes in Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Total Accrued Medical Malpractice Reserves and Related Insurance Receivables (Details) link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Total Accrued Medical Malpractice Reserves and Related Insurance Receivables (Details) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Business Acquisitions link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Business Acquisitions - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Business Acquisitions - Schedule of Acquisition of Hospitalist Practices (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Business Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Fair Value Measurement link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Fair Value Measurement - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Fair Value Measurement - Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Fair Value Measurement - Rollforward for Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized When Options, Restricted Stock Awards, Performance Stock Awards and Employee Stock Purchase Plan Shares Vested (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Stock-Based Compensation - Schedule of Unrecognized Compensation Costs Related to Non-Vested Stock-Based Compensation Arrangements Granted under Equity Plan and Weighted-Average Period of Years Expected to Recognize Those Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2406406 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Award and Performance Stock Award Activities in Equity Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activities in Equity Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 ipcm-20150630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 ipcm-20150630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 ipcm-20150630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Fair Value Disclosures [Abstract] Fair Value Measurement Fair Value Disclosures [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of stock-based compensation expense recognized over the period Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] Schedule of unrecognized compensation costs related to non-vested stock-based compensation arrangements and weighted-average period of years expected to recognize those costs Schedule of Unrecognized Compensation Cost, Nonvested Awards [Table Text Block] Summary of stock option activities Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of restricted stock award and performance stock award activities Schedule of Nonvested Share Activity [Table Text Block] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Shares, Options outstanding as of beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Shares, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Shares, Canceled Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Shares, Options outstanding as of end of period Shares, Options exercisable as of end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted- Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted-Average Exercise Price, Options outstanding as of beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted-Average Exercise Price, Exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Canceled Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted-Average Exercise Price, Options outstanding as of end of period Weighted-Average Exercise Price, Options exercisable as of end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted-Average Remaining Contractual Term, Options outstanding as of end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted-Average Remaining Contractual Term, Options exercisable as of end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value, Options outstanding as of end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Options exercisable as of end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Weighted- Average Fair Value Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Fair Value Rollforward [Abstract] Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Fair Value Rollforward [Abstract] Weighted-Average Fair Value, Options outstanding as of beginning of period Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Fair Value Share based compensation arrangement by share based payment award options outstanding weighted average fair value. Weighted-Average Fair Value, Exercised Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Fair Value Share based compensation arrangement by share based payment award options exercised weighted average fair value. Weighted-Average Fair Value, Canceled Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Fair Value Share based compensation arrangement by share based payment award options forfeited weighted average fair value. Weighted-Average Fair Value, Options outstanding as of end of period Weighted-Average Fair Value, Options exercisable as of end of period Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Fair Value Share based compensation arrangement by share based payment award options exercisable weighted average fair value Statement of Cash Flows [Abstract] Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Net Income (Loss) Attributable to Parent Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Stock-based compensation expense Share-based Compensation Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Accrued compensation Increase (Decrease) in Accrued Salaries Medical malpractice and self-insurance reserves, net Increase (Decrease) in Other Operating Liabilities Accrued contingent consideration Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Change In Liability For Current Year Acquisitions Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Change In Liability For Current Year Acquisitions Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Acquisitions of physician practices Payments to Acquire Businesses, Net of Cash Acquired Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from long-term debt Proceeds from Issuance of Long-term Debt Repayments of long-term debt Repayments of Long-term Debt Net proceeds from issuance of common stock Proceeds from Issuance of Common Stock Excess tax benefits from stock-based compensation Excess Tax Benefit from Share-based Compensation, Financing Activities Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Net (decrease) increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents, beginning of period Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents, end of period Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Interest Interest Paid, Net Income taxes Income Taxes Paid, Net Accounting Policies [Abstract] Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Goodwill [Roll Forward] Goodwill [Roll Forward] Goodwill - beginning balance Goodwill Goodwill acquired during 2015 Goodwill, Acquired During Period Adjustment for prior year transactions Goodwill, Translation and Purchase Accounting Adjustments Goodwill - ending balance Commitments and Contingencies Disclosure [Abstract] Number of defendants Loss Contingency, Number of Defendants Schedule of Malpractice Insurance [Table] Schedule of Malpractice Insurance [Table] Insurance Type and Tier Identifier [Axis] Insurance Type and Tier Identifier [Axis] Type and Tier Identifier [Domain] Type and Tier Identifier [Domain] Claims Reserve [Member] Claims Incurred and Reported [Member] Claims Incurred and Reported [Member] IBNR Reserve [Member] Claims Incurred But Not Reported (IBNR) [Member] Claims Incurred But Not Reported (IBNR) [Member] Malpractice Insurance [Line Items] Malpractice Insurance [Line Items] Assets Health Care Organizations [Abstract] Insurance receivable for malpractice claims, current portion Insurance Receivable for Malpractice, Current Insurance receivable for malpractice claims, long-term portion Insurance Receivable for Malpractice, Noncurrent Insurance receivable for malpractice claims, total Insurance Receivable for Malpractice Liabilities Malpractice Loss Contingency, Accrual, Undiscounted [Abstract] Medical malpractice and self-insurance reserves, current portion Malpractice Loss Contingency, Accrual, Undiscounted, Current Medical malpractice and self-insurance reserves, long-term portion Malpractice Loss Contingency, Accrual, Undiscounted, Noncurrent Medical malpractice and self-insurance reserves, total Malpractice Loss Contingency, Accrual, Undiscounted Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Business Combination Accrued Contingent Consideration [Member] Business Combination Accrued Contingent Consideration [Member] Business Combination Accrued Contingent Consideration [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Beginning balance Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Addition through acquisition transactions Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Adjustment for prior year transactions Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Changes In Initial Accounting Estimates Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Changes In Initial Accounting Estimates Change in accrued contingent consideration Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Change In Contingent Consideration Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Change In Contingent Consideration Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Ending balance Income Tax Disclosure [Abstract] Income tax provision Income Tax Expense (Benefit) Effective tax rate Effective Income Tax Rate Reconciliation, Percent Statutory U.S. federal income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] General and Administrative Expenses [Member] General and Administrative Expense [Member] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Total stock-based compensation expense Allocated Share-based Compensation Expense Tax benefit from stock-based compensation expense Employee Service Share-based Compensation, Tax Benefit from Compensation Expense Total stock-based compensation expense, net of tax Allocated Share-based Compensation Expense, Net of Tax Earnings Per Share [Abstract] Earnings Per Share Earnings Per Share [Text Block] Fair Value Inputs, Liabilities, Quantitative Information [Table] Fair Value Inputs, Liabilities, Quantitative Information [Table] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Significant Unobservable Inputs (Level 3) [Member] Fair Value, Inputs, Level 3 [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Fair Value Inputs, Liabilities, Quantitative Information [Line Items] Fair Value Inputs, Liabilities, Quantitative Information [Line Items] Discount rates Fair Value Inputs, Discount Rate Probability of achieving estimated projected earnings Fair Value Inputs, Projected Probability Of Achieving Estimated Projected Earnings Fair Value Inputs, Projected Probability Of Achieving Estimated Projected Earnings Probability of achieving certain other objectives Fair Value Inputs, Projected Probability Of Other Achievements Fair Value Inputs, Projected Probability Of Other Achievements Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Quoted Price In Active Markets for Identical Instruments (Level 1) [Member] Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions) Liabilities, Fair Value Disclosure, Recurring Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Stock Options [Member] Employee Stock Option [Member] Restricted Stock And Performance Shares [Member] Restricted Stock And Performance Shares [Member] Restricted Stock And Performance Shares [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Total Unrecognized Compensation Cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Weighted -average Remaining Recognition Period Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Basic: Earnings Per Share, Basic [Abstract] Net income attributable to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Weighted average number of common shares outstanding Weighted Average Number of Shares Outstanding, Basic Basic net income per share attributable to common stockholders Earnings Per Share, Basic Diluted: Earnings Per Share, Diluted [Abstract] Net income attributable to common stockholders Net Income (Loss) Available to Common Stockholders, Diluted Weighted average number of dilutive common share equivalents from options to purchase common stock Weighted Average Number Diluted Shares Outstanding Adjustment Common shares and common share equivalents Weighted Average Number of Shares Outstanding, Diluted Diluted net income per share Earnings Per Share, Diluted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total number of stock options excluded from diluted shares computation Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Revenue Revenue Recognition, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Medical Malpractice Liability Insurance Malpractice Loss Contingency, Policy [Policy Text Block] New Accounting Principles New Accounting Pronouncements, Policy [Policy Text Block] Restricted Stock [Member] Restricted Stock [Member] Performance Stock Awards [Member] Performance Shares [Member] Vesting [Axis] Vesting [Axis] Vesting [Domain] Vesting [Domain] Granted Prior to 2015 [Member] Share-based Compensation Award, Tranche One [Member] Granted in 2015 [Member] Share-based Compensation Award, Tranche Two [Member] Common shares reserved for issuance under stock-based employee compensation program Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Common stock available for issuance under Equity Plan Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Vesting period, in years Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Debt Disclosure [Abstract] Debt Debt Disclosure [Text Block] Business Combinations [Abstract] Schedule of acquisition of hospitalist practices Schedule of Business Acquisitions, by Acquisition [Table Text Block] Acquired assets, net of assumed liabilities – paid and accrued: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] Goodwill - current year transactions Other intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Fixed assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Total acquired assets - current year Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Goodwill - adjustment for prior year transactions Goodwill, Purchase Accounting Adjustments Total acquired assets, net of assumed liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Cash paid for acquisitions: Payments to Acquire Businesses, Net of Cash Acquired [Abstract] Current year transactions Business Acquisition, Transaction Costs Contingent consideration Total cash paid for acquisitions Payments to Acquire Businesses, Gross Change in accrued contingent consideration Net change in payable for practice acquisitions Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability EX-101.PRE 11 ipcm-20150630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`"*0_D;G?S$WN0$``)T7```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V8RT[#,!!%?Z7*%C6N'=ZBW5"V@`0_8))I8S6.+=M]_3UV"@BJ@EJ@ MTMWDT3N>>Y-QSJ(WSVM+OK?23>N'61V"O6;,ES5IZ7-CJ8W*Q#@M0[QU4V9E M.9-38F(P.&>E:0.UH1]2CVQT\[`@YU1%O=N-D'H/,VEMHTH9E&G9HJVVNO;- M9*)*JDPYUW%)'J(UG40]ZSU*%^ZECBW8JF&=L#GR/.GL?PR]=20K7Q,%W>0^ MK!ORN_PWRKOSF"9RWH2#C-_>7>ZHZ6I\K>R;U=TJ=O'QMV$65;^7P_;"GY(I MG89FV^F7%>G^E\^R]1(7NAD[N51;!HNCC2F=::W?]W=`[T;/N=$1(')1#@.0H0'*<@N0X`\EQ#I+C`B3')4B.*Y`QW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH`A3&^.R6:E((C M-Z."N[_8_`)02P,$%`````@`(I#^1@QUTFF.`0``J18``!H```!X;"]?&?/ODKC;671NJN@^S]^;:ANWP M?Y]5,?9;8T)1N<:&AZYW[;!Z[GQCX_#I2]/;XF)+9SC/E\9/YV2'W<_9L^-I MG_GCB;+9B_6EB_OLK?.74#D7@QE?]#!L,"S?>O>?[;OSN2[<8U>\-JZ-?U28 MKPTRDP[B=!!#@B0=))"@>3IH#@E:I(,6D*!E.F@)"5JE@U:0H'4Z:`T)VJ2# M-I`@RA49C-&;%;T9HSC-&;U;T9HS> MK.C-&+U9T9LQ>K.B-V/T%D5OP>@MBMZ"T5L4O05T5Z)=EF#T%D5OP>@MBMZ" MT5L4O06CMTST#I7U[O0S;R;T6C^BHJ/1R=#'DWT&"O;^*C1`KLUZ`FM M>VG3UK^W2[&51=/I<]#"#"QN#>>MZ/X8JI4W+RZ)`=K9@U9K6+>7+&X`PU&HHC>2'@. M7O07\&].Y/FO6"4)F_#RI.W*F0%M&CEW0*I$+!P2H\NJ2S$BM3:JF9.3,D@D M;N6O7)$J*,V5?^*VBT?0.8JO")2[*W?4.SL?S MQ1?]):SX5'WHT(5V3EWU=N0I^5]89W:A/4>K4*/+=W!&'<0=B-LX+NQ.G(AO MKSC773HR$`\*5JHCY[O5?#=VXU0%G3R(HC]'#TJ?M3E:H2=W1[6&KIQ"U.Z< M<7.WVSAYFG;GC)N/>=-N;Q6M]?81_3?O=/W!??6\!L>?A>$?4$L#!!0````( M`"*0_D;6?\D;/P$``&D#```1````9&]C4')O<',O8V]R92YX;6S-DTU/PS`, MAO\*ZKU+NXD/55T/@#@Q"8DA$+>0>%M8\Z'$4]=_3^9U+0,NO2'U4-=^'[^N MDU*X0E@/3]XZ\*@@7.QU;4(AW#S9(+J"L2`VH'F8Q`H3DROK-<<8^C5S7&SY M&M@TRZZ8!N22(V<'8.IZ8E*54A3"`T?K.[P4/=[M?$TP*1C4H,%@8/DD9TGU M8K;&-J9D@[XJH^.:!UQ8J58*Y&T[E/U.QC'&3?GK[^Z8$R+.DJ]T'U M54W33)H9U<6!<_:V>'RF?Y,J$Y`;`5$55(&M@WERZOPZN[M?/B35-,LOT^PZ MG67+_*;(\OB\'R8[\S<8UMT0_];QR2!M%Q76,'*WI)&T7'HED(0@O'*HK!F% M(\PW,<'"[N,3!(X'=4(Z;%MH&^MEJ.A\#='AYL25K:UOCZD?T=FMJKX`4$L# M!!0````(`"*0_D:97)PC$`8``)PG```3````>&PO=&AE;64O=&AE;64Q+GAM M;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]' M-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D M$4$P&:>O\,`*I4Q>M5II`,,X?+&A`T%116F]?(+3E'S/X% M/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1TDB`@LE]E`6Z2?:C MTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP'`3@4;N>PIWT;+^D M00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG`J-6T_3:W?=TXZ)QJW0>`V^\4^' MPZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@`%AP=M;,T@.67BGZ=90: MV1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9`%#@`WQ-%,4'RO0;:*X,*2TER0 MUL\IM5`:")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CD MGZ>3UTU"SG"\+`GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V& MF&I0'`*D"3&6H8;XM,:L$>`3?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F M<]%L^P>E1M'V5;SOX% M^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:CFED)O816:I^JAS0^ MJ!XR"@7QN1X^Y7IX"C>6QKQ0KH)[`?_1VC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$ MKYI9+2,6D$N!LT$DN/R+RO`JQ`GH9%LE"0AMNZ5/U2I77Y:^Y M*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KTL@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9 M!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE`T%&UL MK"0L1K=@N-?Q+!3@9&`MH`>#KU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2 MX]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\, M$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T M74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT M%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ`$:MB MOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\4 M8JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5`Y3_;U`UH]@TT')$% M7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%`````@`(I#^1G,VX!A,`@`` M>@H```T```!X;"]S='EL97,N>&ULS59;:]LP%/XK0AFCA1';*4UI:QM&(3#8 MRJ!YZ%N1;=D6Z.+)5U!$NEJAO/J],2,U1/186Y7LF%9$CIJ2R\NI(89;79Q*@W\_VYQQ#A,`YY MPQ9,U2`5#5<1O!@@X/;?B0Q'\.GLZY]&J-LOP(V3;Y.)_W1^NXN?V85S"!S' MCRR"P?P2>B\GG?K^?F*SN$,^?R7Y_[AWJ*\,M==XB21!(#YH@1NG;PS`#V[CH_1KB0-K:+L!MG MZH^19)%$T.]^+P^7C.QV,,+J M\)79KQ/NR/S8JCE"P@F28QK;IY4V_[S2WJ>F3E'MUV]4YG6-8:/[;/6>`05) M0Z@BO)>`S&OAWLBF6VUA[#N:,VO'EF-7%4KT0W`KBB;+<(X:JGZ3E5!V,8*C M_=/(#^:#UW*@B.!H_\(9:=BU53"^-N-_4$L#!!0````(`"*0_D8;E8OU?`,` M`&L,```/````>&PO=V]R:V)O;VLN>&ULE9;;.G\E`2RTF`3,,, MO0"=H=`AG?*LV)MFI[(4))D6OIZ5G=`U40)]\DU[K-4>RWOBIP_6W2^LO1>/ MM39^ZF;9*H3U=##PY0IJY5_:-1AZMK2N5H$NW=W`+I=8PKDMFQI,&,CA<#)P MH%5`:_P*US[;T/S_T/S:@:K\"B#4NH/5"DWV]L1/EZCA%IPGL%#K]6=5PRQ[ MU)G0RH>+"@-4LVQ$E_8!>C=+\7"<#2)LF^JU$Z6MH(/=K-!_VSS( M1`5+U>AP0Y/=OG>6Y7(DY:1CQ&&W"`^>`^,-H.JMU&Q4? MM$'T!O_G#LTQ8-D;&-3B:ZS$+)L,"?@#/2Y08_@YR]IS#3&3P5^IM,O_="9, MNSC;$@ME*G%A`E'$I>F*1TL3YT"#+ZOVQ6Z*=.(NJ[Q;*@XZ(S&LQHK6HA*G M2BM3@FC3\0PB&40^"R*.KA4#%0Q4_`,T#W2(27IAEY1=:1EHQ$"C9X'.E%\Q MT)B!QKN@4^6Q#;MVX`G1+F^[ZG.\,\A`$P::)$"-1P/>BW?E]X;*W7Z2+/P5 M"W^U&_Y>H1.W2C<@KD#YQK4)L?C7+/[U;OPY+/CH-VSTF]W1<;%K$#?J$?@< M\R&7:;@;-P^VO#^F-:-5/[,U;2E^Q\>>D`DC+Y0S]$5Z<0V.)%(.>#0W,4^J M6-<8NF+'*I$(@6A@2NRGPDW,$RH>+'P^XBCN8IZ0\3!JS%'4+.?=IL8!S%QD8_$)%?W@.(KK+1-Z[T5]I9_HLI<@]UO^O]_;Q>(H[K=,^!WW3G%T M#D&A[FO$Q98)L?M?1HK`?98)G_=^&ETB_-?*G2Z>L3EOJLY1W.DBX?1!5,&= M+KC31<+I0ZBFKCFJUSPDG#Z(*OB677"GBX33J6TD4;Z""UTDA#[X.Q)'',6% M+B:;5O"I^Z,&F#[8*O;&OGT--9=E;)CIT/T91^.X.\;K*VJB9UGL=*FI;;0^ MHWM?S">KVGZP(V];Y+>_`5!+`P04````"``BD/Y&+A*67D`"``".!P``&``` M`'AL+W=O]%>$T.BLR(62-S^^P(:UQ7<&P5\W_,<$#AYS\6;K"A5P3MK6KD+ M*Z6Z9P!D65%&Y!/O:*N_7+A@1.FNN`+9"4K.UL0:@"%,`2-U&Q:Y'7L116.,B'\'VO!^%Z+P,?!:7RME!D"1@\EWKAEM9TE[-V8)(__*G/JM+9PC`XTPNY->J5]S_H.(?$!"QY(^TS*&]2([URI1FT"V6_Z9E)/7HO8`[N)LRH.`P*/%.@20%T[`F`?8`#=NSX M,^#H*B(_(/+.(++V:&:/_?;8:X^M/9[9D\4"N(K4#TB\@,2Q9PO`H$BLHAU6 M.$8PSE;6.?5B4@>S66!FH!LA79XJZ/QT#% M89>R75)<#88K%/\I1I$;`2TNBE'SZ:!D,4HPS!8L,+O^&!576Q9D4/);:ZO0 M;'0J/7MLK\\/>9%WY$I_$7&M6QFX#``"V$@``&``` M`'AL+W=OM-<9,`/:A+!)9MB^?9W`T'#.\3U:7M?O2'&(?% MKZ8^]<_+PS"C4=^]:M5^W;4!]/\5NWZ-^:INK^W<2ZO3POY?+CP/?CZV$8#Q3K57&O MVQV;>.J/[6G1Q?WS\C?Y5*HI,B7^/L9+/]M>C/`O;?MCW/ES][P4(T.LXW88 M3U&EC_=8QKH>SY1:_GD[Z?]MCH7S[8^S?YVZF_!?JCZ6;?W/<3<<$JU8+G9Q M7[W5P_?V\D>\]<&,)]RV=3_]7VS?^J%M/DJ6BZ;Z=?T\GJ;/R_4;+VYE?`'< M"N!>(/6G!>I6H%!!<26;^O5[-53K5==>%MWU8IRK\9K+)Y5&;CL>G`9J^B[U MK$]'W]<`J^)]/,\MLKE&8!YY3)1,0MTC16K_#@$L!$SU:EZO^7K%UJNI7L_K M#>K$->*FR&F*2&DL2I5,2@>9Z8MF631EL8CE&C'S5D#:$!`,%P,1@*T-CR-9VD\H5$"T7C2C`\6A4HFY(+G20)+$B@)&OU-((UHXW70 MB(6)"1]\AF94+67BXDIX4*&AQ>II";5V*226M+0Z?!YZ)&%5ZFD M+M78I9):4J:Y:?!#ALD%KVQF<("7*5"9:BQ3H)H,(OTA'B;F'V*//+Q.@>I4 M8YT"]61:D)&YSL4>3@-0I4HQIK%+B%)@;Y-/-(P@L4J$`-%BA0-TKO)7GB ML3GI=>81`[Q&@6K48(T"U2.(]+N!:(+1K;?"9#RA>(\JZE&#/:JH()4/RN-; MA\M9%W)73?$F5=2D!IOTEIG_MF47@ER.6P@6LS<,Y^HU_E5UK\=3OWAIAZ%M MIE<*^[8=8CJG^)+Z=XC5[KY3Q_TP;KJTW5U?JUQWAO;\\9;H_JIJ_1]02P,$ M%`````@`(I#^1I/WF@86`@``"`<``!@```!X;"]W;W)K,<:;:Z;0'G=G9@_:8&!*=1;%`XO;N"VBL M(K,;#^3O?3^>#Q2R@;(W7F,LG/>6=/SHUD+T!P!X5>,6\1WM<2='+I2U2,@F MNP+>,XS.VM02X$,8@Q8UG9MGNN^%Y1F]"=)T^(4Y_-:VB/TM,*'#T?7<1\=K MPG2M]4X\?YZ$*% M@`FNA(J`9''')29$!9(3_YEB_I]2&9?U1_1O.EM)?T(,3HX;-R+'JDM]PZ!7+E*=>J%TF,R,RY[[WD49N"N MXDR28I3X"XF_5I0613!+@)Q_AO"M$+[V!TN(R.X/K/Y`^\.E/S:2&"5[+>FT M!.X@](Q$/E.M6$(K2[AE20R641(M9O$BJ!\#YPGABBBR$D5;HKU!%&TF,E$^ M4JP88BM#O&5(#8;XJ1WZ3+5B2:PLR88E-K(MDDVVT[J;R_*$<$6TMQ+MMT1& MWL5^^RDDH1>FT/BX2IO0#WT?IG:BU$J4;HF,G[Y(GR6R":U$8'%H]>B*?R)V M;3KNG*B0YY\^I2Z4"BR#PIV,5\MK:6X0?!&JFL@Z&T_JL2%H_[AWYLLO_P=0 M2P,$%`````@`(I#^1B]7%?[;`P``!1$``!@```!X;"]W;W)KF.3V'8;TY^#RM MG\J3+]I?=F65ITW[6NW#^E3Y=-L;Y5DHHLB$>7HL9HMYW_:E6LS+7&7BWVQYS7]3'L@@JOWN9O<+S&ER' M],2_1W^I1\]!Y_Q;67[O7O[>OLRBS@>?^4W3=9&V7^\^\5G6]=2._&/H]&/, MSG#\?.O]SUYNZ_Y;6ONDS+X=M\VA]3::!5N_2\]9\[6\_.4'#;KK<%-F=?\9 M;,YU4^8WDUF0IS^OW\>B_[YE9>@ND[W*>U6%3SK=FXV76,_%?UO;>SJMO5]8>0\ M?._Z&9#E%1%C1#TB*XK`G0C;\>].",Z)I2#FXG&`A!)&(Q]^VW)1L MK&1O+\?VAK=7K+WJ[=78/D:QOB)QCQ370%H5"8/"P6"Q$,:BD%!,&A4[-.B: MP91R3O':-*M-T]A8WMZP]H;&QJ'87!$]%BVUB9&:A,&$-A9A*XH)XZQ"*WO- M8%HX$_':8E9;3+3%$=(6DV$D2,#2*"6LE'@S4LH`1"B::TII[=3$MK6L+DMU M`=)EZ61`C!Q.*/2'<7A[4TA;C1;\FND)HGAB(3I6E*.B4!Y9.BI*&:0\82!I MT#Y>44BX&$%K!C)R8J*ZHLAE^8BJ(FD^HAX;9P1:.`G':64123K;B)!`)L@7P% M0=5IK$Z0@2*LC"*`5?T263.(F%##UU&05(W!:B3=RFVRPX(82EJR$AE*&S)1 M#-6N_PEE?(4'6N)Q?5H.S.,J!,!)D<-B(&F1P812FLP9Q:2T:DH=7^-!4W46 MJ],T3TM\7DP8RFA+=ABEG'!$&J6@K=!R0AI__`!Z_HCQ^6-@QN!)3J8BO]D#+/4X?RX%Y]$:1LLA1^%2P8BFKL3)*P1,XI"P$Z`:5]U-_[^3OG1_6)^2O?^G[3: M'XLZ>"N;]F;:WQ]W9=GXUOEVSF?!P:?;^TOF=TWW&+?/U?66?GUIRM/M3X?[ M/Q^+_P%02P,$%`````@`(I#^1N:YI9GR`P``RA$``!@```!X;"]W;W)KL%H<22Y/7G[:&NWNJIXL1;_1?Y5%#^16M_KYF=[]KZ+?I5%U;ZLSEUW?8[C M=G_V9=Y^JZ^^ZO\YUDV9=_UE,ROU2KS7J\][W9K.M; M5UPJ_[V)VEM9YLU_6U_4]Y<5K#YN_+BI2,BK\O_MXNSJ/!_%M=_QPN_CR\K-3@P1=^WPU-Y/WAW>]\40PM]3W_ M.S?ZV><0N#S_:/WW,=W>_EO>^EU=_',Y=.?>K5I%!W_,;T7WH[[_X><Q^]#.[-D M.TEP(8&'(NX;?_2`4@];9.'XM8,=5U@C]Z#%'/08KY.9^+( M/-IQS9-+0L M3:D;KM*)"M5&!,TK('>34C?(!T%K2X=*D@$X%_`C8PDT?VXH5V;-LB,#K#A< M!$X''F&0&0<<%V@-HQ_)E`F[+J!!DH6QD_B'GGZ/O!A3`AI(90?=%]M60#$#D`'04@,C9A@;I:D10 M:9MD`36^1P0Z"S01"9T%Q`F7_(^0>*`A`YV0!3^D[;";*GU`9> M#RCS#_FZ$11=.")?%/;D3^B"39`!AE9<*-,4.4U!49PBQR0D#NC+7)#UCWQH MX84R3)'#%!2E*7),`AA+EUZ"#"VZ4(5DFJ)C[`(5VC;)^--\,0F*KM\T7R<: M-N2"R+K`OD?+)-659LI1-UR5)8P6\6*+7/KF-'XZ:*-]?:NZ M83>ZN/OX//&*PQ:;W-_"\V[ZR/#9S&9]S4_^K[PY7:HV>JN[?@,_;K./==WY MWJ3ZUA?K[//#XZ+PQVXX3?OS9OK4,%UT]?7CR\GC\\WF?U!+`P04````"``B MD/Y&,HM\_:$!``"Q`P``&````'AL+W=OQVFM7H`9 MYKUY,PS9@.;5-@".O&O5VB-MG.L.C-FB`2WL#7;0^IL*C1;.FZ9FMC,@R@C2 MBO$DN65:R);F6?0]F3S#WBG9PI,AMM=:F#\G4#@<:4JOCF=9-RXX6)ZQ&5=* M#:V5V!(#U9'>I8?3-D3$@!<)@UV<2=!^1GP-QL_R2),@`104+C`(OUW@'I0* M1#[QV\3YF3(`E^;$))"97HE7O&X1&F$G:!L$!E MXTJ*WCK45P@E6KR/NVSC/HPWN_T$6P?P"8/X42>&1R(&5O; MB?""Z8'[1A3!&>N.=UZH]=Y+GB;[C%T"T11S&F/X,F:.8)Y]3L'74ISX/W"^ M#M^L*MQ$^.:+PN_K!-M5@FTDV/ZWQ)68-/DK"5OT5(.IX^A84F#?QD%=>.?I MO./Q33[#\ZP3-?P2II:M)6=T_F5C_RM$!UY*$1E(I$(?&/A?,M901NSS?V3ZG:H/XB'#RB^BX; MWP>Q&24-M&)4_AFGS["4G4=]@U"BQ>N\2Y/V:;XIB@6V#^`+ M@*^`#UD2/B=*,C\*+ZK2XD3LW-I!Q!?,CSPTHH[.5'>Z"T)=\%ZK/,]+=HU$ M2\QYCN';F#6"!?8U!=]+<>9_P?D^O-A56"1X\9O"?Q`<=@D.B>#PWQ+W8HH_ MDK!-3S78+HV.(S6.)@WJQKM.YP-/;_(67I6#Z."KL)TTCES0AY=-_6\1/00I MV=T])7WX/ZNAH/7Q^#Z<[3Q2L^%QN'V0]9=6OP!02P,$%`````@`(I#^1B48 MYK:@`0``L0,``!@```!X;"]W;W)KPUW%;JQ=@AGEOW@Q# M,:)YLQV`(Q]*:GNDG7/]@3%;=:"XO<$>M+]IT"CNO&E:9GL#O(X@)5F6)+=, M<:%I643?BRD+')P4&EX,L8-2W/P^@<3Q2%-Z=;R*MG/!P4/X2M>N\V(22&AH^2/>*XS/,)>P#8872QI54@W6H MKA!*%/^8=J'C/DXWNWR&;0.R&9`M@+LD"I\219F/W/&R,#@2,[6VY^$%TT/F M&U$%9ZP[WGFAUGLO99KF!;L$HCGF-,5DZY@E@GGV)46VE>*4_0//MN&[386[ M"-_]H7"_39!O$N21(/]OB5LQMW\E8:N>*C!M'!U+*AQT'-25=YG.^RR^R5=X M6?2\A1_[G:`!``"Q`P``&````'AL+W=O*D4YM&?6'MLH MP+B`U^G?%[#7<5NK%V"&>6_>#$,QHGUU'8`G;UH9=Z*=]_V1,5=UH(6[PQY, MN&G0:N&#:5OF>@NB3B"M&,^R#TP+:6A9)-^S+0LL?1?$9I34 MT(A!^1<YT%X2ZX+V6>7XHV#42S3'G*8:O M8Y8(%MB7%'PKQ9G_`^?;\-VFPEV"[_Y0^+!-L-\DV">"_7]+W(KY^%<2MNJI M!MNFT7&DPL&D05UYE^E\Y.E-WL/+HAD M"_]G,10T/AX/X6RGD9H,C_WM@RR_M/P-4$L#!!0````(`"*0_D;Z.ZVFG@$` M`+$#```9````>&PO=V]R:W-H965TI-7*:RF;*DH/E:(A@9<$67"TU&"?1$`O-D=[O M#J=]C$@!WR6,;G4F4?L9\34:7^LCS:($4%#YR"#"=H$'4"H2A<0_9\[WE!&X M/E_9'U.U0?U9.'A`]4/6O@MB,TIJ:,2@_`N.3S"7`S@"^`SUD2/B5*,K$+\K"XDCLU-I>Q!?<'7AH1!6= MJ>YT%X2ZX+V4.YX5[!*)YIC3%,/7,4L$"^Q+"KZ5XL3_@O-M>+ZI,$_P_(/" M?^3?;Q+L$\'^OR5NQ?RIDJUZJL&V:70PUW%;JQ=@AGEOW@Q#,:)]=1V`)^]:&7>BG??]D3%7=:"%N\,>3+AIT&KA M@VE;YGH+HDX@K1C/LD],"VEH623?LRT+'+R2!IXM<8/6POXZ@\+Q1'?TYGB1 M;>>C@Y4%6W"UU&"<1$,L-"?ZL#N>\QB1`GY(&-WJ3*+V"^)K-+[5)YI%":"@ M\I%!A.T*CZ!4)`J)WV;.CY01N#[?V+^D:H/ZBW#PB.JGK'T7Q&:4U-"(0?D7 M'+_"7,(A$E:H7%I)-3B/^@:A1(OW:9-TQ%?<'?DH1%5=*:ZTUT0ZH+W6N[XOF#72#3'G*<8OHY9(EA@ M7U+PK11G_@^<;\/WFPKW";[_0V&^39!O$N2)(/]OB5LQA[^2L%5/-=@VC8XC M%0XF#>K*NTSG`T]O\A%>%KUHX;NPK32.7-"'ETW];Q`]!"G9W8&2+OR?Q5#0 M^'B\#V<[C=1D>.QO'V3YI>5O4$L#!!0````(`"*0_D9DMN#:GP$``+$#```9 M````>&PO=V]R:W-H965TD%T6. MI:95U7U8J>I#^TSLL8T*C`LX[O[]`G9<[ZZU+\`,<\Z<&89\0/OA6@!/OK0R M[D!;[[L]8ZYL00MWA1V8<%.CU<('TS;,=19$E4!:,9YE-TP+:6B1)]^++7+L MO9(&7BQQO=;"_CJ"PN%`-_3B>)5-ZZ.#%3F;<9748)Q$0RS4!WJ_V1]W,2(% MO$D8W.),HO83XD06!V+'UG8BON!FST,CRNA,=:>[(-0% M[[G8$N73?VO$3T$*=G5-25M^#^SH:#V\7@;SG8&UL?5/;;MP@$/T5Q`<$+][M9>6UE$U4M0^5HCRTSZP]ME&`<0"OT[\O8*]C MI59?@!GFG#DS#,6(]L5U`)Z\:67]T?&7-6!%NX.>S#AID&KA0^F;9GK M+8@Z@;1B/,L^,2VDH661?$^V+'#P2AIXLL0-6@O[YPP*QQ/=T9OC6;:=CPY6 M%FS!U5*#<1(-L="-['B!3P2\+H5F<2M5\07Z+QHS[1+$H`!96/#")L M5W@`I2)12/PZ<[ZGC,#U^<;^+54;U%^$@P=4OV7MNR`VHZ2&1@S*/^/X'>82 M#I&P0N722JK!>=0W""5:O$V[-&D?IYL#GV';`#X#^`+XDB7A4Z(D\U%X4186 M1V*GUO8BON#NR$,CJNA,=:>[(-0%[[7<\:\%NT:B.>8\Q?!US!+!`ON2@F^E M./-_X'P;GF\JS!,\7V?/LVV"_2;!/A'L_UOB1DS^L4BVZJD&VZ;1<:3"P:1! M77F7Z;Q/C\C>P\NB%RW\%+:5QI$+^O"RJ?\-HH<@);L[4-*%_[,8"AH?CY_# MV4XC-1D>^]L'67YI^1=02P,$%`````@`(I#^1E&UL=53;;IPP$/T5BP\(UV67%8N4352U M#Y6B/+3/7A@NBHV);9;T[VN;74+H]`7;XW.9L?'DDY!OJ@70Y(.S7IV\5NOA MZ/NJ;(%3]2`&Z,U.+22GVBQEXZM!`JT`+&K)`Q?K]I?EI:XGI^5__FJC79 M7ZB")\%^=Y5N3;*!1RJHZ_& M:=Y)LQL-)T0W0K00#H%+?#9R:3Y338M.T>9+A`@@HD M3B#Y4F*\*1'#)+C)#C79(0*[C0F&27&3%#5)$8']Q@3#''"3/6JR1P2RC0F" M20+PVPOWE\])@ZR<3U#D5*,O>M0J^C2 MEAXC]Q@_X44^T`9^4METO2(7H\F\T&*X=\:E/1=_`5!+`P04````"``BD/Y&W#<$=*L!```6!```&0```'AL M+W=OP*)XS';9-?"JV@[%PJT+.C"JX4";05J8J`Y9D^;PVD?$!'P2\!H5W,2 MLI\1W\+B1WW,\A`!)%0N*'`_7.`9I`Q"WOC/K/EA&8CK^57]6^S6IS]S"\\H M?XO:=3YLGI$:&CY(]XKC=YA;B`DKE#;^DFJP#M65DA'%WZ=1Z#B.T\YC/M/2 M!#83V`V!3D8QYE?N>%D8'(F9/FW/PPEN#LQ_B"H48]]QSP>UOGHI-[M]02]! M:,:<)@Q;8Q8$]>J+!4M9G-A_=):F;Y,)MY&^7;OG7]("NZ3`+@KL/K5X?]-B M"O.0-MDG3?8)@<<;DQ3FMA.Z.C@%IHWWTY(*!QU?PZJZ/($G%@_^`UX6/6_A M)S>MT):&PO=V]R:W-H965T0/"#;K[67EM91-524/E:(\M,^L/;91@'$! MK]._+V"OXR3."S##G#-GAJ$8T3S;#L"1%R6U/2:=<_V!4EMUH+B]P1ZTOVG0 M*.Z\:5IJ>P.\CB`E*4O3+U1QH9.RB+Y'4Q8X."DT/!IB!Z6X^7<"B>,QR9*K MXTFTG0L.6A9TP=5"@;8"-3'0')/;['#*0T0,^"U@M*LS"=K/B,_!>*B/21HD M@(3*!0;NMPO<@92!R"?^.W.^I@S`]?G*_C-6Z]6?N84[E']$[3HO-DU(#0T? MI'O"\1[F$O:!L$)IXTJJP3I45TA"%'^9=J'C/DXW^?<9M@U@,X`M@&]I%#XE MBC)_<,?+PN!(S-3:GH<7S`[,-Z(*SEAWO/-"K?=>RFR?%O02B.:8TQ3#UC%+ M!/7L2PJVE>+$/L#9-GRWJ7`7X;MU]NP3@GR3((\$^9L2LW%GTO(5?W+1"6W)&YU\V]K]!=."EI#?[A'3^ M_RR&A,:%XU=_-M-(38;#_OI!EE]:_@=02P,$%`````@`(I#^1B.<60ZK`0`` M%@0``!D```!X;"]W;W)K&UL=53=;ML@%'X5Y`^0*N2KKR&2U"&HR(:VF/RF!U. MA4<$P$\.D]G,B<]^1GSSB^_-,4E]!!!06Z_`W'"!)Q#""SGC]T7ST](3M_.K M^G/HUJ4_,P-/*'[QQO8N;)J0!EHV"ON*TS=86@@):Q0F_))Z-!;EE9(0R3[F MD:LP3O/.EW2AQ0GY0LAO"'0V"C&_,LNJ4N-$]/QI!^9/,#OD[D/4OACZ#GLN MJ''52Y45NY)>O-"".`V;ZOH$ M'O-P\)_PJAQ8!S^8[K@RY(S679]PR"VB!1O=(UX6`UOKI@YOK^=[. M"XO#]16N?P75'U!+`P04````"``BD/Y&J'A5(J0!``"Q`P``&0```'AL+W=O M',^R:7UTL")G,ZZ2&HR3:(B%^D0?-L?S+D:D@)\2!K_5B691`B@H?6008;O"(R@5B4+BWQ/G6\H(7)YO[%]3M4']13AX1/5+ M5KX-8C-**JA%K_PS#M]@*F$?"4M4+JVD[)U'?8-0HL7KN$N3]F&\V1\FV#J` M3P`^`PY9$CXF2C*_""^*W.)`[-C:3L07W!QY:$09G:GN=!>$NN"]%IO](6?7 M2#3%G,<8OHR9(UA@GU/PM11G_@^JK!-FET'"FQ-VE0%]YY.A]X>I.W\"+O1`,_A&VD<>2"/KQL MZG^-Z"%(R>[VE+3A_\R&@MK'XZ=PMN-(C8;'[O9!YE]:_`502P,$%`````@` M(I#^1O'1=-;&`0``X`0``!D```!X;"]W;W)K&UL M;53=CIP@%'X5X@,LRCBZG3@F.]LT[463S5ZTUXP>E2R(!1RW;U]`QW4M-P*' M[^<%]"@$57\OP.5TCI+H'GAE;6=<`)<%7GDU M$]!K)GNDH#E'3\GIDCN$!_QB,.G-'+GE(V[G=_5OOEJ;_95J>);\-ZM-9Y.-(U1#0T=N7N7T'982CDZP MDES[+ZI&;:2X4R(DZ/L\LMZ/T[SS&"^T,($L!+(CX-G(I_F5&EH62DY(S4<[ M4/<'DQ.Q!U&YH*_;[]E$M8W>RB1+"GQS0@OF,F/(%K,BL%5?+4C(XD+^HY,P M_1#,\.#IAZT[2<,":5`@]0+IIQ+)KL00YA`V.09-C@&!=&<2PAS#)EG0)`L( M9#N3$"8/F^1!DSP@\+@S"6&^[$SPY@H*4*WO-(TJ.?:^KS?1M9F?B+_"'_"R M&&@+/ZEJ6:_151K;"/ZZ-E(:L*G$#_94._OO&EEW)EVWO+;$#5H+^^<""LG=\2+;SD<'*PNVX&JIP3B)AEAHSO0Q/UWV,2(%_)0PNM691.U7Q-=H?*_/ M-(L20$'E(X,(VPV>0*E(%!+_GCG?4T;@^GQG_YJJ#>JOPL$3JE^R]ET0FU%2 M0R,&Y5]P_`9S"8=(6*%R:275X#SJ.X02+=ZF79JTC]/-(9]AVP`^`_@"^)PE MX5.B)/.+\*(L+([$3JWM17S!_,1#(ZKH3'6GNR#4!>^MS(]9P6Z1:(ZY3#%\ M';-$L,"^I.!;*2[\/SC?AN\V%>X2?+?.SH_;!/M-@GTBV/]38OZAQ*V8CRK9 MJJ<:;)M&QY$*!Y,&=>5=IO.1IS=Y#R^+7K3P0]A6&D>NZ,/+IOXWB!Z"E.SA M0$D7_L]B*&A\/![#V4XC-1D>^_L'67YI^1=02P,$%`````@`(I#^1H95';7> M`0``ZP0``!D```!X;"]W;W)K&UL;51+-#KZG'*LR2:5V#UN5RF'WS&C[J(`8P#'[[Q?0,<;A(M!\CVZDR2?&WT4+ M()U/2GIQX5"? MW,?#\9QHA`'\Z6`2F[FC<[\P]JX7OZJ3Z^L4@$`IM0)6PQ6>@!`MI(P_%LTO M2TWB7QCTT]82HBT8,F(,%^G'(5D M]$9Q'8H_Y['KS3C-.ZF_T.P$M!#02D!SXK.12?,92USDG$T.GX]VP/H/'HY( M'42I@Z9NLZ<2%2IZ+0Y)D'M7+;1@SC,&;3$KPE/JJP6R69S1/3T)[0*!-T^D=4GLO@D.Y\9$VU]LB3- M[#:QU2:VV*0[F_C.Y@=*`[M+8G5)+"[9SB6Y/[0H#;/]W_4VMY$";TS3":=D M8V]:?!-=^_H1F=O\!2_R`3?P&_.FZX5S85+UA+FY-6,25#;^@RJW52_/NB!0 M2SU-U)S/S3@O)!MN3\OZOA7_`5!+`P04````"``BD/Y&_T^\.;`"```@"P`` M&0```'AL+W=OOHJ^! MV80;62GW##8GI65]#0F#FK]W[[)Q[TOW)8_[,#R`]`'D%@#)/P-H'T"]@*@C M55TDLQ)FFX/0HE?":9B M:8*S)"A+,F*!W-MFU6G88!M"BJ+P8!`5L&P"AJ$P#(&A'@P;;4,9)>#!(*H$ M:([#I"A,BESS1#49FB`;54.],UME(TP@>>Z?+**B<5;@+#G*DB,GRSR8?+1- M4@#Q81!51N@$3('"%`A,ZL$4HVU2$D/NP2"JF,+$-5N'Q$PE1G"RB103O@2/ M_RN`FPJ0C_^67L,^<`54-FD+@'L4C$UJ_,?THH^<`9--6P/@1@684_E_#8Q- M"','3#9M#X";%6!N-94"MQCX#X\!W&3@`9>!L8&P-///!!$!FV#!308><1D8 M&PA)C9_Y.(B,I>D4$&XT\(C3]*+L#B@M1N>#R8;M1P<4#7J9(]^+[[S=EXT* M7J4V;9%K7G92:F%2QD^FNH-I5V^32NRT'69FW'8-7#?1\GCM1V]-\?(/4$L# M!!0````(`"*0_D:5^'YIQ@$``/@$```9````>&PO=V]R:W-H965T\SK*06@J!5+0[Z-/R:XIG<(+?E"8]-4<.>\'*5_=XENWCV)G M`1BTQA&('<[0`&,.9`O_6IA_2[K$Z_F%_L5W:]T?B(9&LI^T,X,U&T>H@YZ< MF'F1TU=86B@YI$*/T[SSF.\I(43TB4A71,V'^JS M19^M^JWO<_;EN_I,#*DK)2>DYB\Q$O?!DUUFSZUU07],?L_VI6WT7">/VPJ? M'6C1/,V:]%JSC6\US<<:;#VL1M*@D=0#LAM`$@9D04#F`?D-(+WK9-847B.\ M)K_KX[TBR<(N\J"+/.`BNZL1TN3A(D6P2!$`%&'`)@C8_/]AET%`^>_#;LKW M1WE_(_#5-1W)$;X3=:1"HX,T]L+[>]E+:<#BX@=+&NPSM"X8],9-2SM7\S]S M7A@Y7MZ9];&K_P!02P,$%`````@`(I#^1@`\.3ZD`@``;`D``!D```!X;"]W M;W)K&UL=99-I1GD5GOAQDWW)MAOTQ4>=>\+US:IN$()0E+:^[>%VYN9=^7'V(JFL9$,^>\8](MI M'>?OM^C?7;IF^6]ZB MM&QO+G'4\L_A67?N>1V^%&AT@QW(Z$`FAXD#.]#1@7XY,)?IL#*7US>N^;KJ MY37JA\TX<[OG^(F:RNWLI"N4^V8R4V;V8XW+K$H^;*#19C/8D+G-9)&8Z!." M0(@-"=S)/6`;6F0I3*!@$M3YT[LDWDI=/VN)C-3A>( M9V(/06]^8R\6[G#\"K.NSOPH?O'^6'I/:'+'N(#Q(J859)7HTE3B9J\\T M:,1!V]?>95F(JV9=#\\R4E?.J?Q]`B;&8XSC>^"EN[3:!E!9H#FO[CCTJA-])*$Y MQE_PX82)A3C$SPY&M9A'MOBS$*]V\;T^QHFM`1A4VE)0,]S@$1BS3$;Y;2+] MJVD3E_,[^Y.S:\H_4P6/@OWJ:MV::I,XJJ&A5Z9?Q/@-)@^9):P$4^X;55>E M!;^GQ!&G[W[L>C>.?F>73&GA!#(ED#F!^,*]D"OS*]6T+*08(^G/=J#V%^(# M,0=1V:#S[?9,HZ#1)L5QCUF&QA M-`E+Y$&)/""Q#1/L@@2[]2;W08+]"I/[M2;MFPO=ZR0@\LEEP)\\#;S>*`Y? M?$Q66)U`_[NY:/&D!WJ!'U1>NEY%9Z%-=W!ON!%"@Z%,'LS!M:8)SPL&C;;3 MW,RE;TM^H<5P[[)SJR__`%!+`P04````"``BD/Y&1V,,^#0"``!?!P``&0`` M`'AL+W=O64\Z]>7`>(NEZO)C('I.\-X$M30(`4B"%C>=7Q9F[)F7 M!3M)VG3DF7OBU+:8_]T0RH:U#_W+P$MSK*4>",HBN,;MFY9THF&=Q\EA[7^# MJPH:B5'\;L@@9FU/PV\9>]6=G_NU#S0#H60GM056KS.I"*7:265^FTP_?OB_MV4J_"W6)"*T3_-7M:*%OC>GASPB MZS6'*Z1F;J<'S429;ZHRH4;/90BS(CAKHTFS&37A3`-S<*NI/M<$BN$*$CI! M0F.`;D!RMP%R&B!C$,T-0IMRU*1&TQG-0Y2"Q)TF*2W3\\\,YU`QU`D0T$E[LW@B"U@;Z2C4#!["KL M\9'\POS8=,+;,JEN57/W'1B31%F"1U5=K?YVUPXE!ZF;J6KS\?X?.Y+UE]_9 M]9]:_@-02P,$%`````@`(I#^1N\39+#W`0``4@8``!D```!X;"]W;W)K&ULC57-CILP$'X5Q`.LP0GY$T%*MJK:0Z75'MJS`Q-` M:V-JF[!]^]J&L&QV(N6"[?'W,V/PD/92O>D*P`3O@C=Z'U;&M#M"=%Z!8/I) MMM#8G;-4@AF[5"71K0)6>)+@A$;1B@A6-V&6^MB+RE+9&5XW\*("W0G!U+\C M<-GOPSB\!E[KLC(N0+*43+RB%M#H6C:!@O,^/,2[8TP=Q"-^U]#KV3QPR9^D M?'.+G\4^C%P.P"$W3H+9X0+/P+E3LLY_1]$/3T>P#-9QMR]PKC'?4'D3N@KYNOV<3U39ZR2A-4G)Q M0B/F.&#H#!-/"&+5)PN*61SI%SK%Z0LTPX6G+SYEN,(%EJC`T@LL/PFL;TK$ M,!O<)$%-$D1@BPNL4('5XV6N48'UUPP6T4V9&.;.N]R@)AM$@-Z88)@%;K)% M3;:(P!(7<#<.^ZJCQT\SOG,QX@?.$P4E=WS0VW&(Z0-'BH)NZR&S.R]`E;ZU MZ2"77>,[Z2PZM<^#[Y[D`YZE+2OA%U-EW>C@)(WM/+X_G*4T8'.)GNRG7MD& M/RTXG(V;KNU<#2UO6!C97COX]!O)_@-02P,$%`````@`(I#^1NC0LZ)R`@`` M,@H``!D```!X;"]W;W)K&ULE9;-CILP%(5?!?$` M`S9_840B-5-5[:+2:!;MVDF<@`8PQ4Z8OGUMD]`,'*(DBV";>\_G"S[862?: M=YESKIR/JJSETLV5:IX]3VYS7C'Y)!I>ZSM[T59,Z6Y[\&33='=^S8ZG>1/>= MGVN(C.!6E-+^.]NC5**ZI+A.Q3[Z:U';:]??2>)S&DZ@YP0Z)!";X/4@.\VO M3+%5UHK.:?MGVS#S"LDSU0]B:P9MW?:>GJC4HZ<5#9+,.QFA<\RZCZ%7,23U MAQA/ZP\0"B'4"H2?(`LL$$"!P`H$GP12+!!"@7`Z@]`?E=G')#:F[LNDD6]_ M&!5!5`109(3J8Z(KU&U2#$DQ(-$1*9Z04O\6*8&D!)""$2F9/+X@3&Z0%I"T M`*1P1$(Q$8:D$)("@7@$03$)AAC;(VOY0&)FV9,9=Y+[%S[!WB/`?&$Z=C@( MBF;>&\$6)0&0(#,2V*0D?*!:;#Z"W#>I%@1%=(:#K4>`]Z)@1@)[BB0/5(O- M0I`3)M6"H"B%:!/KG=U'&C8@?]D[:&HI;,12I\L[/Z_%T)QK>D_ M:7?D^@`W=$J^5Z:9Z';;'VGZCA+-Y80V'!-7_P!02P,$%`````@`(I#^1HDA M-+PQ`@``$0<``!D```!X;"]W;W)K&ULC55=DYL@ M%/TKCC]@413S,<:9S4>G?>C,SCZTS\20Z*R(!1*W_[Z`QAADT[P$N)QSN.=B M+FG+^()ZUJL?(+*9LE`"(O",7BA36D5CM'QBF6:LE/0#2"]/A=0!D*5@X!U* M2FI1LMKCY+CR7\/E+M$(`_A5DE:,YI[.?<_8AU[\.*S\0*=`*I)+K8#5<"$; M4E5:2!W\I]>\':F)X_E5_9MQJ[+?8T$VK/I='F2AD@U\[T".^%S)=]9^)[T% MI`5S5@GSZ^5G(1F]4GR/XL]N+&LSMMU./.]I;@+L"7`@#.>X"5%/B&Z$^"$A M[@GQLR>@GH"L$T#GW51NBR7.4LY:CW>WW6#]485+I.XFUT%S%69/U4ZHZ"6# M:):"BQ;J,>L.`T>8)+Z';*>0<$``E<"0!71EL883.KP_8#-%),C*X;\BNX9&4AM("BRR[V9@A(T3ZQZ3$$+ MN`BMDDQ!(5PDD=L4P(``"8*```9```` M>&PO=V]R:W-H965TV$[=_7-H3<#A)Y"=C,F3GC9,)).RX^9<&8S`M64_G&6];H)PYEXZ,\%LIL>%GJC77[LF:-+'GC"'98N6NT MW&)B(!;QNV2=O+EW3/,[SC_-XN=^Y?JF!U:Q7!D*JB]GMF5599BT\M^!]*II M"F_O+^S?K5W=_HY*MN75GW*O"MVM[SI[=J"G2GWP[@<;/(2&,.>5M)].?I** MUY<2UZGI5W\M&WOM^B<+?RB#"_!0@,>"40K)+0"*R80.G"@$1"J>^/=`<`A0]();.`8HGN,6`,53.G!:$!2% M:(("S@)*YKO%&PO=V]R:W-H965T5!,98J&DVEG0YY]R7 M?)7VE+WQDA#A?#1UR]=N*42W`H`7)6DP?Z`=:>67(V4-%O+(3H!WC."#)C4U M@)X7@097K9NEVO;,LI2>15VUY)DY_-PTF/W9D)KV:]=WKX:7ZE0*90!9"B;> MH6I(RRO:.HP4;'O*7U3AY^'M>NI$$A-"J$4L%PN M)"=UK82DX_=1\^92$>?[J_IWG:V,?H\YR6G]6AU$*8/U7.=`COAW!"$/(GM2H36IT)*4;R0U8,*9EV^1><]R"RA.S*0L(!]YAK^=#16B M?]S)R)I69$G+N%";:-DKWXN,M"P@&!M=WRY!$":QD94%A)+`2`K,_OH-82<] M=+E3T',KU.6=6:>Y_@35Z##L&W^5^Q;[5KX#P]B^R6=IAT_D%V:GJN7.G@HY ML/18.5(JB(S=>Y#-*.5+-1UJ&ULC93;CILP$(9?Q>(!UAS"*2)(S595>U%IM1?MM0-#0.L#M9VP??O:AE": M=:78U>3D&^J!]#HG5&N#D&O];C'6#4],**>Q`CX=F#`U2`XDM`=@D_1_EA:A1/\&&!2FSZRN9^$>+.#;^TA"&T*0*'1 MED!,YW;@KIWFE2)ZWC(JGPU8(6S7'6Q!M-5(:K M!AO^:A)[36('V&U-LL(/2+R`Q`&2?P"I'[#S`G8?,RAV=]N<-;G3<*F?BTV1^D\QKDGD`N1^0>P'YX[4LO(#B@5H6'VH9167TGXV67IOR M@6KZ-/<_%MYKG5`H=.VFYN^ MG*_S/-!BO#U.ZPM9_P%02P,$%`````@`(I#^1D%"/9'/`@``;0L``!D```!X M;"]W;W)K&UL=99+CYLP$(#_"N)>\-CFM4HB=;>J MVD.EU1[:LS=Q$K2`4W`VVW]?&TB6V.-+`&<\W_CQR5Y=5/\V'*74T4?;=,,Z M/FI]>DC387N4K1@2=9*=^6>O^E9H\]D?TN'42[$;.[5-2@G)TU;47;Q9C6W/ M_6:ESKJI._G<1\.Y;47_[U$VZK*.(;XVO-2'H[8-Z6:5WOKMZE9V0ZVZJ)?[ M=?P5'AXIMR%CQ.]:7H;%>V2+?U7JS7[\W*UC8FN0C=QJFT*8Q[M\DDUC,QGR MWSGI)]-V7+Y?LW\?AVO*?Q6#?%+-GWJGCZ9:$D<[N1?G1K^HRP\YCR&S";>J M&<;?:'L>M&JO7>*H%1_3L^[&YV7ZIR1S-[P#G3O06P(TL"2T)@"1S-B-+@G'D6,!IY`8/=2W&B*&`VN)7/0/^[-0Y"I8N;U$DR\>JT5TI+DY(D1O&CN?O> M/AJYU_:U,._]=!N&UL=9;-CILP%(5?!;$O M8/,?$:1FJJI=5!K-HET[B1/0`*:V$Z9O7]L0AIC+)MCF^'S7-D=.,3#^+BI* MI?/1-IW8NY64_<[WQ:FB+1$>ZVFGWEP8;XE477[U1<\I.9M);>/C($C\EM2= M6Q9F[)67!;O)IN[H*W?$K6T)_W>@#1OV+G(?`V_UM9)ZP"\+?YYWKEO:B9IU M#J>7O?L5[0XHU1*C^%W302S:CB[^R-B[[OP\[]U`UT`;>I+:@JC'G;[0IM%. MBOQW,OUDZHG+]L/]NUFN*O](!'UAS9_Z+"M5;>`Z9WHAMT:^L>$'G=80:\,3 M:X3Y=4XW(5G[F.(Z+?D8GW5GGL/X)@NF:?`$/$W`\P0:=*E2HT7L9HKCP[]IHTAQYH4![,&E_YSQ`, M0K`Q"!<&>,L@!`U"8Q`]59E858Z:V&BZ$9+$&.4P)P(Y$R9!(<3K=,9;IT*@N.)@'QB.Y^3*%\4&\5>LD6"`XJ`A&([H9-(G\(G M*O*BK4.$,XJ`D&([I)/H&86\;&M5<$H1$%-LQW02/:,2;^/S1W!0$9#4T$[J M),HMD$WR%W=,3Z[T%^'7NA/.D4EU79E+Y<*8I,HR\-0^5>I?P=QIZ$7J9JK: M?+PGQXYD_>/:G_][E/\!4$L#!!0````(`"*0_D8HO.1>'0,``,,,```9```` M>&PO=V]R:W-H965T-G: M?=BJJ7G8?68T*C5`7(CC[-]O$E`QM*XO`N'T29_F2#>3DZH_FKV4.O@JBZJ9 MAGNM#^,H:M9[66;-2!UD9>YL55UFVES6NZ@YU#+;N*"RB'`<\ZC,\BJ<3=S: M:SV;J*,N\DJ^UD%S+,NL_CN7A3I-0Q2>%][RW5[;A6@VB2YQF[R459.K*JCE M=AJ^H/$*,0MQB%^Y/#6]\\`F_Z[4A[WXL9F&L-7*CB=[[1>Y-M'`8;NY9::SV:16IZ!N'_S=HNND?A[IG:-6;U!".;S=8#!&<>3G\EV3UD.0F M30(6B[AXI5!$`QQ#VN MU1"%8R$(K(N!NAB@R[/(O,6P?C()$8)3[FF#@`@30;W$ER`C90+[SQT"QB*E M*(9%<+1XQM%#$.1H``4X>HAZX.@4U)4^X>CT64=#0-#1("/D:`CXR-&V64)O M_QB0Z;ELWH'ZFU&1Q(FO$L"1%,>I\'L%P)=PQCW<"L+QA)$[KVQTI\$A0*+P M)2*@GL:DB5_X!8ADB*4^YQ+FQ)BDOEUA3L93>D\JV$5?$`:DIKY4#+Q9:.K+ MA%`<^1(AE&"^O"$*C5!Z1QK<>1$92,,]P]Q2P+T7T>&[CM[[N\!M#@%]C@Z* M,NPV#!'JZXUZ$UHIZYV;C9M@K8Z5MEGV5B_S]PNV$YZW/D?C!0+6EW9>=Q/A ME7XV.60[^3.K=WG5!.]*F[G237];I;0TV9MN%09[\T5QN2CD5MO3Q)S7[8S= M7FAU.'\R7+Y;9O\`4$L#!!0````(`"*0_D;:1.E$J`$``+(#```9````>&PO M=V]R:W-H965T&41P0"_@H8W6I- MHO>S,2\Q^%T?DS1:``F5CPH\3!>X!RFC4"C\.FM^E(S$]?JJ_HC=!O=G[N#> MR'^B]ETPFR:DAH8/TC^;\1?,+>RC8&6DPY%4@_-&72D)4?QMFH7&>9QV]FRF M;1/83&`+@65H?"J$-A^XYV5AS4CL=+0]CS>X.[!P$%5,8M^X%XRZD+V46HE",^8T8=@*LUL0-*@O)=A6B1/[1L_R;%L@V_28H4"VKI^EVP+YID".`ODG M!_F7)B?,'C$:,>SV2PVZ.E0%ML6WXTAE!HTO=95=GN<=WB+]@)=%SUOXPVTK MM"-GX\/5X@4TQG@(3M*;8*(+'V@))#0^+G^&M9W>U!1XTU]_R/)-RW=02P,$ M%`````@`(I#^1B(T`@9I,```*>\``!0```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`'RS#S@226PF\G"'X_'^)^H"EY0%C=I%OU%A7#HTD1Y49Z7325!N#(-/&H9 M>#'N&WARX<\G"#/E-%.J`$P:[6[ M!K:A&;:/F[Y7L'FW*FX(Y,LPI*T$%",K!%(!3KV/`.7UEN]4`=H6@`$R,8'I M.YABWKH;!S>5B750WSZ1=O(V0%JZ406>AE,0<4^\IQUZW_L"1B`AG&Y`C"
!"U_M#4?M*#9 M;H-\?0.:@T(T;H)(:`/A60/F`'!<.GS,HY!6TL:YP>8"8.D\T)0[9-)_:6W, M9SIM8*4#^YLLW>G6`$.S%8BI@G8GH@[-!B`,H8F>IV.::P722\D8*($Z`4+I MM,_26Q!NS<4A-MOAL+]XL!@^`@U"^"Z`36]@-XK+HNU(=1X1TJ9?Q.G=<.7= M4BE2VVV[RA7^4C*N"X$_LVN![_(O4>,(2'#KO^M[9;SM^8_DD MHL^N@[RFUW7MW171;8X+8P64B&^0MFFUWT]6D5JT;*N<#CM`KX>BK)W\#VR; MHXDA=3192],H*3/@"3DQ@7VK@=*Y@A(W#S8D&@"92-/>-F`?K94*=4PL3^N41]%/F`8,0V0=Y#OH-T^$<2= M>IL!6,$A3D*USA3,=HJ'CSYYI)<--*4[;6X4,-LH0>V-"(!\%@_HK5`J=?5[ M7^[W,;$J.&-AE*_C%(X4(QU'V@#;@F48_U<7/^_FSDUL(5LEDGB+IQ9F-H+J M?;1-H@V<=_2_,6_`5;\%QKIN-SKK37J4@D=/Z[7W;//DT7!(@7>@$,?W9^D= MZMYY>0W,)B)UP3L!!<'[[:__!W2P?9#<^[_]]?_BGS":_GBG]*0%C-5+`FT`&/ZQS=)R;Q64-4_@%3=@3YF1$@'9"[?:@")WQ3RU<:N3]#-^C,X:LQ!L<1>9$[)5)4(*5PFS7 MBL:-4=ES*R3W98:'O4!YA0-E92R@9FI;QH%AEOCC>P6VIS4_X/RSOH1*+3`- MW)J3]\^O3CWX@.WS`!4*VL(`M=S,TX`%25("(&T@C4`VJP&0PU&/RQ"6'L>T M_%*KQ8>)PVLA#CK![J3`DS:*%H4R4&3A.LW`[!:LG+QUFVAQ>>4T.94-#V%/ M0.0YG)B_9_?[-E-VZ4!)VQO"7FL3,6HSV![9G)MH[]U%!?=Q+4*]:P>A]+T[ MH,#@5H%Z`3C-03G6Q@Y(N_06`$2_*#%5ZG]<;;6]@^8S''O0`!RV3"*$!M1^V&HT%],FD MT`L4EAR,1?Q[A*P%`!9*-7JL@<^.:=$3*MP[,NKI:`]:!X%T"T1&8$1&"T?_ M-'&E/[Y\#L9[?NK3WM+`,"'V8LBB79#=BX2%0T"?UP%(20,7:E=9&O-6$?[K MZ(;&,HVOA2WQ(.=H6?9$.,U!/('M(CNZ$^""7_G`P1*B$$]PQ0*[1O=_Y6>0 M:>@G)JT`A@&;RH(V\E!S!X$)T\7WA&7G`#(W8DN2-2[M=!Y*0&96C\:#;NHC M,#"2((U-'GF7`#?MCN;>U^PJX:41[2#[Q8$)Z==*@3X>1T`/1/JH<1CPH=D( M.`]1;KH'JS--?-F'PYPM4YM8K0OF;(ZI<4*J,^N2:8)L;`.'$M0#1#AZ!4E5 MLAU.02-'#0U)!K9QSR*43-OXGM9OIW<4#5#P"W1A,DO)5`1+N0+%-R!EUC9# MM&S2M$A2P*Y58'*!":80%BVXV8&Z4Z@.,:2%&5HPP,RSD!10XFL_C=Z/O"W; M\3`H_*SV)$.LO@"'!(;)B`$'W(41Q$764#-Y(Y#RH:_"D*?2/T\7N@ MNFV0B`L(*,D:SLQGM.ZA80>R<7$2(3O`S>`](HG`H5/XBZG28`9G,]@!*1+L M6"E"SKD6Z7R-\\8Q_:W)FJ1^"`.0'`$F5XI%PMW)CP6L#AC/3A@IT"8/PE$V MT;Y&WD]L*3^7ICFI:8H=LFC6_A MPR]EN.5(-)\6F`X,AU]00"-C19F(3!96$2I4)^1\,-45]R`%^$"Q',"5(+,/ MH\T&V1.K*&GND#6#K)O#:(XVIZE.QP"U_!&>@&2&&Z/E?D1"&'<"/=[Z?.BA M]6"HBF:6L2-JZIQ]X8$ZCKOW1[U[-@#T,@&SOV0Z?P,,N2*?1(GROQV\_*,'`8+M?.26M,5VFG(J+C>QS3=.\7R!1R#9W MF,_#8-80#@*;*',/5/^163:KWL[QTQ:$H8@XX'@G*B,@^86>\.>(@@+%'>I2 M9%N`)28GT1H7SF;HTPES&<$C#(S5X@]-?!"5EUD-C=YUFF7I'6HY%/O`!L`- M"'?`AJ+"72/;]\X2AT5[@:[?UG1!LD2,J=L-:-&QMQFWN&2) MK]#6!X!64A;*I('V)JYG;8@9B-26OFPQ<[#,6$4C3RN14L1G&]2="-Y?X9E`S4ARNG< MWX',-D8I-895`,TA-+YHEC7K[;#FHEGP?0W>O"XRK)O)?DVZ)9@;`9(NAS'( MR'D"R*14&``+V0Y3?("^2,Q421FSNHNVY#1=C8QOY`='*7QE`+5Y<#^3A@BF M-_5O4R5MJ(_,?SP+8B60I`?6X;?JBVQ.:_4;)=Y`A5(HD'8<0P+W(IA\[UI[ M[\A.=7?P5H^P=`^OA3ID_>(V?>0B=/?F6$]Z`5TRF_FPZ=3\LSB_XSR5P*?JP M.)^['Q;$9"9PDBY6GLT-U&-.I_YJM3+_G/N3V1B9WF0*?TW\Q<7<_+/PS\^! M(5[XT]E*H'WBS18`R,3]`&.57NR7K]2OM>B(JO MQ.87/\<5L'<0KUG^%0IQD-!N3V.-&^>U9#^`.?L7ZZV]NX&#`-J9]K?3J=Q% M>&"1*^7HB#-."QAAK>VI):0$E^V04GB="0&WRGG)*'G7RL(XIX0I:SJG"'GET@M#%ET*B;B MFW*F/"/$NO:2]7;1_(Y"9V31.LW1S??,BN4#VJI$=;265==X:(T1R%I@&&X( MO#7F_9)\A(ERW.)-U99>UH&QM MC/XM6+R`?K*2R'&@X^>P=WEPB]G.HJ&5>YT+X/@\P5[*`G08K)%+.N%5L+0` M%>'(N]P9_P?O)*@ZERKQ_V(&I&Y"P5<@>6:U1*Z!)(MKJX7Q%=?.)EVID0.*XH=#E6C: M.D?0M\P`I^2D-"?N3>`H9).&@9J353/Q]6$,!Y]B$S%.LVX6P\&%/05`C$2P M8;L:.<#R(MANG4ZNG?0VU<]AY89K5(\`&U&ZI[A):,#0N%$126[&_KUUQR,A M.(LQD&U*(DH%:$KO-7R$)`5G(K/Y*=U.D0W%I0YB'.L#693V M+O(%6B'F._2"QDBSE`5&06AB(-<8KXICW(-=D/V*YS,`'@%Z>V"RF:S_FON` MU(:VP$=85A1L&=9YWO`#6O..U$1L1;(:9-*[TG')YJNH2?:E=1Q6<\[!\/K1?31`.)=&,NY`F!]EL78GT_/72"" M!SFKH/]D/N.4<5H;]G$/\=?&$&T98SX!4W$!PUQU'923N7\Q/H<6Q`WP>?4)0C9.:2,$>D(17@T15[&5B2=22R28P`4-*. MHY3KH$P+U]'J1)V%H@6(JF7!0)XR=P*V#QL8Y3>HUEBN#P(Z"T#3N$>6BT17 M8I.\9]Y*,-Y(`VD'\P=>>BV7XCA/''"_)N]XJ%"..<+6ZF"*+W*?D!\^]R:T M)]-3$P2NM\0D-TSPK``37*-B=`#B$W'UGXK;P"(@RCF=GP+;A-**Y63<<%\# M9_Q/B1A,3,2@@)T$H^[/9Q8$J2(X,#/Q4,;Y)J M@.3BP7V[&#<&7YV'6/Y1B6N1"F=3]6QF=#TD7I?-/_*VO"7.`H;%)6_;#P[E MO#24X\;CA:0GIY6<$Q:];RS*7C+*I/6TVOHG%[G5EC,MS?2UTD/W?7I$T8F; MBW90[8)-@)]@[#MTDK;(@(?L'T<97/.VC1HMPC1= MLO9/%ZKZE;LZ,7R@CNYE3MBNC]4O/F$?OFN$#=&[[L_&Z+`6D7]I#%OMAG`T MSHIB-/&GYU-0,V;CR=#@(6ZHZ&0/T'\6XX7H0&^UE7H[^-E-5[7F6*'6-U36QZ0&N*E?]?@VHLI)6A+S]+`1UFYY M&;XW&<,_#L"< M^("^"6UZV52\)D8Y4#P9TY#+OI&,@X-8;TKY8^B3&L%YDU2<@816=ZD04S(V ME1QS>1F4@9WG=`KI5*=F%9Y/HC])F-(>0^_DBK]Y$:P) MM:?:R\=9#[I?+>$*/CT!.W7@$!>"W6$V4&]Y0^D;.YP<_]17 M0"[++=`*2`J*7;$K&1K>!E%L%`[TG1/.N+"'WUDRAW_GJ`E,3G8HCBA'U'K^ M=18Q70EH:'MRP2BTJ634Z,EJ7,-SK#!U(:_MQW@T,ZV<2A+,FY[,YJ,+.XA9 MI[U'54.=B=Y+TN MA/@B7<%L9W8!ZRZ-A4WID=I?;T;SC0A2$3'\5R^_>_.._8WCT<5"1!!^\#W1 M!YFJR7K%.U]R28&[4/NQM+\&&>+B.P;-,@NVU"%*^6YH<,_Y.:59XTD@/@!07(;GL2+0*&5*[?R MCN/)1'UOY%9@,W[/(+S%CF1EE^Y-OTYB1!,.D^K95D#RSS3]L);@''ZMP+CD M@&2`7-TY=YUDT$Q90^_\>+2:7;A(;&=&*+:!\X.*HI2YN-*X?NK<9!EPJY", M>3Z)5CZ:.R6^9FU:%,"D."$@'4-0J)ARC)FDFMPI%1A3KB9D';.<-5#UTW8L M-)&K)/J^#.F<>VGMLHR:)SY,\KA.O<7RW/X=^5/5Q-.[EJ=S[SGC55ZLR6(SM_A/S/^ MQ_F+7)XMB*E>R5"4X%/"8;CG`-)&A234'6QGHE3,0'/Y'3`Y?5L7KUV@H[>@ ME!RG'@/G8;L7%SFK,?$DI'SS$(([HG MR-%WC(!96^1^XU<<")^.QRML#K/.\"!+E)"QN?THB4\^(#[-FJ4Q6%=RTY%8Y0V,=/N[$9&&1;GB!7BYE1\.& MD5"_2PW1USKF'3TG,]X-D/UK":^0">WV!$,=:>Z:_'&X`"471DU:W.^]F_0. ME1K?C;J:O4&U!=UC4M M8R`%E=)"G**A5+5$%@B.;1;L.!/=,`SL+>G5.`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`\XZ,493.[[@CJW$,Y>9/1_,*1 M)$^;7`\V=N*O)N?>%)M^T.+:JU^YT'[C]D-.J6$=')6+`C5X>I17F:-6/X0% ML!*26`6BA;D&3L$9T%5[]))1_\IZ06\RX[80>D`,0IU=!5F<8C:3%&3BN/$( M'V:I)'")Z=S7R=15L^G!%9^P;\GR-L6.L?9Q4\PQUF<-[$JL4*EUL`,)OKE+ M1;:8J;ZKZQZSX4F_7^OG3#1IGWF70MK/M4[*&4/-!I;V]?T_%&8?\$;DY194 MK"WNYTOX)4KR:"W9D\UAG-1*?6!0!(S'8_CT1E?E<7W]'76H@!'.YOYBALQP M-AE-QN3=&UTL/%W:6/#"3.1KLT(XJ?-S?[4<`RN>S4;C"V\R&ZW&WI6V#4ZF M=&L3?IV/SB?>9#Z"Z;I!JZ(8^/02+,2+J&OPM".]O05<.Z^U4 M@H;0W/1\X4\G*RH]@+O:06G?BU2+F7\Q7H$$HDO#DY4_G5+I!)BA^;Z4 MCJB"?.(-.]RB[XVM9F,JTN[6/#?UW+FT1[PN8YWK&0+ET;JS<4>\?< M<,+X!]5]6SVET-=@N-E.@2(5ZIH\C!!]#?&:MA=G#?M0^?AXTA#USKCF-ZP- MR:28*#PP%;+-FB#*_=ISGB(("CB=UV6A"SNZ/AKMIGOB+?V+!9V\L7\^ICH# M"W]R3AK\V%^"ZOYS-W%T$^_DPI\ME_XY"!3X.)G._"5(!OP6+X),I_AQO%SY M'0^I7_([IB,8!8Y,/]?HJ5G`G/,W)G<$&SE>\G1/>3JIR,0*Q]J;!1_02VW4$ MUL[))R+Q0+PU<:O.1%>O^CDY:T72Z#&GX,S@V?HA6YF-3UVDYJ13VDLS&0YN M2#&E3F>SF,-VF\V`P]>*?OG%!,AIY36B(UZVJKA]S8>%O/O'^(5 M*$Z8V,^^H0SV%%VB:T!;;KS*.ME,@F9$*9*?RRGU*6SPLPDW^NZ%9:ZW M?ANI.S9L!9'M.+.!2B<*2HDEO:CN#F$&(?K`52V4:;?[,P4U/[1`W$D6)D![ M.)JKZ\>6R2:X3:GXNANY1:`28B=4BX5]$3O9S/\GJ."T90E*:6WR>W35)N13 MIN)%WIM*S&ZLZT[P+;_`6X,^B;DB]/;+ECVF(1A'@(N3JY?/3DT@A)7*9U@: MUN04_*',Z2"=/'OSAU.?TT\NBR+-$L77V]Z@]\&J7J]3*I2?(*LA(P,'>8EW MDM-()VJ]?$95;]AL<%4GI>_6]'"`LY4-)$2'^(G!*+$=S2$B,A99WE>E.`E@TK].\QZ MC[PBV"&?SHM87<,IPP`;;RZ7#&>E`25:`<*"TJPX#09IWY#U%?T^B.SAF(%4 M"+;I*2?'H"2150K8!'-.R;-2S0G573ID)B+(73A_A2X_&RJ+G"IV`#<+Y4IE M&D34B!X:V]YP&1S9>J=`^M:P%3K7#K^0O&:^07RG8E;'7C9(W^S$S+!M#2Z=U&,GQV+W01:RD6B&U(F?>'N;='_XF$N=$E2/;Z-M MFE%T?(3LT'A8SCF:ZW=N()U(BO_%T4;7!:)=UWYKXIXO\%UG72ONW4^5X1:4I.8D&%3FEC,)X0HSBSRH:^ M\A"C6#>S4`4=5-#U:>[BFICD\3HM)"W@N53;P>:4-78+]"='0T1$RZZ19.T8 M!7:#LJ7U:,Y9DP$IM:QR9.@RTU34JYPSSPA%EH4J4U>SAG MF&>'+#-N$X"VBBFQ5Q_6IWXUQ?0H)IPIU)/"8$?/11%'IS-A4S&MF=5^6GS! M7&UD/:33GP`K?3R"Y6OP]"XIQ+`\PU76(>MEVLU MDYG>?+USE`8)G\V6W;/.'5*^!M-"X/V2XO[L4DV\893C@U)R9KOV+\U\O?N` M$\RT1);GV6AL)U1FIU9!2< M<<11.-MMRG7PYKI^$!`HL1;]E)*;+<8@I,[+&1/6,V$,':6E;-D&QNCN=,:L M(51)1"O1W^H#H:=^PR_34.,W6&%"#R/#3U?UO:M<4W"7C,(%2RP`2?]2AE3M M'VMF.4R7@>'0!>EX+MCX!INLGW.$)6Z6QLXL>K/%\)/2_LB:I&R'2K94V,R* M/[H!"CL+$NHE75Y"8P7,@3P2AY98+3KSPLH^-#^OQ5*YQ13APMSVR>A;+EVA MM3JVWA3+I5#=IH4R$LK*8+(TN)(EU3H$^MU@YIU?MQ,7.\R+F[,4V3$+&*J7.T<%-D'2H\N(GH^B>YA4!UEX!A;DWQH+ZB8 M0KF;M$SD#AF=!:HI_&9=I'16QNPEGNN31NXN=C@"=@VPV@7`:IH(J\=+-+0)85TB74BGX/5ZKR0J612BD,TP-8%:\B4!]9]Y9UM/P MB1ZTY:`O]LKMGT0_5Z3#Y7NF(I,+>-ON)&=:_` M@B\(/$=>1?*$T:V2'E4E<>ZJ"9U;6J%OD`&L)YB761T05JPEBJ6 M.P(QWHNL<\9KSNH;YXZ$6!TO12_"`B.]-/N2@02;5@N/\HYC$AWY4Q=_^GSO MB9[H3Z>#QAPV\?$YTN-SI.;RUO$YTN-SI,?G2(_/D1Z?(ST^1WI\CM3(B+_O MYTCK>I[?[^$JJ=WPE];_?*ZEUKCGPC[^^46')5:>=%Z][7KNNCT#:SO&M M[`>^E=VW#\5G?&VXL5O'EXR/+QGWOF0\[#G4(?QDR%MF;=SD^.3:\4&E$PY^VD3?J%'TYZ$.D[`"8'>]QG8XCM4?/SM1_3>J_MA' MJE^R^"/?`O[4DHUUZ(^E+/^12EDV:)-LZGO#19L5#A]AF1]K)1ZH6W>LE>C6 M2NRAR4\JD?@(RCV69#R69'Q@2<9!&NJP0GRM(95C2;^__]IUQY)^QY)^@TKZ M?;Y`[IGG\I4-T#N0FCZ09_G.EC`&D:&-?ST_IEW M\J3!WLR@?T)O(K)H9+>-JGA]$=K.MFTQV89=,LAEU0-.-4;[I7:&S0'M]&O+ M=GKG!EKU>TQMDE%L\GC4:& M8T]0HBL_S!V+JZ+$FS,W'*V3OPZ"^^`16T&N18W_]`/I0C]M#J MF?'E4A3#7I-RJ:!R4N'O?[%1R]:0_Y"I?3<<=U5QY?[I%14DPH=Y&ZMX;9A[ M)73:O&QLCG=]A+>U&R81!7$VYIYC+>8I+PBKT+P1"#)B#P8[[!D9]?7Q`4.M MWU_V/KA#EU$Y2>>A&^@R@LMJ>-G9*&`Q)KS\\`/^J0'H'@[9&8^N]^F(2C=" ME4Z`NBLAI2]:W0/JL*CUH$G[4-C@`MUQ[T;3H`\&'$G5LD36#H:J4'<7724UX M^EHGK4R#K5ZG25:;MX\#_^W"S?69/T-$OHNW/BQ2/V24_@A^UPB=]%,/IC^. MGGZB6/5!,'M$_S!YX=+C82+\CM/FFZ"0ESI9TPU85AFLG^*`1:"#P)U"],I> MHC.*<[=&TB62#QD;@P/E#1=0K]W0228#E+G/2J0OY4[.*_>2UX^8]!]Q-=@* M&'ULY6V67NL+&:E^G`]18*]_RL4&^*3$0=;0O<;CT7C` MH]QR>3V-:2E7?"WL1;#F=78!]4JND37:]VRWG:5V"`%L'>QBIN.\Z4UC& MH]%8(GE9U_`;`:XQ*/LQW/OW^E:<+K;17()VF$OFN7VM]I%`@&FR1B_`5J*X MI00OI>(_WMZGD#[5(=K5>X]'TT6#"CKQ7'O-K&?4U>RB;]PN*O'^W7OU\KLW M[]PO#AW$/S;JS1CH-&)0LS1,-:5+4-2H"??G@_K@H7SL5*#*[)3W#B,K#\!2 MZW'_E/D.K.^5PNMBN7/$.QT1E7RI!YN9S>R>>@M,[VFN';-]FM]B`<>R2+-[ M+L6B*[@Z*52M,RS:9NC,'!HDV_0%9%(M;ZE[ MEZ0E]G'?JL/:O'=>>0^<>=C@=]2[IFAYQ[LVA1/);$6[B01W<@V5._>UJ-9O MJP=FWOZU\]@SS]H^MZSCJ;/9<4KW9G3,![HY/O&O1S* MYV&):@WU2RX9Z<2#R6R>YQ MMW78?CPU[STF@'EZZJI_D]ZW*B3\K=^3R37`@ZH',CUP-:[ M-]/'>KL?ROOK;-_>_!.1>7#T3BP?[-F%_D]8T##$'AKWL1LV((^-A&97+MLG M#/QHI(A&ZBT-3QFW\I1'P?)`1&I8+C0L[>RM$W^/1L*`$3_Y$%N7Y4'4NK[K MSWMXW9&''URWU^!#.VP1#SM8;6,^<&.&R<9VA9I.;X=*_4@)^E"5X',(7==> M>$@ZZ0-$KVB)73^SQMGUJ\F"_;S@/_"\=O.W3V*-7P!VT3Y7FFM.VSGX8+'3 MPPV_).;;#OD7(]3>63NHM[=/.TGW=NFD\R^`DMXM:$OV;O6F\K7`].I&Y&;SCW.4'0/J9\H+[O:I]:<`=:QB4KW^9%)%9@/.T MQ?/*2]E7]G5L7'$+D1WVT5B$5=_*KK[)K6\(R+*=9[G;\-/]=K4A^E8_N9;: MYIVD!EG;W36OC=DV3_.\^/:_`%!+`0(4`Q0````(`"*0_D;G?S$WN0$``)T7 M```3``````````````"``0````!;0V]N=&5N=%]4>7!E&UL4$L!`A0# M%`````@`(I#^1DAU!>[%````*P(```L``````````````(`!Z@$``%]R96QS M+RYR96QS4$L!`A0#%`````@`(I#^1@QUTFF.`0``J18``!H````````````` M`(`!V`(``'AL+U]R96QS+W=O&PO=&AE;64O=&AE;64Q+GAM;%!+ M`0(4`Q0````(`"*0_D9S-N`83`(``'H*```-``````````````"``0@/``!X M;"]S='EL97,N>&UL4$L!`A0#%`````@`(I#^1AN5B_5\`P``:PP```\````` M`````````(`!?Q$``'AL+W=O0`(``(X'```8``````````````"``2@5``!X;"]W;W)KX#``"V$@``&``````````` M````@`&>%P``>&PO=V]R:W-H965T&UL4$L!`A0#%`````@` M(I#^1I/WF@86`@``"`<``!@``````````````(`!PAL``'AL+W=OXGP$``+$#```8``````````````"``1XH``!X M;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0#%`````@`(I#^1AL'NYV@`0``L0,``!@``````````````(`! MR2L``'AL+W=O&UL4$L!`A0#%`````@`(I#^1E=XM%R?`0``L0,``!D````````` M`````(`!="\``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`A0#%`````@`(I#^1E&PO=V]R:W-H965T&UL4$L!`A0#%`````@`(I#^ M1B.<60ZK`0``%@0``!D``````````````(`!S3H``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`(I#^1D8(PZ&A`0``L0,` M`!D``````````````(`!AT```'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`(I#^1I7X?FG&`0``^`0``!D````````````` M`(`!6T<``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`A0# M%`````@`(I#^1D=C#/@T`@``7P<``!D``````````````(`!24X``'AL+W=O M&PO=V]R:W-H965T)2 M``!X;"]W;W)K&UL4$L!`A0#%`````@`(I#^1HDA M-+PQ`@``$0<``!D``````````````(`!BU4``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`(I#^1B-"]EO-`0``+04``!D` M`````````````(`!(UT``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`A0#%`````@`(I#^1BB\Y%X=`P``PPP``!D``````````````(`! MR&0``'AL+W=O&PO=V]R:W-H965T v3.2.0.727

Stock-Based Compensation - Summary of Stock Option Activities in Equity Plan (Details) - Jun. 30, 2015 - USD ($)
$ / shares in Units, $ in Thousands

Total

Shares

Shares, Options outstanding as of beginning of period 1,234,530

Shares, Exercised (46,980)

Shares, Canceled (2,574)

Shares, Options outstanding as of end of period 1,184,976

Shares, Options exercisable as of end of period 1,120,916

Weighted- Average Exercise Price

Weighted-Average Exercise Price, Options outstanding as of beginning of period $ 31.10

Weighted-Average Exercise Price, Exercised 33.07

Weighted-Average Exercise Price, Canceled 34.61

Weighted-Average Exercise Price, Options outstanding as of end of period 31.01

Weighted-Average Exercise Price, Options exercisable as of end of period $ 30.40

Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value

Weighted-Average Remaining Contractual Term, Options outstanding as of end of period 4 years 8 months 10 days

Weighted-Average Remaining Contractual Term, Options exercisable as of end of period 4 years 7 months 9 days

Aggregate Intrinsic Value, Options outstanding as of end of period $ 28,946

Aggregate Intrinsic Value, Options exercisable as of end of period $ 28,068

Weighted- Average Fair Value

Weighted-Average Fair Value, Options outstanding as of beginning of period $ 12.75

Weighted-Average Fair Value, Exercised 13.90

Weighted-Average Fair Value, Canceled 14.14

Weighted-Average Fair Value, Options outstanding as of end of period 12.70

Weighted-Average Fair Value, Options exercisable as of end of period $ 12.55

X

- Definition
Share based compensation arrangement by share based payment award options exercisable weighted average fair value
+ References
No definition available.
+ Details

Name: ipcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageFairValue

Namespace Prefix: ipcm_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Share based compensation arrangement by share based payment award options exercised weighted average fair value.
+ References
No definition available.
+ Details

Name: ipcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageFairValue

Namespace Prefix: ipcm_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share based compensation arrangement by share based payment award options forfeited weighted average fair value.
+ References
No definition available.
+ Details

Name: ipcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageFairValue

Namespace Prefix: ipcm_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share based compensation arrangement by share based payment award options outstanding weighted average fair value.
+ References
No definition available.
+ Details

Name: ipcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageFairValue

Namespace Prefix: ipcm_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Fair Value Rollforward [Abstract]
+ References
No definition available.
+ Details

Name: ipcm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageFairValueRollforwardAbstract

Namespace Prefix: ipcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R25.htm IDEA: XBRL DOCUMENT v3.2.0.727

Fair Value Measurement - Liabilities Measured at Fair Value on Recurring Basis (Details)
$ in Thousands

Jun. 30, 2015

USD ($)

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions) $ 54,107

Quoted Price In Active Markets for Identical Instruments (Level 1) [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions) 0

Significant Other Observable Inputs (Level 2) [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions) 0

Significant Unobservable Inputs (Level 3) [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions) $ 54,107

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregation of the liabilities reported on the balance sheet measured at fair value on a recurring basis by the entity.
+ References
No definition available.
+ Details

Name: us-gaap_LiabilitiesFairValueDisclosureRecurring

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

ZIP 16 0001410471-15-000080-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001410471-15-000080-xbrl.zip M4$L#!!0````(`*F(_D8MWK$*UZ$``'VT"0`1`!P`:7!C;2TR,#$U,#8S,"YX M;6Q55`D``XV1NE6-D;I5=7@+``$$)0X```0Y`0``[%U9WWCF[2HLP&^8_'^!4Z/DKSSJ";Y9<_'O_RZ<1\^0'G6$_S:LC5Z1)E7:/OF35U=&OW;3\_>BB&/2/ M?AT4OV($F9C%KX/]^^_MQAO*M1DG2$ M9!W)=*?312D3/%$RO>!Z?+7;ST4O>UW__Q$(GI>O.X-A7A5??SR^JJKKUZ>G M==.K,NV\NAS_^ZI65`EM^D9=4^9-S6HDUVW>G/AGSY\N75U:"\SJJDEY75J\Z@7P_A M2%`T&U`.&,%R823(I*&%'=!2#'IIV3IFU-(^ MJ,:A?="HI6U05:27*W'2I]`^[5HW=)>\8H;GN'&A:]7:E8^[5O-=LW4$SRV=83+XM-__?3V4^_3'_*NO6/%UE:'(U$21?4 MF'+3G?WC^`T"91A&3.(?3I<'CV4:7&O079@8D"@J#RO#FUK6FE9H M=MV[MOD1:=Z=ZR].*+J;L#OK/?WM;LKI+Q.$5F!V-H*,_GW8(_39@C8F4#6! M0)X0.KOJI.6/0!!K#-@'M@_JLQ-,(!!M77WPFGU0?\D!MJ*^'UE_?X(&NV?0 M8-L/&M-`^V%?,`/>L"<.M%.>[0UF[)Z8[8)G=6BB^Q&9Z8XB,]N/R,QV$)DG MZ_)ODY3_MSJ=[`Y[Z?G%3TGOND@Z5=9)S_)R6-39Y<^0(YJ\^S-H M,1C_-OZQ"Y/?7O>R3E:-Y3KJ9M!GO`\Q@>/U`^$X?E/C\7HS/'XX;15G(O]I M4X%GF-CL@C])WIV"]7T3IP'$HS%F%[G@#B/.@3%/SI@]BS&'->J9K5&[JC[' M6U8S"CEHS_)+D`[^*L$@15(!J/;K"*X964SG*DMOTEJK\PN7%E62Y>?7H\[Y MY<>T'/:J>U$2HF6?'/I#=,[=?9GW\#@R5%Y^KK M6T"Q-V)5H_M9?CVLRE$'.@9MUN=C`C9:&/53\^N1=_(/ M6PS/>HOA$4X"M\P&\GVR@1S8T`8+_C[9@%\`&]K.[(JTFU4QZ8R6TP7C?TQO M!KT;6#,7^^R?^9LZWIEZK9+?666S'"P.W'@R;CSRLK#&TF_3JDJ+\XMQEY=E MX#;=]MJN6PSPFYX-S7[]9U)`5=9+/T(<6NC^O@"KU+^^+/(\/#H\UM'1/>99 M-M[==$O6^\Z6Q$=RJ/E[)`X.]=@.M?$=*@>'>ID.]7:0=P?Y&8A9?$[RW\\O M+E*8K^[V]LR>[^'=JP[V130_.]_3IX<'Y7E[2>'"^C9S/?$F*[NSF^#N_ M*ZLBZU1I]U,UZ/R^?PZPH-8\]UOT.I"@G02A?]T;?$W3$53GU_MY8KN"""MU M.Y"AG0SOT^)B4/3K)X\^725%6CXT`08/A+5GH>?H@C8IZQ/R_C58<'QH/I*C M?M;I*CW/][#07$&]%4CN7=I[9\B[F>YAR8.C/4='^_G+X.!H+\+19I;\OARM M/E8B'\C?AWDJ]^'='Z2&`,E='\%L+=:T%]:'6//XL68GY?0AUKQ`1SMDSR_% MT;[G[)DM.MI9WAGTH7Z':]=*OAUTQFC-N\9?TSPMDI[)NZ;;!S.657W']4T: M;FMT]]`IUBA]1Z.-M'Y$`CVOERX>"+1W!'H.S\/!UG2ZYX M(-"^$.@YY$#+-\PN5AJC)_"6CK<`OA7I\CX19JD0&#UCM[&BN^7((]\B?3BF M>[%O"#@X\Y,[\[,,^/./8!\X\N0C7>T7#:I1$G5^$I,BS_+($=,:[25_;+_`"5Y#=`?7DZ]%S"$W# M/!NSM)M>P#6`ZPOLZ*=).2S2L;?.NDPO-VV=FZ&^7MOE\V&#>=/1$V'ASP=< M=UAVI[9>N'@WNP$F+H!7CWE7?]LKJ08+6[MS:HZ_8O;ZET^^198_+4BS=*FY M27R:#_KU.R)633,Q\2B^?7.>Y:M-V^XTW`"C=J.NU?9;5_W;W3?C5E-FKM,# MIA@CM(8T*R%L7+F;9J\-N&FW=M782RZ/)K[PL?[*UOQGLL8Q.^E4)PJCX(Q3 MT@O#">;&!>4L,\2*&+P+QV\NDEX)K&U\.-17&R38S9+0XJQA)M;!4"$VKYRI(4>=&&UB"$(`F=Y-[W]1_IU(U\@`7M#0%_/,=B>"R599,[ZB(A'BZG`RIF6Y1CT M^X-\M.R.L[WS854G7/7G1!>$6O@FVU$W[61]<#WX_5V<$S):YSBE@6F).0K1 M<"2EUK*FBQ&<'1_5\6!TP6EHP9)A3NH[-3:3:DF!F/72PH%!+P?%1C`J)PEE M1(6(.''@QT)93Z@$@8/R0.&W27&9'IE.)^W5RTO:/1K-,2_?PJ1+`GU,+T?; M:GGU+NEOPJ@:+2&14!YX)(*VA"`;$)($9-).'[\Y>^^._I8FO>JJ`V#\^>@L M[[R:%V=QRI$\J]Z8M.)52:8HZ@/:FJRENZK_/,M-O_X8Z_G%BB'3;K/W-<5! M,0F!M;.;SG^&69G5/5LBR^3;9G,\.J%SD)@0D"9@'1TYYR$8P,22P`S5!AG+ MYV@T6EHI10S8_\/ILU)['PS!UQL"EAVG`5ML!..,&B6",IA*[I%P).)E0YPP MI;Y?2\PD&??[F'8&EWGV?Q!!VAS@PQK<%<+:*D2)TX$CIC2$4NR4@[4V,"KB M,NX"DH+'07VECL\2XW785I)8PQ#/C"@;B!8 M1Q(-\4('`_\HU4"9*_Z,N+ST3J[WQ>!_TWI+$O[X/!E\?C'^N`I,$,H*,!@W MC_M-]YQ6X;:+UR?.F8+,60(J1<%\9,$PP8TVECJH5*6,2`7/B9ZSQ'1#!K^: M&6);0-P3VO/J*BWF/E[SF$!N_/66%8`'YEATD5$H10F*$;&HK?3@!4$0)ED+ MX.B5NA?@#7A>"+P+GX%8`2^!]`/0Y9I!6:>!S#K&&EY*-':4FE9X\=;A_6F\ ML50W_YI55[_D@\]E6MS43RB/+UV'E;Q^X'H4()-RJR\>Z/L)&*M MB%2K%K?'>%?OJLA.H\664:C\@^10$&JKD7/41!.@UM:A&=G17";XN/@]*[L] MTFOB5]E-N,`8Y]0;0;DC6O,([H,(-C88Z>DW"J<79;CR+#\#9;.D!Y#6.<#< MVM4>"Y_8Z9R/&"FE(&\-@C/XSWIC/=.,6*$]6C;>3JVV%KUG9[DG=CN*I=5@ M)TJXYA8A33`F%D'LM"&"ARU;CBBZ8Z?;U'RP&%?IV^PF[9[E%0S,8#)3EFE5 M_E*F%\/>V^PB_3FY'4VQT38GY\K!NN&(YQH;[0RR0%[%-"=,H^,W[S'_]U3Q M^TQ^)_-;,-WT!8NS5Z+<)%EO#%2G`!A3GX[_791Y:Z\C7;D3C8Q@6A&&M)(< M2*`X5/B.>LX<09[Z!A/J91/^]VK*AGMI=P?*BF=-[NHF^_6NR_OD:_W3Z,:, M\:EW&6[3HI.5]22_IMGE%61+Y@;(?YG.Z-D*Y:H$#AL3F7>2.XFAYA-62,8\ ME(4!:D3*]"(.=R>YF+SB?`+%(^BT=0#3[F;PM5?7\PAJ9B.SQL`B@,"GM`:/ MHDX1QS%WQMF5"-)7&FT7P=5*;0^_."@N4@@'6\./!D^`;R0:"H`Y;1DRSD1! M4'"."+X2/_8*LRWA]TVEMH??W%'5Y@[,/K!5\!GG$6'"T%B?I@&2VA`6B0B8 M*@CJ=(T#RVTY\`8Z/3&`:R(@Y5"O(BT,D1P`E`J**.)5P#IR6"71.@"WY;^; M`CB[Z6J<*Y1PJ3IJUO?KC].B:7:1I>7DK..;9%I(D+!BU'(.)4B$S-9X'9"Q MC@2H)A45L;%3J*@:;Q0^0++M:;1DW06-M*",$Q,TLA0J9&24B+$^R8U.&"$; M%;)41&]5(TC_TFR4'+Y+JP<9A0B+G??!$,A5A.(60Z3T4F/"#([-37),"&2V MK4JT"?,'I%X'O`%FL.@AGF/#**^HM-@0WJB1,L-#MT'];ZFYW=)*7 M]-XG&22I+AG=U'1/[MN(`I50?1/+G0\:4D2K0%1A@F-*-@16X"UX4>!V.1XF MZSIPL6`RF*@$Q'AN*#(!$KWY.*.VV![C)8T&K MCB]W\,#5RL(N>$HIF,Y@P3T+"AE&`20;J,>\)9U'?(EJ&VFZ+7!V\S3:*G"D M$DXY#KS6FGM!=2"2"DFBMP:'T#C)9)!0/!4X.WM8>!4X3%GDZ_,7'2ED[$P% M;:,'M!BSEJCF,:]43PG.XS)'@/<0"Y&&,\T9EXIKZWWTS!+&&7*-&VW$FZX]A%+",JF<3,&ABSD`2!--=XV M6(_+*&2)@.4?DC"D."4*Z"0DM=K1.L^,C72,L,D6W#,`Z]%CDX4D3P?-)'6: M:ZD-@T5>(JRQ$Y&Z9N*'D7A&8#TNLXSEL-Y+2'PA!1!"6NT1I`7&1Z,0)TUF M03:]-;#^V$,PXUL?OHGATSZ3-(<[FL]$@W!0,&IO-*3YC`%-Z_N-J4'(UH?" M+;?T]]VQIB`;PR M*N.EY]:"]1QGTN-Z*T3;YFF=!H]I!6?'BCT0S-D%[N>-TAB.M+$0I3#DF.J-C$XXR^1(.8X=E@196-RM;^Y" M`A)+?OT$*CXHM$(I]5I+>P+A"2$'2S-$)JH)%\%;!`F5 MQ*'Y;`C$J8=&[P=H?7>?\=GD>?AD=E/#=.F$0F1NCQ_:AGWX\0$9'81H2(F4 MB3HP#K',(LA2F,)$:2A50N-N+XX8^286?U"#G0&T?(O(Z/[-GV%-_>M@T/V2 M]>ZYTTU41-BP8)3F/(I@(>-$#$&-`0FII8T:6-!O^L[N5-L9J%!UWA,V1I"' MX.J(51S*,8U4DE?0(T#? MZ_[]PQ4G0"XF7*"81VZU<(QR*AP*/@(%&^>$.P-KI4(+$+JDO(+&^I^ZPTW2 MJW-74[FD*+Y"C%QQ$$[7K%.":V*@[(4\1-?'H\K"^H2U1=@+'&@C3$$I@A>= M;2.AMJ$&6V-)81!'$B.N@^H:P%58&R.6=$I8K`I5[$,8R MVE0#<\%WHL;X^?[U-QYN\%R@^'_VKJTWKAM)_Y=]M\%;\?*R`,DB@0"3V#O) M2QZ]=B?QPI$,29Z=V5^_7[6DL?JP^YR^6K:1Q(!E6Y>OBF355V1=3&X^=)N5 ML#E*"9%["2EKI9OS;K"L>GK/>`BZ,XJU$&QSUPV[C<#'/4&GDO*: MAV#[A;4NGDFNS^7\K]_Z/ZYNQ^'!Q)2+B^"S,HR#&C8:BIRR%G;;![)*-VZZ' M[S-MU5;X4SC'PY[5N^;DRG%P9S5<2S$IU@#39``Z%&"M M-B\Y#OBLLJ.D?T2<.,GOQTX&MRC8$[$T9Z2,Y3AE[P'\&-[CM4F>'7#!0&C. MQ8-]=MLC@]#E@;[IL.O0;2$&B\CFJ(SW@8LK``-J%KS#P>K%:)RZW(-OXW/L M0XK@4'"SC*E:><>V&:R"7,G)Z^A,P8>]RO$?XPJSO@HZ#[B%#@3D)4Q>ASV@ M"F`^B'LZMR\X7OWWW0]7MWW[S_<_VW2[H&-X\Y MF)@B@MJ.Z%QG:G"3<*V(JU39KFOU?>OZ$G/3=ZY`2;EH"D1-%5(M)LUR`Z)] M<^QZW[';_UJ!8W8[9ZV]$@'L'*G377*VJ0TT[:&'^ID-6,[0/I?WOSS MU'(08-3<;;!>.ZJ$QP\'/ M/G%94,UF6B*$S8I96O(E8[.*5G=7A@1\;;TQIX#',7A[7U\M^8)_7M_T>%KBSXYX]&[@>T%-J'+&S?6N(CS3U-.X70/<3Y#O!G`1Z]KJN4+;<7'+9 MD-8QPKZ`P#A;$3/UON62V^K+@U[@VEKN)+!!>C*=*/428VRA1MM40U0];A+G MOPSH.4VWEAP\I2T($RAT#?K"D?%GY55-;>P9D,+IVP,??UB=8Y\X54R+"&VZ MBZ02SJ>\[7CKL_FEQQ#`-.:??8VZF#'EK+JL+Q[ZXD?FDN`7:T)1M5]\WV"JNA M(\`&J34$B96WH_5])\?=FB5U&;`SFLT*%D]5J[SO(%'2%SN96GM+T<"L["QQ M5R]C.`4L2U;U?NU%G\)UNIL2R,!@R#513:%:W[1$:BTT[69VK=X-]P',T8!G M]*M*P:_.2L5$%8P/ITR9*$F##,R[6S"\U.E"@.=W;^W<@[PM6"K4+:>6FRW5 MN\0EM*IW:]A=$/"<;>BYM>ZP:Z,E9BI)6?`/Z6QNL*UG#%FD`P$CF'TKI0#W M%2-@@Q+AW"=^?<(7O_KXD/2UUR7I9O,?[HI-"^0"01JPO>BZ]XAL$C;.]HL' M&^T3_'MC.Z=(O^X6B>`$">0U)V\@52ZP*ZD)GY(V[XZ_2I'&H[%YR9Z+M.V' MG\^487RT](>%`_(6S+:8'2*IYQ9I9I62I-5DUE185T"U#`$+0QSM\+7;>U!> M3J3-[E3YKJ\DC_*#O`E_NKN^^=?&)^]SR#9O/*QNJH#O((#ML,/9@>KG:EA% M3;'FK3<>+RTM2GL0["^BAE_GU%"E%E2K@%`G4;-!O'ZN4IPOW4;*CJ/YS:EA M/,R3VUZFS@6\)R3-UB7$J5YV@XLE.+O+Z'Z+:IC?#45.`QBK%&U4Q)(Y8'\X MQ]J1H1:>00T/A7Y_7WV07)!3;PI;JMF4F)@5HF56I8*,J]AM3:YV-]Q'2%K1 MYN75(J!3X<]VB>DJVQB*SQ;\!HO50!^-E_XWK(P=RA(L2(0[`_R'=[GM%:<_ M75_]8W4KO8"D5=#M+]=W;SX\_7=YVOOI^N[7U=VNWN!GG5V[\XJAMFPJEQ9J MA<\VL/@E*WS4H\S]&5]0==)^J^[.KHVO3^>/?[M7G>VD**K&+M>2"'TI=%MZ MM-XX>;:FM/F2<%]%HNSWI.3'254W#W\EG[?\4G3:AO]\NQVMRLEX(3*42\G5 M542:'?^;I&2\UFOS*_VH$W\!?6_5Q+>S"'N<@"<5OMZ)';%2'A=K%4*52NJ5"AA M-.DAIL-MS:(BOI1NOVR?"H[))Z>5M;7;/^^_?T5'/S[J]^S1%%K8GYX(B-+Z\BD M0Z^1DBG9&X0*V7*,TC1ZB!(D_WI#`:>@O:3<"Z]O`;Y`'FZYET+.Q$*UN)Z2 MI($TG\9'Q$G)]OGDGDP,X?>WZPZ1H:$*\WRS4%-MV:."1F:S/I>'0I M93W?BCSW7)C0LJ\Z]K(>J@3;VHPNP>G`"MYT:+64[,3'?HLK\O/J[N[#S.BK M9SXE7F,E:NH1X0\IEQ-^8_+-M^!B&_L"(S*-EUR3)^IZSE69)4K.PE`S[`4^ MU8,XD@TM4(B1E6O3!_G_^$\7)HT+OUN5/>=&IA:2CJ1;8"&F4M,8[#: MX`=S_ZVMRNV.G[.[".TY5Z,IZQ1KRIPL!>-3D)Z)G!IE&)8ZW`.,?;PNHJ?G M6`GZ+_VL*\&Z&Y,K(Z*E2BJ[P$PNYRYMW\MPVT7>JO-8^*]P)LZYDV8'GR=3CD'5L-:;N ME+2\ZT,_"1.MW7QZ7$!T,OHY3U]50OR5HJ%BR*927&C:!T2U8$@U#86G1&ER MG7E1]`L)Z:&XWBEH"U\HTZ]BX42B8)MBSV;H>&.EUON+HI^]EB&?'",VIJI% MX86R=Z%[;*4L%\MCRUJMTO'H=[;OFLL+D"ON&&PG7R.9UHMWON8DE7Y)\=A6 MQ*F8)CWDMS;7.JZ96#"F8;$E;;]1E"ZQ.A4K[6(;F/S8?=Q1=,GMC^:QKQ-_ M$DMR_V!T\+(2J43<.)C2\7$'SF0\=\9J0W]#KKM+T^>7.3A;<3^&>9]G$.9W M__/I]NXX]J^@4BQX4P@#ULGZ1#64[G,N-KD\!$POS*3'^UZPM@JR[G/[X;'4 MXKQBP>R6[)F;JI9D8F*OVKFL2P9\"@-AVRG6`2`WA+R_XO_;]>WM_=7XF/U7 M5K]=WWS.$%K=_OC^ZOH&;FQ=*[JZE79BF]]%.O5(>>3=']*D1]Y$=RAGP8NI MS#A8G$S73+GJE+H8(T6Z6)=I2V\$G38OQ[^@=%^55N>V7(XJ=^GE$HLG951L M%A3)=>=*:K"@@W]"V.W_TNJ"UV_2DJN!WP<$6]Y2ZC%D8VIA6YIVX\`.)XFZ M?VEU?J\6KC"(-9MD,_66$E$C&RUTK(P?QZ`8YTA_15K%]WN@/0^O5`?;P-J3 ML=6`SB.*]"RCYGRT\'XMA.[RX+@]Q6V'=0!R--AYE@'"VS+6*032#)\-JA9S MAY/V[-J6\6S)V\NA73BR'@0BL[1T-(Y4S<4T^.%4M#%^VTP$LG[;B3T?V'FK M7/N93-IV$/8$N[J5^6U#@]@]MD`JR16/T"%* M5UT@+"W7VCJSBL'7P;M$-^GX-V(X&.*"*J/2OG>3D_-,5F)-;C9&%WM4#*QC M(M(DPEF&N-&7\(>K?<8]'J[IIE6IWIM@`FQBSMQ2J%%Z0LO,OK'-NYNTDCL. MYT5$78I>;*Z)@P_!*8)/+2WA[++J"`1R#6,UO??ARXGZ>9+DP6MH0FN!%<.J M&R*8G0AV5HUTFXTP1P/#34'ONX:?49U!C(7UT2UW0S)Q.6NBGF0$24A6@[3E&MY7.:O&DOP7 M6J?!+,QC.E6"I5BR9NU55MWJ0HY+M#T%R]GG)E5\`U5`\#EZWY,D6/".Y]02PNT;E/:&QOK MR.'0,#LI+V:#*,%,"UYEIM6E9'I]L_H(S_78'N6!$L`(KK_AMG$$^[0/T=9G M'5Q.<$B*Y0D*W-TH"XO&8(/#_@N23CDOX#Y`+R+K4@,/N-T:/)AN4U2EWU63 MBM\6##:J,<.SYPLO@\#/+NOMIQNI,/AL)/OUS8]O/GR\D;%,;P]LDEG`@B!! M#3`*9+5-(//!:D>(9[6/@S.R3MLI=UL`="K\V6;[FKQ*L.*-`CB]7`YB78S* M,GHMC\&')6NF%/FL\(^J>>-8P'2:[0P2;6$CI$*$4O9(;/_]@;/-)Y@EAE86G0_5@#K$$*S,3QI,7IV3] M-&QS>NN%=70]$!"1RCZ9[%3IW7E?,,7@X`Z=@H\D&:H* MMMFARLJ)>^"Q2YT?8LV-GW\8MB6&KVRQ#6XA@T)UP]F"1960BHTQ1!H9_G#Y M-8?M\:;Y_OYIE^YF\T)`[G2!*;394.ZYN-"UP>GEJC4"QL$A3]`-"(Y".#\R M1)[R4]:(8X$0!R3D7A0;9N)0QQO_\R-<:C@82]'XL7`TB1#/I9QKU>M3HAV" M[2G""\";O8OQ51Z3,ZBC)85P.<.M!S#U%ER+?>1A%53!W MI`I%6PH#DL61,2T.?@TF,$[F_>X*;V:HER&P+9VJCM3\K M8Q=&+R/W#L6$`&Y=COS']8=WJYO;^\>CPY070J;.&1%.MS+;+Z9$*K#W.1.4 M.!S;+7.DEP"=B'YV\BJKV%*+6N/S9$1E\@6L+"9XDD*CH]LR>_I8]$>%8#K` M'BH/0X[8Q<@]AC!B[J9Z&$L:3E"*(#R[X&Z+3TYM+*)L6M-+"<,P>*D5,@$6NR55HI$9OD:UH'P8TU2_ M$[68I>+K('F(D3A7&.J(36XS-UUD,!WBUL%&?R=JL4ME%UP]#D>ODM&DBQ3S;!ER=5`Y`?:8"=OG$\1GU^4V<$`.V6RODLCNY(:UW4A4_0N2D:Z MOI]*-#;=F0X!VTNJ1S0R(NC]FM+UE4QF>XN/WOR^7*E[#KDG$U&B9QEOQ5A0 MTLFF:!`O.4>)(@+RIYOVZ8P(0]LE7Q!P43&/P9:4Z^Z37'M6S?BGT;;CWKRR MO91".?B"6-:FR@7DN&RV`'BJEV3#@F9V2;BHFH>*\W)]_ECM.R)."B9OZ^^O/->VDX M^PRZV;`B,3@.1EIE=.D:E9(&P7::F4W4/F]YK0DS5F19O$W-7%_]_LOJYD^9 M)7+L97H#S+IH;[I[;]^6I_S5[_)8^#5NS=[YDY.YDU2 M;2D8W]S_LW=MS6T=.?J_Y'U=?0'Z\I(J]&TV6Y78ZWAF*X\'MT.:F:3BQ$EDB0`:EP_=N`3"3"YI<)$E&RP%SFZ7\YBKYX^1 M*??+=&\A:H6%I2O_M6^<5Q%,;OY^>_4T(6&'192K1\`PAZ7OL!C#89_S1N>+ MTLV99&1R0R>%5%:OWJSM1=S(;'VS]%_??YQ>/=ZPU2W]T&_O)_-I9K=7[Q@I M/F_WGLY>^N+RS>3ZT_U/"^VY2H\R2^SM]//=C#_VI_1+SX:FU:318^*_.=_* M,AZI;?MBE%)`-W97091YZ<'+6F6JCL M9TW)17?JF[HOX]]-=D..S3(GT7,$83C&#B($]FD!595]K[(NL6-5_/,NAZV+ ML"K"POFHDRNBA@8C,9#7A5/Y&@&*Z39:.K>V%_[?382[6Y4L:V^YN9+9_;!) M$02V=0(`JC9T]Z]T"S;.)+N#;A$Y.I$#&SDQ9Z_;I*<+0C9)6[*9UI>)R`8H MY>/AW/7=XHW&Y$686O,M:03I3T6$6`(PN#%2HJE4C;7;QZWQ3R3.W\C"3CX=2\2AV;W*:3JR5J&10FI4F3@6`*;8&/- MZ-$7UBM[A`%NR*K'9/4BS#!I8EP!SK!(4>6:2,DXDU`:,@)UW?((=.Z(,/@' M%>L>�*V42C5!6.-4@!<1):M=447U9<:>B\Z+D.1@2F[7>FF@,%&R9\Q"- MT64#9&J,W9DP$+6Y8(N\E,"(,K(_:!]B2ZC`D9&13RFVF)I5U%-$HNT1]RI_ M4+'N$2`SLDY6&<8JK=XZ:N4SF.0A0++=:=O=@N0QY/G+]"%/[C^^F=U]N;YB MK?CZ]WO6AG$&/D/U3A9W9ZG!BQ38!U'-GDK3J79O7?[#KT&IW6D;C:5MHQES ML;8XK,X9U`QC0I7%B<4%RR"@9UN+6=\R/2Y/BRJVXXY)"\I5WE2E(\HV9*49 MP+3F57:.>>Q.9@&U5@6[.W6C,;6M.)"]?TT`LC0+D\E!R4Q>6M2-.RHOQ5.>C20DM4'`QVBI%(PJR[;ZGLP=>&[VQ.W&C\;1M M#%>)V29(S15"#.(@8O+2_5]`M6XAL37.[V11._#T,NQB[_KBX`*XJ,2M5:9: M)4=>`]/+CH&=0O=N@4TFKI/]\OE[4C8\4ZXBUE9SR08-INC1VZB)C,/FNYIO M5%BKMS^8LFWUQ"B]$MHG_AUC0\K(O]?HE;-4H7/4P6/'S1Q,V&!S>J;*F!$8 M+K(.RB*VX*7T*I>(G/EW=S.@[CK`72BC+Y/K&^D;>GCL'A20418M%28(<<O]X\]"S[W15("DRK&*C4TX'+^4E'.*3SY`4H\$"8:-`U-X"^4;:4W?F M`3!?)Q,5(T*PB?$J^WH5*FL=Z1@X-^Y!AIP5K*:1'2(.('%P7IH-5"N@D5L6 M*#'D:%S@;"3)F"7;+2Z0WG$8E\1M\^>D_9*TBZJQ/8 MG-W:C>P8)`Y/W6T>H"7E&487_O2:O"PS9NH2X%)$] M7:T2?M&FDC*CBE01U(Y M*$M.X63%90JMX7R=0HB9HR`!L%&5;NL\*KV?+-],OLYG>KZ[>W*A+S[U;[-# M2+;>60:+#F6=-9:A);FKSYI!!V*W'%(>S7!77CKDC;V1VKZ,/7-S>36YE`*WVNGS]UGFQVB832&UH- MYMHJ%F5""0@3&?S!91;"R56D5_%0+;9 MR)$?.(QQ,B*WI\59*-IV-BX\?\BB!4@OL;03;:.PL_;*O,J.C%3U4>9>L[-K MX(-6WK.J*9-K@%+/Q@6FJ.448+RJ-1F$)IR63/R57C!*.=@_B? M[N\?]Y:Z+0PT@&+4`I9DE&VTQE/A>$G&K'3"/1.^A>(%&0=3.RAFDKMPGUJ0 MI30N6A:SA<%.MB2/2ZF`H$_IJV2ESS99G!V;E`MVYMQM)6DHYE8%ORXGU@D3?%"H_9%6JZ0.5@G]DH4^HI MX3/K:G0\`\L=B?N_I<;('D\'71AKZ>8".Y6D9=YF:)SC#,UDV$[-T<1O2\2" MI"HUJ@H6"[&WEN&M43<*'">[Y>^V)S#NRT,_M.Q,=]KF@1@19JJ59$TZVL+) MB6,D3YP-*S94Z#S[!1\[JK^1E"-H'IQG:$N$BDA*^LIL(6\1H+2HH*S%R`7- MT76DO1O-;]DS+5#]D>H=`^,\ML;&T8CEJPAAHG=-5F69`%C)8\YZ5)4?6I*L(.N>90>N5:>WI5)S/I#[^G]^\?/SW> M""0OT]^OW_>-T1A29O;6B=,";(DY9'4@JW+SK!N,N6TLW0Z-X!3&-;JWD70T M!T.JK2%QVFD5^<*./,F@]9R@I9P+`R[54U+"T?0H#GZ=W$SOWTZ_3&\?I[]. M9U^NW\_O%?:_O\\<.PUD-LN('$M3MMJ3R[F2]DUW'+CVLA)EA?(-I!Q,[I"& M`X/"S)Z#"BC4T1,2>*FAY-A9:^LNRV8E6MNP-RJY6^Y0.8,/*(T.(3(ZK%EF M0;H2+:L$>8[^7/Z2=#C_"EM_VMT]@'&5Z=M:\@!A?\+2]+6$]7D2P<]L6C7 M-*&7CH-(W3I$UV'^8-D M^OKR1YYNO>A?D]G5_!__6)1L+H;"Z*W/H?/O^?;T^?Q_ZZ?/-W=?I],Y]'S] M>7DC[\MMBD_.!=<:9T[(P%=V4FBMV:2#0H3\PX]OX+=MC!_&U:6)B[_[][O9 M)P&-BYQ_(:R7:3!"RLIW/,VJ6?MS3\2L_,D-[,WID)K]C]/7M]/.X<@XD%PX M:&$#!-G8E%/0GA,2PU^(P(=C_SJ<,QS.NW_==0XG@S$(.CO);CE(!_00&&%X M'W/37O]E.4.'FRM"LJ:Q)B"9HP,*@J ML7)R%K,ORE3G0[UX)[.8`OS3+;/YN$ADY5KRW[V>_3:^GHN]UQ MR-^J).=U7FMBE#W+_5J_^CBN;/+<$S'>K\@^^_L[%QQLUI-7!Z2!9] MC%)?R4E8EH$*1;6^UT0=0XCV'(>V*J'O=--22P#L M+=GV:*.YP2OX#B=W*1;WR]V\`W-ZM:@"'IZU'0RYP*L M37W%(!:M5W^&4]G3`Y[*C);=7PLN2=U4U!K0YS#?F8"$R:%*OFUV?_C*G??( M+L[S'7":IS`_L_+\V51J4>>8*U:G*0,IQ5D`VAC:^OJ"5>RH_Y2G^?KQX?YA M"_F-"*-]5``.F/B*TU'2*6I$H-1F_TE_I5.$OT MVU.(XQSM1 MT'-#;KN;S<]D3T'5ZC-!AN)"16U-B%H6>S?KV/?#RO259T&AB0''B-A;.#F_ MN$1:YK_-?SW>3OU`V7_6U2L55.88F=AF2R4+D93CO!TA];E;,$;;$^C6:63V MY`#J_TUG[Z_OY>L&%AI,OHF*&U4U&X$ M06WBX5026O./3U^9OIGMLMU].2[4AJ5A50R?66K4$CD#+#AO6.FH;FR2L>H5 MC*%A^[$VJCB7;G>W0:H!CR;%ZVR0)LH:3L7>3;5"C%0AZ9Q][+N:03\&%MK, MQ:A26D+#/S'HO;Z]OWY_0$-"=$HSF$=.P@,&F9)FHFJ^&(S:`G9V%')H`+=# MTQFJM5.L:K.?U^.\M>W'VF6(2X*UKY3?0["C,CFN?'LB^I@23B[(CJ68;*Z,_4*L3=JBBP\Z M-/:G&R4,K]P^JCLRFUT9_W.[W?QS[VL(^O!A-OTP>9BN8H0E0SO/7?$*H M.9*M6OIAFU3G6T>.M.5LL-8.>))IM-@%3]])8..<7#=16/U`O1\>#4:679KF M0F$'WE(@X_@OWV17"W6'MIN@UALU3L;)J02VXVWVQF*XY>>7EJ-/Q:H('E'' MF'V3>DUI0PM9+ZIG_<]Q_<+^O(R,*LC]GP7,#H+4&!3D&,A7F;@A3>3LCK6- M)?J2TJ)",/RL.T\?Y^5D59+BQA8=]N;*E;X5L0/2"O+C6TI`/*QE4, M%4)IH)LV5%DV:L7E?;M2=3$LV^?>5':9?!HUN'""^[7AH>4410O>9L3=3$RZ M4JJJI_'^_GVZ9W:;M3RWC)N?]O,;8M2:5+);1XH=QVF_Y6N*783#*LIHJS5C#\2QD/11K+DPI]+P80O%I.]B^- MVX&S-2D69HMMT@,R-B&7+'L\DJT.L6#OV7K'>=$9N'W]^Z:?LJ^]>A-E,T>1 MZ1B<[#EB5V]";LXE&5K:.T7'HT9V/UOXW$SCZ/P-G&)1TD9)+66P^_P&$7)_L4+X6_8)E4MAJS2OG).GC+&'(LLSX)Y67#JLTDM$YR] M,9?#W\#Y58Z+##\BD0P^J2U%"[&I"NR'&)KUOB3Y8&3/VDGYZWQ3VG6$_S)W MB1SZXIW7-J-)B:AY6U0"LL7I2+W<:6,#;.>NG\*1>1LX.>^JX\AH;&);HB@/ M,9H"YW-$LH:S_^14B*`O@;=AJT,`REEQ\$\%32[),=@AV70HPZ?Z7P8X&0L. MML7",_$V<&YYCEX0:@J`)7,*Z5/-!+&`RM[T#H7[?_:N]KEMF\E_OINY_P'C M/NW$,[2C5UNRGW3&L>->GFO37)(^G?L(D9"%A")9@+2L_O6WNP`I2I8L6:9D M*48G320*KXO=W[X`7)PV6^W."HBRPMSPB?Z]?^'3W57H*L2A],?F[R\PC[?A M@PF))B9UH]WLO,/<0_4VINOK=-J7H+4:E\W+J\O:=>/@YY_"]#R0MTRGXU"\ M.>A#DT=]/I3A^.R+'`K-/H@1^Q0/>71.OVGYMSBKUY+T_."GF_1\IGHH(W$T MH'F?U1NU'\\3'N`4CWIQFL;#LTYR5SQ*X^2L?@(/<`Y',L*KQ<[J6&)11_A\ MWD!E-`!7*IVM9[YB\3/*HNV;)R,SO!YX":9IHC:+^^PCK`L,@KQ7[.\UEL\[ M?PW37&7&Y=DT&]7-ANJ]_WC)_EOP,!WXP$0>>Q_YQPRXB,E4LQ$X/N'X*!Y% MX.#JK*=E(+G"2XE>I0/!?N+#Y/P'X-#:.;KI/!I[Q:/Z>?EGZ&713R.QZ)=, M3_V"@RK]&F>J].LA`X)S%A&E>LIA2 M^<)TL&U@2)`IS?I9&!ZEP*F,^Z#(V&"2,YW*);%.C\Q/DU[R]O4Q^Q.>8ZHS M3".+5.*^[1/U=!;Q+)#VX@$-TA=@PA;6-Y>5P<`U9JJD,"1+,H49HE*6QM20 MRD*AS9SK)[5S'(L2-YCR!7U\9#/51(K2Y57'\M%?K-%+DM%#NW* M![`XX.6S,$8H$6IHGY.7PV^4L%-?6XX?A*G*!?O+`!C_9D!K/'60?T,)H=&@Z!BFA\6(\7'/9D.V,EOF^*6C.F;7F<*@OF?FBTNB[6H_ M0!XE4"?C:!1'AM2WZ3-"7D"@1R& M^9L,$JTT#QK2+8@"#4."J@;UDC)HVY=.>X&KZYS#&U-BLK^(A-B-5:8C'#"_= M$']ET%TX)JJ78,.`J4DY1(V+_(Z#51FJZ)51>U!-W`'LXF_W%_V87<"X:;5R MY=,#3HI\"VC$2Z@]L&$B?D^(B(E0`G^0*,BH-'PHMB\0]#XB>8L3&<&H/O'\=I%`,/ MX+6PP)*XUVO'!%U8]6=7<)B$(/4+='UN,4!)5)0J0`8Q:/S'\>=C=@/28&`( M?A8)Z>?"F$>1AB:A?2#2+Q<7'P]+C`1$"Y"]`P2N>"A34IPEVP(KT&3`+%AB M9(`H#:0_("CA20(6,$$1-$+\+8<+K(4+-,X476?C&<*#BH]'./0RX?0@SD(4 M=BC+<[[_FD4D'(8890-E.2?A\'%YM%E)&"X!Z=]8>PQFT_C'SYYXG#O)K;.\]3+GMN%U'P6=Y$$I0E)A*=;@P4 M[V/\YV;CZJI[?=IJ-J];[7?-R[?-JPLZE_P6_.I.M[8U_QE50*-5L6^\FB=L MP&9"438A*XQ'TPJAKZ9L5)1>J>-?:@!*#1Y5<
(79C\\!&V]X)/_.84Y&@$@$P49GY]Y' M/G;`M#)-)"HM%$LCK61EF=>QX9N!S((RV%M!';#,^-"X16B%^-;R[6&_84C? M<\PEBSJP-S7;D^V$GJ8ZC@X<4G M!Y6V(DQ?!GF$@.<6XP+G&9<:[0UTGHB_254K0?>2@NQHY)4A6L[YLEL^T#H; M)E-.$AH](![XUCL\\:TY4S!MSH3P&Z<;VSP&TMH#D47/PLL974_;R]9Q"7(Y MS=60X7T]<6WF*V`1+$'(YG"8'_6J>XP#Q;CO`N2Q% M4V-"TE?OWW[X=%CV9^>,Q)M=F)@,.GOP&EP=Z]*4FRE<88"FGHQRWS"RX29` MQ[$-/][$<3"2Z(O!@"7@F%1(>A.]2?"N,DWE+&41*(V-;GB`VBS/6T:W<7@+ M'[YFP0VVE&,3=*>SWEA)L#T4MI M^R!'?H-J8.72UD%)13]NS/D(5QHVX7<"NN'.F)$FM%924GFDL,#-D'`4XZ,# M]$LMZN+/N(?2$^D(HQ`40U3RQNJK21"QM!BY#H.^"F/8JGD*>YE-AVEZD"[( MU`P962]6*AYA6`"5"14`#"#:@;*6:7F.9M>A-$4P6IPT5B2-Q^SC3*B)PK%% M_'N.<3J]G&8E:>],4^"OAYZ4C8`G63H5DPI$GV+J`*F_@L4:LH8M9/U,LI^! M^TH=#@6GX!-8H&"G?,!87K.P`J@]F3/LPB;W)2"+FF@Y*ED'7P36I%;Y]>=S M#=.%[1AQ75H?3$<4:6F41?>8 MXSY'-.NV=R(E2B'AK\C%_L7ZT+LAZE%"H+VNW4>AYFC+Z;<(CK( M4`72:7D'C!"E`VTCL`C_K&+4Q[B[MD:-9J]HCG&F@0GUX=G::[1H"4IU\F4, M13\]J\VL(WXO-VHV0*:9&D1C)(!_`1 MY@1Z`V3T""-@/-'B+/]@!@X@T?IQJ8=+RW-8F%>OKUCO92H>+IFT7[19\?0QV6$J;TUKG M/>Y_PP,Y48`+$ZNS'WQ?B'[_?(J]&C-GNLK?[;&O\B/:SZ,XLKLAQK]5^T"/*M4OFITFI7IN:=2 M;<*"F[,6*N?20ZQZTRBYWO?8 M?5>(7IUMORH)MTRQ#=@J[8[7ZMZ/S6^*<'O!1Q6:.J\I-#6O_-8&MDZD;B<& MM_50+VX4V"/;:1;@[N7,VR/S-SC,NU^^/;ACX\3]&-\187]E7*5"89@8]\#8 M2"A1G-VFPD"M<$P*P+.'K6;.-B\_S)/OMXYGQJMG]XN)H@]C_`Z/)`M"MI#.B#^WAFUE`IB0VZC4?>WZZ.0_*?T=[ M)_FK([^53I[]6BS]^_P,VG[(VY]T5@ZT`:W6O$-U^'J%NL63#_1R!&Z2V=.I M=.9%2_AEWLDY\XY!?A`13S6L>+3.QC%(T.F-;WOXP&.]_(TL.B:KI'U?",^\ MX2$U$BZSF3B0.HT5S<64X"F(/[TSMF2HGCGG-N<@87'FP&QL*C8`6:5W,0P% MY[Q_<:=HV_UM MN]YV-L+<_#95K[,GXW3R]S+Y\WN?WW;D;^^#CYWU3.M)M2*R^(BHSF2P[2?N M&&QX8\`7^#I&->2:[V8]?,YJBV0[F-@!S]9<.<[].W@-R#%8]@SDT M$N:4-U1V6!ME>=(#A! MV(9>>/OADQ,#)P8O7`SHU,M.RH&+A3A9<*Z"<:/AA;QO!:Y$ZES]N.UVGK#:S8:&Z?77K`- MUGO*V[1[!&,[9P`X!',(YA#,(9A#,(=@+PW!VB>G#KX[=0%P2I!L+U_&?WI)/RUN`;V M\8?!BE$_]4J5=4CZK#>G-!I>MUN=$"XASZ[PRJ8-!F<7.)%R(N5$RHE412)U MXM6;]R^:<"+E1,J)U'KD:G6]>L-I*2=23J0JTU)UKWVZH>O6G$@YD7(BY43* MB903J2>*5-L[.=G0A;1.I)Q(O4"1:IUZC:;SI;:Q9[5#6_&;I.WR!!;/?FGX MHH78%1)N[\+PIVS5[\QN?+/M-1OUYZ?9KK#/I@V&'0*RG;,D')HY-'-HYM#, MH9E#,X=FM/U]TJTNX8%#,X=F#LT,\S997;SHTI4L?Q(A=^#[P<@K#8A^5C'R9 MA$NN8%IETE,S+/%Y><;-6G4SIGKO(_8;'[-&K=[R6#H0[%I&'&;$P_(L/Z<\ M"K@*-'L;PS],:IV)@''VR\7%1Y8E`4\%._@D;D64"=97\9!=0F>*^ZEF(YD. MV&6F846%T@?'[,M`ZJF:2OR5224T@RG2=58LC>&A']]$,%KX9-H=#43$9,J@ MW4CWH2V60$]2PTANXA@&%RN&-\-)W[3@YWTR&3$.?X8X'Y@E3Z'-?BAH=/@- M&A5W"7V'HN+.'_#H!B8"#2)-[K4^9PX\U/%D(L-8"1:(E,L01A=([8>QSI09 MEX@0(5BF<6AQG[KH%V37*30W!$I068!,*(7DIV(13Z$5STX%5DP.<7WPYRSR M`9RYC-(Q-IH3#7_RN1XPM&`TXTIJK$%KY$^O44$OG)Z8FAU,%N`:""1O#5GZ M,"48[!@D7[-7V(G$Z\[D$#I.,&<*])'`=R0<-@YD+5.+!TDA_0%W?I0+H$"!!9LN='K,_899`;M_#`GG84I+58,L^+X5,^0 M]OAA76$___-UIH]N.$_.WG(M]>_]C]`VC)J:O(B"SR#VL@\J-DHG\O<1!N># M6'P!0KP-8__;S__UG__QSZ*A#%94:'T9#WLP=FSHJF"XH@HM-GSY)/IO#JZO M@'+M_VW\WY>K`R8#>``$.KJJ75RWNM?O3CJUBW:[T^BT:NVW5[5VL]NZJ)UT M6P<_ST!9&62^R"%P-Z+CIWC(%QO)JR)AHU4QMM]#\IQN`'0@M6:I*T;Q'+4; M%:/V-4A@@I(+8,1X:?@@-**$G#P,<[;G6@O@8"JL1."Q<')[(/Z8#1'0(_Q_ M3+P"D\';\%`V9&!YGO'4-#;I\H@$J<^E8BAU!G`03"-M^B>TQJ%"=25"DC$_ MUND2@5F5UO6331/[*E,YDMP;\3KM:7D'^B%*!ZCO$-7^E46"-6L$9_=?IEJG M"V(#/QZ"78+DGEDR9(E*N@%85ZD0][-CK=,8&\0Z(=-+IRP9C#5`'BCMG,U! M*8&M`MP8"<-+I+)@9GJ!!*C`V@4C"5R(7!E#:05PAU9&7Y(.!J4%FE[B1RL@ MQ.^:=`>0:3(.;"`?(>,W2A@=O2],_$M."%#/1N-H8HLD3I$<,*=>#H=Z'`EU M,S8F`I;Q2;$`-4NZ#S4A:$YQ9VE%R&&Q9;)F4!V\OIL!6E^`"9S8W:@HZ#$2 MZ2A6WXC.*KY%E('E`VT-7Z`<:!%^@V!!RMV:*M!7J0@XC*%A!ZQH%];G.9.# MRSD")I$1L`9'T\7J;$`?IODMM*59CZ/]F"50`^>J)_H7ZO45UZG*?#2ZD*\& M_!;-NEL1`BF"8W9!9IB>\!O7TRRWA-F(AW')^SA&`9A,8X3.HCA%(P\,J;^I M+MI<9+E,S).2H94IL%6@9B]+J;:MB=8,FK#\;E($@UG52'^];6RY2AK;%SD" M#,+^B,/`&B7SDM@KG-&4"9=!KB[1%A/(D(*#05M2B-Y$->,*@=N!:%:`"ZU> M-4A=%4C'66%([Z`**2N"DOX+]D^#YXA(++#0'`,.[`EBM9*W!.7@]Q#\H!EL M`^:3@%W(6KB&UEW,41T(5')S"I-A&L^Y+M<<"HX^!C6(9J!Q')&%K8B@$\7' MAI=S5"M-IAA9/R.$%;!@\3@?'\&Q`(#/'=*%9*A,3/J@T_:*$T&_"K%Q7ASQ MDHI#+\!PIS8KW$-'%IS]"&$XGZO5P#A1ZXS#`YUF@2RX:-8J-1RT)WK@3^!6 ML'R&Z/P0!T\<(!20Y0)KA1/G#LH-76J$,R7UMZ,^,M,?QY^AJJ+F`$)BL&+&4H306!B"/GHB1+1!1.*^+Q(*B[/>F*%QA)PRY.H;ZCV.6PH2 MVMP?:QHIVP?;,QZ1--/,P(.&&4$Y8UBG,3D*LP;B/JJBW&NW]LZ,)SGEMA7, M^4HBLL>9!BM8'YY5OEU1JC.UGUF;67K\7FXTBM60A]/L@F6*ALUB^J!W;)DW M![4#^JX3[N??'Q\`&\D@'%N@%N5R:RW*Y;'$-YM!]MXYY5)"%?W;[=.^X MM0A:'>6;.Q1Q*'O0#P?L-YQT:5?H5-GAEWTZPM+J>J?5W7N[*TN)]78U$=+> MX\GO9@-@-@R[CBY;FI>L2EWVK`G)3BI,EOZ"CH&]6*5]+>\*^W(CDO6]9?S; M4#(&E^QO#4!N[[V']\7$G:;]O!D#VBF\!Z_"K'FMQHG3>4[GK>.H\N!KIE,* MP_?IE):$OY_BM;YYZT]\O\/=T!SOLPWL2H3SN]*?=9;6Y-; MIUYW(X/\)DEXB6?L:0<"-6KY9,5&MB'<;H,+&T[S7P5[#R_0CWK5JGOU1G6W M@RPCC#/=OGLRGE3*XFC=UJK+JSA_"D7B5PE$NDO--Z:&TM*O03@GZ#O@A\3F=K=Z6Z(-YNJ(]-DO"#`/DLA#?AX^*UUKF)##8AO7LG MA%VOWJW,8]L51G@667HAVO'C,K'R2GEW\+5[RM#CPI@/:L*6UZU7YV*-Q>]L]GHM@&MNE;7KVVQ7O`]H&- M*L2^Q5E`EV2%6RF9VU3^-R@ZE'3B3%]$0;%'@@GCULL#UZQ===]V6M<7IZU& MN_FNT7W7Z+2[W>ONU?55^Z)5^\[RP)7H1Z\X3E'PP:5?^X5T>E#EI*CXPXE+ M?Q4W2ZX!WYGT=N]-5A"`#!`!A>GH,F42Z&#.J3Q1E6>R#/CQ$%W*VSC$C%#H M6]I,%"9GIA(\%9B\*L3Y,[MS3S\F*O[_]KZN.7$DB?9Y-V+_@\)QYT9WA$PC M@4#T3$\$&'NC]^Y,]W9[=V,>RZ(PFA$2HP]_[*^_F562$#;8@"51@GSI-B"5 M2EF9)[.RJDY"[(770EMS)(6")Z0T*K(]@`+FS@5%PAPN1/K*.?-RGUXX&)_] MG/./IOPM$V0\P%ZSZ=3U7,E^!](5I&*1X*Z).\BT7&JK2[\'(?D*VT\,N$3P4C7R7,>YO(:BL@W4A9)?0B MMPV*-^1W+F".B*G2X5\_TI(#0ZA7$@MYPSU1`F)]44$$:X7@KQ$<8$Q#YH\0 M:9_8!%PB2%;RHV:4HDLEW8]<5$>ZV0*YJ"#S>-KCC0/A]',FD1)7!YX#=[J7'(3HBPWD%VC.Y4)V7:;ZQ1=,),O% MC[Y@)&EG](SH(?@\CB="$MR';M.A<3K:9LD^F9$Z@KN#*@U2MT(T5 MW)+KX]&MQV)PP33X2HO9'`.`*/;X#0`A#U/\!R1%DG'!%"Y")3!6SM"H1'O" M*G)%OQ"_;V4(8(`0;K#;X+VDV,80)7W+M-NBSQ%ZFHRW7&.I^>4T=/(6_@"0 M(;..N9:YD\R`A-ADM+="[8J"JHH2JNQEWNN9,$S!NYLJZ&3Y(KR\@*' M.OI&O1-`(J@)/7>:,1,+94V)`*4[N`)=X]+[(3MW+!^_0D/E/A%>:]D+1-?$ MQU81`Y$(-26LQ0?(?H#I(O482XL!Q*Z80CA>,DG[M&)G*T.&]&<>1D[+:-S' M2"I"LFM^NZ3'%22UH`@Y*FWR!P!#8(C"D<%MERFA+5[^&2GU[\".4A-/G>": M\11!W(968)S0-O+6"IB1-OA=F&[1]+$]PTSG'\*R4X1:N@(YV9*(M7X@TAA` M,Z1>I`4FUO1>=@9F.$OI8MLK'6:W*.18^_SU0O0N@QV4--P(;C=R)RX+D;EH M,_*EOG?C4_893'V)9TN6Z>PM9Z"&\4R,>>Y=BCY>2UU[1JZ6^@L=WH__D=?! MN!->BV-L/F%S=IL1&0MK@0D//`/?6[J`S7:DIY)[TG+69.'V8#X':<#$$S\& M0J@XM9)-'X!X&(Z^B`3T"_A>'5L0"A, M/D-.M0DO7#Y<:L>+"IKZ?U$ZXCM?Q&DM"CO7\""%A=66,1*`6&>R>ILI2UAT M,WI34-`5K)EP1Y!L9E"#/)RR*]#,%;\)I0;)T!K:`O7R,U1]+CFQ[!Y*K``? MZ(HWRK[-#.-I%[XLP&VGOND+IG"SYM+'///.^_A.\SF-SS[-/-4J`8I9VJ4X M&.@9D<@8C.WW!$P7TPE)7/0/4CSX11I.%P4)C\E&)(2I"L*%\&.!5WA*IH9I M\D;*5Z!GRO#-_5M!;[[TW8*K$W3NL:;\C#DH.V\7(]LG)AQ@2A\)AAT06YIY MD.5[BN$&)KYNTFS#'9:D$+R9Z(N#4'R;A`Y?3J]D!H;+"&#"[X*8Y['`,NP1 MV0)9U$>4?0$\F&)-"_UISF>E)RA!.0>I*']S3!F*,5Q[)Z?J_Y3:74N.HG1U M'7JQ#-IC$3$"N'F/Z-L+P)]:+ZHU1#B>EU:2X@PNQ;CH5GI`/\B9$Q]!C2)0 M:XZTU-`H.DLFL5U'Y?KBQ('`_K:XT^QFGB.:`2K,`D]@[%+"6?)7SJ-21^07 ML`K4#C=%.H`;69";QW-C")GO1;R9^KN<\UNFTC-2$.R)F-,AO$-8`',X&6$$ M(G$21H6H+BNWY+.Y+'C`X/5A<@/.U()"5<96X`@E*T"EA MO(41:8@<^3+CICP!Y`L,1CT=%"=.9"6.1+9)=W%!]1 MF#]IW6)XO''H5W`(8I]`)&9S]R)"KD4(45]:&,L2,\0LG%J&`Z"UCVF05VCP M^6/U/),NW6`Q);Q9BAH(C^5Q6^8>TY;$KRMS5#?:8%$NN9*]7,GS%>7=EH=7 M5I;'_";>;PEY<#$T^MVVU6N/Q];`MD=MHW\Q&O;L[F@PNAA>'MD2,@JJ&4NK M7Q*L8@BX+W*9N((H$MF2PCVO/**]NY#?P&`*I_8^RYY&(B>5W2?R"DA"+Z\N MJZ[4_S%,J]4&4P)\7[.1?Z^Y09;2E;-[/V+J"\7RO\]Y#C3FL.^9Z^48\K#0E5)T)MGI]T\Z\ M]'=9P@[D(8IV8HM9/CNODY46N8M:VC`J33"K"SOE%X6;,8BQ@C`4E0O*Z_;_ M&;2K,%B/HT^-JH"8=JM3;G\A'A!U6O.%I7+ZV>FV^B4+-K>+9<+OB>TWJ0[' M1F\D8CD(?7@Z!\,)3N*Q9>$5MBR>`E$7%G$6(6-:OR,$*8GH]Y[C-INTR(8H MXI669KGATT`LAX&.\@BK\;('G(1,<-7/<=,8,JOBEB_Q9`_U`_];ZGY]'7[[)8B^EZ%N[U;=^*,VEE=*045J71&PNTGS"HZZD3F$R!@(7@UFB M-!4397FCJ\M\0,$Z/;'$;;>.7&G4S!ZW'QPPP%IN)_.MEC0E%F-*4K1!IRPC6J-J3?+E3_4` MJQDF3*QJ+7?2KBSUKJSQ3+2O83"%V%P6IOLEW9-[D:8#\[V265BPS-DZHJB9 MFZ<0HWR2#`_%!X(!I3L7TIK:8D\O9DCA_[2/01@5'("VK#(@MU6L%AU8/^=* M?7$DTHT!6*8#TZ1@CJG%9;X(%XE\EFT\0A/#!6XY?6&8+<3BL\5;L2R<*+R7 M&:'T5E&AAAFFX.[2;743/F40$#5J7K/*:-4P7A19^DWGL"]R+_1W3_B-T>E_32IF[Y-GZ%W;_LM^W^L;%A37H M#$;]L65W!Z9].;JTQV/KR/)LWV,0R[F0EE84:#-R;T/UO5J>(\"MF"AK&8[) MPJQ)#KB=F-$CY;V;Q&=(%J"=$WM\L\$`?IK<2NL]A7"+^U=]A-\>%_NDR,_2N:>K&FC(N>\DL%5:V@IA*$%]-@O!JVBV3 M9[9,Z@/:X)+D)#U1<<.S'=XR&L3*H@L\S('.CTO!KFP_AKF4.#C3%-^$<^K4 M/972HF4.=-MZ?AZ][+%<'<;TN(788)0%[GA+0?7S"M3%?90.CKU8@90KS%,N M`J_TN2LCO\VH-R24'6*(N)`)'ZGKVE*:\2>Y:E` M-)C\(#JN.)*6]JIN0$_H#MRBUFV=(XC M*7-05#&^CHKQ1N^-)>.[@YI+QAMUUZBO_3YZ054ZJO8+-IY8S=[/02YO>Q/I M=%_M>@\.Q]72G,3EO?09Z*:9M:591(WXIK M->[#V[2-`*]2EOTJ%/"Y)+?G_3NTOJ[-^1\4"$OC3%07)4E)=U;2TECYR5NK MIH>JJ9IB>$BJ=KRJMC6J$?W_:Q77HE?RR(<>"6E.&VE,O6T]9X$BI"&D(:0AI"E3&AV]9]N$ M-(0TA#2$-!774&V;-'NJ-+%S9/D;]J#=<)]/W5CNLBPQE5-:C>/&%7!\U^N7 MY^^W%,Y2MZH#K-+5[_TA?=N1^?X3-K>^7=Y$GLR-S(W,[45S,_1NN[SRQ&1P M9'!D<*\8G-4E@RO5X&A1_ZV+^KKFAF6?7$5<]CU%=+_"B27(9N MM)_S]M8N,E6TA_+MBN;;"`C,",X74DV_:5BU%&P68"EI&=]$W6>0 M[;*_WR38*&O,7T6G;;?$@;J*"O4"M[M:KYXV?#KQ= M7,NR0Q^>%6%1VLVJ(L#ZO&F3G*9AZ`.COOW%JBA#U>Z1O.`!D$9A9V?NY^S* MW3NPE]*KLZ7@.JNFF-;O8VZHW3$O$76R.'-F&PHR:4&XIB*3K%LF"D,^+YWF M1JOEMK+JD&FY)EDCTE_6=UQ3KHOAKH%%$,:R/NT+92-;FO;BJ[W8]^?UO:#O M$RYK+^*N`]%O)BH%\/,+%GJ!%KGSQ).;"^;!A'LM[?_Q1RR;GLS3THVN?+>7 M;A+;"/"BT(W^.)]B[0L7LS18[@VDR?7E3H2[`&\4]==Q&X,3A&(_A=Q>`9&M MZ[B@,$TI(X9CM:SK+CP=CPX58G^[_F"2A:&96 M4OG:R'V`\1%5(?A*58CR-LW0UI!*2H?UW[@WI+/WWI#&%(+:\[[:-\WL>Y_9 ME(X>>\FQ>G8]-22KH=S,XJ#<"(IO0OHNBH?2-+9\9:,=;QMWS9QO&Q'6VKNA MPAMX+A]XZ+BO$`P>;*L.SF\)0@Z1"3O9C7<$(?OO`52Q=Q?P;2BKQ2O9OVL> MS@GB*$JJ`T1N;T-^RV(U8>0SV*GK1ZZC9._^@TEPLE.R4PI%TE!DNU$_5"^O MF!LJV;&=@*0AB3G%]M=OG9:CTP>'UYWF>B;2'M(>U>6C\MD5]:2EG#:IBT4U M:)/K+V4&D3XIUDDHUL&='!VIVZQK7])M>4$21S'S)V)+GR!8&G.'SV]X6.!' M,L16K^KKHM5X%J`2(MI.5[J5US8J5%F\KV.T#$(: M0II#;S4@P9'@#K>B5*,0FR`X9835-(VC:.JTHRG#;/6?GV2B:.I(US+?+L*+ M&;(Q1]E9.\F8_/(I-J57-H\?D8_,8RF6]E5./J0_)!^2#^$/Z8^:\B']*3O` MWG)^;S<]],[.N6U-_'R:RY'ONCU]8%>_1/!<4:J3TN&JG5-RK89-O-498MW& MU^FTVN75<3SV?!(9%Z7\27!-$1RMSI'&40!1]8)4IS6@[3V5SI>/;%I\@62> M7HFSX@I.ZZHS.39UJU_>?N8M177:4V1R9-4N^AYVPMMM]8RR-$45U:]Z7DL6 M0?(A^=`R$NG/X?7GZ#RRT6V5=V+O6#PRG0C=YT0H\OT73H-N(OYO1/4R9::@ MAF[877W0KZ]0TM&G@1IDR,HYPK>IUCX"5%X=J5;J;BD`H]4N+05`8$9@=B@P M4TBRE1ILM]4;D#:JKHWD6LFUFK8^Z-)$@7PKH9F*ZDAHMEOFPVSUR]O;Q\]0EET=#1(5.)5*73<]0FFTJY4X+_\<11JBB7/5%"TT"FTZ[U:TO*%!% M%PAHCA!HU$[YE9:B)]TB)T9.[&F>KMVSR8N1%R.D(:2I.(=FU9?&4$472DR5 M?8@Q2[3N^MHZ5A":Y_K\?";KIAAF^X<5731ZH'E"K*X/8!1_[+3ABS+E>CWC MVC3P`/!PTY^0C!8E\SD+X;I(B^'GD$=QZ#HQ1UT*G#\T=L_"B<;\"9(?3H-P MCN?/5G]S8O?.C5UHP?6U(`FURS\3-W[4OGK,SY@3L>UG4MKG'2+W09O#][-( MXR"FB4C]:1LS?OL\XF5^QY>&<]-@%>Y9P>CVDQ''S\5&?92WMZHE>$W>L!Q# MAWM>>LVGL_:9^`RFZV2?U[S_M3N'\?J5WVO?`AC2ISV_=R?Q#/Z$=TI1`]#` M8XN(?\S^^/$I`BP[54Q/+U&DLW:?]!89;M&93V<]XX=7`6H5#=,;[3WOV_=Y M^]XW:$@_^PWII]KOUY#U'.5"Y.U9`DZO#O'W&0,'3O.Q0\S':E$PE8I'-J/H MM8I]^\;GS/5AF)7LW05\&T)0GS!/R?Y=\W!.$%>^/WV5Y^GT_.GP]C;DMRQ6 M$T8^@YVZ?N0Z2O;N/\Q+7I8;V2G9*84BA^W;%7-#)3NV$WPT9"ZM4M%D]6K3 M*"8=Q71'.7^DF'SJK73_&VI3<.&;/TDVC^L/IJF@7WD?G M614,5TEP)#@JH*"*X)015M,TKO1`5WF/2N7-5X[]6'50_:@R]F^-IAJ?-'Z[ M"*F\>=,0F3P6R8?DHVJ:3SGYD/Z0_BB9*&Y\':Z_A\R/J3CU*\<7![9N#SHT M)5%12XX,RDEP)#A%@P=*\)+&U7SV[6@JY':[K2X%$#7F-!L?F?^'1R4&YHV. MO]\9;4OO=DO;AO)\T*N3!E6X5=@1D7Q(/I1W(_TYN/X<73W/KM&R2UO#5\7U M'B2L/95,]%403KE;9B[ZE0.DQYFK?M?5!U9YNV?>*L/3#K$I"42"(\&I(CA* M=)/&*1K?'U&BN]YQS/XZN02@C#Z://__MKW_Y*6OKDH7(51U]Y:&X);\*1.RC M'+_QZ:>SJS'.(_]E_G8]/M/<"7S!G/B\/S*L[J`]OK*OAE:O;]GP_W#8;_<, MV[JRAN.SGY^,2U'&K]0H63>L+Q;8,;N+TNKIB(_/F+PR46D@*TT(Z\4QW[;C MN$2Y4AC(+.]%Q'V@!:ZC^3S67-\)YAQ/`FL1]E]S(PTLT4F$WF@WCQITVA7Y MA,+ETR`4%7[D`6*\"C_=9ZRL3!*@:GZ"+$F8A8"[YH$O'[&:I2C4"Y*MM;2Q MZR7X\*KZISWOWS8=TQ9>(HLF3;"#[AW7^'3*G1@;P#)(Q;M7LC)832E]@AM% MB:CAD\#0AN(V/E]XP2//,CF+)'1F8*7P..9K291U(@XY`P-_3"^;\W@&PBI% MWYY7HBI;X;`2539LHJ0[B.Q&*"'*9O+2@&=C^>Q-]^E'/`M!T&(\W(=26EPM M3E5*DUNF[/;J+;YZ*2VM93O;KTLPR"Q*"Y5%VKL)%IP*17$Q4/$D@BY'NL8? M'+Z(A38L=6/"8O:>RG=54KZK]\;R7=W:RUNU&U)OBEZ07K#2!S9^L>RP].C] M`Q1<4(J@^%I$2;_(P.82`YM5@:Z=[.979`4ZJ\D#J%!V2[D\'*EN7A'/?:A- M<0EFJ:Y-N=I;YM8,@D52M9=5K?1CHJ1JI&J$:J1JS4`UJHOQR@+17L2P=&2` MC@PH!H.D<:1QI'&D<:1QIZ%Q1(H5__CKPMHG)?DJ4]-K MVG@\5$Y&7^_8MM[K]FHSY:,G?*)E@Q*6#[H M1[N6;ILFV2C9*-FHHC;:M@=ZMT3NTI.WT<8?)*J4D83V+U`*KCH\:[=H^P*E M^BG53SA3-<[TZIO5J*(*A#.$,X0S->.,W2><(9PAG"&.Z=`Q33[I MT+'"LT_*$-(0TA#35(PT=.B:D(:0AI*D<:>C0L7)K=XW/ M_"ASZ/B8SEF4?:;XV(]14-*_A*3_25E8V2>"R<+(PLC"JCS/2Q9&%D865N5I MW&.W,%JH?W&ZEM>V+\[;-/YGXMXQC_MQI$W#8*X%"UG'/0Z6!>N+:_R5F.UA MBU>6;[U=&\RW7Q%IU'/YJ*)]E/-5R!4>FTUU!J;>'MAD4V139%-E^:E^3[=Z M9%-D4V13I=E4KZ];G=+JHIZ*3=$JW`O"O5A9:F/^9.,DKGH3/782-+MOZ7TB M*J3,9X/=Z+';J&58^J!34=Q*-DHV2C;Z=C]JFGIG0&2B9*-DHZK:J&7U]$&W MHKGJ*=HH$?YF="]K*7]K4S3:W'YLF]O;K2X=UZ-$-1VB(9RIFL[7()PAG"&< M(9RIF,ZWOGF7*JI`.$,X0SA3;Y:G9="\Z0UIG`^"Z6S=];5UK"`TS_7Y^4QL M\OYHF.T?5E31Z('B";&Z/F!1_+&#FEBF7+\L#_G*W>#Y=G':TH#N7' M[GF^9SV!%$?N1:'G$5)^)@^8<[C63#1Q2W\P?&2"9^D&]F34.YYYV*WQ"*) M&7:UI0TCW`[_3.+[R.,?B<^7*-UIZYK9-IZ[]7V:UN7;!C'S"IOX\U?<7OKW M+"KG92U#[ZS)P>S35.ME0TS__NE#$IW?,K;X>,E"'W0N^LK#[YA'O`8E'WGP MCC__[:]_^2F[ZHJYX7^8E_"Q&SE>`%K"H_Q*T`$?;>,;GWXZNQKC./W+_.UZ M?*:Y$_B".?%YM],;]:WNZ*+3;5N&80S[W=[5:-0>7UH7G:N!1]BN_U[X%,`@;S6Y;8S:[Y=FN^'@O'W03>!/9$(I+$_+2?A$VQ><`&J4@ MD5TU$'W'M#+8`QJYY[(;UW-C%[=&`0S,Y9:6ZD3?@4W@1^CX3!22`2*'0?)-Y$N^'8!@<0FN"9F(A[GH"Q*`+\`L!: M,%?\$(?,CZ9@I2SOT*/F^GBM$K>H[P$%`U,%IJ-[SGWM10(%PS]K0O>$BP6 MGHU=F2\'19NPF&OOH"W^X,:RD^];VC5BX?I76$>&!\EX*`#TDD1S$5;5%@,/[3P(-(/GJ9J/XE$UAJ:F\_!>_M&/I+ M%E8'=#*UOD]G[3/Q&0(O)_N\!5IIFXQSW2K6O3N)9Q][[6W"W-7H#$VZ_,@CH8594PC[--L_?VB1R\Z4Y1]K-7K3+LEJ9G`"1`M`76 M%@,*_H]K?R8!!F$"M2*!B8X(ZJ0EH]V%X(01`.`]);)&"*T%8'\E8-@BH:LTM[B#$Q.&W`.(Y%H$?)(\"D\G9PN)Z;%N2C.LAC. M,9,PQ$9@Z@4S%=:())7V#MQ)/`N2"-Q&]+Z,F=/&;,D*_K2?)!CP<[%1'S-A MWFIVM%V$K-)F3D]Z+MV`T89W2K/E`$4>6T3\8_;',[19[U>6$-9;NTUT"[\@ M.O/IK-/[84>7E-YH['M?O^X'UGU?MRD=W?>^QG14[1=LR'Y@Y5:QMR]55<'Q M\5=DN49^!41WP!WQL"`)>S\!VAOS]O\2\[FE6+_BQ&[Y\;._K1>NM==#,;]< M=O,7.0E=?@$!L)(=_YQEIHHBCN(PF;]ZWOI074YSX,;[-\^L")$(D5[7M^_P M&'<*H@!!YK+]@DDD)@^2:>>E[G[+)W^ M.6$B=F+ZN-T'-PO!GY$+6BBV98KUCT6("Q@.UYCS9^)&;KJC)UT,G>#:Y8(] MBLSMQLM+@Y-*]LIOU(CT:2)1K2S'6WT[[%^UG)=D7($HR]^7G^]T,W^X89#+[G38/PGH63=:=<=]E(G$3BL/YR(6WM[O-\,2;? MA_Y,D/N\9CP+.1='2B+WH906M3E\.8LT/'`ZH?W1M#_ZTYG]QNW1/9MV#Y=\ M7X94;0A7\?09Z5>[3&V58% MN\%5T0*:/:KCC!IG%^],NU.VHBP'O4'SZ*T/@-(L:[,0+V;,O^623?CE)2R* M!%],<[;+*_)V['%@@TRON7[M>$RKJ]MVEXR+)EG;BO`K>WR=LN]DPL6./NB5 MMOYV&@&C>N;27#_4/(/IZOUVCPR&9ECE"/%25M$L>1\,G9VDLY-T=E(-Q:/Y ML**[A`@D"20))-50O!+S&G3`_.D!\\+1<'F(_+5DOBR('/-P+NK\RK/C]_"S M]XCW\@76'L,6Y=4Q=V:^^V?"H[R@91[,Z9 M*/@[36(LP;OZ_#C`HH*BIG)>@AAN_YT[^&2>E@%?OLZ?B1N*VH;R"$U6-RM: M<,>=NO#+TR+*D:R:_+1OKG\7>'=114,V:'`E=2E0;N<+NDE=:A=4G^*VB34RYFY_`XM(99EO-$PA"X_57== M,"B4]#:*C;==N70=<*L,S$T6-0UN4+CNW6LEA=5!\A%WF$"D+?$;OH5/'B!V M#D/6L@CZ(A87M90ZT.7>=FMH%GQ,^#W4QS+<;I MSX2%(`XY>.YK9:_3OW_ZD$3GMXPM/EY!A_Z#_1F#P_`"'*CH&I1SY`7.'S__ M[:]_^>G9E?]<\LK\DM+*?/&_920R(^Q%WH)X+?CPC4\_G5V-\=CPO\S?KL=G MFCN!+^"MSL>6,>[V1F;/OFI;@ZO>H'?9ZUP-1V9G<&6,^IVSGY]85]$,7N$. M61>;4KE/HK,Y+CH;*O>IWGU'3]C3F(ZJ_8(-V66A7+J6&%ZHW*J-PGE?LD+&D&EE"YSV+.<;4'5.Z3 M-H71IK`71-D(V@+:&?8V\:F#ULH%%H24A)2$E$W1/D)*0LJFZ"HA97FRI(,& M!)($D@22!)($DFJ`Y%:GL;;^\_D`!\RH@BE5,*4MWV_>\DT5 M3)6[CRJ8;A5R4`53U9:]J8*I@A-@TEBJ8*HZ*]GZT:$*IBKCBC+".EY`)HT[ MHG"U##8&JF!:7;ZZNG>F"J9J+).1[R$8."H8H`JF-,?:<6_\A"J8EB!&JF!: MIE]6R/:4<]@G:%Q4P;1R;W=L3HTJF.Z$053!E&:/5&&G>!]5,$WOH_HZ)0B1 M*IB6E.:D"J8TR5+)KQV/:5$%4YID[21"JF!:#!>I@NG.`:-ZYM)OJ=!R4CH/2?+@9<0B!)($D@60#%*_$O$8=9^:W/?&^_DC] ME^F5ZT.XYS*O4!7A*PR,\[C%&?G1I36Z&@VZ_>[5P#*,SJ!C7]B7%_W>5:_= M'PY'ASTC7R8+JOR(EW]T8]`\1W[S['P-2E;[3U9"+A>NMD?-B1=?UEY4S`?P M)0G%L@K:J"B.E\X+M&C&>=R8"F>E5=H<)6+T`]Y.%;M5M MK`,I:O\^B**KV`4PPP(1Q4U6='.Z+/CHWF$9Y&@6A%GE2_$SH!)<'M]S+DOZ M!N"/81#$;DYY>\2+@Y%5D81G\8>%K#`9;"LPNOR&*RQK*LL:5]3<(H8;+"Z-^'PZ^Z M=L^7I;375#1='4XYDCC@DNWD&;])5F";A=CL5)3G!DA-"W1D)"@00H%!X?.1 M2J7PP)1O)6IIWSG7?@U`YSLY48IHS\T4=F.332F8BY[H=502\!.A78AJP?N> M MA/C`*1*O"*1Z.<+='*6^%$2NA)V?Q?M?LX=E.=M=&)DN3&MD7O:'QM65;0T[ M]K!K]480@G:-OF7;_5ZMT6;IP>6:XA]"6T!>2E6HP M:`W:9K>3_6,I5):X6P^E4NT<3D=/4G7`^]I-Z:C:+]CXK5.'I1GK'X"T22F* MIN>D8EK&O%36(@&M^)&^;:0$VUG;"/"(I:Y21JJF&:K0E>[-B?EZ3+2_+A.O=D<:] M1::*]N!]M('ZY#=0JZ*.!&8[B:NG6W9IY^4(S`C,",P(S`X%9@/=')3'Z$=@ M1F!&8$9@=B`P,TQ]T"N-+([0K/'KI26P&3S;3KI/;O=5\JI*T&VY>K6FQ8-R MCG3L5KMVS[`3),\?3BND.($Q>^#.69?#R,&,4L3N(@?-3^W?K> MTJ8<3P5[Q9.->%]I[!@=J]5^/K;[M*1-$HZ5/.8LA$OQ9#N^"B_TG$=-.A2> MLD/`0[6%9*QQ!1-$2J4!_\<\Y%$L#CXNN,\\P14AR!^0:",HCEF13<+UB[\@ MJX,?\98V;`3EB60J<">:'\3:C-WAD=='#<20T4:\*I7$=P`_&1[)Q(U'078T MOB&J@7:,'<=J-1'(M3W`EP+Y=N`EY_A:P0*Y/0(866@MI?:X>13&/6>_XYEC M]H!:]7L2NM'$E;5N\`;)V0#R1=J&*+GY'#F8*=I?[((?Y)Z\0K7T'5#:I%T$2"R!)B6=6[G28CS9Z@Z#,491$BDA M4O.+'W_49L$]C%THC/J&>RY'UY1I2>))HP:]C@(O$2*]=SVO8/H:_AXB?Y!T M;<@C$CRE=EJ2#&7&KF.3T+Q`O%2]X`Y=@Y<5]#T8'S<&$?Z+=OT'%R]^@]"7 MH6$V++G3SAE\0&UO!%,'^)6<>42POB0@WZD;070IAEL.L[@Y"HJT'V"T221; M`@U8"'!8)4!('8MHFOD2F-UYRD6T*QO'2]P:*R0FMVKP?!BW+6&%X>E?3/L\M1'?L3+7Z9] M^P7M%S2B(%PM(^][1/*W)'R55%D9&H__(J`X,%D2"CM/7VU>>#4`!_`D2!<& M<`*JF_@3T#H,Q@117.3"+ZC5CL?<.<93PB],!)B&?!&$?1K]_>0^2*A(?"`--03UJ)CD]#SA\L"Q0G3"`=.D'<+XW^1P"M9."9N1%$ M[>)=Y!4L1O<(SNOJE:[JTCS302R2E.5$79(-*!1>_0:IPZ0$H:'%$R:I70W[ M-7M=,6XPJV$>%7\-`S_`8*[`QR/_W85UISNT.[WQZ*)C]'N6/>R,VKW+D6U= MCJYZ/?<]I-I^5-S.(3YXPLNY:Y]!65UW(57-F]/(7.P`@#MD@'@ MLP]`]BCHU'1AR$;0FCH3U@XB;11`/^!PXN0,XM)AJED@;&%=I:%GL)2 M4'E1ER,9YUQ`'`M.*XS.T(N"PRS>&2)#(`"-!J^8D_RA5=WZT%OX2[9[/P-C M%"Q?1!!N083`7`]Z-\G]M.@73,004"!D"*,L M+%G&92)\EG2#8H(&L6@4I\2#&L23T(J>OHJ.%(8X/OAS/I4#+P2-9D++61A% M&`>1NRL04HR1LSI&N;QDH%-\.WC99;X$Q5((BR+M'3XDBVDDDHJ9NL!MV3B( MM7C+>T#.6]?W1>>G<*.6T?QIAB5FR+V,-@\?_1!+WB40R-/K^FLF)!P)VN0L M27"QS1?,B3-)%U_K31'R$]'N"O:[XO<*^*>F]DW:"'9G=[2_:/CF4:@]FTX%=S1\,PNBA1!-E),'0COGT,QY>KN.JI[.?E#Q`[`E)%8, MICS"LVKPH"ERKH4A0J?$+X$J62YAP1X#`<68L4/3E($THIG\RX7@"U2)W2(; M(QIT$-XR/^56A2AS&97A)`M^29,56=\!MHHR<:-E:)DF.E+J5_@DH267##XM MEP[X@XS*]LD<$0FXQ.<,F\!38/HQRI$T`3%D\;'L'?B=XA04;%PVX@J.VY3T M=E?L>-7\5\#BNS/CD\3C7Z8C#(]AO(8%&LS18^'3+O@QM*YZ5W9_-#*,@=7K MMP=]ZV)T<=D?VX;=;0_MP^)'/8R'R1PS[/]#OXZYA0#4,%>>?%I0F-&4DJB* MW(=5.L*,8Z5$`L%"CCB>K?"FHA87X"+G5H4P@)C]5GLNF?V,=KL\+K_N&ZG\ M!G7SLMGJTJ0IM-&_RM5B`>\BSQ$A0ZLNUQ&F^#&9/R%7_[]9@7OC1W#8[J3( MPOZR0>_+F%#C&"B__Z.$O=Q/4R:-T]:_PUQ;+&R<9Q,ZN=0B)OU,9OG*VB7R MYBTRQW#LI$F'1[H#O6\_7^W;\\U5&B^17;;UKED<80S[O^'U>8:):V*8IJTVY\.];9JVGZQC? MF79%AT`V"Z>19T#>*^`YZ8C6F_3OJ-RGT:W-;LF]JG%XLDH17N"^&K$"(;9, M%]:K*UF&H-4&2ANNZE\):P\G.(]ZUS5TPRR->_Y5P5#H=NS3K'P3_).ZO#2; MVLH<]7Z[(AY&KL`L[.FD(MWT M:)9]4JC:RCF'F8"I(ZNF9^DJ#0'E:2P\Q"5W(HK-Z:H$A*JZCRI%B,=QG-QX%^PQIU?(CY=7'1PVS@@'NC$H;<:FBB(U6UAA1Q/S>YA?SN$6>6STJN[H["^ MNAL'DE@%R_1=W6A7M/5T7>V-)JA1B=BWF6+UY=/<^YS/WG#`^R*8(]&8F`Q? M!%%\%83?9RSD(Z1.`HS"/6K#PA']H0>-B:N_3)<7/FT%^O#58_XUOMXN)\0O MN^-NK]>YM'KC*VM@M`?M]L6E==4?7EY>#3J]X9&=$/\>@UC.)4N54Q!ASO[F M1DM6&_`%8%9%6@)!;X.?@T7J,9"[,Y1D@1&VK;%[).'1\8XI'FI&,H3B+Y*9 M(0DU/E]XP2//?ETD(A.TQ0P*1O!`^,TD/Q=/R[CN/?1N^-Y[^[@YK/?QMU'SBO_3YZ054Z MJO8+-GZ69._G()>WO6D%J:_VY@V'(_]9.=(2GYZQ4UW/0G#HOP2"^.5RA?BE MK)#^\*N7ZJQ8GKR^?7<>"6E.&VE,O6V5QLRH_-@3TA#2 M$-(L^V"6D(:0AI"&DJ/A#5-FGV5&EBY\CR-^Q!N^$^G[JQK+!68BKG MA%DL>OWR_#UQ6"AIE;=?&Z4(&1P9'!F=U MR>`.SY6D4.KI\(OZ>5F^F#U4HYME'0Y6/8]1W\'@HTAR&;I1%47D+B)317LH MWZYHOIW`C,!L"S`S^^65KB,P(S`C,",P.]B6*M.ND:U%=>TA,",P4T@="U)RK][BJY?2TMH3=?MU*>0K+%T3I)X*(ZW(UJ5K_,'A MB[1\::X;$Q8S(O(B(B^B@5*KH_2"1.3UEO"5B+Q>D-4AB+Q6!;IV7I!?43;G MUP'H"IJ6_2#5W<0)5J7B$LP230DQXC0!%DG5B.>+5(U0C53M^%6->+Y*4$RQ MO/%R8G5?I:Q1@$VP9F6$=;PP2!I'&D<:1QI'&G<:&E="7LYN>@#WZW(K!8OC MT+U)Y-IS'.#AKGG@R_->,XB<>;A+8>/Z-]JI(E*EZCDJLVW.UOM6?0<:5-&% MC8L)E.:H)V@@H#DUH#':>J]=$>\+(0TA#2$-(4V*-)8.&D1(0TA#2$-(4^F9 MH[9NUWCH2!5E>"O25+ERU_C,SW_%FBB?:`SDP&ZYYB?S&Q[BB9LL\R/+JP=) M',7,Q]?8)R6Y&RW7/J<&&T/89?3UCFWKO2[1U-!A:`7"#++1M39JF!W=[A+[ M"MDHV:BJ-MKI6KIMFF2C9*-DHXK::-L>Z%V#_.AAY[-'N.%T/0$$[5^@%%QU M>-9NT?8%2O53JI]PIFJ[>\95YF\;_3-P[YG$_CK1I&,RU8"'K MN,>!MDA"9\8BOK+&7XG9'K9X9?G6V[7!?/L5D48]EX\JVD)Z)"RGPVV(T>NXU:AJ4/.A7%K62C9*-DHV_WHZ:I M=P9$)DHV2C:JJHU:5D\?="N:JYZBC1+A;T;WLI;RMS9%H\WMQ[:YO=WJTG$] M2E33(1K"F:KI?`W"&<(9PAG"F8KI?.N;=ZFB"H0SA#.$,_5F>5H&S9O>D,;Y M()C.UEZ_YN^?/B31^2UCBX_?G1F?)![_,KUDH0_:$7WEX7=,@HB*2$-_DB9* MKK']:Q#&R`NGVGN!+Y@3GS>N[R\M"XOQN/+H6GU+_L# MXVIP:5^,V^/AN#TTK+.?GPQ94?S7[IQ'VJ_\7OL6S-EFX"O<[KD^/Y^)'>H? M#;/]PXH=X1X-H1*N#S@:?^R@%96I$]Y#*2UJ M<_AR%FDW;COW4D\^S@8M`9ML]O)_K%^R!R$@W);1/QC]L>/3\%^V<5B MEGSI,'IK5T:V2+2+KGTZZW9^>-47K3J^]$9CW_MJ?R"]8,GWM9O24;5?L/%+ M8/9^D8;]IFE;WMF^VONE'7!$/"Q'6N+3O?1E-X$WR>(TC(1^D<'+I0A>,.[0 M(-R@-$%I:0+2MTS?OKL/;],V`KQJR>@K4,!7)'EHE5P[JR*L.Q)52Y\BIFLO M'^=10`^?3Z5)#X]$#U53-8(\4C754(WJ^FU6S,]KLN5EF7`E"Y7*[SZN;P7S M515MPM*FI7=ZI<4GM'>]0;"FG+\E,",P>YNX>KIE5T081F!&8$9@1F!6'Y@- M='-0WRYZY;6'P(S`3"%U)##;;0>MJ0]Z]97545Y]WHIFC5\O?;L(+Y]M)]TG MM_MF+H.]T&VY>O7:!O"Z#;5CM^JC&WFN7.4*[X#:^4-90J3PX\#&>FASK,]K M[F6.9'!D<,=E<(K[/S(X,KCC,CCR<.4:7+DG+W<^-;GA^.7?@V!R[WK>+J&&-QX.A85X.KJ[:5T-[.&H;E\=WNM*9,?^6I\?EX",+PT<\ M:\GF00(M!E/M-I5CN6?R2*#1 M;I=W"+#[QC.`MEGW`:N>N@>L%%HBJ-+/9$"MG6LW_-;U\>"]=L,\YCM@O['V M#^8G+'S4C`W84&,8J'R>M[QE@F-8!>BV;7U@ET@]^W2Z&E4&?>#F,Z)./CAY/GY0X'F+P=Z9=45IC#ZDU,MWQGKSD/B$[S-Z? MQNO;,0XIM?UGZ^.=1Q';E\"55X7$*HA5+%OO#FH\;]($/2HQU'E[NO=9EG9# M-O<7YBU"C!0<_MF/DA#!9I?,KF&.+CJ69?8'HZYE&7U[:(W,_NBJ.S+,JUZG M=V29W2!F.(5QP@1F,',^05W6YDL9:B&/>'B7%B8,N<>P_(.;21:^<;A[AX,; M:?><\JAUYU$[YAL3J<:@YD1JW<^K^[YZ\L3T?E7=9S>DGV1_IZF?Q_Y^]=A? MX^?FA^7U,JQ39Y9[>1L"[3@C%7NSBHUA;C6_X:'6D2O:U1+;$+@1K=)&51Q& MR*9/,%E&> MA^K=MWS-B""8_'T-"G?A,7?^,AP?SA;$\BH9`AE"'7YA].LW,@,R@Q,W`['K M14D[H%P(V0)-%6BJ0.9`4P6*D<@0:*I`9D!F0%.%`RXTG,C9TXLD#/'@Z=<@ MC$NL=;37(;--$F_$J2$EF"6:<>K,,/6.:58NKT:H#=Y'-/H*TN@3@A&"$8(1 M@A&"-4<5"<&VKS/9ZQ-\$7P1?"FDB@1?NP1@=GDD:\U6&T(P0C!%5)$0;!<$ MLTJL]-UHM2$$(P131!4)P0C!",$(P9JKBH1@VR?!2J1=;;3.$'P1?"FBB@1? MVP=@';W=IR18*0C6^,/H;Q?A/P/L.0_G>VP&RWO]UHH#^XCTH(4%3%,?#,HS MPE?$HXJN5!TP4%Q`)D4F129%)E622?5THU-1(6TR*3*I$S2I[D`W3/)29%)D M4J5Y*4.W^A55(R*3(I,BDR*3(I,BDWJC25EZKU=1O48R*3*I$S2I;E\W.S27 MHIK:I;-VGJ'\F:5[#_[$(MBA>NN7_/W3Q^2Z/R6L<7'[\Z,3Q*/?YG^ MPKQ%R!P0-,]K,U[#RX^\P/GCY[_]]2\_/;_GU\"_XU',)]]G+.1#N/G.C1^O ML2OYK2!?'X7XC4\_G5V-S;9A_>&Y=C2S[PNR-+JVVU38[ M]M!HFY=#:]RY'!E&VSK[^S7,ZY-`P^P'9ZIB8'3HF0^9R%<%VDQ M_!R"5$/7`U=^D]%UHP?6U(`FURS\3&`WM MJ\=\;9*$XF'0]C/MVN<=(O=!F\/WLTCC(*:)]H_$YUJGK6LXP*4\XN.+9O#2 M<&ZA`BONJ/UDQ/%SL5$?Y>VM:@E>DS\^FL?28^`[(XV>?=E??> MG<0S^!/>*44[`"N/+2+^,?OCQZ<`M>Q4<4OJ$N0Z:S<:;[&K573FTUG/^.%5 M_%Q%\?1&>\_[]GW>OO<-&M+/?D/ZJ?;[-81W2+G9P$'/2KPBRY?#N.I+)(IH MB`JI'V3J68N";3]GJ%[9_BN^X)/S;<.E6GLWA#%CMZH6>9\SUX=A5K)W%_`M MSL<21>O`7O-P3A!7OC^E8LC/0>3V-N2W+%831CZ#G;I^Y#I*]NX_S$NH:#G9 M*84B*HS83O#1D+GTYI3^&\17PTRZ=L1003J*Z8YR_D@Q^=0*3N]^ MXRR,WC=76LIIT];1S1%&+^]<7X/`C/3I)/3IX+Z-R&,VZ]JW?/G[PX;E[D@+ MDCB*F8]OH#'X.-7&W.'S&QXNQZ)CB/7HZFND[2-^9;;EF#U+-XWJZYBHHEUX M'VTB5#!<)<&1X`Z8L*M1B$T0G#+":IK&E1[H*N]1E:@9ITP\U;5:/8JF3B9I M_'817LR8?\NC;),N3'G<8/+R]E>E4\C'C\CDL4@^)!]5TWS*R8?TA_1'R42Q MW?30Z>\A\V,^47):J\R$Q!C8NCWHT)1$12TY,B@GP9'@%`T>*,%+&E?SV;?* MPHG:-=XV67=H:OBJN]R!A[:EDHJ^"<,K=,G/1KQP@ M/K]=T1QAC;!4T;2W&JMZ=JF-BV4FJ"&S,&NFG6Y_)540;R8H0TA#2USVD- M`II#5M?9IE+.AB([XHX1B_CD(I@ON!^QV`W\[SB__++`/Z.]"^^,QFWS:F2U MQY<7?>MRU!E=C#K#8=LPQ]9X?&$=NO`.&E&9&K%%X1TY;0^$7*FD#I74V:JD M3O^-)74Z>Y><:4HMEV.OQ6.83>EHNRD=5;K*5$/RWLK-3+9?4#H]]G2J&D14 M_435+]I1F:K_\H&'CANIV;FOH>M0M8^#9-*H\)A2EJ`RA%#AL;?TCPJ/4914 M%XA0X3$J/$9VJKR=-B,4V6[4#]5+*D&FQ(94*D&FG'04TYWF>B;2'M(>U>5# M!>P:K4WJ8E$M!>R6,J-*=J>B6`=W=OF=;/3U:T.'=)4 M4D^.#/9+AWKEM8UJ.:V<-37H.#@AS<&1A@1'@B,^&54$IXRPFJ9Q%$V==C1E MF*U^>2>>51_[MT93C5_+?+L(J3)FTQ#YR#R68FE?Y>1#^D/R(?D0_I#^J"D? MTI^R`^Q3X;//SKE1;=57^.I[^J`\GCPBI*?DVENA_G3(FCN=5KM/^20R+DKY MD^".3'"T.D<:1P%$U0M2G=:`MO=4.E\^LFGQ!59W\.JK\M;LR;&I6_WR]C-O M*:K3GB*3(SOBLJ2=;JM7&I.S*JI?];R6+(+D0_*A9232G\/KS]%Y9*/;*N_$ MWK%X9#H1NL^)T`/7!#S.]5E#-^RN/NCW#B]'532PZGA;(4-6SA&^3;7V$:#R MZEA?S::C.$/1,5KM^HHY*:\]!&9-!3.%)%MM];56K[Q:Q>K([,BTD5PKN5;3 MU@==FBB0;R4T4U$="UM.'LSH-':>NN3R:(BHT*E$ZK+I&4JS MK0^,^@(/5?2IZOB"PHCFV%6#HX4F@4VGW>K6%Q2HH@L$-$<(-&JG_$I+T9-N MD1,C)_8T3]?NV>3%R(L1TA#25)Q#L^I+8ZBB"R6FRC[$F"5:>_V:OW_ZD$3G MMXPM/GYW9GR2>/S+]/N,A7S$(CZY".8+[D<,DU#?X\#Y(\U'#9W8O7/CQVM\ MU#7(9>3!CS__[:]_^>EY<__V0^X$MSZ\\4J#%T$4_QKX=SR*^61XS\))M-H> MC(>/0O_&IY_.KL:8W_J7^=OU^$QS)_`%<^+SMMUMFZ9A=KM6SX)_AK8YLOOV MN-N]NAI:@^[9ST\&L3@@U^Z<1]JO_%[[%LS99BPLW.ZY/C^?R3(PAMG^8<6T MC!X8DM`2UP=LC3]VT++*5).A2/T]4XI]FMHR?[A/T[H6!S'SM*0P\#"6RY&' M#U$<:2'W&`P]7*V!QI]+18"'P="?WZ#ZK=[$PA"I*><@V4B[A;_QZ@0D'6I! M$FJ7?R:@D=I7C\&E_D1;A/S.#9)(X_*'!4.$RL05<%HGKXAG7[K-JENQ. M%(Y,:2]1V(]8+TKC#PONI'W-7PIN#2*>O@R8#&9FIX$'WC72WDW@#[S3]?&R M)()'1>]?YM%\2<^VT,T57]A^HHKXN=BH'X1SYJVJ+UZ3-RQ01'.XYZ77?#IK MGXG/`)%.]GEWJ[IW)_$,_H1W2M'904DM(OXQ^^/'ITB[[%1Q&2!'Z][:[>A; M+"2(OGPZLP8_O.H'5IU.>J.Q[WUVW0_<\S[0O%UN;,B"C7(Q\/;$$Z=7:/@: M752JVF14)7PHV"["4M(QO?,Y< M'V2[[.\W"3;*&O-7$:?N,4M4V3^K5&E1O9.XBDE',=UIEG\X+ZQJ,X=#&S_P&F4E-,BOL.EVL02KM9501(B]AKK="@W>6T748] M+WADSL[#_(B7?W1C4!]G0X8!1(B+]+D0MTW2 MOOAF=M7;.*YG'+_#X5(B3F M`(`P:!]Z$82XL8'-(3B.Q=5P,X\C7?-<=N-Z;NQR^!#R.^XG:?.X'<*/\$,L MVI[`@\4/T%?QA=P_`;V;I5>L?3_<,R'EP".<;69A M/O,>(U<,Y6T03.Y=SQ,==N<+>!2*OJ5)%0P<;`6N2R4+#\8F(I[J@&BS^-ZN M?Q=X`&_:[\GD%EO2M?N9Z\PT>%R4W/S.G1@[R'Q-Z#^^Q83?AER\6N*G6A<_ MMK2A$R<@"=#BQ(OQ31)OHDWSRZ&U8)%*)LJU3@P$ M/-+%Q*8[SW;QH)KAP/@<7Y>%8)YP"8Y$[-[QS#ZRIK/&H"&P,;'_!_Y&<"AG MX]48>C&_X6%A\Y51XN:KULL.\9E36W5"PC\!./[Q<1H$,0B-_Q,^:`_BJS#` MCLSB>/'QPX?[^_O6PTWHM8+P]H/9;G<^X,\?\,*S]/KX<0'7`Y""^/CD3+3] MX5GC\/5/'[`E]R/^"Q__/U!+`P04````"`"IB/Y&CO';;CT4``#1R0``%0`< M`&EP8VTM,C`Q-3`V,S!?8V%L+GAM;%54"0`#C9&Z58V1NE5U>`L``00E#@`` M!#D!``#D75MSV[B2?M^J_0_>G&>,"1#$96IF3SG)Y!Q7)6.7G4S./K%P:=C< MD4@?4LIE?OTV*-F6$UF2)9*2LU,UMB(#8./#AT8WN@'^\ODJ7Y17O[[X<$E.+E^=GK[X^W__YW_\\E^$_.OEQ=NCUY6;CJ&< M'+VJP4S`'WTN)M=''STT?QZ%NAH??:SJ/XM/AI!YK:/9IU%1_FE-`T=?FN+G MQEW#V+RMG)FT3[Z>3&Y^/C[^_/GS3U]L/?JIJJ^.69*DQW>U'BT1_T5NBY'X M%:&,I/2G+XU_<83]*YL-VI^7_/E+_.)!^<]I6YIJK8_;O]X5;8IE!;%9>ORO M=V\OVRZ2HFPFIG3P`C$X.OJEKD9P`>$H_OYPNJN2DF9E0TDY]<-3Z. M98Y?FJ9HSL)Y#0V"WL)U4OK+XJHL0N%,.3EQKIJ6$QRQ\VI4N`(:%##*^?-U M#>'7%\6-&R,L-$M$FD10_K9#DY.O-_#KBZ88WXP0LN/A^M1CWPZFCY$Q?CJ" ML_#JVI17T)R6KTQ=?\4B)^-8]BS\HZK\YV(T>@T34XSZ0&-[(0X`M_<5-H<% MZBGX=^"Q_.B=&=W4QDT*AW(T4'^"!MN[@%'47:=E,ZWC[+P`!ZBS[`B:(:#M M0MR+U@-G#ACOJW[0I2FB:$_?O:=$448SUHJ^H MTY]4)]ZW'\SHM`Q5/6XAVU1';-E>?[VYY__"MV?AG_?US^0E<2EPTJ+1_U M]4LSBMKZ\AI@LH&@:RKV+-^YJ1&D:YC$96AK89>VTKWDE[AL0#NH:".:YOK- MJ/K\)(17-M"OO*?HW(YA6V$?UNY&TM=@)^OD62S3W5,WG,1+BG8DPWPC`57# M;Z@9)E\7%L2U0FU0MQLI?S-UB5JK.8?Z\AHGV#K)'BO?CS0;CN&::OW(MMF* MN[I6-Y*],47]AQE-X1T8M.+;Z;Q.KE5U^I-J%VMSV_;ZZ\W;PMABA`)`,__6 MGTSN"IZ5Z$I-ZQI'O_5*=NCF3@_JK_\7U6B$J'\VM7]3U4\3\@,:HE<+?MF' MLK+1)XW3X[2\F4YVP6M0P?K#=S,-L[YF-Q+.K(/WYLMZD984[5R&#>GQ>(W. M)=ILN!ZMT(T\EY/*_8E$!O1'QC=0-AO9&ZMK]2G9+BO"]BWVV:/[W8'E?__M M2_P8]]DJ5#)_@?]X#>793>N+7T`SJ0O7VN58]R1JL&@ZM/V(CM#]M]$T1/&K MKS#[]GQ:NVM\UCEZ3*VET?R!C8'?"LZ1AM:1^L?^!$+?B@]U+_]>XK6?>PG8O`1BJMK_,O))ZC-%2!6 M1>7/PO^`J9N(M&N?=`?V>^P.M%)T-,;/KZ>],F`Z'IOZZUE81F3LPU(JG[A) M\:DU-4[+^Q[O-CZ]R3$(>NV?9RJA3W">^I@^^[Z9(;!)W:52.C-RTU%;^BT6 MFA>-\O0:;I_)`E\F@-/9[TN:PY1JUZCRX+;I_KR)W&20ALPEA!F:D8QE@5B3`A$TL2F7EF4RK$-A@>`GM3NJ M:C01?GU!7QQ];DV#]N.L!5.[[WC_,,EI7N*XB8M!;)$4$QC?UH])6[V.442@2 M*$(I]\1)JA1STC#@^U'53^K'>K6]37,YEZESC!M"FDJ,5$`2C^/#-6*E`]7!LT-6 M^0=*OYT07F#@+\??^!\_CE.R))EQW\[7,I>_6YG69A;V_KC--^5[%V77[+W> M!>R=#QNGV`WUU/YQWC`#;J!-BI.F67CTDG5U5B"W&96&!TK0>Y#$)IH3)A)% M9&:"$$G*%-#]V+`S`=<;IP_*Y4(&KD%A@UE`K\0FEAC(#`&M:6JU=&"V7/:' ML3JW&9:J6T"&L!-CTF*I0DU MS!"I;$I8D(Y(9AD1/@-'5=`IDX?L'73'C(YA.HC]PV>Q$9T^,Z(\\TUG=)=N M3.'GZ22H"\\FUU!O:F1L4#M/&9,X+S1Q5GL2O)$$,HW_%,$J;3-(I-F.*OR9 M4:4?M(9A274#]2RI/JJ-'` M>>EQH>,T(3X3@609E\18:H5B8*W;,L@XI/[?B04]X7001N4S"DIGSX$(KN904O4`NB/%4$9X&223J=IQ%EK-,&:JE>"84V6IH']F7 MZP>Z(2AT>]YF'C%_$G'6ULV]T"YS./>"DPD^VDCBF*5$,PXV%:F5F3UDK[IC MNO0!V!`DN8U.OZK&MBCG9X'F<=M)#*D6.";S@.RL2U_7LV?[1G.A.34X9W`J MI9)HA9\\U0D!%<,?3/&$;FF4#^/*=TRK09$\N`2U9Y<9.2I2R`XZEM"9 M']45/`>WYCS3I.C!K9N=Z+.7E.=#LJ$W8ME.[>8LR(S3U)`D*O848A8)$PFA M0)W47@<)6V9.#&[E[,2UH5'`V4;35C;ROQNFS>):5S!$EZ_)]D6@#A3@;"$QFCQ#8HFB:> M9EMF:`ZS';SK4'V?4M4!1(.D=E?C<55N-.[?%LU#\(G62L?@L2)`S2*SH[N35N2E\O)>D/1VS*BZTO$;NG?7HIW'" M41.21`0@D#FTM%%!!@=>2+'V-,H^_9..Q[\[F(:@P44\8E6"O[V/%EVIZ7C: MAB/0EBED&L MWQ.ZV]R[WML9O0WN4!_HK-[RPSFS&^M.2U>#:>`US'ZO6DV?T$S.A54ZLXRH M$#*B(97$2S,I,<.TL>BC[R2V*QT^P"^=U]0D]8__RZX*Q5<>M!Y*0/1I2%HDU7B7)81\M'(@IG:$WS"F"APON:?G]^=H53-FD>AZ<3&W@&;'2 M!>*4YL2&U)"`KH3V*2[BVYXG6_"#R/,G3D]@[H=&\R.5MT&!I4_.FQ5+O)66FU5 M@[D)RKO`%#HGUA('DA(*GA%.!4Y3ECFGM]P,%C_2^C@8NGOC7A3]THQ,O07- M%NOF22+0:,P4222CQ#J6$2<,SC=MD\`L5UZI[1@E?WA&[0CD?LC3*ML[>+;5 M5H^VDE.'EF:;9VA2'0.Z0(RP"4*=9AGE1FFVY=Z`^K$)U26DJZGU_5L1XC=/ MR,I9?-O([.I]G`_S&__._K+KW_2G-Y#Z1E"M`)'S*B'92$48I)2!ET(KRS&WK%-.] M:L2=1_W;E*5^0=T+O1Z]R.@IY'JTD3R55%$3#\-D@J%3%AQ!$$_C3A.G,A@5 MG()M[[L<)M:P[Q6Q&TR'R<*ZF4^.L[!X2FIE[M7R*GF692K+`(B0.&T@59QP MEP3BTL2G'#R7L&4J_GY7NIU'\[M4K,X`'"8YNW(`OGF#>)TVS33F847OXR[9 M=&6J]IJZN?7@4JD2HE1(B1,I)T%EGCB;"FN-2.UAOWAC(,[T`>0@MWI\<6C" MO3=?7D()H9A$^9>':)^VF.W4;JXAXXH[3Q2`)4&CT\[BJ5^=`:<*$JGY0:]O M`Y%N:)#WI\TV7/K65\[1`;%)C`LKT(HH@_V77FF2A(P!$SS>DGO(:<=[U6<[ M(CE<.O)B-O`LCVTOJ<#[2U'L+20S%S+R8K;!.472S7=?<0!>0JAJF)5#Q03- MNZ*LZF+R];2<0(U>(YK]#UN9Y75F.G`Z]).U'Q>0S#TT;WM3NQ]=[@LD\S$]Y(% M*R2AVL7K%.(+291+'7CP?-O@UC#[>MTJP6Z1&B;;]];UFYF`JYV@):5S""9A M00J$*L,?"AW&Q$M-\%M!I3!,)`<=J7HNSG4WV`_#J1DLZTVL;TKFZ"("E=@! MP:4EE`(0IHPF3/+$*^&23&QY['>@A>OYD&E7X`I$DB>&IE,'3W7-:>+K&) MS??_.OO7E9O&V1J3Z5`7Q%F.TW_\P.+JX;&WMQF=0]T&I@=\U&I,^]47']N) M"/[D$VK;*_A].K90GX77Q6@:@Y-1O.9L.FDFIHSOTENA1Y[84BX9US2@?<_! M!N)0`1,NLB3^,"FCF8"P5K\,BLEW77AIFL(]'9'E[>1)B"^FX)XXRN/Q#Y^1 MN(00K8+.A*".I0>]4=;K^%?#(CO$2KVT#X^A=>+_=SHS8I[*M_4MYMY[X[5T M1`7.B%%HR8`UN):Y^'Y#[SSB=LCNR-Z9UPO&_9H*WZY![^.![3Z7]3>FJ-N[ M1-^!::8U+')YH,?=WVJY8%+T;]`L$V7AX.G\6W\RN2MX5EY`O&Q[KL&:_)JL`?N25,L%^;278.?C@#MFZ5_GSNE]SOI'Z^A M/+MIMTXNH)G4A9O,K^\^B9,YZORV4_$6U/MOH[\U?Y=?^^WYM';7^*QXLFFV MLOV!C<4[7O?GK9R,6LMCOM0^AD1[R`_YNL)4>EI#>19D<)(G1%A-">.,$J6E M(MXE(+30/F-K<^OVBD*/5[+S7BE@1*)'24&($^G29 M59HF:2(`=K_MLL_=R0$)N3?(^W5AUJV6'\KZ;DE<+!%S<)KYZVK?5[]7Y6Q= M>\02^+\AS7"[`YE`A:'`BJX(,L,`JAN!]29:IQ"R.]0_#71(1C$H])+!-L$K MZ!"@=U+!KABP)@4HD195^J=A:Q\`/82UA8#8K^&9A_#^@'L!+`UI[@PN%Q)N M+-OH@Z22@!J!'`!02P,$%`````@`J8C^1D$7*AC6(0``^)4!`!4`'`!I<&-M M+3(P,34P-C,P7V1E9BYX;6Q55`D``XV1NE6-D;I5=7@+``$$)0X```0Y`0`` MY%U;<]M&EG[?JOT/6L^SHKXWD$IVJJ\SJG(LKQPGLT\HB(0D;$A``X"V-;]^ M#RB)EFQ>0!``H>TNCWY?9J4?YQ<%_G\Y/>\^"/]%)^>/M8Z>?@T2[,_KN(R.?E2IC^6D]MD M'K_-)W&U?/)M5=W]>';V^?/G'[Y<%;,?\N+FC"!$SU:U-I:H_W7Z5.RT_NH4 MDU.*?_A23M^<@'Y9V:#]QY(_UK].JU6%YX7YV<./JZ)UW1=-?Z;+LC@,P[/E MKZNB9;JN(#2*S_[QR]L/2S1.TZRLXFR2O`&X3DY^*O)9OVC@ M-B_OTBJ>I67UPR2?G]5ESG17`YJL[N^2G]^4Z?QN M!NB>#:=3C[J-1L>:,=/%++FX-K=Q=I.4YYF)B^(>BJAY7?;B^F]Y/OV)TU@<:[848`6Z_YM`<%"@6R?279`KE9[_$L[LBGE3I!.0HD^)34D)[E\FL M'N;.LW)1U+WS,IDD,+Q=S9)R"&A[D/-HZ/^ZE*8'N%XVW)%^BS+-DK)4DW\N MTC*MQ=@M^I8Z_4FEIM/EAWAVGEWGQ7P)65-NMFRO/VV^4O_9MQ?7?_]:__TC M^1OWOTZ?TI_F#;O'SIK=2&CR^3RM:D^O'EU,ONQPX!PVF%D;5.U=QH;<:-Y" M5Q)G)0Q:TWJHUO&L'J@_W"9)U4#0'15[EN]]7`!(MTE5ST"MA5W;2O>2?X!I M(UD:%7R3N+SUL_SS7@AO;:!?><\A_IHG;85]6;L;26UR5>V2YWF9[I[:L!.O M*=J1#(^Q+@P-#D:&ZO[9A+A3J`9UNY'2Q44&HU;Y/BD^W$('VR79IO+]2-/0 MACNJ]2-;LQEW>ZUN)/-Q6OP6SQ;)+TD,#ORR.^^2:UN=_J0ZQ-MLVUY_VKQ- MXZMT!@(DY>.W4U6M"EYD$$4MB@*LOXQ*#E#SH`?UI_]E/IL!ZI_C8NKS8C\A M/X(C>O,L+ON8Y5=U.%IWC_/L;E$=@M>@@O6';[,19G?-;B1\\`Y^C;_L%FE- MT#U4^^0.(G$`\,K]+LK*1O[&]5I^2'3(CM&^Q M3XV^9@?6_^Z^U!_K%%L.@\R_DNGOMTEV<;>,Q2^3LBK2R=(OA[JJ'L%JUV&I M1QT(??VV=@U!_/P^>?CV_:*8W,*SWD/$M/0TRM^@L61Z$);CUF48*W[,BI5Z MSTN8O*S*Q\3IK_F[/'N0<0,IBZ+.V7`8CZ/ MB_N+ZW5$!AW64EE-JO33TM4XS[YJ?)A]>I-C$/26/S\,"7V"L^]C^M2]F2/0 MI.Y:*>-B\B3HX\?GLJY6G=.L.INF\[/',F?Q[)O4VX9U[:>EZGHYG"\E?5:S M2X'@,V@-.I].D^MX,:M:BK>QG9Z$S>=QFATNZXMF.A5UV?+I/)E?)45;.=>U MT:60M]!6,5E<):MTD\2!*\J5*8#*< M'DF840IUZ$Z`T8C?VVK[2L.E?J#A+)^LZRO+?G(=EU?+SK(H3V_B^`XZ#69G MR:PJG[ZIIR%VBO#C/J>_/'X=/1-V)1H@F)Q7R7PET2R^2F8_OP$)HD;UHH!@ M1[BWUDCNN?,84:JT-8P2PB0*7JHZJW=UY<63+7O3]:O5UDF_G(2W:-R@=B2$ MPDI3*3'%SBJ,F?!/>GM)^"Z]O[)8%9.3O``7^N$MK'I1$(#]W] MUS0ISJ<@#HPA2:&^I-LZ4\L6(TZ(M,0[([$4@3"AQ/8)T-!@.A#=MDS&W].O M4Z+L1\*.<%P2LV>.K975OO`>U_!H2ZU(,>2<9XQH[:06E(>"/^DH#=+16C^Z M-\YL]-_W9LSA5LW[1O'/R9CAF?)"F]=-E'T(\GT:H?XF,K,XG8/C7"]D)=.X M=C'O\J*J_=#G`=PSJS>I%A&-F'`B\#Q@UENNC49/DG.A=OIN79E]73#ZO&SP=&%8OJG=Y]23%N7YWN8]]-]6.`D.%E0'U-C#<:11(O9ICG="VE9G) M*S5S1R@-,<[_/8EGU2T$R\E%<1-GZ;_BARVX5V55CWA;QOH=-2-$I/!4<8<5 M9T;YP*+5,!AHZL?5\?L)8[K%:`@^K$DH^+QXAHZI&9YM(T;3)B+KI2#">JK# M@!)'E$"KL<]BZL;%D,YLF0\"URC(\BY_&!$/X\O75B+/O>3.6D1EH`567LE5 M1Z2A;Q>B]C;-'(TRK1$;!6L.X4J$%`S.7%F.N+1(**^I>]27^D"$K1A"_W0, MV1.G(7CQ3+JW>5E^/0MQOTR(Q[./V30ME[GS9-K`06G57B3!(P\#1:7AVC*+ M66#8$RXPSK)QC3#]N"U#(#*<&\)T00S1AFACSAX+QN-Y#UYEB-F%M[(OF,43^=O=R7<(R]"NLV MEW6Z?6+G$?:^G]9\\_=`FRK6"+EB6%4?Q$RA+\6/^N_<:M&BM32(`/L,E71ON85C(#+D?6`YA..W3M+Z8Y$D.Y?F=]:-C`I#&S+C=``J8R<( M]0TT-^T2[OOG'%[5E-,UJD=D42WQSH%E9]W(0]P+$;'@ M$E14#&EM_9,GR9RQXYU\.K1E,Y8.[%W5*4[.8R*8&"Y?9M9LU;B#1RTM58(:\"R82T!*9N2P():NF6>P!Z M6U'IT#[Y$'@-,3B\6]2"?9U\D_+1A]J6K=Y<*0I=8(433%O&K3'*8:T!011J M@QB5UL!&X(*O8/8ZP)%#U>G M]KU^T/<*2>/;30=Z:.\@-[QZ=)!';KE`M*_G-[@+=(A'K[O9L\OG?G^#9]>M M'W,-KQZ_P7PP\::5CR?U77+W35;KMM:+N`LE]D0$C@M.!`Z\5!XB">(HETCM MS+T,I^NNE;:-=2(A,?4!XU@[Q)%5H674<1NB@,)_>BCG;NO:64=6ROO!9+3K M7B]5VY6)_*YP9+7E5"LI&.$0(KO`>:5"`E&4=A*3H0X0[)5Z[,"HWV8`#@5F MD'S0"R%WIX#6%(\4#F3@N6?&!L@20K37AB&C.<<2.1H)7Y^90CSKJ"2<[`?($&:^3#[ELT\01+R4=V.6L%&]2%@E",RO##O+B=1:&XT%QL9I MYOA@SD+3W.!!ILK[`V8(`KQ-JJI.33V(N]/NZXI')`2E-`ZULI371W:IL)0Z M$T)GX00/M?9X#'-W@,<05OXM+M+:N[F$0'*'@_=MT0@\Y1`[+!4#OUEQ$7+* M,"/@)CG*1,M5GIY7EKMW[PZ$96@C[YRPOR\<&4I@2E-.!M8AP6W`S9.70ER` M_"MT[-I;;8OY^X'K-3!$8!=:O71D'??6:^L#'09AH!5SQK4;Z/MTZ/JT_WY@ M##*7Y]DTS\XSF)&NXNR/B^OK!$;`6N2WY_IB\PTC>]6/A`'-M?0<@AIN%=!; MPL#I0AIP2@0;[`:A9K/](8;[=J[O`9XA:/&^@/Y2B[F3`-^4C'0-D/16"B\Y M%S:$H,^<`R%(#\(@1% M/!,>:VX"&`-;&7+_4V-']N':XC&8/7>'W5]+11!)&.TD#3S$D"K$@MA@Y7\8 M(5ZAN];"0.M,W`]`(V6!0)I3B@--"/<&5,#84F,-.*1(B\%2+8U=LHYMO)?Z M@QP+!CCGB_E.([XH%V'G!=5:$@58A$8%,*P):07VPCCO!DN5-IMI6UG@V\.Z M!^@_S/'N+\WL^+QX1IZ[&@X-@!0UH>(TB!D\+FAJ(PX)8R#.PFCH?$*Z<#&SI" MZL0$T+P5-=CKI4;GD`U!GGH+XWE65L7RM=[+G=H?[F``FUYDSQ-0>`MMFC81 M:4J0!J4Q89H3)$,E`F:,5Q0);$6[")Z_+L+T!-:QQIFO.[A]4K\M<5+?^'.S M[Y[,#:U$6`<$(]!>2,,=)LIX[47(`6(K719C^\#H69Y9+#DE9+1/; MB_K]U@^OV=R3-)N:B;Q&V&*(U.!_/,14"4T,A'#8$6W#L-VRGGS]K.D(L#Y/ MYMA\LAP7Z_?N9M52YM5E62^EZ'(;OXN+>KJNWP&\?*GO<$\ZYN$!!0!/T]FB M2C\E'^HWS2_?3.J^3&8+>+@'HM:O_UP\7.!VV'?Q?/?>LUU5H_H='%@X MZ@TW6+'`(6^T%WQ#@L?I\5O\6R1_)+$ MY:)(YL]>MS',TT9WB?Q*R/,,B%.^3>.K.M4(M/J?15PG\.*:;,^$;9(U:M]H MY*6D0DCG8(Z60G&*EA>PHE!KJJW;>9/L2%#:E0]JUV"$#0\Y8LQP&3)M":;< M/J'#S#CR/D,8/S\"FJ/-Z*RTU_>KCW]/DP($OKU_FWQ*9CN2,\T:B)0P&F8. M1!1%3""8.NC*.MRQH2Y8W"O/TCEU>B2'J^*34=DT>,@7@-"=Z8S MMM2*(.@)M0CJ^U)$&$A)E`E6CH8R@S&D6=S9D_UV.%'M\1K?<4/#31ABS)6W MB!`&$;#B3_(K*X9Z`>*879>V8(WS%)H+`BJ4\A@[K`"'P"/\I`,U:L3O#6AA MARW'T=KA\#IM.KII?5A3#F_"=B<++:L/2IL086J5,O5MU:OY2:E@J.7Z%B?2 M&EM@Z\G"_?0?[\E"+\$558R8T`=(4%4?FGW2(Y2D73I@D).%K>UX@/Y'\)/M MXZMEZ]VBS?WDY[6B@#"-C0:'`@?"@X;@0#[J"`X&'FS(W=-//EKF\0#P6ITA M_.;Q[XO\_Y))E4SAP]6#\O?U=?CU.T'2[,:553J/'WY^*/>T`+.&'IVV'Q&G M07;J+,9A?:27,U>_;,0BR3#,AR,[>3@@D8X)H?;X[515 MJX(7V66]'EX?B5B>R!K%DNK#BU14-ETC^S.!H<"[/"M>R+_7*FL7SXF4$)YZ M+X02G&M'%?7*&\&])M8'GNWJ4N/%LO%:[*'/B'1]LQ<,O-IQQ!$*@S!$`5*! MH<92^&%4R[/#LF:3WS0PYO_VB[@!)P2%'#,%8:AU1AEA%`^<$%0'0=CN/IBA M%G&'(TN[==W]P/WS+L`%7@2<6H.0"#0)%!*,/&S"UL*P5[D9OFL&'+1$US&^ M?UXB"B=0:+@.I?7<"*))*,$F5F%!*"FW;]4KP,#3;#[UCK03C5BO!C[6@ M*TE.M;,2$.4L`!V-EP&'GB1IB-7([KGKR7X-5H+;X74L3I!6G"!/&7IGM`N1 M820(N<14,\84XLQ2YB0A[58H^D]6#6!1@#],J M#:`CA!KSG>'QD3).@W.B'5Y#<.)9S+`2O,[70Q0("*V"ARW\:-A"%$"$P6OH MK.-<>G#-+#;2.JRL!^=KJ!AK7ZX<-2'0#[9#)RDO\]GL.B\^Q\74Y\5^*%JPN7JTAB2FMO)\:#)MY+#SWE67V&S_PF2 M#A\7*7!=E%/_W]ZU[;:1(]%/6MXOP+Z017+@ER3(>&:P3PW%[M@"'&E7DK.3 M_?HE=?$MEM1J=;/9CA$@46Q)39XZ1585BU6$!.=`Q,6(1)I:%SVBD!KB#7VW MY/RI-HYT=O2H2MNTQ2M)+FP4\!Z'2OBUS&`F,(?RY M0^8'W$V6Q^J*'/QM^X MEQRS?5,$[R!9R-Y'IZ9>+F'^[/[YUD_7W]VLO>0G>U'>62?"&>I@]J_I MZO;G\-/S"2X_OX@`;M>9]7>=>(![]O,JY25H9<`K1Z)[X[6)_]OBBIPIK)!0 M03QK<$"<6SHELW[/-#_=+ZYN)\NZ4:BBXT=6TF#FO&(H[K%!,(N2C+?H*HW; M'4WU?USY9KC?L8#.R\KO9NQPFZY++2]F%XD8D[MHZ*5K+4\N'QS/Z,\VDDHZ M+3P@SP4!YH2PCH8=OMSS=K>[^S^;+48!QB&WFOK]"OI0US.++^G+R=Z:''$XGZ?99 M?6.W+LDOUYQ55WW=1$_VF8BT7:C-;MZWX\ON73Y,>Z M1&U:'9KDZ)S_Y54``L#!2^,HMY@9H:QE0GF')#%NH(RXW#?'Y@V! MSGQ&%3R`T,Y:BC6W5D8?4S)N@V:(?J^RF/!0B!68T5XW)<5UH0P. M-H`FW'+@Q%#IK`LT6"I"_%U99Z'#BKAQAY_30,U!FL_U+Z7Y MVOLK0XP*3*'`F.=`L0&'%->$<@TR^,*J^!5%EBX`S4&43_5B'8R87=5K;)9' MJ;+G$Y5R7F*;LK>PX-)B*[$#3(AW2DF&VN71]7;05A19NH$T!UW^C+1.U_P. M>X=/WE5IPX@7'EM"(\L)*(\B[9EBTD=LRJRN/;QOV![!C"PX:NT^>U]%F$#! M>QZ(VS$6?FDEIM=%W0](Y;)!> M:Q,H77S''M`)\R.'+YWWD'''GXEDH@'C=100V.AK*5 MTC#+``Q2!%*HWY?EAN3B2%M\LKB?)S5@D<'X5&;=&TTY!:5L2@>6(FAO'85V M\CW=7T^:?18ZMNK@8C$((A#E&%&$^S6AKK2S-_>IVOIC^KSYT&[7S M9U4$.X$EDEH;Q[D!([T0C&&-D#2.J++6A2'SD@:&?DQ4_CZ9WB5#.LP7O\7/ MKC(P^N4C*X[!(N5U],C3$;95$O&`@#JOJ=8MT\>'.R@KG]AG2J!H?J__VD81 M/M6+Z?P:]\'I5QY3">`$IY(/(AHNQFD5Q2PE`0O6&M'2I\W M&U[/7'\2ZWCU]_[O]#+5X9S?S-)N\]=M/=LD2"Q?G(.OI[]\>M[Y^%,SNWZ6 M8K&[(YL.63=JGW"KKX?,F7\88+WX/MV>UOY,@[NU9L17'[\^@K*1-LR7JT8- M?#I^4B6=4D2X:+@2RXF6RDDA-<;!$X2T/6I[]9U-W\U\FV?6=_B\"FLK"0?' M!7,\B!"=?ZQQ""90#9*W"V!VG&4_&)_VIMP/)X%BT^\WEZ)^7TU6F[9FVZD? MB:0?^%1*27%$:DZ.:S./:,]>CA_\',5 MD]X$+C#H0#T+J>4?;'K*:.6%'&-TOA.Q-J-*/R".ETT8A#%(,9#*<&64I80I MYA18HZ3RN;;+YE'^_%PY#:(<5/BMGM6+R5TTTLWUMPA_-.O7G4FWQO_1R'*C MSU<6$`.J920_XP9TG*SU3M`0$!.`LU&CF0/:D0SG_2.5@R';?3AZ>J]NT]OA M'Z!(LR^HF.""^."UC9NY%=0:P"I8*;P!$F2[DE:]<:04N[L7<+/>?SD$X.7D M;QO5YNMT%:($3J-=-P^H0#OAHW7ID'-JL"[FI=!R$/#+ M60T_U*N/7^/TSEX5=U]4.2<90Y:"Q-';HXI7?(DF6U]W%)?_S&+Q/#_N4^U M#.\FLVBL_%5/;V[C;\SW:+WI#?99Q.O1[%>PV4 M_><3A@@=F:PE8IP'P2U3F*6KA*RPT1/\:NV@S M"^MXM,J9(185T7@])U5ZJX%R&M#%!F';U4`)1#DAA=-!88ZYLIIQ:13!RF!I M4:YNP@,E,3<6_<$:**=A6,0A_AC*0YATL!Q`>:^"=!YYR[=Q1ZXO..T+*B&9E"9XB;'@R=47@!!(PX+%($AAF>]%4*17A(L)-'^8S[ZO(R6; MG+7+^6IR]S*N\F&^^E>]>HQ4G1M[;O/,BB)&H^!LH$QR(X2*.XN,&D6P)4CB MPBY6#^C_EB*"45-\$^T+\\7V1^E]A[*6\PZD`DH%5I92Z31'B&BF'`CDM"%! M>WRTE'!AR_D(E:$+N0P01[__]FVR^)&.'7Y.8WZQN3W^_&HU_;ZNR7\Q>XR0 MOT>Y][.5^929IQ0"`YJ#M!:E'DB0FJ$2"D?WJO5'NQE3I+[\A>7C"[,3NR1`); M@?I.V6[0+3QF/2JFCBO\B`5BTNA@@]?88L\MM;O9,&X*:],]K$#;A1]/0[B( M%6T?B!L?\V(6IWZ_1OOCZK9>7-Y.=G=P'_SU9EWH\PZD"A*$9]H917P@+#@* M#X*6"H_M-*9'%Z9DN;P1#=F4F1A6.39CJ*Q`UE-0FB@5@J<:J-CA;X+,=7.S M;[WHF9SY=:B5^,:M/NN2.J4`H&`0,:I&92,JXSFY>W'_\7"=^Q)_#?+;&Y7YR=UDO^DFE MZ&.?>ZITO7GY.Z^;KKE#3&F2FO*I4I70I263GJG6-C)!Z0W;\0G MZVC3&X&(WJ0*/5EY2M*B)\.JD!6I18?B%*/`I0S13WZP[)$H\;2I;#8/K7_M MA3MNR_/!MWZQQZ]#J2["%";3Q1JA8DY]3QEIQ9!C`;0//D118AO4[OP_[@3( MM2M%7EX,I60W+X?@?A4E+%SSJH`D0TPBC"P/06)APS8?QF(B3&&%%TN`K!7G M"]3=$T4_;H5]?M!8IM:>.,9*AB@FQCS6SH+RDGNL=O*C"+>+TY07$/UE5+=? M^8];?Y\?=I:IOR>.L=(!*Q(E:,$;$U"ZI;GS6G!TN_`;B>W\,OK;K_S'K;_; MH]8402]3>4\98"4E48I;(1%3S&"BL7B0'&?\K?BHOXSF]BC\`>^N/ZG5T^9J M^F[4G0]P?:?RX%/_^8_TJQ0JC/_Y/U!+`P04````"`"IB/Y&U*W>F)I\```= M9P8`%0`<`&EP8VTM,C`Q-3`V,S!?;&%B+GAM;%54"0`#C9&Z58V1NE5U>`L` M`00E#@``!#D!``#D76UOVSBV_GZ!^Q]TNU]F@*8A)9&2!C.[X(L(%+<[+=K. MSEXL+@S%5E+=<:Q`6K7U[!-^"5DZ[F^2);7?WRZK=/9^03>_OVU=_^^I__\?-_G9W] MDWY\Y_!\?GN=KM8.*])DG2Z<;]GZB_/[(BW_<"Z+_-KY/2_^R+XF9V?;OW(V MGY;9ZH^?U/\NDC)UOI?93^7\2WJ=O,OGR;IJ_LMZ??/3^?FW;]_>?+\HEF_R MXNK.5((U=EU7:+1NK+OS^Z_IM7 M70VC*#JO?MM<6F:'+I2WA>?__/N[3Y6=9]FJ7">K>?I*LN$X&SZ*?)E^3"\= M]>]O']\>A1>=JRO.5^F5HOQ#6F3YXM,Z*=;ODHMT*7%4=_M2I)>';[$LBGMW M4!1%BB*(%45_>>+&Z[N;])=7979]LY3\G/4I7A_> M<&C`GV4/3H>%_/B60X/>!%N\6IB(X8>W'1K\L)C-!D>^3I8#!\>C6QX'O527 MO9.?ME>JVY^0X:KUK;CNW3G]ODY7BW2Q$<][]W:RQ2^OY*?9;7EVE20W,Y%D MQ3^2Y6W*LW*^S,O;(BW)1;DNDOEZQHGK0]?WO1@*"AE%`#`:,2X\-W9Q%,ZJ M>\[2U=EOGVH(U5<:;024D9"X+@D#%R',(]\%G$./(5]XQ,>O=*AXS+)L*K\M MYIM,)<&I7+W!^U<%RZEP.7O`G'_5T/[WY_.=1?>IS.>'HJ-"=)F4%Q6LK?42 M'O3/T^6ZK+\Y4]^<`;A-N7]I0]-#=O/YL.QNR%JJ\B(OZIB\%SFDF#MYL4@+ M6?K4?Y44\R?XLW634#IUKEU+013Z`:<^@X*AV',IB"-& MF*"![T-9NB_T]310V50T?[U#3#5, M:>J4/L,6"U4'8UHH55>*6DO5KJWWERR_ODE7937&_)@N5?G"\G)=?OJ2%*D: M\"T^)'>J"^\$%!&(N`]\S#AA<80#%'J$5'!H7MP2%'(CI1ND"V7VZFM]Y>["Q_>I:1W'V3G^YQ<+-.=+G+`0Q;P M"!#@,N[",(1^;0RG`.E44W9:8+A*JXU6`E:N):"M2,WWQ2S]KCZG3I'.\ZM5 M]F_Y^_QK6CCK+ZES4TTC:)9U=E+=,EW9"=YPL5W?9O_[1'4OGXLY1!,A"5U'@3%?N3N+I$^G5[LBS)"M;3E+^G,2D:6;Q7;,L\'D)*N%\RW-KKZHR>Q$)O?D MJL[MJNF[-"G*J@Z8;UMHH,@J()>U006A_C?YQ=7SN- M#<[&")O2;&?N6R5-\YZU+@6.8/+1A#86W1W2T^%\^4DIY?L;];$D\W7V-5O? M/4#FR>SH,'9W\9I-9-FBS MM'M",.L==G`O,5' MD\%(9'?(!4TJJB`>0Q$(EW("U7`)AB3D/FTR4N0#K57;@9L>3^/E5>LBFS># M"B=1R;L:.LB1PF5>7*MM>_=_US\3#.,?7=4?W37=%7Y7T%=8K13R-G2V$NU! M_6*=0`]KW5$Q-D#BD\*;W:+):Q*NU;//MJI(-E0":!:H(A`Q'L0<@ M"#CVHE!P3#GV8Y]SXB+R1%]NWQ!C/J:$>#&G(?+DP$)XE#&.*`($!LCDPG&] M-USB+]/M_IW]#P^CE)L43D5+$?BTM8*;=;:BH5)PCJIA097@^G% M`Q)."D97PJQ1C,X&/)*,?E2TT@QV6Q2R%9&5\V3Y/VE2Q*L%3];IC!*,*(04 MNB&0;.PJ:A'MWY>UI`1J%.3T.ZL3:`CASCXHB4]*;.`C7I;T,^8"QI MUR$B6Z8%DTU-:>C7W8%#Q/2JD/OW9EQ$,2`T\#E" M!+B$RA%7Y'(F:WP*`ZWG^;K7(!4FIP:E78!HTM6V_##'5*?BHRU)@U4>]^P_ M67=T8\H"G>@%_U'-T8>&5NI0SZ)\EG\RBS@(51U#9)3+?ST6X+".!!$*`3,L!XT\WX*C(8.Z!'SM``8XZ3CI/-I M.@;H\?L&'^GJG3BQH(]WPYWW#(8.O;HYWJ$J+C@G?BAPZ*.(8\PYP('7C*(] MC^IV[_MW]R`.,?E*FT4:TMF$`RK2CXX..K*1K4UC(19^ MA"'$(J"$NH!QU/0&6?'XW91DOX7(<[%'L91#+T019B3R0BB;A1B&U,6FM\D] M[!G;]-I/3;08U-434^3U4Y1VO`VN*7MDM%*5+N19IRN=C#BJ+-TI::4M1+:T MJ%I;)EB`0%'(>X2@FG#>3^E2T>N[_\5TCX`>"N5%((X%<&(5HIS-&BIPYM&1E`#^Z9?$0#NM%B0;_O"#SO M&Q'Z>R;RZ^OM8P'5WM3R_>U:G0:K#MJ=$1G+OA"A\!BG022((,UPW`VPT-Q` M<:HISXV($)&`KJ?67S"IRB0OAK)X)Z%KNIJH=PA4$#,: MZ-WCPQS4$S+;AY_V('[,ETN1%^J7,Y>X$`5Q@`*$780%];E0"Q$!]GW&_59; MQB:&:%@I-Q[6?;AH(F^=%M!GY"@]X3UZW,^>3>K0GX/'""GLKW=/J>X9Y_Q+ MF>=L[1O]V28C7CJ@_I:$A2W/2DW,PL-GJFQPRA19ZM?;ZXNTF,5^C`B'``'* MA1_`$"%6`XV`Z\YN'KPI84SU:XE11_@>FJ.9IQHA<_(]'4M*]1CG17J5K5;J M9_E#MU/UQG?OZ!G-@$^M2&:OG8UESS>+;?"/D\`TH^#EY2Y=`LREK4ZN:)^Q MU"CN;5G>I@M^6\CFMF_>J=1T__2(^'M:S#.)=A:$&(<00^$AC[D^#V%`MDA0 M$"`TVW^7R-/2-3R`5MITXBTJK7--`TDWCQ@@O66BF(CMR3-!;4_I9*OM&MC8 MF4";^E-2;\Z/MFBY00L?BK5I,D<;/\CAS66:K=6K#=ZN-E;,F`C<&*@GJ*0; M"!0`$K>&*E@`->5Z`H2CZ3E3Q^LL]>5\"J^-,S`PYJ[)$\*>9=.EA.&]8W!X MT"<6;$DJ4U(P\!"AOSLFG-:*0M_UH.OYZJ5WC`4!H%X-E(J(;*>UZIC$<=;%8']THZ\0[L4IW`/7$RA9GCE-@F_7C MY/,MRJYG.O/^R#,&\U/W*'@A^:D'`0/GI[ZNF**H_GW[7A&R>:U(/4WUH@M.4`@X=N,(>91PEP=!;0D!FJ]^L0^^X0Q7PSQSMD";266G@CK= M8O)@_A]]M7D*UUNR'%V;?B2:IGMYZ?CN'6?D-W2LO9#4:Y(A/FFW#J4_5Z9N3\LTZ5G3;Z M0R&OF>7B`=U;)]\ M/$V$/9>T/!$[NMEY2B>.EZ0/;'LY:8=`E"`D`(>>RT+J48_43WJAR,.MSEVU M%OS4B=K4ALG1@V"D3#VE_R?,U0?W6KZX;*WI7)/YVE2PBM7RRLFV,/!>- M'9N6B28K]=PVQ>[4D_"QBSR?08+]T.]5B_Q;5? M1(R^\76T8+!D.^PS&_<,X\AQ=L\.$DHO)`,/3HNYG;8#NFVT#$P6BTQ]2)8\ M*^?+O%2#M.;EV+X;!TR];"9F2)!8``2:!\0A87S,O-L/Z=C9]F-ZG635QAN6 MKRJ(M\G2^9P6UXXLUQQR=554SW@[;^5OLU69S9U_),O;L;??]G3_.$EV/,]/ MEUIW-CI[1C[?[;,G?68PBPX3*R\D=PY$QL`97)BZ=!7V@/M!NEWQ-Z MI?/NC"`/NB#FV`LYB[#+*6L>N8EPT.J]2#;CMR>G#C`O^'RB1B/I6@;]>:3B MTYMBCP?A%!EZ7`<_E;;LKFM%!W*\;9B'3?S'Q_@'S,%S@+7!PB)"`,1 M"%<0&N/F,`B!W6#,S&\"OXV9W\`\MF6LCY3YIPX86^>W7TSF[^!@@YG?9+B] MD,QOE**!,[]Y=TZQWZ>9I:TF:6^/IJ^W062LV=_JQU6SR>^%OG\5K55P7GQ<7;/ MVA<4;P\J.N4N5:=1U`^1S M0D3L>W[L4D9KW&%`H_8G7%H#6?]IWR&.MMRIIIEC+:VAUY)2<-`PL+SN>W8A M8EY/MI5[U]UL0R:I0B8_H"G?ZI!)MB%SJ4+FJ[+Y MS3,HTB:LR%J'Q)^D_&K/Q\BUEJ:CQBFLF@,RCZ(67@A$B.3_B,MBCQ$<-:A) M$'JCS:;UASKVELG]0DKW)%)+*!NC1!K7L5,52(V5MI1'`P3'B,71N$$R=6F4 M-L%B^&H)8V/40^/Z=:IZJ+'2EGIH@.`8L1X:-TBF MKHFZJ'A@N$EU$,#LC%D/32TD^Q9>1/R/^3%F(=N@(5Z>#AH M<+LN0&T/V[4&L/ZZ6_]3=MNMNG4[8??/.3'>ULLO0?,&Y6/LB7$]1XTZ,7[@ M&?1!(N(E5%&#\F%@+GU` M1[5_BE7VWPKB^TN6E%_$,O^V.RF2RA$J@!!%06I_(&L>7ARU)7BL/JBLS7V==LG>V=RRJ8BWV?!Y@V/(!IH3M)@TWP^VP3G[11N8KKU=$^"WCI-U&?VA%(:=),E^FG2PGRTF-?7VK/,C;W892(0 M,/9E@82`5S<"1.QJRJC&G0TKI.JW685&7Q=U^&DM>8:HT5>S#1#G!P7E1X>L MUT5V<;NN1H;KW/D@*^_5>GS=VM%S6I(ZT&B/VG0!_UA(.E/06B/(XO]NR[4J M`LO/^<=4&9@MTWM-?\ZU]0RJ=3P<^0S''/JNS]U&SQ"BH8[43`+0L&+MV:0Z M8E%;Y:P:*5/?JY_FJB"YV2M(\@/UX$^:PC>-T]OII_7^UI/A!ZYN#'(>Z[/\ M];,I/TUXZ40VF#0H+$DJTW*06]1+-5,<3V^DPF;5W*/\O$RK2 M1N=63^[WX;UV&H";-Z^U8MB(7+=A[83\#DJZ)7(ZK$VYP2@=Y.SI&9>R&M`P M8E)BN1O1B-.@;LWW@U;[]WLV85C2/JWS^1]G!Y90T^_J\S`O.'R:QY9K/^8I M[+!GX,0/-&E8F]D4M>)=R'.AM4@G1]JF#\JSG=#YRW4Z<;-[6D\(7D&?&&) M#)JP+#<>R+WEDLSG^:T<2LN!=)I]5?/S,T9C)B+5&I!E(<>NYS;3O51XP6Q5 M'?']Q*,%@S;9JM]&FWZ[CZ[]7-D6DYH0W8+JK8M=J.VJB*8X'5(+&XX_MN!X M)`E\S)N6^/6@W5K9ZV/3DX+7F[`>4O>A2&^2;,'3R[0HTD6\&9K)H?'[]9>T M(%5U-/-C-P`"QSXBLE`-`(K#W<@XB&E?\1L$A'$YW**LAZ^;HC%7")WY;5%4 M.W\KJ+U%W$KEVHU59Y%`@H=!S)GGA1Z,"`E!C<;E1&LF MT1`$T^OW=1%ULP&Y64#9P-P?U@]6O?;S1]]Z=C17#%OA?MASSA:X\ZZ-T_1VZD0'L1?U@KTL%:V+I8')+6?0*NV/R7+I%`-8P%#=9X4#4(OHAX+`D:W M#5/&L.BMQ5JMF9?=JA//6RU/F&*TAYH:(W,HX:SHK1':()#[C.EJ82>V;9:] M;@:U4;@>5/59)5(E;C/[NJ^G(4%Q`(D'PQCZ,??_G[MK[6U;Q[9_A1_/`.E` M+TK41S[O#=!S6K2=&5R<#X9B*ZT&CI2Q[)YF?OT59AQHOB'??,_K&WE"=/C.D;D7C+>.1G&`G;VC=DI_W$&:4P)YED:] MO:/!SIBM9EHP[>W=(TOTJ=5W(;NZ*/.ZIM7#75&V&9!\T[YI.2^WS:>Z6+5( MGMVRKO?[SXW2/\A4]L/]F5_I?ZPWXDE4&[I?:?R_/-O@Y7]V15VT-[,7*<,Q M0T)$''HI"P3R!.V-0Z&7JBW17I=-8VR`=0EN;XO\>#1&I\S'U;"J4B[F:HQQ M%Y]Z"L`)!S?@:!)X9M-II9DF3]B;"&Y+L.<"?+@_^ZNG/WV@1-8M!1TI0+(" M3FGY-?NE1HV:JS%*IW^:%;*YSGZJ5O-F+FY^);^;%3[E;CB'ZCG71UIUSS+P$19BD"8.QSSUR1(#)8EMML[7:HH'%9K76#`X(E?7V#]5+HLZ* MAKQ-O-HZP42\/G/Y M,A(!2C%F/"(IQ3Q.4N[W2"!-E1X\<]B\XY77`S3K@CF(\T'".1;=5@7TZ(@Y M7'/79U9?4VVX:=[::L5"-8VU1Z:RUG9U*^LO59L/;_(^)<_K!N2^M%[W+ZM% M1&CLQ2B.:.(%?DI\%/97W$D2!8'>R5:K38^PNGF<+K35K;\]U<6RR$K0;W;I M2JY=ZM7$=GS.C62VARFKBG1PP!'I35M^I"_OV<,=65QUF+P@JTX<,A-!=6-; M-4*/'BJBC;`WZ?+VZ6/3J[>X7/'F;Q_ECRRB*,:11RDD"4TB3]!0'&1<1!X< M**'F#;N_$-#\_3>Y12W%LX/9G@_(>XQ#]7,`ZX;JZ9AN:]K9X[P!+=*;EG?^ M-N_C*.=9%G5T<[@KYJJ:%BQ[2S-MD>=@BK^`H1=3XD5-QDL$]!'A).@11$%$ M+2R,FC0[UL+H;C^W;/X_XAS_;=)MS^VM\NU\3C_;B;R5";RR+V:BF"XL,YZP M:Y(W5#%%46;E\O4E`Q)0%,8!BCP,8Y_@,$CA`4D:1A8618.V MKG?RW/J'^_=5^?5+OGE@^5W3A1YS9])ZAU:AB+5JKAIH3G'6MHC M!+*#@'6#[%WS+0]@U6#3G;5;X%9QMCXNK9JS]&>,]O#DVLC[`[OL(KMNYN9O MSB&/$#<%R&*_90P%'O]HTDD M\"*AMS9IW(SSE<@C,CG>!JF9.9=J&N:61"/E>L[>I&IUCIT+&C68T)DHTW`[ M*LL]S4J.1:N'AZIL:^$N>(H1C'PNN-\H8<3""/=5G8B7"CP\Q=)IS7&&)>=0 MC\]R@N(D)UBV0$$MD5K)M[1X'I)NN:+85K:UQP<^7V9VQ%SKA##M5,N$[)GH MF46#E!(M(NF`@C$44P#3V2<,Y# M'A_N7S)$M6H-NT7B6!GWX,$V^P'N]O"[85R?J9BN*9".W:0FGO/QD)ZP=LYI M@(,.^=XWY^JQW[RZ&CBR\`XB^X(HC^/$F0CV2,964XP39ULSBY@*+#S(H4^B M`$DH]("`^(F-S6R39L?:S#Z]Y?/;KM\@N!]SI^9M%]C>H;'*OO.=F=ENQUC9 MAE'VQ4Q4UH5EQMLNFN0IZV=[1+-EFR9(&B!&&& M_31$`4R81S@[W#D*&/-T%-1JPR-HZ&^KD^(^7<&?HMQ+JSS1UW[(CY9HBJA= M/ZC)Z&0NT!-2VE/@/V6,$K%9A&EE(=*B^(J1./S$1.W=A6C="EK4@J M;I1^LWEJ1/V?V7J7RZ-*C*,DQ9"S&*(4Q?YAX8.&:;!X;$%_WF:;[1!%U6U7 M9QR_A*@_I%^JY@VXR[\692GS(GE6O6W`BI1J\S]$0UV2;DT\,YF?[E&"%N8L M-/,%==IB:4K]K%72V"@E>1Q&F65=#`B/4Y12WX&$*(B8#82_OF>:1WP-E6FXYW0TYA@E51 M+]=5O=OL-XGEF+UO8#=SP@-NW6=C;3&OEKE,0;I>[O*,[U8>)49P`G*ZH\R* M[%T01MO\ST0:K9OU\H%:)[1IU")OA".OMQ^S8O5'OET0"A$1(?4"C[*4DK"1 MY4,S-([UZHWK?;=CN>OA:-<)UV1(3:Y(C)BU7:7*D*A5.:=+6B9:A%,Z%>O&3DHF08TS<;U3"WX.>B_3SF,(>60I)2),&8H$4AQ7%QHP4L" M^=A43/VDF4S"B)"8T!3[/DT$"YC#3?(C*-"CFBZG/\_0A?%B@=:9C!L;EE36 M^YSF.")97=0?[C_*EVZZ`N2X7'TNOI;%?;&4%39^@O0E_[$E:WD8E44A]V+, MT@@R"IMAAW'4C[34IUKO4PX"DJ2(A7[C1.1#&(1(3E]8"#%,0XXXQB\"?$CYH\8\ML$.XOB#!H[AP M)B(]CJW5!&-$4^C_IZI6?Q7K]:=JO1;5YJ]LLUK$F`O?9S1B49"PV&>(AR0A M20+C)EFC7$>_3;[?L2SWD,"?$A3H4%T8Q/:(4]-2UYSI2:0V74XT[Q5.+DC9 M$`9GHE"#3*CL=2A#/5GX?N0'R(]3ADA(>1*Q-.V^'T8\X/H'I2S-X=A M\>[DK,U=MI9WLPREY&W.]/3#*E%FHC&12BA(@S(Y,],#==QG1$#3<.V1WU>J M9;N-3&3:\;4@@B#&/)8&-$G]A(0PB@]MBM1??,\W=Y5N4F'4E$ZG/T6EKPQ9 M!P^L6GQ`OF=E*`UFI.K)A7,VS23DYE`>&^R1=<>5)Y*6UUA2D)M!Y,Y,@H;9 M6QYH#R(/4)B6,_2+Q> M-6.>XM!,P6PB<"YL1S#@OMJ`Q\9%&_`DW_C;2C/DS3?UMRB=^D)/^*9R@JD> MGN!MEZH.9Y.-&\D/=H\K*7ZP_3]0^C7PR2\S+E=(4ITV]E:3%X87VX\,I-!Z,BXER?Z'5*H/)S? M5_*QW[[IIS]V#W?YYL,]R^\;A<]DP`SD$1/,4LX\B%+*O9#%?<,!\[4.LPYO MS?%NRAZ1W$)='3!I3@$L,*HFBN.2J2>$$MN)^CW=@".S3(%9)]KW)F$7],X> MV3/1.(L&5:[ZI>XMI>6W?+5;YQ_N?\_6_2.`MV4CHS)'_9+=K?-%DQ3YF(1) MXH<^9]CWHUBT38=!()(`:MU0LM">8SWK(3DI]K?>Y76%PK(W'(2HAMO,U"1(<43;3 MM`:G96TT=XD5O1S%&WH::L$14VCH.2;-=76P;ZY#:X>;J:>_EFA5UN17&V35 M0U:4"QQYG(LH"@CA"8E#F,:P;S*AGE85X2'M.-;6\P-YCT]74P=1JJ:;8[&I MIXT#B'2BB1=8NJ![-KB=B;99,:6RW_44-:IX7#XLZ#HK'NK;G#3T+FJEKN'_C["?&A]!FLL>E\$ M`&FTE'7HQ:'7BKH*#:^HNE7V)I9UN[94#KJ7N;"3W?:/:MLW>TO^^-0UC6@8 MLP2%@B$*.?%00@YK$3PF2@4(;+;G>J+?(+$H\N:T:FO]*(P.D_P&(F@P'G7I M-PGS;Y/R;!P$1N';3BPPY]TD+)PC1BTZ#*9U?D%BN$GG8X4ENI37*UY;-'E? ME/GM-G^H%RCP>0`%8S2!`G+A>V'8-QHEGM)DP$Y+CL/$F>T;B0^T`'47+0;R MJK9L,1ZE>G%B")M.5BXN$G5A[<(.P3-9O;!D3.6B#VJJUO_FV7K[C6:;_,/F M:U86_VWCZ4DMD2")18@A]S&,*!:(>8?%741"H:-;0]MRK%RXKG/MB4];,J=ST1NTB@)TJ?LJ7>?%= M'@@0U>9$-JE,_,KM@HDD#F(F0I*B,.`!CKW#H@#S0ZUB%=8:'6T??G,`VE[) M>CA)(99MAGP#EGO,0.;&^M64[?E!3?PF<8'IYONGY^R?H+P!'<[1:Q2JT7=! M%ZU[8"8":=^NGZH<.B'.GF3^496=&"P$%`GDC'EA@DCL8X&30X89ID+S-JO- MEG7&K=$M5BWQ7%?EUW>-0C^XDD\=GUA24$?.<"&B1ZAST]$CLB%2:N"*:U%3 M$]-T!=68/GN:NO!P,SN'F$%/OGT68T%"WC4<"A2G.H\Y#F]-*_'4?\%12SO; M[[>MEV_S;4DEK5)M7QOGIH=#5%"9ZFO1/G6#=!5/DRJ3#8T7EY'PM_ ME/*E'ED=(%\=YOY)0+P4X3"AD+"(^1&B40^F266U'B]R@\#Q1/Q]D=T5:Y/7 MOAT1KKT#,A'7YCLC/]^3[##?@%/4TZU(&I&KMIOBP%DSD53'1I[??7%&J1OI M[9<08`H3RG#`PT1@CW*>^.D!2Q,7G"FO*@#7.\_YJEAFZV=YISSK5^?K^W?% M29;:'F$:O`KJQD<.Q-J%>YQK]52+I2;,VA)J74==HTYKVSA$ILT(=:/2)^L2 M./4CAOV8^,Q+PU`(&.`>3A0@S<*GKE`X7W35UNNA"Z_._.5`M!TY:@3=GFQ] MUI!?6^IMX+%K%'`3,X=HN#&M;F1\D3`1X3@2(@CB@$21']&@!\$%B776=NVV M['B=5UNN3=9Z+?O"@3!;=8-S.9ZS!-L27F6/7*/Y[)DGRK#^6G7"I[@ZI]!.D?974GI4,N<-^6C[MM\\\-H4&N-8W1PCM<_I#V@->@&G)@$>IM` M58*#5:`U2XK%T3#06@:>FV98VFI\SZMI_:R=KA<.IO*WD\AAVR\7@LMD76`F M\6>J1/=)W5=5O^QJX%'0-8J3!)F%)*.6 M1MK8?`(M)+.R7@.YU!1YYS3J*;8N@VZ5]C5R5&1S$*EST\!AQIP3-`L439%C MOX3=%<^),2<)99Q`P8+43P0+>UEM_F#I1$FW(=K1LG!P]P1^&O%FA;NF9VW\ M]'H$]YKFVV:>G7O>_#KAXR32`YT]MZ@R/2'N4FTKKE(KQ$-V=5'F-7]M_[2H\$!$%B?`PY"S$H4"AG_(>2XA)H%R9QQ4` MQS&HAPU.<(,.^''1>`N>03>J->/,0Y?#S6R"=2CN&$.5866]<)FF:;C#ZK-!-#YC'QHN2\^<^BWRO4`QJTO[PZ\T5#3AP M-STT=<@4\8YFZ^5N_^+MIVJ]%M7FKVRSDMM(C/@AE5/:@`2(8/\PE<68:KWJ M,CW:JXR$-^#$6O"GM!=T!D\8&$W[R^A10:=9+YAY!7W?>..%T8,?Y M]6+K4$+0]7.4]7.;#DO'[7B+)7>BY^3"S6#WVS] M9A[P3DP"?S4VO1+8ZA>1K8E^/X7#XXYC^[U3!3B;#E():I-TB+D%LFE(.!>\ M)G2)\X!U!NO'9IQ_R^J\7B38CQA'D>=A*.*(>#*P=GA1ZFL5.)D,I.-)(5ZM MBC8GWW[;5+NOWT"V_,^NJ+N_VV1E+6\F-#UCI!`VW*ENH]BH_APUD%V*8S?@ M8."5!+.W_.0@GEGK&E<>TNSQ8"FJ67:,VHD8RV#IMV:HY_5M>5LVVIRM\;*] M$-;\'*^WQ4.VE6:P-.;4XS`.:,3BF+!0]&9`#OU%F7]M?G"E<)QFANB5A#/= M"^>IH1JA\-^[>MM*IBS7]]A,_C;@*<\V)G%PKBRJ'->9(>SQH^:_;$3-SO3F M5T%G/#A:#P[F7WN?TCAJ-$/X[D\IS;N/J9UU&M]QYXY)S;@+S>&$U9SIJ:Y# M"2;/\V[+,P?4%C[U4"2\T$N%2$D4)0E->Q.:OYX\QS-'[CR_VP,$10FR[H#H M\GA`='F*=?)X/,#_4^5WCAT_U]Q.AMUSYXRON1M-G=*-TYUFF\Z9=:L),[FS M_AHUBQO>:W[9#,X"-TS6G3:_7:83$Z][G^G$D/%VFDPZ MR*^YUV3$A-O=)G/G3'SR+_(@DDDD35/NLSCA/#ALCE'$2'?RCY>.0]DPE/KG M_GJ#E)6Q^06E(W^STJ]Y'?I2]>*5JY8E$D8Y]*7G$HVG^9;50_XE^\&*>KFN M)-[#4RW"CU"4(A'X:9"@(&$TE2^LPB3&!":1ZEW&(4VXRY_VJ$`#"QQQ3??> MT062+HQ^&]3.9`Q;,>6GA^!LT:,_GOB/Q[RL'X"&,WHK;-B'K<5-^+6GWI=3![FDKDD#AC%>HP@=\Z M5'^;2H&>DZ.B/H9TSDUY3,TXISJ#:%%6''Y_GR^WQ??\T.ZG;)OO%_!V33+Q MX;%;O*L78>`3%#%/)#`@Q.T#@'GIB)[+FPK'+>C:V(X_/^ MB;0!'$<81IQZ'D18@=H7/AHN&K:Q>-83@^H MP#_^_OGOX'Z/%13'[,^:Q%KVTQ#MG'C68N_(9*4HX))NY?#P>?DM7^W6^8=[_O"XKI[R_'.^^5XL\\_?LDU.LEI6 MJ'N06?P>Y;IU9//IP[W$_[4L_INO/K;+U+2JM_7^404A8I2*I$':?&(A#Q"A MA,41CU+$_4@K8+A!Z*6!O'V@--'Q]9Z*>H!:2YM\)](+4M/YW$K&< MN.A"#)NV2\PDJDU,0C6G46JT3BVC;;L_];Z#TCZ[@5(_C7$4)XG'*88QY7[2 MJU:4<*R_5OUZ.ZE/6)"D+&PL@5Q0XLO_41K#%#=QW1MGO?J`#?3@S-[I&<2H MSOJU>S*-UK`->'2XCOTJ26^N90^C=B:J:,645]>T;=`S5*&ZQQ/DJ!$P]FDJ M0AZ)IBL$Q\PJ3K3>$+O+]]0<@9RA*MJ@!!IB9Y,6B18KH_GKP=:,!=%\$*IVO$@&> M-V.E*M./L[(@ZLU:_[W:Q#2&VMRJVT_KS3J>-HBYCW8OL"UL;RE"3$NO(>'< M.N-1>-W.,A9$2F&O?B-J`XC!,@RF"%5&!AVULPQ[#P@SL#:+M4(>VI\_%K/; M]]ZE=NTHC'@_7AL?[#1^>QGG]*8;98BN%W(7"*\L\C,AOL)*;6L^K*D[;T76 MP->GVNB0&N^0)IA;+3!RX3^PF\#>J*0#5*5EXU8(Q"R%&&F*)!>6,RXA##(" M('7M';GR*;3K[*8:HYN]YZ;>C"V>F#M]QK:-NKN+=_<.4>V[KX^>@?9F5Z-B MO>.KQW\6%9NRD49ARUS:]IOH&9B)KYE,_:?;@9.:H;?_:B58W7Y?P-:'WF@< MAA;(*A46SD$2$9BIXR=`:*_&B8E#$D99)$*IC:6:8:T,%%YSYI1!GM<^3O=V MNP\!YFZ_7?[>TLORG$]61RD3W48IM/MY@PF`3B/YDX#/NO(NG!^9K?LA=X&$ M"T,_$VXMK=6VZO-:(Y)_N_BC/>?L`SK?DPXJA#3BPC&I"8->(BI.<]="D'81 MOY!01MIXM(198"V-%T!8;/X`I9,>4BMLKRD^Y-)]/&GU[BAC$Y^KTL0ZEO$* MAN$C62WO>%W_I5:TK#ZW[`SHNPS^0V/L<@:>"?V/K75.1%T:],*!]*O5_O7[ M(..-5QPIHZ33,/`,#<&\[YA&6H?9S3[&GR4#ZM/0UG)"@,:&0T0-%MH(0XQV MU@--`R1)@?5)RL*!]56S6>UC\F:_^*-*D-W?$B6#[2I&J!5T7S6OCC9X>\D& M$P;@'9J#`_%DL\R$D6MIEQ689X+8/T!?W,4F5[N?5G<'.4YWG`''`C)/$)`J M_*,415)+8SV2E`=B[QNU/??]7CC@,13$($4U4A(:0)7@\?``Y$15C,-:D6+> M^CA=I[NZ_QP\E\*DH8C.9)H-U^-I*%,&F.RI\W;UQUX'#7^_X081`)B&QE/G MB`+"HF[NV/`R:;_IV5$@@A1AZZ$A@)+@:KTPDGE`O!1,P-I7]K^=1JG+RWS\ M\KBG#G3#R2?*U1P$FYI^3@@E\$\ZJC,EH`Q%7F"@7&C2JX4=:P*=M3G]Y_UB MLU_O%\>[4^^W=Y_:E=SA7+BAD@)"#.62:(L@IE9S`Z36F!B1=(2HD@B5R>NA M`F);XO!1H^2KYESVYDSXS!M"M>S4CP=G8*(TDJQGG;IUVY+PO4"QE0TV$_ZM MK>5SI=5J@IK.W/KKZ>7_K%=WX0L^?+U>?0DVB.?C%3-:`0V0PH`P0*''IAN= M.H*SF'K8D*,Q\U5SDB[O5DTIC!-9=CQX M8\"2H`VJ;+O[5H[VB+T2C`CIC09<,PH\DX2<:-=S.K3O;_[(XT6F9Y,T[[I. M8<@3>7!TM+.#S!2@1ZO\^RQF?6BQ*/9S8\>RRO6HP%L*PNQU?>1FW)ZYCV4A M-!,<(L>DX'&?371#:F7RF#%CG,H\^//ZU\WZ_7H90O/OMB3XVT'8!O^0>_=G M$,9Y"^]:\.;'@:?E]1',J2[X7``J89F<`^_//AZDLF3@C,E/(0.J@DT<(#V`V!C;+)<[WG]XXS MV_.67DGX),SX"M!DS?EIUDEG$+PT[Q.!FM/,3Q7]>W,_2_W>L_\?Z\WZT_VG M[GX\(336)`<06Z6,QTZ?%D%*B:2:3VG?7)D!6F%R5QB)*/5C@7H`I?%`?VRJ M,,$C&"YP01Y<,V.&W)9Z85$98_'$VB.=``T60D5X`AA4!XA1T2(Z2MJW2 MOKDV(QR%R6:$-)1Z,D(U@!(9H3R/>>8Q39E&&C.%,4`G':@M'6#4IP%Q9CM&:7K[!(<-8V6ES.=R%[9>TDU M3#6/4TO7/>IDC&"]F3#Q&)H./<&4"VXNQ\=6>=O[S?Y0=E\@HJ'1D@(HF">Q M]SMOAR2&PJ2LT)!Q*K-T)\NAY*/UY^6GI^/]=+?];;7WVZT^+X]O'SW6G]V^0TY`"["R$$D.A*7&!+*T%G$!$0"_F&E>BRAQW M)F^\N;KH)&Y6G1\/Z!RBG3^A51_)/TOK/G&W$ MQ&YY(J6W4\Z7XJ[^]?[#ZNXHX?$4WXW&4AK.';!$0`,))@@&482'L58],V4= M>_KX4[GQY>INOUAOFFV4N-F^^^W88I)3#KFN->N[Y('=S+O@_O[@+?AP^\VF[NNO_JQ6[=-@P36EMO)5$*$T&$5EZT%;,U4UPF M5:0M)Y76GOH0.VA'`05`"BF!`$H8;"P.;XRW#W-^)^"J.8E^:)EP+OS0:^+U M#9F8/)R5#;.=;3GSU"AF$XEE#57B+]\WY[ MC.YB?=8?-R&B.VS9_F-Q]WLP6?-^>]?\>!OH8[U18-9UI%1XYT:60U3I<1TI#YY!A(;:(1%B#A$K ML:%(21S8%--N3C$"!A-:-XYU1CL)#$$B%D[$FA"B`"46$\<1JGV$^?P:Y7&1 M^OJYJY2H*'?UQCF?NVI`7(J[T)RX"V5Q5RJ\,^:N9%5Z<%<>/*,NZA_._U`G M!%,:&P)M"!>)X!AWLY!SFM0!K:QDBC&/O6=,,4JUPPI[Y0VC7B/KA:_=D>9\ M!A_U.:P&SS3J5HVWS79S:!J".L?.9>CP[SS9-<)UREG-4 MT\_-BXRK?(640:X)>GNJ,Y%.\L;#7A^W4;R3;#=46L)C62GBF5`XB$!(QTC6 MFJ2JR'W'%"'>I`QA9!VEW"-M+30\K*.5]=9X4-F[J.7R[O[0C&&S#^+$/HKA MY6X='M[C^>^84/@_[]6X=WPA!^7JS_'A_&_YXO6D^+[X>`O9G M/_Y#HJ\I9K-^7F0* M0";;=BR4*^!2J+><5(XR[Z@(LAA$60A3N67:4BX444B#VOMZG2+Q+$R?SKB[ MBZUQ,[?\1K1Q/ZJ>IWG3R'QLRU9A_6*&N.`7QC?V3#S'!(IOIYYGJ;W7#B.$ MOSF6$8+&,"^4X\Y!XB`2R'7L8A%C2;V*'WVS1$RSJST`E)(A98D$5`4"@8 M0D]=.T0_3/$H35YAKT28^I%P/832B#0!G#H=R\YQN,!C>7C-A(LRA7_:3FP` M!/TCTFRJ>A!O<_M3>,9>+3ZMVAJJ4ED&J#?".>%#U`RTV=\1(@"#6T#FDC&&"5&+Y)4CF\9P/2/.N=LLC3,3 MS54G=JP`Z:4P/`U\BT9[ZJ9]!.-6QBVEWG?#-:K>_ M6\<+'(?Q(O6M[@Y55#9M2_1==]B#`:N8$BS^%"+,)\Q.ZSNL>UV02!R2<<*Y M\HY#R&AL`IY-_[*H=_OCE]O;+[C1"J!.X>;?!6TVE9](DMG49X+SA^.<:1/,]3`I-"X@#@*,8DTE1P02D-4J8F`<0\*"Z41AK5]5)\] MGA>V>*ZSC^V-82#:?)M[R(_)#L2CFSSF0],:;&J9F3TF"G MYTE6=U_6K:/Z1M!7V\V7X-Y6QSS.[NUVO_AX_K[9[O:OMOO_6^W?K);;7S?K M_ZQN;SB1`#`C(#1:"$-C'>".?KQ/J]]?3TH,"/:::H\)IXHQX07D(:)"4"/` MH:SL8PY"-O^*ARM;B1[35)0Y-VLSOD43LSZS-F9NUNBHU+,'1*Z:DV9'![.[ M^M;BX3/[YNMJWSSH-E7BJ;2-^B2N)GLN9N*H9@#$R8T0B35.%D9-$-Q@P*C3&WD@*`)!'6,&!E M4$8Z6+L<_?^NUK]^B&3X]\67U=WBUU7@O+@O%._$G,G9'(6?BRO,?`HF]H_U M'X"9.R;"+[1Q5%HA*KN_@S#_E>K6AF'7TPN-!ENBTVCEBM1^=!A7A\NSR^:73KK1 M=^DO076)CHM`/!?V+*/,4[(K"%%O;GJUVO^X66X_K:ZWNYWZLEA_C"?BWVX# M@7[:;@[;.Q^V'P.>NX,X-X!`H!UGA$#)51@9NQ#W6:XU(]R2I+YTJ6-CY[DA M&"'`3`!`**4)89`!#Z%PNC9_!7&;]4'>9K'?WZW?W>\/5TKWVV9YD+C9G8F< MR'/%[="/^:8T01H71O2/HC9_B\+^T)S$C18X"MR<2]QRY<@$F8CH!7=J_O][O]8G/;5AQ8WBB*J/-&&DNL M$@IBC647V-!`^RDTFS8R)@@#YJ26PE'!L?),$-)H]X=\*VKPZX=\>W3D3=AJ&38+R`K_6 M,;A\#T1(+ME/#-$D;!FU\I8806$ M3+INNH2E7-+Z^:6QA/'."$<\18)"1I3'3&&@)>.Q'A&L',JUX@S-^"4CF$*3=EJ_,"2PV#J4+^KQ7H1@KJ`FY*`^&-`A8` MTAZUY9H[3M("J_3QK6&"LH&LF><#>]BB= M":QAB/JYP%;JV68#6_F*Y`-3+303:JVH8'9.,`_*85G!=LQO5M'J]K?[W3Z> ME[[Q'!!&E1""(J.E!U"=)KWV6`S.#_:0`4+BN>("QFM96D&I+/?""6>)-]). MF"F\C<+'KB/G*<-F]>_[]9?%QT.ULOCP-=OVRGB@C,]AD`^+W>H1@Y?(*Y:P MY8`,X\AF+)-K[(+=;Q..S8/<R3DBP.Z]!MG^<$ MNG$,,>$XT[$:$%(20O<0S2G`;O;Q>-.@C9]GQPXK"Q)K6]@03(;74%%H(`4. M4H21%CZ)T$]B]J8#\VA_)U:-?XZ^RVSXY-M@T);/*/!7W?29)I1.A#-]XV>P M8>;,N"74Z[?Y4PC&H1G7&VRLE=`RHS34P+DP..]FL:?$#-L`.HVBN/780D<` MILPB@;1F`'*($(92)%WWS7T9R4,:U*(3%,JWS2*^FIU5[ MHSD3LAJL1K\T:B(L&07FU6:_[M:=/\>Z]H>B]^Z/8PL*'Q2/9]+OC_547K]_ M*F?;=-@RB+7@%FFE'1$:="V'N";4P[PJ\T5$4\`1IKAFSA"*4+R>#9R@CDLE M@12U5_OG!%&HZC8ZK^S.=XA]].]<'UYL?Q^3]R'7&UD[CY$D,7;G\ M?`F37'`%$]E^)AYD*NV?K48_@1'ZEZ0?)IO^^OTO.%3,ID)`J3RQ!!)J25@V M2]8Q6?AUTM&&FG)Z"9B"2'$,-#7*:<\H(YHPZY2AMG8_V>=(+:]V_I3V[.>9 M_BRF3'-3N5:L4^2_'L07W,X<##L3'S0+*)ZV,YB#3"6\TUD!;1ZK9S.'O:$& M*B(<\*:C).0L'^YBSJMU:Z2]HT')F.6P4`*K21@1^_"3F]I-"YYAF*LFBIC; MQ6`XPD-(OQ*X19B[-ZXC,GBOU@'%H)XUE^;HTXL0LX$:*^:^/I7%LYYI0S34 M$AC@'-"(TVYN8L_'#+`?A$)(64T1=S`L5#0#0F*M+(`.*$8DKGW(N%B*X#J[ M?.EX]ATEX*YCVC+1=1VKSC$FO^Y1UG1T0\_:0]34NVQHG0O\6!Y'?=K>;_8W MDC/&C`QA/3"&.864:QN?<*,=(B.ZFU8BX!70/@C"A*?0,X&,L)`ORWF[DH5'[Z_?G!=7>K#XN]K$&VVZ_^Z:4 M]^[MZH^]#@C_?J,5B9:.8^090!I::Q'UA@`DBJ%#I4%04.E==1[0ZG# M2@!F"9$.4*@(J+Y,.5PI^+O^IMICHC.H;I%^;F!.QDAS``^21V9_5%>S%?Y0 M7W-W];TN";OFEZA#[5< M1E<2G,M/VX_KY=?COP^C,T^$`1Q+;(64+E;')`?FP(QIQI(Z'/0<4A$GB>*8 M`1/+95ME'?3AM:"82LUKMRLX2!E9XJ?PH:X15B)?EP*W'RU/@&L:^YX@?1#Q MJCF*U_S2_IR.8?O!=X%("^,_$[XLK=6VZD.;R'YO5E]6F_O5617@IP-#*Y#' M\3`.X$YCK!S'W=RD3B;U"7MY-.X@$H!XA@RAF/&P-L>0V=@=&"(L:Y>X;`5, M9+D"(/8CN''Q2^.V5K;STNLSXK87D;M`:^50GPFC%51H6^L!3>2Q?^U"5.EV M^_6G$$ON;A@@6`-K<8@1!5)8&:2[^2:92R*M)U\-`)3*N1"N.$L%ID+A$)," M3HG\?^ZN;+>-),O^2@(##+H!-1#[,O,4:\%`>6Q4>6HPZ`>"DM)VSDBDFJ1< MI?[ZCD@R26JC,C(SDJEZ\"9+C'//C3CWQG:#493]''A`4Z_)-7@2I2J5IW:Z ME)&B-!%ZRLZ$%.@Q1R?DIB.9$]&6KNB7@_2H1-7P\VKUV_SF/K3EJ\5\<57- M;SXLUIM5_?+O>MMG9E1R+ZR4&$L$/9/>0[L?)-@GU9IHV2(W4C#L)>2$*@-U MO(WKG.=",N-9[GV>"+*H4<;!M,=9'`%-E)V!B&ZG1N-SG"92+>B=D&ZU8O.$ MG`WKC8FHW,!&+7-VX$1-_#B_N8L%UZJKNCB06=:3TG+13$EG"`M"I+(&0:B` M%\X#WXQ2`T72&=0W&\.2N%CB4#$M*`H3)XT1Y0)1&+3!RMQW%3Z6U]55&)I' M.(N?J_EE=5-M'N*`O5_%)[\3U;`_Q>V$<%1VTS3P$:$!6W$$;D+B]Q:#)W1O M,/(G(GG#V;/,U$N3*S_^?K3HMEHNPE^ORB.%?3IU)4IHY2@32@%E+2+('29+ M5,BTIU\2&Q?4,T:X$UY:RKQ34`.,K%+".N8XR"R$`>_1HG7Q>56%J'1WDSS_ M')[T=E)X5K[3I/$9U<=@)Z2-J92>T,ILWIF(=N:S[UE=QZQ$)FPKA&RUNHIE M<.+!CX]E/#(X\SQ,UUWX;.BX!O$V)2;6<($MTA0(EK:5\%(+"BGAB0">$$<- MALI8(*A$F$K#O=J6RG.&.PF*8YCPCG+YD24I[<9RV$[6:+Z_!:D+A90 MC;?!H;!62>H89](Q*GCXES6">.4M12`IKSG^7*G";();[S.X.2K?"'$G\M).17-2D24=;5K*HQ1$%)Q2B"U$3485.T)?]^TFW MT=_.>H1]9*@ZTQC-3]6P.$B$Y:$7_\R9)B&W)^)!55\7Z<"O&7.8:X MID*1[!>^]GV]6[&%1):25"`#01UUX#P%$Q[1\+86)-(U+35(!?^R'G2BH'TA MS/W)]>.S[75:_B7N$7TO/RW*74IB%3#.&J^THH!+Q#0382109(7$`J15N4QH M-Z0^7&/)F).$8D>E\AA8Q8QC02!M[@/E/P4\<9;_>54M5_'1B5AIONN495"^ MVRG/N:A.TZ7C>SN/[O?40"^*'=0B8#W7G">!R!/*EL,=$]&]+*8]K=>8C;X! M-?/+[\MF*<)Y$-098&8DY(HRH&TBBUS$-R'K4,6*>KEGLB>ZEENCO>C5IV,"U9+;O2 MUU6@/=`A:!GG(UZ2RE"JCN&.,$"@!X,JBW%>!'K_&$Z]`KG[$`ADA=:W6 MZ_MZZ?A^<1V?FJCOMF\UI+R]NUD^E/4[:@X?'CI.GP3(YX]%G0P;!JAHKMCT@/*")U@VF%G#`+:!:?17#%Z"&L> M+/7+59T@SP0U0%G-*?4.A%35`)>WY9@-)H=%`.!EF3"@DTUIP0#TP MV#J)99A_#G\^)E"5KJ#QXU<67T[@0#VJ'?4 M%K[32/;442,$M,Y]XT\6U[KSD"F\]71,_BA7_[;;K?AIW&X:/3#5?Q2-J[FYI9;JC&#DAH/(1&,N2$HUPRC33ENNWQJM<^ M72'`H$(^)-Z48ZJ\XTY2BRT@!&>M51@`%4<%"__>8!J]]."+S)P8S3VIG,BX M[&O%T_I_0Y#2<:P<51'TRA+ED'%.`\:TC._*[0:+)U`GU61]I0WGG,&H+DZ! M*=%<&@8Y08Y08`QD)'-J%&&EUE7MRE87:5I:?WANEQLJJ]5[,]JO2XW6Z"K M\EHMKINJ2?$%U?7Z_K9\])4FJ'"JG23<...P=H9K(X"-1ZBH1-Z@I!-)Y\:: M6?,;O,6\AG]1+,I-K?];Q,7-`7+Q[_\F$(3_6=S-J_#]B_#KZFIU7U[_1VHY M]W.[OW/6/%G/]T^\+XJ#<<6Q=<76O.+04X+GC^PI=B9>//KBE++X(;V6-A$X M2W^92'2;#!UO3T?.Z*;6,?.GY?+Z]^KFIL%C[U?[K8(9L=)ZYX$$0!$O.8NW M([=MG.*KA-B M,0C+$QGIP]BRS-`-SYB7?EAL0L^M]M_\:?.]7'WY/E\TALVT8=X19>)K#H0B MSJ!4C1%:RZ3[WM-"GED%:D!%M8>YRUW/F(4.X.SQ<])Q_3R)#/5@\NYG+HIM M9]H$LXO&[G>.NK[Z8[],=,90V\.C MXX?8<9PYB=#:F'I17_C87-3?N;?W'8?45WTX4BCMWX?^A"%T`%(RALZA7':6 MD+G]EAEPDM-8Y-`#(93VD.!]<%!E#H9?EIOYS7:3_+!Y\F15ZHQ! MLJT/QX^(&=PWB?"GWLB+)A_FMM\R4DQ+[`5_P@"6RD#&:-7)&/P^ M7Y>'AP74]?_=KS?UJP(SY0`RSANOF96,42`-;1IG@">=IQZFQ?%V,N9[5/4] MV;NZKEW"MD9.VML%B/$93]/\!E^8F^P0'C^-0VH`XEY(ZPB&VENQ7X!#(.G`ZMC8SI&@GSK==,9L MO94KQT_5A_;B)/+T8-0[3M(#^I$R]!3G3R1PG,W\C+EYNAO:/WRSO7V\_K+< M(6APE^O0ZJ>O9K[^OL?6'&YR2&N#C=4"2J$-ATXUAYLXD`XEO8J3`T#FL!(Q M;<^_QE3]Z)+$.O40;![ZVT6)LS.?%@H:N+'8]PY6<4!<:WH,ZK5O]A'@;`=0 MNY![0M2S^FHBRIW7QJE_D.C:*4(JW M^'WXM-YN;0A#2'$#"(<9`ZAHR(061W4!E3UPCUE_9I\QG1=A#T M+UTJC.Z>;M\4`?^Z"IV_-F!D- M$2*H"MJ)O!">$Q%O4^S:%4+AQ$2R=W/9,\;MLO#5J[/XX2;Q+?GM/6$?D-@L MD_,:WW2FX#6<;M/M-*8G(J/#V=-^&MV%J#78F!F`GV2PHCS5$O*&`8U&HQ*>)?D*1)X6O= M,^^4M.5[UH+^IR"&LV]O%YQ1HP!"AC**'"46$.";`VU"(=;W=,19,&?> MWHH[*5=[[;V;/^Q?;VB*?O7)EJ="8O>S%)/W^1!G+([67QY!/JZX'A+[0XS> MFEIOP;WRHX?:,`_G/WV1PXEIIS+.VHTF,C&9'"UOG^*8@-LR!-D]EAE3&CL& M#;**`8ETF+DUR^O"8J1GVU/4>P@V>X2#!(YT'[V[(-#!Q,Z"WI7.K.+L M'0NS,0*,E4IY"(6P^\D8)E3MQ-DM$@]]#(DA79H;N$,*<[FX;B/)?U(%:.NC M=ZP`K4T<0`'2Z&RM`!\65\O;\LO\CY=>&F"8(^0-9Q0H:B4)S4@MC?7(6>RM M35FX.-F0$Q`;[KG@6E%LM&28,*,PUMX(JVSFU88MMB*`2[Y^T8^_=CG2:-2E M)4,'UB;R\L@IGDZ(VR#T3D3%AK%EF:'_)>K2ST$@PZQU55Y7&S^_JC6PKBP_ M0T)RQ!02W!(!(2/,>Q-T45,*D:1)U0I?;X5QB+T@%&H'*+!*6H)=&,-`X/!+ MYZXL&('5ZU@UM*+!MJNN?V)@#4UF.X4:A\>I,819M>I6A$\+4G]6)J-(` MABR'[G")>O2X*?5'M9X1ZQR*+\@;3RW"GG.,F[$C$*HW1G('A>,G@Z;""I5>+JPUDYQ,A.6)C6I7&51F.>,G)"6 M'O1-1%/Z6+`9&P$1=EB M:*TIB21.4E52;3BI*YT(::TLOY0_EC<_JL6WQXU^+&\OR]5, MO+:3G_$H3=.A/FQF4:231)V0IF$(GHA?,,DL7U,UR*IM,.+#2`9;-%0:F4Q)01IS"S&SLB0Y5&4O63G%M/Z M:&VBHS9U8Z_EBDYNXA(7FZ37]"6HO+ M;_-57=WFE_FFK"=U!C&%&2*&$:4$$2!\^&YH(.V<2A&69Q_.H)#00:X(9511 M)BDFD"`.L8L+XKFWL!H\1034;;$FG:]V4I*5JC0926,IBX(\9>.$>G0F;B+* MT1W_U$,Q=M,U@Y'C4#DNK`.,6D%-L\"`G`"^JV;L/IY!)ZVN%S`<]=9K MZX660@JMB#,N=RKR9#QT6YCIPEJZD:2N>ISC"_4E&E0\B>B8P,;]712E8&R]I4] M5M5M+:J[9I27'G+`(*0"4@ZH1:89@PB*I.?,GGZVCCK-O>7,T$*R=/:=*41%&>DAN/N3BA-%U9FXBF=(;_M'Y& M+QIZ'>B+7_NP*6_#A,X;ZZ1!T",HE4!"DL-2`S%)>^"G6Z).\M`*$R[>=`L3 M2<^5-QX@A\,`5-D7?U\[E5;_1PUQB--]"Y8IIY M%:U+#V"H?)[&.*$<%P)([AHV"D"`@F66C;;S?[$;DU79$ M7C9(BZL=U`'DK3O]W=5N%.8'$;^+8H>UV(,MS)ODCZ:%KQ&9*(V]_3%AI>QO M6POA'(C`=@737@*@?LRKFVVMRB`6\W5IR^V?,^5D?5%**>`@5,0PT"0MV%C0 MZ@A`AV:)<>'3G<482$H`D%@&)A`)>@(PS+Z'IZZOZZNC\YL75+.X7X2.6*Q> MT]FO.^M:JFL.IYS6UC/[HX.R?GI!6?=@BP9M\9<&[U_/R/WU\NH^%OZH;XU. MU0>/0)[-%^WJ\26Q]$+HRDCU%"K;9;)LF;V?]DC^9Q`"1['&X1>GRB+'F6M& M86C;=4WNP\S%>@D0)9)[:H33'`,@'.3$`6%Q[E.SN[I9=ZOEC^JZO"XN'YJH M,O^V*NN"0CV2]K=I2T_*!V4L>??EV]\"R;?%X_3[C)EUR\RY-6D3S(S;8S^1 M^282T&N%X).,;GYL%AO5O5THG[-XM>[D`=>?UH< MG_.!,^22&@\LXRCW'M8!20@+Y"8V+VV=<9$]'.+*:UR#N'H:^7@G[8I5CUJ?+[^+3: MY[K:Y\Q!JK"SC#`BN8LK#F8_A"$QG9<*WVS8:P`M!$"'WZB$6#&-#'$".J2M ME+G/-[UZ#N!Y,CJ8C'9W0G<='87_@82TP;H]E[E%6WP^1U7:%"83M;2W0R8L MIOUM:Z&F`Q'86DY_O?I>7M_?!!SNZ]?R:E/]*/>%)B.&QT]7UL7=#E4GN<`2 MJQ!(93@9T2CCMAXFX'=Y:CS'+; M8(_COMK68]W,_]CNY*QC%>H@LM=%^2_NKJY'4AS+_A6DD69GI6S)&(/QSI.- M[5%+75VEJNY]Z8<0%4%6(D4&.?%173F_?@T$!/D1!#8VT/O2]=&5W'./[>/K MZVN[\:OZGZ4`ZUYSZ[:QALGP8MI)3Y:[3=0"]SJ7YU:J_!+\^9)*;[Z[=,>0 MW:/L)SH:T!-5^("(X7M[J9[)W9Q.'Z\;Z1N)2D"0/BA3R#GA$`B:-A:B?5N?]3\M&.M*=&4 M28##&<_?_Q9#'_[SZ>'YD*_S='=Y1NR0;M-]GE5O.^ZR^_Q8IW&*XT.VU[TU M6Y/=89KDD%@](6HX;:!,?4/V"QYZ!,>0L(6HC"GZU_=ACR%AL)[\2PV9?;JE MNPW=/.:[O%2O,@URUK,5"BFB/.*8@2`.,`R(@(U921*MN&:L+<>*&U3U2)$MDA>B3=;<*=ST19U#LM,\ M]5W_NS(1_&V7_R?;K"A/&*,\I%"PA,E$(M0&=J$,T6J7?4N/V8WW7)?LP2!A M(+4P=)W52EJM*R_*VMK[--][W]/MJ2Z`N#P/O>ZZHW-:=*&\#CGRNU#H[N:* M]QX)O_I&N-=UVJN]]GY6?UV?CRF/O5[[R=;WYA]?O/__T+4T3C0OU`6=+F9V M-'I\5\O;KE;8[FK#SEG/TW;OQ$=_A9ZTA)/?2Z>H^.L(@_:IIZ=]MJYW[LNX M]+'8'_/_U/I8WGT.DP#$..$$"Q\$F)]-4@89T3OH9&['\8JV"ZU>UG;`:9]> M&D'GL`7M5$SJ!2A=5'>>^M,V:_GL0KSS?BUV3_MB'#]5OZ(5[S95QR[K7B;-H1D#($+$9)1+KPIT1Y+AX:0U&?EVLU` M'JM/BR@*(4Z$P!$&K9F()]&P'333KSO?W6H/D&:W]KKML#54/QS09*@=9W[F MJ05X142O8IA1MABU,(3_1BG&T*!Y[JD,:*1RI]BZ]-'Z@]\&H7 MO(X/=YTSNV5IKOAQW*=*\O)=NG^N7YJI$N9EN8?"N:T7I35/LYSZFZ1E>R>; MY?6OQ4QD"Z3FW1./"\.H-P&K%4`GJ4`C`BCP`TE\$L/$3P+36%E\=FMQ[T1G7K#0HP1F;"UDK!J"+VQT&,W^+M)]>0WKX5.V__*0[K/V MZ`XB,(JB."$`J04PA%'(@C:?1O0>Y30VXCC3=1D%U>52AQ);SV$^)P/B&C<] M8V,TG0L9)N/]*"SWLY&#I[RBNB(3,+CH=- M!6+F85)AT!@C>L0M=(!H.G%C=)A08CPT>+X]';/-*B0PQC*$/HV5`:0,LJ@= MB2#4*CHSM>&ZX*R&,?,`.:/0&"*Z]"UTD&B[<6.8F-&B<9:YN9'TH-8^;=WH M.L\./#^LM\7AM._@W"^NU>&\-8S6JW2OI`Q:M>GUY=#V2=L\'C\I/I- MMM]GFR]'->H_I?N/^PK.YG_+@ZY-@+52MH&(<)P$G(;"9Q0AUHQ(X1.M^UL& MF@QH$D=)2'@3_]J!C*V&!ZF M>3.0JZ=Z%UZ_U+PJC&K\UM=J;KP*9GF-N5V.*@C@FB($H M0&$H:<0H!I`$B8\)X,K[J16O2K:KY46+<)3RZ3-KHGA.21VI=#4VCP[@\W48%4SIGB1:F;N3:^*C21IE'K]?#BF;MR7:=&TF.N3\U"1D4%<4@QAL)78R<1 M&.-F**$$R5':=+8!:1)3SB@-`A["F,$-.E>CZ?CX9CN-OGNVPKZ@C(*L0P# M'R1A`"`";1H%0=-5WUM#"/-`A-+'7"KG6!1'%$`9R"3R47D490X)*B[XQNJ0 M%J>&8N2*3AN*]'$(E=/(4@>*CC:9L+M4@3+RY99*F1,T6*IDFN^KQ6)SZV>> M'3YD:5D)M?FX^YRM3_ORR>2R#/MP*8T2/H-1&$5)@LI(C<8H/#]QXP7GI\<4/ZSDN]?0/?^UKBU]0\1XTS3`SG;Q<]E2SQUHFO M.Z_;/`WFLD%:U%X%>_[GB(U([M%8MXVV$/%U[&0QY3AP*->_[XJOY9M<91?_ M>?=T.KYZ([G%&E"!0RKB(!8!C57H%`K28,5J$>Y*S:T!="SVGXOM]K[8_YGN M-Y[ZU=N:B;]77MK]S3ODWW;Y?;Y.=T?OU&'`RTL*7$X1]CJ$_1EDEK[@?(*Y M\[I^>95CWDO/_EIST-!FLC1%6>\5?\$9S#X'(R8X1PTR_/#$^B';G+;9Q_MW M#XK2W>9\$JX:5!P"[/6I3ST;HZ-;6IH7J[=VX9T'VFW%7;#)MM MEM`L>A-*MT4:S)=-^[MJ"JE;Z8Q\_KG"D.2>Z>%^?NW^^N_X<5BTO/9HR;]OJS@/+:5;S><%UBSJ>)48UP:!9 M8YI&7MPL,I';5V>5*6D?/,N\`XK^R`\K$"8T(``D41)%E`@,05*;\R-&`ZV" M#U,;CF>!]W3"^Z-$IBOGQB0.D^/*;Y;I500GA9BLYB9=L7$43B;!@C$(5C%4C/V@Q:=.*W2HG8RW7K!F*:"F;&]8"TS=&B`JHVA2J.>[=U8CCW_ MIKY3"6LB0<2%4+$>&O.*]NNK+;4LJS$:!9W62!Y M:)7;E/SJEKJ-I-91P=L-QGJKWFRQO1!]L^C0F_HWNU2-U;?2[%E8I601DC(* ML;)%$6",R[-A@D2BE7<<;VTN?:M'H%GX9H'C4?+FB%Y+\C:0V2G5[4*8OKH9 MD+UL=3-Q:)BZ&5-U4]WRI_7CBJX?\NS[^6ZU)-L?E:'V9&D.LB'[/%K MME\Q(+`HY15(&F,480[5XIB7%\HRS.2@6UMMVW2L=!VD9;)]76/MO'*]K]%Z M?]1XAXJ>=>K[I6].UO4$L$OXQWOO#-.[/'?[>2&$;XKUJ?Q0_83\$HE_@="T MQX]I@%>34.<8)U MTG:QD7(=V213I6%O\:J7F+762@L)]IVZ>#MY:YG.X<_'G4K5O^SA9X=S&GFS M(B+FD8@0XRCD24*%SYBR"`A+``HPUI'?$685%UXOL)K-J:GO3KA.4(_F M66!U(=)FPY/73_W9(F=8YD+FN_R8_9)_SS8_JU7.[EO^=9M19?9X^/V0W9^V MO^3WY?.`(BAC3E"#($##"OP=F'4L9)^R?5YL/+6`^_,A M7S\H`M5DDM_GY_-D#7POK?![Z6.Q/Y8W[E3'V([I#^_IM'\J#N5U`L]9NA]Z M^,Q%^PS(<,S7-'HR6./T*J#>!:E70[WS:K!>B?:N?'6Y/BLV(_<:R8[YVL`L MWV&[+88E/;18NI;W<$/U$E(?CCPKG/=3S4"[MM<^8**F1H`)A3`F$:,^CR&@ ME"6,"$ZD!$@GN-;\M.L\>H5&,TC696=88.R0&,U4=SWGSO:&T4LB>H)>0\86 M$NB:HB^L=!LC04A.^[V:R"X/_R*.`X*HE((E*)1,\*@Q!B#4*D\WL^"ZH*"& MQZOMDF:CERXY,M$->Z\AK*9Y>,5,3=5Q)3(18F)L1/O:LHX2H;7,*6' MA_)50_6+4*OR[^FV>N?PF*3[_7.^^U:=\%^!.`(<(4P#'B#`,918-,9CX&N] MY6/'HFOI4>BJ(]3K\C?9!>?4139#R.HKM+%*]D*&FV6G7A?<.*!L^$R_7AYSML[RZKJ,7[/C60I67!E!C`,"B>204DA9&UT@3+0N1Q]ER'EY38VMO`GI M#.ZNO&E"-P`8Q>7`.&`J&C7#@8;!SQT&%;(V0)@Z*NBAJ2\XL,'N0D3+CB^O M0P5[!.D\G/64YAOQXRG;'3*EE!^/#]G^1="R*A\8A`30$,&8$R8`ET%C6LA( M:S_0ACW7^?0:HI?5&.N'Q8L2IK=^L8;1?U5K/-7#A&QJEO7TK"'X#*_BMP+H MO5KX3/_DUBW6>N3-)N<+43FK+KU]CEH[CF.D^]`8T%>A1/"6"-HL$S]JR@V?^;;[8K'.)0^BP@2(182 M\83)YON!TD$=21K\4'PT9GO&@C9#"^GW^KB+D5U#LS^_KLM00T?\ M6&]/Y7,GK6W,)0@`8Y3!)!`0!B0"[6Z))%I]W8I!Q^.@7@R_*=TSF8?M\#ML M/IZ<6KUY^9W"+X70^T>+T6M`_O?$`C2$N!YQLLK[0H3+KD^%PXZJ+7B'TSY5 M'%RRO++8?TBWS7F#7Q5!YZ5.(),P1`$4%```D>04AFW.E_F^GN[9L^M8_EJH MG2VCJECY\8+66V_3_%$-X6UY*JM).=G'MI_2Y7.PI051_LS]EF[=05B3$,@I\$05AC$)* M.//;/6,98JT$LDV[CN6J+1Q]JK%6`41:H^UJF&$IKA7F!R[\9B)=>`LY4N#N`Q;[5IH.V6(@P.G'M2I6O??H&2Z=X?-H6SUGV.=NFQ_<- M$QZH%;6`@9]0'B?<1W%CF,1,ZY3R>&ON9;(:H>OBL2Q&3/M3R*X8'2:$TY*I M)W\-MI_V-;@E2-Y-OGJ$SA[7"Y$WBPX5KKJEX?622?'X-=^EO3>JU9B>&T1Q M**C/I%H0I/K]Q&Z9S2>\PM9V.63U!;4DM+_AZ$9G.>)2VEZP>7;1#\D*DSY(SA8M^.'J'9)50 M$8002X*Y#%$D,`Y@8PE*AG7*00P^/TEI2"-+YCE%$^),MT.L?;UV*E;(X"!(%'+Y4BHX"L$&(9- M.I`&&&EEY0Q-N*XL4:A^4C_WZ&T4+ET-,61MH(ZX)TQ32UJN2DAWWJ6.O=E? M_9`>3_L;:NQ&8][EJD]GQI&[%*T9Z<5KO;%!RF#-Z93*_E*4B\+S2G#]7.7' MT^WONTU^J/8NLDT'#H@PBQ&'"0APA"CU1<@;.$+Z@UX,R';/\]6T;1NB'5/6/8=>,M9)`[=[.8=DRX3[AW0&$" M$29)(GW)"0!44.XWH"),M&XY=8MD_K2[GDC,T5C.TN^.VFFR#/P%__*3\(.T M?9HV7(C"3^3L^&R\,<4C$_+=HU0<10!&%,60<19")-MM78EA!EFZF]^=Y(4O974_&V*M'/R5MDQ3L;/EX,?EGP?S-)"=,(( M^O5TNZ;[@T=_SQ$J`@@6RE@0!C'&D*K_-*<6:$BI5K'!"#..0YKW3FYF%4+= MYD=$K3`MT+$2,; MGA36^Z+^1=UUA%29KI\M"!B+,/=9+!+)`PD#Q-#_M721>6Y-*8I>SM3GL0<61.#.L:*0I4IJ-_WT`4I0XLBT1?`'#R<$NB9;% M_KYN=7]XL%'?*B2HU7F7?;Y_[#FRVB2G4#8MG+^`7P"`SDN2.Z_*P(4#T0(` MH/XXQ9/\E15.ZVJ9,5Q4'[[-Y.;+=+8V,3K9>_SAS_J^+X M]XK8NQNLC=6`^Y*:*PFJ#Y&69*9>$+YOJ-V3CO;'#.V>GW?;QGUX0",((.4> MC@+LQ0RY)WD600RT3A32_?*1LU!E3Y6"?OE!"D+@6@J">.%#?Q$!7*X(RK>N M[RY<$-4?KM)3=<;`85_LY0NUA)_LG;\=9/;RP,)11XN6'V#I*BT/U_9@>=5? MJ#7%EW2USU[3C6ZS#7TOMDMPHSI0+[L=?6=!:KLDY4I>Z\R?)4FMN_V79S?U M(Z+]D^3K=;GFEFR^)-GZ;DN3EVR?;)8L"@("W(A&V`UYS-T(U"U\XP`0+7G5 M]1XC)[>S68XZC>%3MG56E66ZSX1WY;!=3IF"/KW4TF!.F:2.7Z>WF!OGH>X? M4W,EP?0ETY(\TQO&Y8/9@]#2.NM\3?=)MDW7/,FWLN(7\6IU>#Z4CT^R]"%; M9?LE(3ZB,N&Y*`Z($("%^"3?B">TYJ`&N-W(N:BVT$F/)FJFH"$(;9>-)N92 M+S&=:*RM<_[:L,\Y&CAUB^/;E%U)6`/R;4GN&A+1;K3@[#V;O@1!0`G",05Q M&`8^]ADY*;90#D%UEM0Z?/TD*VO%3^?0>T^AW^:OZ]3YH-2--F5N?)Y<:WZ\ M-:>6)*$^"&[.AVN2,5ACUB7B2&!$?9^!D/K`$SP"I^0FD-9Y;KUO-O72?K7M M?*B$U)]K[>T`X]/<>8]`H_VJ93U7V^TAZ$>M)3EK.#R:O54UB6HOFM0T,$F* M=$T;[:?B/)=1F*K#I,BW\T>^)-_4I?C/)%]79MUMBWU^4!>+\M28WYZ2[>>7 M<@?Y/W?;U[20LN_K;K,1NUS]IZ7`-.!^)%.PRX5J?>]1&!-&?9F;<0B9UK8& MNTP?>ZM$.5^O*^GLHJBM7+3+ZA&EJ$+QZ5[!<)I0G096Y_Z;T_S<$:]3`E[4 M^K6!^7B6\5ZB=HZPR\VK%7#Y\E"NX>P>JJ\MG#\4&35F?7_6N<)DMW)H1]7%JMBXQTY?K3JZS MH%+_*K]B7]QMOY1581E0@J7*B`4*,8U"5P1G^UT0:#WG:(W1DXR8%TYIE?86 M7&M8,EY81_2JK76U@JPVU7RYH65E]ZTLC5;5C.,V^J';E9;*:VLMQ%I34 MWTM!<+(?$HH#CT.*/)]Y(>0>]"K["0!Q#);;]+%L)F\X_6J:W2K]1E7Z;2+4 M+JN57=9455WOFJZJ8[C5\JI:09YA57WK2R-5M6,XS;ZJ=N5ELJK:RW$65%6Q MRQ_2K`E!$,""R"<>)R+V$'1=$M<0D,#$EL*J;_EDM?5DFC7EM8.;35?8D?QK M>9$]H9YAG?W.HT9*;?>XFGVU[4'-9`6WK_LLJ+F7L]N^5`;29B9")ESBQ9X7 MHQJ`ZU%V7,;E6^,U5]=R_47<&N1$2[BI>G#Z]N+M.TNT-JZ^M0V5V2?9SL08 M6WW3=/V#-&*AG5)@> M#TT7$+:.C1H/S3V(Q*WF1R9_P0T!-!][=! MWNMKNL?'O%R]O)-(LFV1KM@(Q5?Z-S638Z@A;9<18 MP?3NE,2;*8RY:XD&5)OD1)=@_*B*HA-7ID5%=P=;L*IRV@]R,6=2/E'&)%:1 M9'D)L]E=Q0?,%S3B@@N)$A(11K"&&0/FVK&N,@ZVR;=?*"N[SS^\(V:-KX.8 M#QA;%4:CF\EWZR`E.XZBIQ&J<]RYT2D\S&[0'"60;5(G[Y&^Z3=[CA@&[TK# M+`7`/O`Q@(`@(3`,B"!';-`-8FYE5[7^L/3WZG=HN/;=GI!S-9AU%[8!HN[] M")]!0VTV:N<#2AS+=4WK./V_F.G`F84*1M/A%LB6MTU[;@/$0N+P?0XC1FC( M,>(PK`%Z`%JRF75H5%-O9&V*%KO;TPT0,:9UA\E@L55\7#:X^W`:1#,HC`B1 ML0)W]FID-.(,]=H;VO46Z)*W;8]N`XP$#%T)D5`>QP(0)KQZS0NRT(=VZ)*A M49G4)5;W]QL@8$S+$I.Q8JLLN>P0^.%DB690&)$E8P7N[&7):,09:E8XM.LM MD"7'YE#J(>86H@N[88A(@($?^C%T(QBW MK@OD4&3;M"@DLOML6P([M\3Z+?WOGD@W_F?)0A&YD`G@,T"!ZQ'.((FH'!G+ M*A6Z5&?0V/*6*!*Q%_J8R:J'@@`0$3/H0HA8`#CSZTO5ADWY^^'6W6_^9;3:-GR3C+H8"81"ZF`,&.8VKGR3B$,1ZS7*O MW"?"%`()(Q*4(A*Z(<81\U$(!/)C#D8_;/)HFI)ZJR=5SLK=%:LDS[^56O!Y M=]CNU;\^'DW7G<7JPW'+J:6)Z-6<[VDP6]LE$UQR+R^92W-7N+HF>`=@V)*$ M-@B42WDX&#T=4M<_DLV+>I0L6Z529QYR-;8[WU[U+O4!$E)4Q,#G'+DQK']B M@'E>MS1V_9Z,![$;!2$$7H0"^4-V*9=&Q)&'7"2$-V%*V^_VR<9)5JO\D*Z= MYW2=K>3[Y[/YCORB-)<2W)_EFDU0+N4=0\LHJS5[5CU97^@WF(=TD.)US MNB?$AHW.R4B;LN-5$EMERF'<8%W6'`C63S/HD+0ULFDSD/XN7\F+]27YEUIM MD5?^!U!+`P04````"`"IB/Y&FRXXDQ-&``"-DP,`%0`<`&EP8VTM,C`Q-3`V M,S!?<')E+GAM;%54"0`#C9&Z58V1NE5U>`L``00E#@``!#D!``#D75MSVSB6 M?M^J_0]>S[/;`(AK5V>G<.UV53I.Q<[TS!.+EFB;&YGTD%02SZ]?4#=?(DL4 M15*2\]+M2`!TSG<^'!P`!\!O?_]^-SKZ&N=%DJ7OCN$OX/@H3@?9,$EOWAU_ MOCB1%_KL[/CO__O?__7;_YR<_%-]>G]DLL'X+D[+(YW'41D/C[XEY>W17\.X M^')TG6=W1W]E^9?D:W1R,JMU-/UKE*1?KJ(B/OI>)+\6@]OX+GJ?#:)R\LNW M97G_Z^GIMV_??OE^E8]^R?*;4P1`<+JH]6J)ZE\G\V(GU4X#;9>:;\P7R<3S\ M,Q[Z\J,_H]%]'@W*9.#E*.+\:USX]C[%H\IWG:7%.*]ZYZ=X$'N?=36*BSZ@ M[4#.G:%_.9&F`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`SC*!_C;[./Q1#'GEA^]HL%AE&U5`O3OV/Q^NKQ0" MAB0RDFK((#$$*T65%A)"S9Q!1C]7X-H+PT7U;@L$VS M(1/:"0&&I(P@J+`*Z4_?Q M0NZ'Z7\WT"_J3S M=T:U3_'7.!W/5ZHJ0]9GV=JZ(;,0<8`=11J3@#)E40"IT9P"B`+!&Q(,_7P$ M:QOK/KCUN8C/KVU1)G<^/B]6$.EYP1``**2U&C!K"`\(EX$E#C""!26(LX:L M"7X^UFP%;!\4>=QNO'9)&J6#I-J>\%I/TCRFL<;#"N;4JA\2I@6G@1.082(U M5-PR:JUC7%#M:-/0%_]\A.H"[SYX]B2]^WU6%(\YB0]K*;:N:A@(;#F$U&/) M?40?2!4@PC@BT$%CA&S(+O+SL:MEJ/L@UH?XVQ,@\BSU?P[B)YVA?CBU:5,A M)XY2S/RD41A"G950@$JT)9A(\1,>H(M MZHT.]S]L=O40BVQESE>HL2&B??)AE:CO6$UIL_%"SOV+7)0#).[UG*:S,_T'.NTQ%@,"?0<' M6`O-%6&.2.6Y$B!$E%F[B-Z-EH_V>F*E\2Y_)[LBJD:=AB M2)#WP\A9S2"CG&K!H)EC(S1L.C[M(?E:9S310/PW#MF=!UA7JJYGU8\9[]4FH1U%R5YREU9G+ M>!A5<=+Z%*G6H@4P-12[@C'QAFBM`*+D8#*IAD8>\B75NR7 M=09M"Z10X_)#5LZE.%,?/FW"C==JAUP'U#`>.,,UL0IPIA9NVE)E=I&DQU> M^-,FQGUPZ8\X&I6WVN-VGM]$:?*?:'KCV?KIZYJ:(4",ND`2"R7!6CINP&(H MYRK8299E_CVP:4EJS(NRY^@HRM/FZXB5=TF0N,81=2X0`D>((LD M!8OQV\!@)QNH/2PDMD:*K!?<]X)U'[+I$+\=\1Y;"1UQC%AC0,"XHE`ZR18] M.A"NZ4+!_N^Z[8Q]C<'?"P)N0[L02#]@$&D((,P`*IT*[$S?P'':])C'YOG4 M3TYHOF6J;0CX;O-?)ULFT>AS.DR*R7IR/*P1N35J+V1^RBRX#)@FRF`#,==X MCHOW_?CMS`^ZB>?Z0'WOV+@^XFO27$@$8=I(9`/F)-#6,B@6J/A.^T:COXXI MM`UAFUEF[_A:*U9LV&(H!<1&0JJ@`2((G"-(SK'!B+_=;*T]YFUC\^P===LB M;,B,PY)BYQ"B2&$,L49S'*Q339WKOD><>TS2#4VRAZD^RVZ`.M#<',JJ6R:P M%VQQQQH3! MA`-'L+2@Z4'>?8^QVK#\JRD1VZ*\!PDY&[%J90NAL50B0;F?00E"(9!(6XZ! M%`'Q$ZS^UM'>$L/:1+SS<63MXT`]#1%S071V=Y6DM7?`5E4+2:"X@Y9A[!BA MR'$L!3>4^"';*&_.W0P32T0V/LP89=4EV[4NIZG5@)\&.AEPS`S!A%`*E),& M(@B)=W76K-?^0`>/=ACQ\GJ:+B#?1=^N?XGU`?=[[V*A%1PKRI&?0R*'E5!, M`Z$TP$"L36'N>E!?9ACU\.1?BZE(63VID_A^]WB':ZU!?ZM?"#7"`6>:(P:X MM,0P!9C'CWKP#!&H:4+3'J8-M$.C5R.!/LW01URZ1)\UB>"OU`@!T3(0`&A: M':$1EB&@I[I!JN1;RDSIG0VO#%W;66!7[)J>!XW7IGROK1MJ*8016%O%OJ4KJ8=)"NMJG[6V;J@=H,9:WPT9DPCY M?DCP3%^NB&Z:$+"'^["[]EYMVV*'W*LD7NO'UM8-G5/5*C0ES*LH,5#*N)F^ M`EO]AH*S%FU?CU6-46YT-D%Z]>.ODQN3SJ]UG/LY6'I^/Q$EO?D4%V-/M=7G M$^JW$"I@F:VP`DYRABDSR/M^@SCS:JG&ZWR'PYHFMLWZP'I'D=4K,+VO<8:A M06NA==IJ%TC&7&!]L"&8-'/,D9*H(?^VNI+T;8Z8W5NGEVL!QU57>L0P+N97 MPZP@YNN50F&YH99B93`Q6DL+E5K,Y0/V5G?2.B7#RPL!VT*_T6CJDC0IX_?) MU^IFBC)*;Q+?B:27HBP^%_'U>/0^N:Y>1YQLG+\VH&[42`@!L%H@B?PX(C%R MW$^!YEH%6#8]2KSO>V=]<*IS:^QB[?UQ9'CRZ?GU'X_U/\ZV#7=ZD4H7*_*: M:>=',@F-%810RP6BG@!,^I&LNC%G;W;B'E^NI,TR(AL((1!HUV@'.I',3!PF-)!9ONBN[[*T$_0S=J9.$^ MIRK;WKV]^M)G63V18IUVBAI!*0%"D[G>%+"F*WW[_D+1OC*["Z,=FH/_$/<5 M*OE?"@F$1`/$'!?&X@`J9_@B&$6@Z<4#6[V4]!-W@-V:MX^N\C%ZF/3BRVPF M_..NDA?X_%I'Q>U"K?7KK4V:"RU22@?:*`X%5YI!*^?684#8IGO6!SC]WGX1 MM0<#["R1HBAG.SI>=NN[7ODP>5"BVLJ9?KUQ,L7Z%D-FI>,,:8TP@4@)("V: M8T/X^C,.6Z^GBBDYT_BF>@V@/WIVRZ0ZR12M6Z'OTSCJI#2Q6&?R7E M[>=JA&B[/T?EP6U4B2#OP@,1]7QGFU-CS999T/'P\7<5F.XG71=7<_ M&DJD&(2`PB#P7*1(\\J\LS7J@#2]?+"^;*3%L_G0Z:^NSZ2XL_A<]NV0R-LI&6Q%"OY,C( M/*_>$IU(/'U6]"R=OR;Z2I5YL46/ M#@%&/J0T0LEY/,FM;'RC7=,N<;G;$X>;1M>';,L=+;BT!\T"$E@CO.]8@I!H M"1#2A!)D"38``S=?F>42T:;]Z`#7WCM)^-D#F^U7?UFHT0KW%ZV%5*K`4JB1 MD10(I/P8/9\X<1.@WE;:=_(*[X[9W-0*/PO4XN3Q'*<"9I=2>5XE8[*F97<$+M1ZJ=WZVW M]E359M>CU6\N-`HJK3`(K"4:!4!;9^;(<,&:QE@'F,+:@"W-[TAI:H"N?8'' MXRZ9[C7+=/AX>VBR(V>P0I['NZIJ>(>-V@F9Q,980@R'A%2/)POJ`F.IMPEG M!*T=%G>(11U'L5E#H8_DJ0,!\G@`XG'PT9)%?M`B#D#@D7JC+J(CROQP:K]# M6^S06^SRL-=NG(8F1"$-N320`084-7CJR'T<::19N[/>#18O+H&>GVYWJH??E#!D) M3,`$Y5(#9+3T`9PWB)#6[&@F,4N)JG'_^+."(3$:^)DH0EQ0Y:>^'`$YU\:Y MQBEP^SZTMVOIK$6(^UAVF@HXV_"HS9D7Y4.,#0L$ELY9I3%QRE:.:*H70&@G MEQWV<UB>W'._^_ZI3)UV@T&0%+'>7Y@Q^E)BD4JT*H M.O5#P"DP&#,9F``#PY!C=JXW![#I,N1A<*DQ"5[.)#J`NA=W-$UT+QX?SOL0 ME^O?]UI5+31>+:P,$$@X@Z1$4BVZ)69B)V].'QRA6D2X#Q[U^4HP(M*C&ABC MN09""@8QF6N/>..#_UN=ISPX?G6$=B\)=7E\'R5#^_T^3HO8>]W)4>=G\*S* MJ5M?.P12.S_7DP0C;H2RP+A@KK-UM.DQ^7W/?6B78>T#W7M\7C.8"A-`RME<#X)UTX,=FQ_GZ_=UM9:'O"T@[_7)N5750E01G4C. M,:2LVO*B>C'/-4XV7<,[C%AIZXE;1X!5D6EW48SHB#B@IL";,.&ZW< M7/J`-'YKYS""G*V)T1#&?B+EY_>T>*K:[X/1>.AGB34(4J=Z];(D"(!24B$= M6(0"0<'"`SO1E#R'$;]L39X.(-Z+*5BM9Y`W:"4,G";50U=6`@`0=D:BQ=0` M*]CT3L!]O\2@-9IUA71_,QX("7-TZ/9=<"=9TI7KS<_Z[ MB(Q;6JG>$,0^S/_TU'\ZO"BSP9?;;.1-4U0Q6/E08V>C;A.A08'!GO^2`R2, M1?ZO_R?ORIK;R)'T/]K%?3PB<6PX=GKML+T;,4$MEAV?7;Q8E MTCIX@E5@B7YHMT,&2L"7'Q*9B41BXT_H>+6WYGL])^L)_,K4._X8;7>G+&6[ MJK3FR1`J0_!);(+RE(C2>[]#/__HG@&[*78>Y#7/03Z,?JZJG$S'JQ?;GQ59 M.?Y8Y(BO9"MU4IQ&Q:41TMD`=!/?2%)?ZV.J7;!BQU%)]ZC78%Z\^W8[^]F@ M%7B[ND)]"M\.]LW6MJ'[%!FGW@7C`Q5F/5]KH#3'9.A[9P\LZQKK@=YQ.DRZ M\H]F(Z.CD'`+D992IX37ZW"_(W`X?^N-!K5Z8&,U(=2@Z1.?]T4.YDJ1CV[_ M>SJ>+%9*OAD?)FC)YW)0+H@0DZ;4<^6C%&J#2E2N]%!YZ"&S'JA9`?X:I`R/ M4OL\^G'2GKRW7XXF4HDS9,0*;W$!I@3K>28F2I.MAAXRZX%F7>)\&;?U)'Q:""M!^:<#6X5NLRF7S\W\[O0_+D\*G"_ MO4.V!`CW:'^JB)N^))K)MC_A.A'C&CPI.I3? M@Y(E"`9.CDMNM&8._UB[6TXZ5QJZT+^["NH,\DIW+QY$M1KUH0N(6UIG#J!T MH*O2/H$GQ@6(]9P,R%)E-/1SSRZD_/J"Q9GH5KG$.KN[FTV/HLO+ICDJ;RFA M/K;9+9J[(-E&J5JJ2X/R0P]>],"5,Z&MDH(Q'J]RFT:W'T:3\;NI'ZU*7NQ+ MM]C>([>/,P$J86\U,]%%9HG?N`8$2E7,T`,-/="F&X1KL.=C6_)HVHSC:#Y% M#W+A;F[N[^Y71_5HXT]N)ONLGL.=,X"0'A<,PUT=4B+!Z(UB!9Y*K9^A!P%Z MX%3G8%_&F#[)B,Y$*0]2.T^<,4IH$6"C;@WNS-7\][HN6`_T.1O<(:1'GY$6 MG66424LO1"#&"$3M&2S.)(L38]8',G3?*2QN,X5*NKH/X%`70!$#+'SD9OA/=)3/VNM,=05\_)K,:Y<+= M+_]":?RK&1]-MI<=LR/&6`%$<2%E0DO,:=2HW%-M2>#%[]8/W_NN1K(S(;\4 MN=XM%O(Y`BGXM:8`5R=5$=R5XX$%^^,1 MO;-4PE,JT`[43!H;++-$$B(%@Z5N7;"MKBG5V:!:]`B M@G!!>A:!QT`4U29(8>!P@Y?BUMGXGT13AW<#7?TR`PM21?`.,R2TP63Q\!ANNIW]\^*%X3<#.2T*]*I; M!HV6!:72:N,!'6\3]6/JJG>XH@^ZIOW,M*W0BD/],)]]GR"N\/._%\WXW?3] MMU4:X_2KNUE.OC\$&`_/__2/Y>29$FU=6.Y31!)&$L0:%0NR]+C\#46%SF#* MK#+\-?88G,2[*:J'55[X?J[]:I<#VED\,I]THE%(HB7AZWF05%QO9>@TZE/B MK\E5C'>=5(S_O5\L']\\_]C+LN@5U$P1/&+;/_XCV7FO(&B@S$G&F`3"S1J!5)XT/O13HT&1LS=Q78:PKQ]8.8FJ MK[MG#]$GV\Z3X*X0%.-L8\=#XJ5W]([?Q.T#2:?-UU6%JFHT[8,9!\EWM@`N M0[O'5S'6]PZWOHYQ$A&/^6`6D6F2%'J7#K<0360TO\P6'4OUY_&;^V]%S1Y$ M@8/.>&4^N<(6MD6'"EENC0-_N+:M$.!7(QJK;# M_C2Z'ZU]H_%HSP@\M=:\.%2!#P#^POY.JT:WV!3 MJ@MW?B4;)Z.FCE,3J8A!,+:N.>!!B:LM]G`1_G4EA?U,G'R[N6OY)8GB9,6N M]BY6K[DEK/\*X(!W?3;\WBZ[R2?9\ M+(O$#!K[(0JPWD6E;:1K1*2WI07[AGXD4#.?I#OXJUP&&?U\#$:O%/F\6>\E M3?M(V@-D9%?B&-;&WCV5@WG#% MVC>8T:P&QYF5&T0L+[VM/O2`?DT[LCOXZUPJGMTTS7B1$+/V@DY;O.+]EZ8!19+UE@1)0>"[U9LZ\/DG4$_N64V)/K8B?KL"=] M<[3.2$%CBA17E0CH8ZUS68#8XGIS0]\S+Z[/RF50@W/QQPUZY9]'/Z"9-E\F MRW;LVY-&MR"VAX]G?3>'Q$420EI.0,<8>52;D[*`YLV5GI=7Y&I-^0S+(^G$ M$\G*)Y>(C)*B"V9:*/P&`:#%C^T.O?QB18;V)HPJ=_';^.9TW/ZO#2M]']VV M%LB'!B4T?GD0IWPF&Z&-"XY:;IC4@4`,F^,F%D*]!R=K5P3MP2GN$?C+ MT<_A@IK/?^+:.5@W_9C^;5PJ1*.MDS$H:2S:T1MKQG-;>I!RL@[\MA(+\F"^ MO$K:G8?[]?"-05366(_`!KO*Z;._YLUB:1KOR>5M'O@6IQ4=Y@NR[334JUQ0 MO/_V[7:%QNAVC<:[Z9?9_&YT;$'8X[Z0F9;HIP5!.)>R+O2FM3 M#OT6=N>B?I5T>P[,E5*\9W<-NM?-XAC6O&R<)>C$N`=G1?*,1B?.F4A?JN#6P\"?CZ52M:V'7[T9S''7L+?UR"`XKM+$J=5,@%,4UZN# MX`4WEA-^H1I;G]#L67QLOC?3^^93,_\^N5GE*.VS'K;WR$K*MN".=B8D$H73 MN$^NYT=]*LUN'+JV/UO<+PV%3N"MH>4W2;^/%S*/R7;8V2<[G5#IR!@-1,H] MFE5M[OWC_'2QL3ETG=\U?;H"N$[)S@7:V&N2[W.0GS7,R0E"(I74LA"L938Z MN9F),==:4*T#T;ZJQ7D&KC48\A_-%.=\VUZC'=]-II-VOLO)]^81@3V4.=`S M"^F$"ZI];X(;KAFWD:WGFJR_5G73/8>Z!7IXU_XV-Z\>VK558[Y.=U0\O^!H ML@L>P(6V^@':[\DG(3;RDTGVGQ1XJ6R:[BC]=L17NTY?67F^E\7>F*:<>4Z, M]NW3893P-G:VFJ,#!J6W3H>>U]"]SNT.Y(OX":?X!UFFY*RT`:B703/J"1'K M^>#64JK7AIYJT#UISH6V*E6.*K.\I75&QQA<=%Z)Y"%$JQVUZSE%1TM+]@_] MZD9O;F0QM'7BS.UUD7;"#\,\%&A^U3IS<%2CQE1.`4`0)`6VT9:B.+-]Z%M2 MUW0Y']J:)UF'O<<7+;,(!LN]=4R4_F[2V]XRARNRJD>^ MCRO[,;'ZF'/?YSVRHXD(*ED*0#3J!<=\7,_-R5AZCC3TK)-^Z'@NO)62UPM> M57'*$DA&^:I):^XO#9'%S.UO<'[5%;N^0 M@V-$4<=20O`TERY%':T,/!`A.#]H4]68W6?$%&[W7P??T2/'&#UG6@JKN!2@ MK5=4"]8^$N<]5:5G"4-7Y.=*^]7I4Q?HUEB,H5F.)K>7>::UJS69A'->H&0" MBU*AH9:B:4LM>1G`2G&A-8GB:"_W(^$GRS2Z69UI?S[PZ,O./EEI=#F,D!20 MB20X&P2/,EAB./X'_;_T,JAU>;3$9_W@6R7U[]DHW8_)WO2_5XUS@"`Y.*T$ MD]+;:&)RSK+V_#)JRDJ/^8;.F`Y$_#(%\%QLZ[,ES.Y&DWTY*-N:YV!$TA0@ MY!`VYIG9G%20"VX@$:Q8,!5X#QZBZL._=:+1`#>`%4ZP+(&0_YG-)^TV^_' MT;(Y8,2\;)H5-99&JIV02CJIK.2"BC9]+W*A_+5>A#D3V=H\.6B^O&[< MQDAM@"23\%&FD"`D`]98`TY$'TNUR-!WGW+)[J%($:15MIO9=#R;KG(!_AQ- M__'^"PJF&;=#_ML[>/_Q\/YS3/^L/,X<=%M)6,%31M/_G3M\\ M9\Y#M(K;U%Y@.6##;-IDH[P5(ID@B,'Q*XL324(E"M(;U,K5TJS?NO%2"FDU M2ASVFW^URE(1D)Q3`XS)U>MCE`;N@Y?!$%#7ZB47"'$;#8I`K$&$/R;3R=W] MW4$J/&N7:4R*`VCF$`OKG<%EH710-"D?4[S6B%N1*&?=`5F%$*,?QQ'B:;N, MPT:?'3=*@T:0%*@8"5@GI;8\1>U*2W0.W8SHA!!G`%G%=]FR,;8_>[=L[O99 M%'O[91FMIHDI$]'=8^C\)>V23X1%+C5QUWIAM'LKHTN8+T6GQR4`L_E\]L^' MQUOQ7Y8_3V37KL]D'ES[+GN*PD5I"+C)JM[KJEI/C3SFU;07T]-+-WQE4S!,$IP]DI[ M&2ES/D%25B+.06E6:N6??MGY&IC7'_"7(M_Z)O;JR.=^CAK[X=63$]FWZS,Y M`:&!$@+XA[24.P7,BVAH9!"L+8UH#/UR M-#?_]G7V_=_'S>1A/>-?7BYC_%%^&-W'YNNJ[.1T^5^CNVT;Q:ZFV:-W&`Q% M&XPD&:)U-FE)HV#)"V^HN;*83P_"G76*\/%J_S2&>)SO?'3[#A?2C_]LMKE0 M.]OFE()3BEKB%/J+48)-(E*9O`Z<(A&7!4^Z!ZE('9*A!EQKJY!R` MNZ?'>K*?\?L[>/&T218X/$<\VJ61R(A#11*C[4N"UE8:4N\MU6L@Q!G(]L>$ M#^L7\_;L*5O;9DZ548%;X-9(S]%OH31)002-,M'B:J9#C5;4X<8Y$/='DE_[ M7,*?;,N9V-,Z4XTL#]XS*F*;;8S^,R&14`6:0@K7%E>H0Y3S0.Z;*@\T/IXL M3]IGRYGBH-HXB)%6>6=8F6R)T\@R-:MM>J8N&`>Z@R3`+4MI8:IT.M41:O\0X!]K>(B&SN[O9 M]--R=O./526EQ?O[Y6(YFHXGTUT,.=PQ-?>[)?EN8[T8(^O4F0RD21.C?`, MI&-@J2<2C/86_ZI%969$/RNL4PIK[S,%950R'A+U@DAAT30RWJI$1+)&&=HT M!C]6WW=[/*^H3=>4PGUOTB&+8[6Y5X%:/$:%R6R3H)VA,1AN\:AUG(KJ9L'] MK'!3Z[+!,I\]5U!BJ`R1&Y.HS+U_=5(&_Y"O$]I@+BU>U1[OZU0B;4CE/E(5 MGE5I?DQ]_;!\HB/<+N?(RW55A=LC1RIX3-H+SAA1'BEA`)P0BBJ2*#71#8*X M?D#6$!.'ZFNW3N\^L/=W.?MT>U=.X6NYFGPJW]SG*TA7-S_II%7(.VJ<@@O& MB8K661.ET1R2LMIP'9Q77J6F^<]CC;IV"\(N2=\'!%LJX\V]%L)+[]#@]GA: MN,"I%(YPR8.038W4HR&%3/BXO+SC\TCZ#H&;7=GH!FK8BR<+XU/T)HHDF9%4 M"4A<`2?.;AH855=E/;-(?V](.HW.XU+%JLO&'SU6$3P*?)T$4,6E(=$Q9L%+ M1X6D$@G>ESHVN`QK#)3&^EDS%CR'Y(5H)6T1_]SUDE???T>WR/-9^4Z?KN>WT_+Z;;YYN*RW/?7!ZBHXMCAK$6R M1`%EH/%$DQZB2THJX80*$6VDT+2DP`C#!4.!WK19S]_F2^_E^7&273U M)1.KLB#BWF>*F(A*6@CGA94V@K.$!LVX1"'@?&,+_FS@UX35+Y79EHA[!D?_ MGS5J*[8U1<$8!+0A=:1X-J$98"QW$`B-!)2PU6TASZ>'R64#Y$:.4A=H`+5VL=Z(87VG6FZD MP?EG6G(!T5I&/(M4YBR4B":\L9$[:@(J?<-D6OZ0V:\GSRRF.Z?6A@MU-GK]^F2_ET+@329K?XU MF=^7_RPGN;_KT\A?KR+@\45^])I=UQ`#AQXKM/-@`&6^T6S3OT0P$@+E7HK$ M050:R_VMM,Z&/_AS/%@N7O-XV6O(FQ1=;.X4N6*>2@G,`[,YTU0X[8EUC@>2*ML]=;S2 M/Q:H#J[_G$T^YHIOJ"S^]_TDWYB;9!7R"5NJ`CW-!BRHEU:2G.BHK7"!X8D3 M'J@C?..`SEF+@]J(V2<.NF1!'V;MXT+<]\>/_S4K5SCW[?<_RZ_EO"(H4V^` M`I1W:.D0!IP(1=#4X?YAY5GQN1S#M&MH[$-BF_3O%7E/3JGUSTNHC(\<-4X! M1@ECDW=$.R5)4E8\;GB1M+Q`'+8$C'VXZX#LO<)OMTTS07AE&.3`4T52QCIE M'\( M:I#(1)^Z6#]G8U-Z]X:7HWI41F.X`LBUO2@@'4PB]&$-W$/3>JYCU]\;,/%` MC\KCB-@'$)KUJ`PB-U/SEE`>`'SBT3T*50`S2+Y2SRT):[/R8(_*XPC9"R`: M]:A,&I4X$,S;9(CBD/NX/JS#:M;4P!K[B=(*($X@Y!"J:N6I62?)HOF@2"'- ME=(Q3097(A-%=VQW]D9RK#OFD$#0#B[XG+X^]WK=65K/%48)ASU M#DF;"Q/B)D538K=&)#6]5&VH#U0*_7]T`DJW\.EM\BNN[&2Y\\_7V=P^AV%=PUNKX!8L.WYW'0*G-C9*EB$C? M$(@6%+752^NW,``BA^17=]B]NKLM5]L7WGI23D+J3Z,5J+98KW4D01CJJ>"" MH5H43*(HJYEJ>NGLI./Z%X+BJ0P9(EK\A'*[OT[A[O&'5XMW.=]MM;O@OKZT M,#*U#BT(ZCD75((D-G\$115S7G@Q4+K8XRO#>EW>K6$Q?85+3UB#/WBS7*R> M<:IV9/G4.0KGDDPH5EV41!)BC;7$$#">^\#QBTM7ST["U3X%K&>N7%+\V4C& MB)54@!`R1`]>>9`F*L6=,99<.A[[@TZS^/1Q_+G<^+2*BE@OG=4A28^2@5F- MQ`B`4H(S5IG"=.XX;0DE)P6KC^/!4,%JVBA8O7NJ,$E+[F+02%$I#*[1)VUD M%$YS2Z&I47`V.&L7"#4BU\T(/Q2X6"-PL8>8"AK2T1)4:8R5FG(GA``B1>`B M:L::!J?.QA/2.[B:$?X\TVP,YXII&PF:T=($8F@*$;C!'87ZM;RT7I7#@ZL9 MX7L%UPG:[5&QLC;F*4"IQ%-2"I24+G+@"9)7,CD6DDE-`7PVTG%X4V0`-O:Q M'9ZLYA4_Q..R#@"]Y@B%0>K++$E"E%(GYD*@7H=((:3@TV]KNE4`+?M@TA!N MYG?+^?QFN?K/9#5-R]5Q3N>_UOCI_>S38G8SNYXL[OY:+#^NR]77+"%V@&H2.!!>$#4E0XBKO[W2\TL-;8+:WSJN'M/ M+4U56)?U8J,9)WV]NB^G?KFXP]='\N*G]0P9/3E8R^Z4X0J7!-.)@(PA:^J&TUR. M;;M2/"D;=XH]%V`.#Z%E[UP\,W%^E"NKQ>D*T))#!,92"%X!-PR-VAU5J6E\ MJ?9L/%JC46&&8^J9;14_F5_?SSR;U^?.S`^.79[^ZOIVLRUK*6\M3%AJH"-$(@IIQ4L*1S.,==8VE%Q^2O)A-U#*G3[OT MTLZ[^]M\Q7?]Q^*/!3)H,D<[+U\_>W*WI_K"3&]O4NA@5?0D2L6\"$JYP-,# M?664W?=7M=N=M"@_Y5M/YZ+'M;1]SH/KX]E5?RSVN$MZW5%[WZ*@/M\H)9S8 ME*P30J,2\$!7_'/3W52_7]KOW31JCI^AGO>^O+N;[[WGV?VD.8W/T<0(9TJB M-DV"H.%1DZ:J:;RQ?E^W5_?4;VUO#-P>\WX:E_-!$&GR(>VMC33DB\/L48_V M)C2]IZ.:.1_BXO<^&@FKA\BC&[!-1Q>);D$RRZ2UD"LTH#(@0!,DN!><,J'T MT&6\:\#^J-K]QXQ71.I0DBOEO8B!*#!"R@?:.,$O_G[@27@YP?7?E`-G%A=K M&[AUIRLX1"TA&FXB!\-0YD;[0%6MS<47SQD*UQTQJ.M3$\%?BP_3+X-=.P] MSO^#;S5.O0-/%0YLM`$$VKA*.DV,A41%D,HE:00,=.B]\L9U1,2AQXIH4+73 M21OM0'+OK.)">4!#):$Z=;%U;%MA_K(S.O>X8X>\F-'^QD5&&6%-8M0R;9@. MWF8I+;4")[6H3'[J>)WQVY=RL2Y=N2AO9K76^/R)PG.2+P0@*'%YN5(NEVFW M/F]E&J2EY,#;M3;+]VW7DTCH.5U]V#MM# M3LSZ@Q2<46=$($E+YAR-**/@D0+17&H`N@N0=4;UX7#W7">%NU3F>,'\/?+[ M'G'P_=F/CP;D4:,7*@:)!J`2@/:?)$3@4?I`LYBHZ3S`VUN:7G_@[)(#/>HU M`[KAVE=K2&14,64\.(NDC4Z)W)Z4F"PFB*[$>3?K?-)AM0:2FC3./7K80C+# M$3FEG@M#8]@HHZYA2N7.@9]J3=#6@'/_@:Z7?.A:[GP_@[?R4W6^4;*YZSM M/[JH.E+FQ)$+EEL)A(@&@9^&("D+8 M2"3=N`XN5-#TA;+ED-P:1AR-KBOP6$55,LX90J)7GD@7P''K0J]L<(Y3*YW3(!-:"BY9 MW`T2]^1O\742\O:J4OWRK0\OP?;E<+J*PAO/?E=$JD1*S%EJF`R"&FY%<-8% MA0JJN]C2`@,`8=D>&_J`4W.Z_%C98OIV/EF\F7PN*XMH=#%=8:D3N;Z7\"3( M9*R1QI/<<]5ZQI'*%PKNAM!Z*2N'YT@OSM7/7^;+[V6YT06OOARLE5'Y3*$, MT.22MTPZZ24#KH,+B2?'5<+O+A1QPV+EI3NU)>[T@;YW)6HTL]P>9_.VU:UO M7_M]@3:;2<*0)$24GE/P@1AI&9?6ZQ0OM\* M*WF^@98=,4J!,E,[;M%,LD+R*"TD3@(H'Q52=QC72*?X.9;W]0S&%F@[#GQ]^,^R M!7P]CE(H(E%6*PX4U4&G-0@GO`=BF*<"5+R<\ZTO?#6E;2^67C[!*[2?Q]\4 M.D$TB=`(EDONC7&YS(]6R487N&^*C='KUH,K0DU9T!N$JET$/WY5H"P5$:A& MTY-)0HF5@4>:]1$D, M`?6SK)(9YX0R,1#-(#0MCER_AM&OJM_TSKM1H_W-?=Z_.VZLX?[N%A'P?^6A MFL>MSU4P&A351%N+Q)/@04>EA*"6$"0Q:WIY8NSGS M>98X:;GZ!SY[*)VPJRD+2;TC)EK'0DYA<$83F8CG(5IN;>/J7&-75"Y@AYS( MRE%OE,V_=JZMMYN*4[2+S?'*-(7RDM'<%42A!0+!&F2SULP[[QRHQJ;M0SIT5HEDF<_MQ-&!H10TBA=*P.< MG=]&?&!LN?HZVR4H_+R%YIL7PT]7-S_`M-TI&P+4S\5O<;Z"6J>9]$$J$612 MR1A'+4T)$K=>RZ8.^+$KY7TANL;VWF:]P;\Z,/W>KJ`@+'7@J M)PX%IFW@N"09DW<+YXGPW.H004CP%A?K8E`\)2*4I[\8P(X%P[)[DO=Z6^,D:5\G MR-'R3(4.QC`5).7,26:U"5II2VF*N?J[:^KE';T/:U0'];!,[>46Z/;ET?)^ M=6V[_7T`]_4&*(22BL44K4,N.,4=>&J2TRJ"9TDWK4TV=FD\&(!>WA[M@DNC M$>`?)M]V50`3%MR"6U5"`AR%S&2^5R^]1&FZ@,/91>'JHAR%@0 M/@@?QR.AWY1W5S>XO),E]<-`10A:".*XUQ2/3FZ<-UYXU.<2<1)ITUO,8'DW MF?]Z>.Z46T.'"/Y:K!ZI]O07&]KM?(?;O$;^(KVRZ=RRZ*KF_\I)ZMUIN'U9J9''G[`Y92; MM_@=0/C97$5A\%?([CR/D5\-&2$<<\L.!!@N1,#!4.`B=C8[A\[XH;%2NT" M/L=QYS#Z]K24?IF[M)C6KYARW`"%TD)K2%%3JF2V]I0GQ&L0R5&OV*7>OQD% MUCIEU2B.]X%O^`!3ECEI-1%2)B7=_[=W;;N-Y$;TDU*\%@GDA5?`+SO!Q@F0 M)\)K:V:,]XFVYH!!C."1\VN.H=DG2H6N2*\:;:E MC*6,S!;7Y%1MH+ M=ZDQ^6^G*P?VV%@J&2UW$$D.F4!SM$%@9T.T']_-64]?L['`-EB2XC!7E9ND M\(Z!S[^-CQ*U!#3HN_<07DZ2)"L]_MO;]SOS$H=9O@CAHH:\A'1YQ]24>TCN M@3$'NIL9K&"JK[A1()Y[HFF45,1!3BA=#"82.!H=;0R:6!*$9;9[F[P&S6F* MG!0,_?3?P[Q3Q#0ZL?[+0U.AKQ2XYKINA]:"Z2Q&F>NK<178W73Z)7]T=Q4- M\'4$?;;,W'YHC?[M_N=B=?[SHFM/L%$D?KV]N8FWJ^8_#4&&7@-ISE#+P+4W MBH9(>?3,;68R5.3+9J"/B.%CT6<,!\^$:NN^0-.R;#V&9"78P)S25*D8`].. MR<[^)N)H1^;_W8JYYC_\[8)S).1,;/8J%N/I88*?(\Z663^ZA\I)89QHSH M[$^9ZRO%B'Z18EB>V#A=G'@8%NKFHKFZ:DNN+FZ>*BCV*>Z9:$0)FH2/XXY% MU!R1"^6A\XU4\^VM-$?)])B>KIN%WQ[N[^XOEE?7RQ\ONA[\NFARGOES=[ML M[?)P<7.^6`V3TAMBG,EKH6F03DD7G.5!!*L[/WH=)[F;M63&CD6;T6@^/&A& M(_]O']OGM\/]^>/'JHW`SK(1KI=WUY?_O+AY6.R["$\QIJ0U$ZB:L\E*H\?@ M%8^=?QP&,[B.5!FIC[0,5^#K67)Q:PHKB8Y;PTI@97/UI1*,0!2(T8F-H"=` MSKJ6H&Q:3$WD_BBI>U.]">M?[#K:A)3/9HH7UZO60L44!QTRTL3!\^ATB"%F M5Q(;55<'F9<4\'UO!BK^8L4YAL)C(."KL+EP"J<(R($C$+`B1B32QL<"8TNH M-*-UMY]K4=(P%"IP*C@0277S_WD929F3P(%C3!BSFS@/1'OK5$`1B.K\QX#T ME<9F*V9_F3E@6"#5/1$\+V0I=UN;AKOP MW\7J\OIN9V/GP[\LH9)2$4DB$\Q1[A5!\V@1@2B&[RU;W:FL@;`^M.MJF/JW M@O\A#R^^_[3D(M(`PNJ8(65(#B\,[6P:'0XO39_H4(AO:^#+M%LEK3AEA#(. MX*QSB&!99T\;==^JZ(,UW)ITG#+9\EG?UL"5QW6S:4/2L1M,%(B3[& M:+)_K::ZLR<+I.^Z4GKM0Z6Q]F?]5P,?WC^GU.TP_[:ZOFS5XN]C*E1[#B9% M;X0"+VG0@EGCJ4?L/&)`]TJV-&Q/@TM#\1#$5Q\MR/Q"QWEO;K#HU'RJ`-)FCH1K&TN%<\S M-J6(SG>>(-&<.D*4S\DI`5$%-=\0;Z8BYX%#25%8(T0$3QAURK(<-7<1O-!, MGDZ*UT_/82%1!$%GLX]5G!#OF>'&NQ"#EM*(S;XE?W22**N@Y"1HJ(&)6T+5 M1$S<;*TX# M.@@V!B>B"1$$;%+]Q(S7K[/XFRVG(LPQW5=T3Z'>7<[H1^09=S3)"$8H!"^9 M\DY+ZJW;9'2TQ$EN.JQ@6W@DH!^K2]!H`*B!E.^OVN]98=`#4L*'-RH;1QYY_LP4`4@4 M$,A3"-RT4#WIDV,3K``W5[:V/7_7D9:P%P]-(@H9FGRH]$I)RYE073%I_J3W M(=;2]8R"B52"GW3/Y^=^7U4:7=H&1..)@F5+>NS114WRD0,!KHT MIK0NRIY\DH7S:62YHQX/E\JD"6F3F*44!??&Q,`9#]0ZVUE0H>U[\WC955E5 M0'9D>AV(A$FXM#FG-C:3/GQPBDQ!5"+_8:@+S!FI-]8SJ-C,5(8OQZ!C(V`2 M_FPNS1N;/Q\^.!F=@TI"B=3(P-+`$+KH4J*;7?^^+\>?8R/@M)=[8P;*OP0+ M.8:D*&.3A,"-!2F%ON?N2ZY,^G(\.CX.IMS)O:'CC[67V_7HA`;0.@H2!!>6 M"$-9Z"S(A.Q[KS`6NAK5K!P;%Z_4O$O>X[R&ZE81N+EIQYA_^MOWMV'?6L2V MO?M:/)QG!-C\GW[?E9"88CS)@U<.O08#U'E*E"*\\XVWO?<:I9>ZC(7HE\F( M"GP\2L9O8X=_+%>+R]L?R^O_O7Z;3;_/=IVXZ\&DWM^>M(W2AV`T53F>"Q]A+Q4':@87HSEL7%1_C9CMUMW/39^_;,'R/M^>6*9_-P3K;QBTB%' MJ55G,'-D550)``.-D;I5C9&Z575X"P`!!"4. M```$.0$``.U=;6_;.!+^?L#]!YX_]8!UG,1)N@V:73ANTC60UD%>MGN?%K1$ MV[Q*I$M227R__H:D)-.Q7BQ;<5+80(#*$F?XS`MGAA3%?OS]*0S0`Q&24^(`B(+J3N0;.8X7%B*BO."1R@CURUA@K-3EMM1X?'_?& M7$ZH@J92[7D\;!WN'QSOG[1!-!"6R5,Z\<)*!`%EW^<(G@8BV.-B!"WWVRW] M>(`E29HSSE@49A/X2K34=$):T*@)K8B@7DI73C1/H!O0`F"42869EP)[6A#D ML6U:'WSX\*%EGJ9-I9_5$-@>M/[ZX"A@5H5\0@> M$%D3(,-K;43:RG4A,KQ60E3D23EX%DGTKV9"U]2WF@>':\*8C;1J,!*Z6F!\ M:&'A:7.#Y3S5)$^3`#.LN)A>PN_EH`5"S'&YF#'1&#]HC`N$LQJ4-7"X-CDVO_PE+>(0Z)Z/*_8I MB;UE8EL67?*C.6.R*II("*ASIDN'VDS"]-=*47:.KT]H M92P)C;Y8'P%Y\L:5(:1$YFI]$)0]$*DJ.XE#%E^O[R(,4\^DXH,J2&94]K(Y M8[`B#DF]RB@2&GU1`P(U$=4A)$3FJ@@$9HPKP\G<2^Y.)I0->7P+;NH/8VS:'%5VYH(/B%"42BNG&K=,!@+,CQKZ#E!,ZG[__9PL`=U<-)D MH8/Y$L/D*R#QHL"(<34#F7#0\?NL(4'?`4F$W[A4/AE6E0I(**-O6:@`#ZH* M!20D>*OR3`2I*@^02)@JK^9[FL,=M$`4)GSG6%+9'UX[##O,OZ4C!M-N#S/5 M\4P*IFQTS0/J@5`-I#GY^@QL*Y>I+HA'J$/>!`0N6&?K1-RN5L?O91;&S%0+`>*!4&. M)"@1Q3"/A4&I-,@19^?\K^U)7=#'X4\X`BSNW3#8OF%P9U3VLBX;]U'H7NW] M@_;^88V5J>UT^UP@DI01*3O>CXA*P[>2=;/(2R:4AUD3RI@/VQO\0`T2"G1?S]W.<:`G;K=C0E0U@^7Q*+(3C"GXT^/J%A1HMDD: M,\UXH9@9LMQVIHG5>HT%2#8F2L_(Z[#3/,,RHQV;P;6DT="[.>9;/;Y2E<%D MO8OE^#+@CZN.LVQ>):9KEXRW&5.SO`]LD>&[,YI5=(^!+4@-%HL9E9CKL)*Y M+,]M,]4G,E`5#&*:EU1[1QG5GJ;;1M56K]Y6IFCJK.55L4,2FR"C[:4V6?A[C7.JRV?)S5YFVS4876#"8.,AK(F['4-M4 ML,L":4DD>I\1B1(>")@@PV7;#5`]1N5Q*(E7[S-69!?-L;W1Z[E:*R^BY3`H M64![G[&`EF66+5T]N\14_(F#B'PA6&M'A_(*-LDD+XE;[8RXI?D@PP@YG';& M@"Q=S_NGRJQ+HET[8V]!MA%W+Z"6LO,5Q0,:4+V'.K[K=U3:L,]NB/X0!Z*6 M><5>CP.LUF>Y9RSDP5S/(-#P(84X]8^)=< M5#/IO80K9V?&/>,#O6M'Y\(>FT2J)D?;#,9RQUQX/YKKF`YB!/^NZ*@&^]S6 M%Q<]LO!W[NRZ2N6RL(!)26G8SB@-50](B;4DD.LZ(1/-FV-+X8E$>XD(\+EF7(W M55W2VK/-B]G/+Y[TI?YN@4/I^S_B?QL3UI_H1_*&2"6H9]YY`FU'E]AZ3<\H M6V\ZF-W5;RC"2<"GQ-Z]CH0WAKZN`\S,LIW\$Y@1ORX_>Z-BE7OXPKRFP,/= MK9^YS6))T4Q4I&5%L;"_H)FXE@FRHOV"')'GGMCW0['8\9-$<*0EMPNQ$EG9 M=R,NSS7OF4B-XK;HHJ8;Z=`9!^9*4X`DTTXX&4R]Q5!XKU@2*M$&0U8H>E'K>)4IJQ M5I!5BP9E%(,2S>B^4]T@HYP8W&X\S[MV%(983/O#K+P!;IB9.3J>H@]F#:K' M9DY;VVBK'U+Y6#BI,A8L0.UUV>G'^&I.`D(SI/J3=-?#=ZZ9[0?FLHR%L'.995VF\@I)(9N2Q9*3C,627.-NP<+)Q];SL\3B._-G MCID3Q^(3AQ$>0/S$GCIK*!&1AC&M/J/I[XXWIN3!-.H/NT2`E\,,!Y*^_AP" MHFX4*/F%A`,B&N9(M;-&)0H:!-H>2; MZF2/&C[U>0B<>_!`R]Y`MN'$%")WIJ$?B7AYJ%5!XN1K*G";`66V4+2?M:[-)CR:$S.21)L^35V?22BZXY3%+I MHG'^@^=<9;X6GE6L8^^$G$%R$-/GYAG83Q_.&IX@/E5OU&JI=FR[V0+`1FQ4 MU/O;LTAN3.D&F(90N)BS4_WS2'WE((L^AY+XO?.O-_,A9.G6;S!ZSF/'^NP2 M"[Q(Q*QF;U"VHHW2G9@H$7#)MJO[L)[OL-'Z(3]]76XW'UP+_E\S+03SV M]"?I.J=#?Q<`+\3VL6V7[)U,!*^1WTHN`/8')7@@XX9TTU=C(IRBIYHFLJC? MCMS.EH=O5(T7M]KH@,P\D,5PG=^HD\;N)-;GQ/@%?6VJUQ=,(#X9K)/17T05 M$&Y[>D9ASIR*S]M)QM^BTVZRYS=L"#T'(U?T09^^I4`6"C@[4A(E[R491L$5 M'>H7^T;J5(<5B587/Q%B_2$/DTQ]CJ2I>RZQ9VNN!TP#:W`HB&`N_8G8?Q-! MJQ*]2L5F_SL.52W5/U_RG%_M-"^FY@N:*@1O8*)G$!6]$#F?SII]%*BWRH+HU2IZ_<'HI?19V])+: MW(R#PEQ^2`#>BZMSF8Y^?G7V(>'#&-#_1=I+*W2YKEYKO.=FC`V([>Q!?S[= M?+7>-S>!M8O8]K_A@)__!U!+`0(>`Q0````(`*F(_D8MWK$*UZ$``'VT"0`1 M`!@```````$```"D@0````!I<&-M+3(P,34P-C,P+GAM;%54!0`#C9&Z575X M"P`!!"4.```$.0$``%!+`0(>`Q0````(`*F(_D:.\=MN/10``-')```5`!@` M``````$```"D@2*B``!I<&-M+3(P,34P-C,P7V-A;"YX;6Q55`4``XV1NE5U M>`L``00E#@``!#D!``!02P$"'@,4````"`"IB/Y&01&UL550%``.-D;I5 M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`J8C^1M2MWIB:?```'6<&`!4` M&````````0```*2!T]@``&EP8VTM,C`Q-3`V,S!?;&%B+GAM;%54!0`#C9&Z M575X"P`!!"4.```$.0$``%!+`0(>`Q0````(`*F(_D:;+CB3$T8``(V3`P`5 M`!@```````$```"D@;Q5`0!I<&-M+3(P,34P-C,P7W!R92YX;6Q55`4``XV1 MNE5U>`L``00E#@``!#D!``!02P$"'@,4````"`"IB/Y&3=$95'8+``#&;P`` M$0`8```````!````I($>G`$`:7!C;2TR,#$U,#8S,"YX`L``00E#@``!#D!``!02P4&``````8`!@`:`@``WZ XML 17 R9.htm IDEA: XBRL DOCUMENT v3.2.0.727

Debt
6 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

Debt
Debt
Our secured revolving credit agreement (Credit Facility) provides a revolving line of credit of $125.0 million and contains an “accordion” feature that allows an increase of up to $25.0 million to the Credit Facility with lender approval. The Credit Facility has a maturity date of August 4, 2016 and is available for working capital, practice acquisitions, capital expenditures and general business expenses. As of June 30, 2015, we had borrowings of $90.0 million and letters of credit of $0.3 million outstanding, and $34.7 million available under the Credit Facility.
The revolving line of credit is limited by a formula based on a certain multiple times the trailing twelve months of earnings before interest, taxes, depreciation, amortization and certain non-cash items. Interest rate options for each borrowing under the Credit Facility, to be selected by us at the time of each borrowing, include either LIBOR plus 0.75% to 1.75%, or the lender’s prime rate plus 0% to 0.75%, both based on a leverage ratio. We pay an unused commitment fee equal to 0.25% per annum on the difference between the revolving line capacity and the average balance outstanding during the year. Outstanding amounts advanced to us under the revolving line of credit are repayable on or before the maturity date. The interest rate for our borrowings under the Credit Facility at June 30, 2015 was 0.9375% per annum.
The Credit Facility is guaranteed by our subsidiaries and affiliated Professional Medical Corporations and limited liability companies, and is secured by substantially all of our and our guarantors’ tangible and intangible assets. The Credit Facility includes various customary financial covenants and restrictions, as well as customary remedies for our lenders following an event of default. As of June 30, 2015, we were in compliance with such financial covenants and restrictions.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 18 R29.htm IDEA: XBRL DOCUMENT v3.2.0.727

Income Taxes (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Income Tax Disclosure [Abstract]

Income tax provision $ 5,364 $ 6,586 $ 9,291 $ 12,963

Effective tax rate 38.00% 38.30% 38.00% 38.30%

Statutory U.S. federal income tax rate 35.00% 35.00% 35.00% 35.00%

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Subparagraph 2

-Article 4

+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32698-109319

+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 19 R28.htm IDEA: XBRL DOCUMENT v3.2.0.727

Debt (Details) - Jun. 30, 2015 - USD ($)

Total

Revolving Credit Facility [Member]

Line of Credit Facility [Line Items]

Revolving line of credit borrowing capacity $ 125,000,000.0

Additional borrowing capacity under revolving line of credit facility 25,000,000.0

Amount provided by credit agreement 90,000,000

Remaining amount available under revolving line of credit facility $ 34,700,000

Percentage of unused commitment fee, per annum 0.25%

Revolving line of credit interest rate, per annum 0.9375%

Revolving Credit Facility [Member] | LIBOR [Member] | Minimum [Member]

Line of Credit Facility [Line Items]

Variable interest rate, percentage in addition to base rate 0.75%

Revolving Credit Facility [Member] | LIBOR [Member] | Maximum [Member]

Line of Credit Facility [Line Items]

Variable interest rate, percentage in addition to base rate 1.75%

Revolving Credit Facility [Member] | Prime Rate [Member] | Minimum [Member]

Line of Credit Facility [Line Items]

Variable interest rate, percentage in addition to base rate 0.00%

Revolving Credit Facility [Member] | Prime Rate [Member] | Maximum [Member]

Line of Credit Facility [Line Items]

Variable interest rate, percentage in addition to base rate 0.75%

Letters of Credit [Member]

Line of Credit Facility [Line Items]

Amount provided by credit agreement $ 300,000

X

- Definition
Line Of Credit Facility, Available Increase (Decrease)
+ References
No definition available.
+ Details

Name: ipcm_LineOfCreditFacilityAvailableIncreaseDecrease

Namespace Prefix: ipcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Percentage points added to the reference rate to compute the variable rate on the debt instrument.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_LineOfCredit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.
+ References
No definition available.
+ Details

Name: us-gaap_LineOfCreditFacilityCommitmentFeePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The effective interest rate during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 22

-Article 5

+ Details

Name: us-gaap_LineOfCreditFacilityInterestRateDuringPeriod

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LineOfCreditFacilityLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 22

-Article 5

+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 22

-Article 5

+ Details

Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VariableRateAxis=us-gaap_PrimeRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 20 R30.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock-Based Compensation - Additional Information (Details) - shares
6 Months Ended

Jun. 30, 2015

Jun. 07, 2012

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Common shares reserved for issuance under stock-based employee compensation program 4,943,170

Common stock available for issuance under Equity Plan 529,851 1,422,130

Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period, in years 4 years

Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period, in years 4 years

Performance Stock Awards [Member] | Granted Prior to 2015 [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period, in years 2 years

Performance Stock Awards [Member] | Granted Prior to 2015 [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period, in years 3 years

Performance Stock Awards [Member] | Granted in 2015 [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period, in years 3 years

Performance Stock Awards [Member] | Granted in 2015 [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vesting period, in years 4 years

X

- Definition
Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 R31.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized When Options, Restricted Stock Awards, Performance Stock Awards and Employee Stock Purchase Plan Shares Vested (Details) - General and Administrative Expenses [Member] - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Total stock-based compensation expense $ 1,784 $ 2,059 $ 3,688 $ 4,024

Tax benefit from stock-based compensation expense (678) (789) (1,401) (1,541)

Total stock-based compensation expense, net of tax $ 1,106 $ 1,270 $ 2,287 $ 2,483

X

- Definition
Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.
+ References
No definition available.
+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 22 R8.htm IDEA: XBRL DOCUMENT v3.2.0.727

Fair Value Measurement
6 Months Ended

Jun. 30, 2015

Fair Value Disclosures [Abstract]

Fair Value Measurement
Fair Value Measurement
Some of our liabilities are measured and recorded at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The established fair value hierarchy distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (Levels 1 and 2) and the reporting entity’s own assumptions about market participant assumptions (Level 3). This hierarchy is used to measure fair value as follows:

•
Level 1 inputs utilize quoted prices in active markets for identical assets or liabilities.
•
Level 2 inputs include quoted prices for similar assets and liabilities in active markets; quoted prices in markets that are not active; and other inputs that are observable or can be corroborated by observable market data for the asset or liability.
•
Level 3 inputs are unobservable inputs for the asset or liability that are supported by little or no market activity.

The following table presents our liabilities measured at fair value on a recurring basis as of June 30, 2015 (in thousands):

Quoted Price In
Active Markets for
Identical Instruments
(Level 1)

Significant Other
Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

Total Balance
Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)
$
—

$
—

$
54,107

$
54,107

The following table presents a rollforward of our liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three and six months ended June 30, 2015 (in thousands):

Three Months Ended
June 30, 2015

Six Months Ended
June 30, 2015
Accrued contingent consideration for practice acquisitions

Beginning balance
$
56,308

$
44,911

Addition through acquisition transactions
1,262

9,301

Adjustment for prior year transactions
—

(283
)
Change in accrued contingent consideration
505

4,884

Payments
(3,968
)

(4,706
)
Ending balance
$
54,107

$
54,107

The fair value of our accrued contingent consideration is determined using widely accepted valuation techniques, which include the income approach for estimating future consideration to be paid based on projected earnings of our acquired practices as of specified measurement dates. The income approach involves the use of a probability-weighted discounted cash flow model based on significant inputs not observable in the market. The significant inputs include discount rates of 1.27% to 1.90%, 100% probability of achieving the estimated projected earnings, and 10% to 80% probability of achieving certain other objectives.
Because our accrued contingent consideration is generally based on a certain multiple of earnings of the acquired practices during a specified measurement period, a moderate change in such projected earnings may result in a material change to the fair value of such contingent consideration liability with a corresponding adjustment to income from operations. We reassess our projected earnings and the related fair value of our accrued contingent consideration for practice acquisitions on a quarterly basis.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 23 R32.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock-Based Compensation - Schedule of Unrecognized Compensation Costs Related to Non-Vested Stock-Based Compensation Arrangements Granted under Equity Plan and Weighted-Average Period of Years Expected to Recognize Those Costs (Details) - Jun. 30, 2015 - USD ($)
$ in Thousands

Total

Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total Unrecognized Compensation Cost $ 903

Weighted -average Remaining Recognition Period 1 year 5 months 19 days

Restricted Stock And Performance Shares [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total Unrecognized Compensation Cost $ 11,916

Weighted -average Remaining Recognition Period 2 years 5 months 19 days

X

- Definition
Unrecognized cost of unvested share-based compensation awards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=ipcm_RestrictedStockAndPerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 24 R2.htm IDEA: XBRL DOCUMENT v3.2.0.727

Consolidated Balance Sheets - USD ($)
$ in Thousands

Jun. 30, 2015

Dec. 31, 2014

Current assets:

Cash and cash equivalents $ 11,565 $ 14,913

Accounts receivable, net 121,699 122,092

Insurance receivable for malpractice claims, current portion 12,322 12,564

Prepaid expenses and other current assets 14,121 20,876

Total current assets 159,707 170,445

Property and equipment, net 8,960 8,798

Goodwill 458,494 408,988

Other intangible assets, net 4,924 4,957

Insurance receivable for malpractice claims, less current portion 22,999 21,574

Total assets 655,084 614,762

Current liabilities:

Accounts payable and accrued liabilities 7,829 8,388

Accrued compensation 37,544 40,907

Payable for practice acquisitions, current portion 49,611 35,411

Medical malpractice and self-insurance reserves, current portion 12,889 13,079

Deferred tax liabilities, current portion 584 584

Total current liabilities 108,457 98,369

Long-term debt 90,000 80,000

Medical malpractice and self-insurance reserves, less current portion 49,129 47,239

Payable for practice acquisitions, less current portion 4,496 9,500

Deferred tax liabilities, less current portion 13,622 11,737

Total liabilities 265,704 246,845

Stockholders’ equity:

Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued 0 0

Common stock. $0.001 par value, 50,000,000 shares authorized, 17,414,907 and 17,242,209 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively 17 17

Additional paid-in capital 188,144 181,841

Retained earnings 201,219 186,059

Total stockholders’ equity 389,380 367,917

Total liabilities and stockholders’ equity $ 655,084 $ 614,762

X

- Definition
Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 35

-Paragraph 1

-Subparagraph b

-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 25

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 25

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 35

-Paragraph 1

-Subparagraph b

-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

+ Details

Name: us-gaap_DeferredTaxLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

+ Details

Name: us-gaap_DeferredTaxLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The current portion of the amount receivable from insurance and similar arrangements for reimbursement and payment of malpractice claims and litigation costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InsuranceReceivableForMalpracticeCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The noncurrent portion of the receivable from insurance and similar arrangements for reimbursement and payment of malpractice claims and litigation costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InsuranceReceivableForMalpracticeNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of the current portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

+ Details

Name: us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of the noncurrent portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

+ Details

Name: us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R6.htm IDEA: XBRL DOCUMENT v3.2.0.727

Basis of Presentation and Significant Accounting Policies
6 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Basis of Presentation and Significant Accounting Policies
Basis of Presentation and Significant Accounting Policies
Basis of Presentation
IPC Healthcare, Inc. and its wholly-owned subsidiaries (the “Company,” “IPC,” “we,” “us,” and “our”) is a national physician group practice company that operates and manages full-time acute hospitalist and post-acute physician practices. We prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) on the same basis as our audited annual financial statements. The consolidated financial statements include all accounts of IPC Healthcare, Inc. and its wholly owned subsidiaries and consolidated professional medical corporations (Professional Medical Corporations) managed under long-term management agreements.
Through the management agreements and our relationship with the stockholders of the Professional Medical Corporations, we have exclusive authority over all non-medical decision making related to the ongoing business operations of the Professional Medical Corporations. Further, our rights under the management agreements are unilaterally salable or transferable. Based on the provisions of the agreements, we have determined that the Professional Medical Corporations are variable interest entities (VIE’s), and that we are the primary beneficiary because we have control over the operations of these VIE’s, provide full financial and management support to them, and take all residual benefits and bear all residual losses from their operations. Consequently, we consolidate the revenue and expenses of the Professional Medical Corporations from the date of execution of the agreements. All intercompany balances and transactions have been eliminated in consolidation.
In our opinion, these consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial information set forth therein. Certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to GAAP and SEC rules and regulations, which are applicable to interim financial statements. As a result, the following disclosures should be read in conjunction with our audited consolidated financial statements and notes thereto as of December 31, 2014 included in our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on February 23, 2015.
Revenue
Net revenue consists of fees for medical services provided by our affiliated hospitalists under fee-for-service, case rate and other professional fee arrangements with various payors including Medicare, Medicaid, managed care organizations, insurance companies and hospitals. Net revenue is reported in the period in which services are provided at amounts expected to be collected, which excludes contractual discounts and an estimate of uncollectible accounts.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions of the fair value of certain reported amounts of assets, liabilities, revenues and expenses at the date and for the periods that the financial statements are prepared. Significant estimates include the estimated net realizable value of accounts receivable, medical malpractice insurance receivable and payable for known claims, liabilities for claims incurred but not reported (IBNR) related to medical malpractice, fair value of contingent consideration related to business combinations and the analysis of goodwill for impairment. The process of estimating these assets and liabilities involves judgment, which is subject to an inherent degree of uncertainty. Actual results could differ from those estimates. The results of operations for the current interim period are not necessarily indicative of the results for the entire year ending December 31, 2015.
Fair Value of Financial Instruments
Our consolidated balance sheets as of June 30, 2015 and December 31, 2014 included the following financial instruments: cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, payable for practice acquisitions and long-term debt. We consider the carrying amounts of cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amount of our long-term debt borrowed from our line of credit approximated its fair value at June 30, 2015 and December 31, 2014. Pursuant to GAAP, we determine the fair value of our long-term borrowing using observable inputs, which are defined as Level 2 inputs under GAAP on fair value measures. See Note 3 for the definition of Level 2 inputs under GAAP.
Our payable for practice acquisitions consisted of accrued contingent consideration for practice acquisitions. The accrued contingent consideration is carried at fair value largely determined using the income approach with unobservable inputs defined as Level 3 inputs under GAAP. See Note 3 for the definition of Level 3 inputs under GAAP and more information.
Goodwill
The changes in the carrying amount of goodwill for the six months ended June 30, 2015 are as follows (in thousands):
Goodwill - beginning balance at January 1, 2015
$
408,988

Goodwill acquired during 2015
49,789

Adjustment for prior year transactions
(283
)
Goodwill - ending balance at June 30, 2015
$
458,494

The valuation studies related to the practice acquisitions that occurred in the fourth quarter of 2014 were completed in early 2015, and as a result, the value of contingent consideration liability related to these acquisitions as of the acquisition dates was decreased by $283,000, along with a corresponding decrease in our goodwill.
Medical Malpractice Liability Insurance
We record our medical malpractice reserves, on an undiscounted basis, for claims incurred and reported and claims incurred but not reported (IBNR) during the policy period, based on actuarial loss projections using historical loss patterns. For claims incurred and reported, an insurance receivable from our carrier has been recorded pursuant to GAAP. Total accrued medical malpractice reserves and related insurance receivables were as follows (in thousands):

June 30, 2015

December 31, 2014

Assets

Liabilities

Assets

Liabilities

Insurance
Receivable

Claims
Reserve

IBNR
Reserve

Total
Liabilities

Insurance
Receivable

Claims
Reserve

IBNR
Reserve

Total
Liabilities
Current Portion
$
12,322

$
12,322

$
567

$
12,889

$
12,564

$
12,564

$
515

$
13,079

Long-term Portion
22,999

22,999

26,130

49,129

21,574

21,574

25,665

47,239

Total
$
35,321

$
35,321

$
26,697

$
62,018

$
34,138

$
34,138

$
26,180

$
60,318

New Accounting Principles
In May 2014, the Financial Accounting Standards Board issued a GAAP update "Revenue from Contracts with Customers". This GAAP update requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. This GAAP update also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The GAAP update is effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2016, which is extended to December 15, 2017. We are currently evaluating the impact of the GAAP update on our consolidated financial position, results of operations and cash flows.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R35.htm IDEA: XBRL DOCUMENT v3.2.0.727

Earnings Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Basic:

Net income attributable to common stockholders $ 8,750 $ 10,609 $ 15,160 $ 20,883

Weighted average number of common shares outstanding 17,388,646 17,123,840 17,345,822 17,089,410

Basic net income per share attributable to common stockholders $ 0.50 $ 0.62 $ 0.87 $ 1.22

Diluted:

Net income attributable to common stockholders $ 8,750 $ 10,609 $ 15,160 $ 20,883

Weighted average number of common shares outstanding 17,388,646 17,123,840 17,345,822 17,089,410

Weighted average number of dilutive common share equivalents from options to purchase common stock 487,076 392,098 476,568 467,535

Common shares and common share equivalents 17,875,722 17,515,938 17,822,390 17,556,945

Diluted net income per share $ 0.49 $ 0.61 $ 0.85 $ 1.19

Stock Options [Member]

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]

Total number of stock options excluded from diluted shares computation 51,349

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 27 R22.htm IDEA: XBRL DOCUMENT v3.2.0.727

Basis of Presentation and Significant Accounting Policies - Schedule of Total Accrued Medical Malpractice Reserves and Related Insurance Receivables (Details) - USD ($)
$ in Thousands

Jun. 30, 2015

Dec. 31, 2014

Assets

Insurance receivable for malpractice claims, current portion $ 12,322 $ 12,564

Insurance receivable for malpractice claims, long-term portion 22,999 21,574

Insurance receivable for malpractice claims, total 35,321 34,138

Liabilities

Medical malpractice and self-insurance reserves, current portion 12,889 13,079

Medical malpractice and self-insurance reserves, long-term portion 49,129 47,239

Medical malpractice and self-insurance reserves, total 62,018 60,318

Claims Reserve [Member]

Liabilities

Medical malpractice and self-insurance reserves, current portion 12,322 12,564

Medical malpractice and self-insurance reserves, long-term portion 22,999 21,574

Medical malpractice and self-insurance reserves, total 35,321 34,138

IBNR Reserve [Member]

Liabilities

Medical malpractice and self-insurance reserves, current portion 567 515

Medical malpractice and self-insurance reserves, long-term portion 26,130 25,665

Medical malpractice and self-insurance reserves, total $ 26,697 $ 26,180

X

- References
No definition available.
+ Details

Name: us-gaap_HealthCareOrganizationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount receivable from insurance and similar arrangements for reimbursement and payment of malpractice claims and litigation costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 845

-SubTopic 10

-Section 15

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6813998&loc=d3e30298-108410

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 845

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457341&loc=d3e32102-108422

+ Details

Name: us-gaap_InsuranceReceivableForMalpractice

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The current portion of the amount receivable from insurance and similar arrangements for reimbursement and payment of malpractice claims and litigation costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InsuranceReceivableForMalpracticeCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The noncurrent portion of the receivable from insurance and similar arrangements for reimbursement and payment of malpractice claims and litigation costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InsuranceReceivableForMalpracticeNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability) at the end of the accounting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

+ Details

Name: us-gaap_MalpracticeLossContingencyAccrualUndiscounted

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_MalpracticeLossContingencyAccrualUndiscountedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the current portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

+ Details

Name: us-gaap_MalpracticeLossContingencyAccrualUndiscountedCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of the noncurrent portion of the accrued liability on an undiscounted basis for malpractice claims (including general and professional liability).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

+ Details

Name: us-gaap_MalpracticeLossContingencyAccrualUndiscountedNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis=ipcm_ClaimsIncurredandReportedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis=ipcm_ClaimsIncurredButNotReportedIBNRMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 28 R36.htm IDEA: XBRL DOCUMENT v3.2.0.727

Commitments and Contingencies (Details)
6 Months Ended

Jun. 30, 2015

defendant

Commitments and Contingencies Disclosure [Abstract]

Number of defendants 29

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of defendants named in a legal action.
+ References
No definition available.
+ Details

Name: us-gaap_LossContingencyNumberOfDefendants

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

XML 29 R24.htm IDEA: XBRL DOCUMENT v3.2.0.727

Business Acquisitions - Schedule of Acquisition of Hospitalist Practices (Details) - USD ($)
$ in Thousands
6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Acquired assets, net of assumed liabilities – paid and accrued:

Goodwill - current year transactions $ 49,789

Other intangible assets 630

Fixed assets 7

Total acquired assets - current year 50,426

Goodwill - adjustment for prior year transactions (283)

Total acquired assets, net of assumed liabilities 50,143

Cash paid for acquisitions:

Current year transactions (41,125)

Contingent consideration (4,706)

Total cash paid for acquisitions (45,831)

Change in accrued contingent consideration 4,884 $ (3,304)

Net change in payable for practice acquisitions 9,196

Payable for practice acquisitions, beginning of period 44,911

Payable for practice acquisitions, end of period $ 54,107

X

- Definition
Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Change In Liability For Current Year Acquisitions
+ References
No definition available.
+ Details

Name: ipcm_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationChangeInLiabilityForCurrentYearAcquisitions

Namespace Prefix: ipcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of liability recognized arising from contingent consideration in a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 35

-Paragraph 1

-Subparagraph b

-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 25

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name: us-gaap_BusinessCombinationContingentConsiderationLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of assets acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of intangible assets, excluding goodwill, acquired at the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 55

-Paragraph 37

-URI http://asc.fasb.org/extlink&oid=35744172&loc=d3e2207-128464

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of property, plant, and equipment recognized as of the acquisition date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 55

-Paragraph 37

-URI http://asc.fasb.org/extlink&oid=35744172&loc=d3e2207-128464

+ Details

Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

+ Details

Name: us-gaap_GoodwillAcquiredDuringPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 25

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=34752592&loc=d3e961-128460

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

+ Details

Name: us-gaap_GoodwillPurchaseAccountingAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 31 R7.htm IDEA: XBRL DOCUMENT v3.2.0.727

Business Acquisitions
6 Months Ended

Jun. 30, 2015

Business Combinations [Abstract]

Business Acquisitions
Business Acquisitions
For practice acquisitions, we recognize all of the assets acquired, liabilities assumed and any contingent consideration at the acquisition-date fair value and expense all transaction related costs.
During the six months ended June 30, 2015, we completed the acquisition of thirteen hospitalist physician practices. In connection with these acquisitions, we recorded goodwill and other identifiable intangible assets consisting of physician and hospital agreements.
Goodwill represents the potential business synergy from the combined operations of our existing and acquired practices through an expanded national network of providers, improved managed care contracting, improved collections, identification of growth initiatives and cost savings based upon the significant infrastructure we have developed. Amounts recorded as goodwill and identifiable intangible assets with indefinite lives are not amortizable for GAAP financial reporting purposes but are amortized for tax purposes over 15 years.
In addition to the initial consideration paid at the close of each transaction, the asset purchase agreements for ten out of the thirteen acquisitions completed during the six months ended June 30, 2015 provide for contingent consideration to be paid, which is generally based upon the achievement of certain operating results of the acquired practices as of certain measurement dates. These additional payments are not contingent upon the future employment of the sellers. The contingent consideration for four acquisitions completed during the three months ended June 30, 2015 was recorded on a provisional basis pending completion of the valuation studies as of the acquisition dates.
We estimate the fair value of contingent consideration to be paid based on discounted projected earnings of the acquired practices as of certain measurement dates. The discount rate that we use consists of a risk-free U.S. Treasury bond yield plus a Company specific credit spread which we believe is acceptable by willing market participants.
The following table summarizes the total amounts recorded during the six months ended June 30, 2015 related to the acquisition of hospitalist practices (in thousands):
Acquired assets, net of assumed liabilities – paid and accrued:

Goodwill - current year transactions
$
49,789

Other intangible assets
630

Fixed assets
7

Total acquired assets - current year
50,426

Goodwill - adjustment for prior year transactions
(283
)

50,143

Cash paid for acquisitions:

Current year transactions
(41,125
)
Contingent consideration
(4,706
)
Total cash paid for acquisitions
(45,831
)

Change in accrued contingent consideration
4,884

Net change in payable for practice acquisitions
9,196

Payable for practice acquisitions, beginning of period
44,911

Payable for practice acquisitions, end of period
$
54,107

X

- Definition
The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=39739317&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

Name: us-gaap_BusinessCombinationDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R3.htm IDEA: XBRL DOCUMENT v3.2.0.727

Consolidated Balance Sheets (Parenthetical) - $ / shares

Jun. 30, 2015

Dec. 31, 2014

Statement of Financial Position [Abstract]

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares authorized 15,000,000 15,000,000

Preferred stock, shares issued 0 0

Common stock, par value $ 0.001 $ 0.001

Common stock, shares authorized 50,000,000 50,000,000

Common stock, shares issued 17,414,907 17,242,209

Common stock, shares outstanding 17,414,907 17,242,209

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 33 R17.htm IDEA: XBRL DOCUMENT v3.2.0.727

Fair Value Measurement (Tables)
6 Months Ended

Jun. 30, 2015

Fair Value Disclosures [Abstract]

Liabilities measured at fair value on a recurring basis
The following table presents our liabilities measured at fair value on a recurring basis as of June 30, 2015 (in thousands):

Quoted Price In
Active Markets for
Identical Instruments
(Level 1)

Significant Other
Observable
Inputs
(Level 2)

Significant
Unobservable
Inputs
(Level 3)

Total Balance
Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)
$
—

$
—

$
54,107

$
54,107

Rollforward for liabilities measured at fair value on a recurring basis using significant unobservable inputs
The following table presents a rollforward of our liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the three and six months ended June 30, 2015 (in thousands):

Three Months Ended
June 30, 2015

Six Months Ended
June 30, 2015
Accrued contingent consideration for practice acquisitions

Beginning balance
$
56,308

$
44,911

Addition through acquisition transactions
1,262

9,301

Adjustment for prior year transactions
—

(283
)
Change in accrued contingent consideration
505

4,884

Payments
(3,968
)

(4,706
)
Ending balance
$
54,107

$
54,107

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R1.htm IDEA: XBRL DOCUMENT v3.2.0.727

Document and Entity Information - shares
6 Months Ended

Jun. 30, 2015

Jul. 23, 2015

Document And Entity Information [Abstract]

Entity Registrant Name IPC Healthcare, Inc.

Entity Central Index Key 0001410471

Current Fiscal Year End Date --12-31

Entity Filer Category Large Accelerated Filer

Document Type 10-Q

Document Period End Date Jun. 30, 2015

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q2

Amendment Flag false

Entity Common Stock, Shares Outstanding 17,415,207

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Document And Entity Information [Abstract]
+ References
No definition available.
+ Details

Name: ipcm_DocumentAndEntityInformationAbstract

Namespace Prefix: ipcm_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R18.htm IDEA: XBRL DOCUMENT v3.2.0.727

Income Taxes (Tables)
6 Months Ended

Jun. 30, 2015

Income Tax Disclosure [Abstract]

Schedule of income tax provisions and effective tax rates
The following table sets forth our income tax provisions and effective tax rates for the three and six months ended June 30, 2015 and 2014 (dollars in thousands):

Three Months Ended June 30,

Six Months Ended June 30,

2015

2014

2015

2014
Income tax provision
$
5,364

$
6,586

$
9,291

$
12,963

Effective tax rate
38.0
%

38.3
%

38.0
%

38.3
%

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32687-109319

+ Details

Name: us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R4.htm IDEA: XBRL DOCUMENT v3.2.0.727

Consolidated Statements of Income - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Jun. 30, 2015

Jun. 30, 2014

Income Statement [Abstract]

Net revenue $ 184,026 $ 172,268 $ 364,797 $ 344,994

Operating expenses:

Cost of services—physician practice salaries, benefits and other 135,677 125,687 269,844 252,960

General and administrative 31,317 28,334 61,109 55,941

Net change in fair value of contingent consideration 1,174 (695) 5,858 (1,078)

Depreciation and amortization 1,461 1,366 2,976 2,631

Total operating expenses 169,629 154,692 339,787 310,454

Income from operations 14,397 17,576 25,010 34,540

Investment income 0 1 1 2

Interest expense (283) (382) (560) (696)

Income before income taxes 14,114 17,195 24,451 33,846

Income tax provision 5,364 6,586 9,291 12,963

Net income $ 8,750 $ 10,609 $ 15,160 $ 20,883

Net income per share:

Basic $ 0.50 $ 0.62 $ 0.87 $ 1.22

Diluted $ 0.49 $ 0.61 $ 0.85 $ 1.19

X

- Definition
Business Combination Contingent Consideration Arrangements Change in Amount of Contingent Consideration Liability Amount Recognized
+ References
No definition available.
+ Details

Name: ipcm_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityAmountRecognized

Namespace Prefix: ipcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total costs related to services rendered by an entity during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

+ Details

Name: us-gaap_CostOfServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(1)(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(a),(b))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueServicesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 37 R12.htm IDEA: XBRL DOCUMENT v3.2.0.727

Earnings Per Share
6 Months Ended

Jun. 30, 2015

Earnings Per Share [Abstract]

Earnings Per Share
Earnings Per Share
Basic net income per share is calculated by dividing net income for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing net income for the period by the weighted average number of shares outstanding during the period plus the dilutive effect of our outstanding stock awards and shares issuable under our employee stock purchase plan using the treasury stock method.
The calculations of basic and diluted net income per share for the three and six months ended June 30, 2015 and 2014 are as follows (dollars in thousands, except for per share data):

Three Months Ended
June 30,

Six Months Ended
June 30,

2015

2014

2015

2014
Basic:

Net income attributable to common stockholders
$
8,750

$
10,609

$
15,160

$
20,883

Weighted average number of common shares outstanding
17,388,646

17,123,840

17,345,822

17,089,410

Basic net income per share attributable to common stockholders
$
0.50

$
0.62

$
0.87

$
1.22

Diluted:

Net income attributable to common stockholders
$
8,750

$
10,609

$
15,160

$
20,883

Weighted average number of common shares outstanding
17,388,646

17,123,840

17,345,822

17,089,410

Weighted average number of dilutive common share equivalents from options to purchase common stock
487,076

392,098

476,568

467,535

Common shares and common share equivalents
17,875,722

17,515,938

17,822,390

17,556,945

Diluted net income per share
$
0.49

$
0.61

$
0.85

$
1.19

Outstanding stock options and performance stock units that have an above-market exercise price or that are anti-dilutive under the treasury stock method, are excluded from our diluted computation. As of June 30, 2015, the total number of excluded stock options and performance stock units was 51,349.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R11.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock-Based Compensation
6 Months Ended

Jun. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation
Stock-Based Compensation
At June 30, 2015, we had a stock-based employee compensation program, for which we had reserved a total of 4,943,170 common shares for issuance. Under our 2012 Equity Participation Plan (Equity Plan), which was approved by our stockholders on June 7, 2012, a total of 1,422,130 shares of our common stock were available for issuance and no new awards will be issued under any previous equity participation plans. As of June 30, 2015, there were 529,851 shares of our common stock available for future grants under our Equity Plan, which included the canceled and forfeited shares issued under previous equity participation plans.
All option awards previously granted were issued with exercise prices equal to the closing price of our common stock on the NASDAQ Global Select Market on the dates of the grant. The options under the Equity Plan generally vest over a four-year period from date of grant, and options terminate on the 10th anniversary of the agreement date for all grants issued before January 1, 2013 and on the 7th anniversary of the agreement date for all grants issued after December 31, 2012. Restricted stock awards generally vest over a four-year period from date of the award. Performance stock units granted prior to 2015 generally vest over two to three years from date of the award based on the expected level of achievement of certain operational goals that will be obtained and adjusted as appropriate to reflect actual shares issued. Performance stock units granted in 2015 generally vest over three to four years from date of the award based on the expected level of achievement of certain market conditions that will be obtained and adjusted as appropriate to reflect actual shares issued.
Stock-based compensation expense is recognized over the period when the options, restricted stock awards, performance stock awards and our employee stock purchase plan shares vest, which is included in total general and administrative expenses as follows (in thousands):

Three Months Ended June 30,

Six Months Ended June 30,

2015

2014

2015

2014
Total stock-based compensation expense
$
1,784

$
2,059

$
3,688

$
4,024

Tax benefit from stock-based compensation expense
(678
)

(789
)

(1,401
)

(1,541
)
Total stock-based compensation expense, net of tax
$
1,106

$
1,270

$
2,287

$
2,483

As of June 30, 2015, total unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under our Equity Plan and previous equity participation plans and the weighted-average period of years expected to recognize those costs are as follows (dollars in thousands):

Total Unrecognized
Compensation
Cost

Weighted -average
Remaining Recognition
Period

(Years)
Stock option
$
903

1.47
Restricted/Performance stock
$
11,916

2.47

The grant date fair value of each restricted stock award or performance stock units with operational goals is based on the closing stock price on the grant date of the award as reported by NASDAQ Global Select Market. The grant date fair value of performance stock units with market conditions is determined using a Monte-Carlo simulation model. Key assumptions in the Monte-Carlo simulation model are the risk-free interest rate, expected volatility and correlation coefficient.
The following table summarizes the stock option activities in our Equity Plan during the six months ended June 30, 2015:

Shares

Weighted-
Average
Exercise
Price

Weighted-
Average
Remaining
Contractual
Term

Aggregate
Intrinsic
Value

Weighted-
Average
Fair
Value

(Years)

(in 000s)

Options outstanding as of December 31, 2014
1,234,530

$
31.10

$
12.75

Changes during period:

Exercised
(46,980
)

33.07

13.90

Canceled
(2,574
)

34.61

14.14

Options outstanding as of June 30, 2015
1,184,976

$
31.01

4.69

$
28,946

$
12.70

Options exercisable as of June 30, 2015
1,120,916

$
30.40

4.61

$
28,068

$
12.55

The following table summarizes the restricted stock award and performance stock award activities in our Equity Plan during the six months ended June 30, 2015:

Shares

Weighted-
Average
Remaining
Contractual
Term

Aggregate
Intrinsic
Value

Weighted-
Average
Fair
Value

(Years)

(in 000s)

Restricted/performance stock awards outstanding as of December 31, 2014
265,219

$
45.69

Changes during period:

Granted
198,893

44.43

Vested
(105,444
)

41.89

Forfeited
(4,959
)

46.10

Restricted/performance stock awards outstanding as of June 30, 2015
353,709

1.80

$
19,225

$
46.11

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R23.htm IDEA: XBRL DOCUMENT v3.2.0.727

Business Acquisitions - Additional Information (Details) - Jun. 30, 2015 - Hospitalist

Total

Total

Business Acquisition, Contingent Consideration [Line Items]

Number of hospitalist physician practices acquired 4 13

Period in which identifiable intangible assets amortized for tax purposes, years 15 years

Achievement of certain operating results [Member]

Business Acquisition, Contingent Consideration [Line Items]

Number of hospitalist physician practices acquired 10

X

- Definition
Finite Lived Intangible Assets, Useful Life, Tax Basis
+ References
No definition available.
+ Details

Name: ipcm_FiniteLivedIntangibleAssetsUsefulLifeTaxBasis

Namespace Prefix: ipcm_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionContingentConsiderationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of businesses acquired by the entity during the period.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfBusinessesAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ContingentConsiderationByTypeAxis=ipcm_AchievementOfCertainOperatingResultsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R19.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock-Based Compensation (Tables)
6 Months Ended

Jun. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of stock-based compensation expense recognized over the period
Stock-based compensation expense is recognized over the period when the options, restricted stock awards, performance stock awards and our employee stock purchase plan shares vest, which is included in total general and administrative expenses as follows (in thousands):

Three Months Ended June 30,

Six Months Ended June 30,

2015

2014

2015

2014
Total stock-based compensation expense
$
1,784

$
2,059

$
3,688

$
4,024

Tax benefit from stock-based compensation expense
(678
)

(789
)

(1,401
)

(1,541
)
Total stock-based compensation expense, net of tax
$
1,106

$
1,270

$
2,287

$
2,483

Schedule of unrecognized compensation costs related to non-vested stock-based compensation arrangements and weighted-average period of years expected to recognize those costs
As of June 30, 2015, total unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under our Equity Plan and previous equity participation plans and the weighted-average period of years expected to recognize those costs are as follows (dollars in thousands):

Total Unrecognized
Compensation
Cost

Weighted -average
Remaining Recognition
Period

(Years)
Stock option
$
903

1.47
Restricted/Performance stock
$
11,916

2.47

Summary of stock option activities
The following table summarizes the stock option activities in our Equity Plan during the six months ended June 30, 2015:

Shares

Weighted-
Average
Exercise
Price

Weighted-
Average
Remaining
Contractual
Term

Aggregate
Intrinsic
Value

Weighted-
Average
Fair
Value

(Years)

(in 000s)

Options outstanding as of December 31, 2014
1,234,530

$
31.10

$
12.75

Changes during period:

Exercised
(46,980
)

33.07

13.90

Canceled
(2,574
)

34.61

14.14

Options outstanding as of June 30, 2015
1,184,976

$
31.01

4.69

$
28,946

$
12.70

Options exercisable as of June 30, 2015
1,120,916

$
30.40

4.61

$
28,068

$
12.55

Summary of restricted stock award and performance stock award activities
The following table summarizes the restricted stock award and performance stock award activities in our Equity Plan during the six months ended June 30, 2015:

Shares

Weighted-
Average
Remaining
Contractual
Term

Aggregate
Intrinsic
Value

Weighted-
Average
Fair
Value

(Years)

(in 000s)

Restricted/performance stock awards outstanding as of December 31, 2014
265,219

$
45.69

Changes during period:

Granted
198,893

44.43

Vested
(105,444
)

41.89

Forfeited
(4,959
)

46.10

Restricted/performance stock awards outstanding as of June 30, 2015
353,709

1.80

$
19,225

$
46.11

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the changes in outstanding nonvested shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the total compensation cost related to nonvested awards not yet recognized and the weighted-average period over which it is expected to be recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R15.htm IDEA: XBRL DOCUMENT v3.2.0.727

Basis of Presentation and Significant Accounting Policies (Tables)
6 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Schedule of changes in carrying amount of goodwill
The changes in the carrying amount of goodwill for the six months ended June 30, 2015 are as follows (in thousands):
Goodwill - beginning balance at January 1, 2015
$
408,988

Goodwill acquired during 2015
49,789

Adjustment for prior year transactions
(283
)
Goodwill - ending balance at June 30, 2015
$
458,494

Schedule of total accrued medical malpractice reserves and related insurance receivables
Total accrued medical malpractice reserves and related insurance receivables were as follows (in thousands):

June 30, 2015

December 31, 2014

Assets

Liabilities

Assets

Liabilities

Insurance
Receivable

Claims
Reserve

IBNR
Reserve

Total
Liabilities

Insurance
Receivable

Claims
Reserve

IBNR
Reserve

Total
Liabilities
Current Portion
$
12,322

$
12,322

$
567

$
12,889

$
12,564

$
12,564

$
515

$
13,079

Long-term Portion
22,999

22,999

26,130

49,129

21,574

21,574

25,665

47,239

Total
$
35,321

$
35,321

$
26,697

$
62,018

$
34,138

$
34,138

$
26,180

$
60,318

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13854-109267

+ Details

Name: us-gaap_ScheduleOfGoodwillTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of insurance coverage used by the entity to manage the financial risk of malpractice claims (including general and professional liability). Disclosure may include a discussion of the entity's risk management policies, a description of the insurance arrangements (including type, coverage, coverage limits, and deductible), description of the insurer, and whether the entity is self insured or retains significant self-insurance risk.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 450

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 720

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28247444&loc=d3e9100-115647

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 720

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28247444&loc=d3e9113-115647

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 720

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28247444&loc=d3e9127-115647

+ Details

Name: us-gaap_ScheduleOfMalpracticeInsuranceTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R13.htm IDEA: XBRL DOCUMENT v3.2.0.727

Commitments and Contingencies
6 Months Ended

Jun. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
Commitments and Contingencies
Legal
In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated clinicians. We may also become subject to other lawsuits, which could involve significant claims and/or significant defense costs.
We believe, based upon our review of pending actions and proceedings that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, consolidated financial position, results of operations, or cash flows. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, consolidated financial position, results of operations, or cash flows in a future period.
Government Claim
On June 7, 2010, we received a civil investigative demand (CID) issued by the Department of Justice (DOJ), U.S. Attorney’s Office for the Northern District of Illinois. The CID requested information concerning claims that we have submitted to Medicare and Medicaid. The CID covered the period from January 1, 2003, through June 4, 2010, and requested production of a range of documents relating to our Medicare and Medicaid participation, physician arrangements, operations, billings and compliance programs. We believe we have a strong compliance focus, and that we operate with appropriate billing policies, procedures, provider training, and compliance programs and controls. We produced responsive documents and were in contact with representatives of the DOJ who informed us that the inquiry related to a qui tam whistleblower action filed under court seal in the U.S. District Court for the Northern District of Illinois (Chicago). We also were informed that several state attorneys general were examining our Medicaid claims in coordination with the DOJ.
Though we cooperated with the government’s investigation and would welcome a resolution to this matter, we are now in active litigation with the federal government regarding this matter and intend to contest the case vigorously. On December 6, 2013, the U.S. District Court partially lifted the seal on the civil False Claims Act case related to this investigation. The unsealed portions of the Court docket at that time included the whistleblower’s Complaint, which contains allegations of improper billing to Medicare and Medicaid, a Notice of Election to Intervene filed by the federal government and a Notice of Election to Decline Intervention filed by the State of Illinois and 12 other states that participated in the investigation. On June 16, 2014, the federal government filed its Complaint in Intervention against IPC and several of its subsidiaries in the U.S. District Court. The Complaint in Intervention contains allegations of improper billing to Medicare, Medicaid and other federal healthcare programs from January 1, 2003 to the present, seeks to recover treble damages and civil penalties under the civil False Claims Act, and seeks to recover damages under the common law theories of payment by mistake and unjust enrichment. On August 13, 2014, IPC and the IPC subsidiary defendants filed a joint motion to dismiss the Complaint in Intervention or, in the alternative, to sever claims against the defendants. The federal government filed its response on September 18, 2014, to which the defendants replied on September 25, 2014. The court’s decision, which was filed on February 17, 2015, granted the motion to dismiss in part and denied it in part. The Court’s Opinion and Order dismissed the 29 IPC subsidiary and affiliate defendants without prejudice, but the Court denied the request to dismiss IPC, which remains the sole defendant in the lawsuit. The parties are engaged in active discovery.
It is not possible to predict when this matter may be resolved, the time or resources that we will need to devote to this litigation, or what impact, if any, the outcome of this matter might have on our business, consolidated financial position, results of operations, or cash flows.
Derivative Lawsuit
Although the underlying government lawsuit is still in an early stage and no liability has been found by a court, on October 20 and 24, 2014, shareholder derivative lawsuits were filed in the Court of Chancery of the State of Delaware against certain of our current and former directors and officers. We are named as a nominal defendant in both suits. The actions both assert alleged breaches of fiduciary duties related to our billing practices, and incorporate allegations from the False Claims Act case. The lawsuits seek a variety of relief, including monetary damages and injunctive relief. On December 4, 2014, the derivative lawsuits were consolidated into one lawsuit. On April 15, 2015, we filed a motion to stay the consolidated derivative lawsuit, pending the resolution of the False Claims Act case. That motion remains pending. The litigation is in an early stage and it is not possible to predict when this matter may be resolved, the time or resources that we will need to devote to this litigation, or what impact, if any, the outcome of this matter might have on our business, consolidated financial position, results of operations, or cash flows.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R14.htm IDEA: XBRL DOCUMENT v3.2.0.727

Basis of Presentation and Significant Accounting Policies (Policies)
6 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Basis of Presentation
Basis of Presentation
IPC Healthcare, Inc. and its wholly-owned subsidiaries (the “Company,” “IPC,” “we,” “us,” and “our”) is a national physician group practice company that operates and manages full-time acute hospitalist and post-acute physician practices. We prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) on the same basis as our audited annual financial statements. The consolidated financial statements include all accounts of IPC Healthcare, Inc. and its wholly owned subsidiaries and consolidated professional medical corporations (Professional Medical Corporations) managed under long-term management agreements.
Through the management agreements and our relationship with the stockholders of the Professional Medical Corporations, we have exclusive authority over all non-medical decision making related to the ongoing business operations of the Professional Medical Corporations. Further, our rights under the management agreements are unilaterally salable or transferable. Based on the provisions of the agreements, we have determined that the Professional Medical Corporations are variable interest entities (VIE’s), and that we are the primary beneficiary because we have control over the operations of these VIE’s, provide full financial and management support to them, and take all residual benefits and bear all residual losses from their operations. Consequently, we consolidate the revenue and expenses of the Professional Medical Corporations from the date of execution of the agreements. All intercompany balances and transactions have been eliminated in consolidation.
In our opinion, these consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial information set forth therein. Certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to GAAP and SEC rules and regulations, which are applicable to interim financial statements. As a result, the following disclosures should be read in conjunction with our audited consolidated financial statements and notes thereto as of December 31, 2014 included in our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on February 23, 2015.

Revenue
Revenue
Net revenue consists of fees for medical services provided by our affiliated hospitalists under fee-for-service, case rate and other professional fee arrangements with various payors including Medicare, Medicaid, managed care organizations, insurance companies and hospitals. Net revenue is reported in the period in which services are provided at amounts expected to be collected, which excludes contractual discounts and an estimate of uncollectible accounts.

Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions of the fair value of certain reported amounts of assets, liabilities, revenues and expenses at the date and for the periods that the financial statements are prepared. Significant estimates include the estimated net realizable value of accounts receivable, medical malpractice insurance receivable and payable for known claims, liabilities for claims incurred but not reported (IBNR) related to medical malpractice, fair value of contingent consideration related to business combinations and the analysis of goodwill for impairment. The process of estimating these assets and liabilities involves judgment, which is subject to an inherent degree of uncertainty. Actual results could differ from those estimates. The results of operations for the current interim period are not necessarily indicative of the results for the entire year ending December 31, 2015.

Fair Value of Financial Instruments
Fair Value of Financial Instruments
Our consolidated balance sheets as of June 30, 2015 and December 31, 2014 included the following financial instruments: cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, payable for practice acquisitions and long-term debt. We consider the carrying amounts of cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amount of our long-term debt borrowed from our line of credit approximated its fair value at June 30, 2015 and December 31, 2014. Pursuant to GAAP, we determine the fair value of our long-term borrowing using observable inputs, which are defined as Level 2 inputs under GAAP on fair value measures. See Note 3 for the definition of Level 2 inputs under GAAP.
Our payable for practice acquisitions consisted of accrued contingent consideration for practice acquisitions. The accrued contingent consideration is carried at fair value largely determined using the income approach with unobservable inputs defined as Level 3 inputs under GAAP. See Note 3 for the definition of Level 3 inputs under GAAP and more information.

Medical Malpractice Liability Insurance
Medical Malpractice Liability Insurance
We record our medical malpractice reserves, on an undiscounted basis, for claims incurred and reported and claims incurred but not reported (IBNR) during the policy period, based on actuarial loss projections using historical loss patterns. For claims incurred and reported, an insurance receivable from our carrier has been recorded pursuant to GAAP.

New Accounting Principles
New Accounting Principles
In May 2014, the Financial Accounting Standards Board issued a GAAP update "Revenue from Contracts with Customers". This GAAP update requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. This GAAP update also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The GAAP update is effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2016, which is extended to December 15, 2017. We are currently evaluating the impact of the GAAP update on our consolidated financial position, results of operations and cash flows.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13279-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 60

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of the accounting policy for malpractice loss contingencies accrual (general and professional liability) which may include the method for calculating incurred but not reported (IBNR) claims, the use of actuarial and individual case-based assumptions, whether the accrual has been discounted, the types of costs included in the accrual (for example, legal costs) and other significant estimates used to determine the accrued liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 450

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 450

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

+ Details

Name: us-gaap_MalpracticeLossContingencyPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R16.htm IDEA: XBRL DOCUMENT v3.2.0.727

Business Acquisitions (Tables)
6 Months Ended

Jun. 30, 2015

Business Combinations [Abstract]

Schedule of acquisition of hospitalist practices
The following table summarizes the total amounts recorded during the six months ended June 30, 2015 related to the acquisition of hospitalist practices (in thousands):
Acquired assets, net of assumed liabilities – paid and accrued:

Goodwill - current year transactions
$
49,789

Other intangible assets
630

Fixed assets
7

Total acquired assets - current year
50,426

Goodwill - adjustment for prior year transactions
(283
)

50,143

Cash paid for acquisitions:

Current year transactions
(41,125
)
Contingent consideration
(4,706
)
Total cash paid for acquisitions
(45,831
)

Change in accrued contingent consideration
4,884

Net change in payable for practice acquisitions
9,196

Payable for practice acquisitions, beginning of period
44,911

Payable for practice acquisitions, end of period
$
54,107

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

+ Details

Name: us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R34.htm IDEA: XBRL DOCUMENT v3.2.0.727

Stock-Based Compensation - Summary of Restricted Stock Award and Performance Stock Award Activities in Equity Plan (Details) - Jun. 30, 2015 - Restricted Stock And Performance Shares [Member] - USD ($)
$ / shares in Units, $ in Thousands

Total

Shares

Shares, Restricted/performance stock awards outstanding as of beginning of period 265,219

Shares, Granted 198,893

Shares, Vested (105,444)

Shares, Forfeited (4,959)

Shares, Restricted/performance stock awards outstanding as of end of period 353,709

Weighted- Average Remaining Contractual Term

Weighted-Average Remaining Contractual Term, Restricted/performance stock awards outstanding as of end of period 1 year 9 months 20 days

Aggregate Intrinsic Value

Aggregate Intrinsic Value, Restricted/performance stock awards outstanding as of end of period $ 19,225

Weighted- Average Fair Value

Weighted-Average Fair Value, Restricted/performance stock awards outstanding as of beginning of period $ 45.69

Weighted-Average Fair Value, Granted 44.43

Weighted-Average Fair Value, Vested 41.89

Weighted-Average Fair Value, Forfeited 46.10

Weighted-Average Fair Value, Restricted/performance stock awards outstanding as of end of period $ 46.11

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AwardTypeAxis=ipcm_RestrictedStockAndPerformanceSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R21.htm IDEA: XBRL DOCUMENT v3.2.0.727

Basis of Presentation and Significant Accounting Policies - Schedule of Changes in Carrying Amount of Goodwill (Details)
$ in Thousands
6 Months Ended

Jun. 30, 2015

USD ($)

Goodwill [Roll Forward]

Goodwill - beginning balance $ 408,988

Goodwill acquired during 2015 49,789

Adjustment for prior year transactions (283)

Goodwill - ending balance $ 458,494

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

+ Details

Name: us-gaap_GoodwillAcquiredDuringPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_GoodwillRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267

+ Details

Name: us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 47 R26.htm IDEA: XBRL DOCUMENT v3.2.0.727

Fair Value Measurement - Rollforward for Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Details) - Jun. 30, 2015 - USD ($)
$ in Thousands

Total

Total

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]

Payments $ (4,706)

Business Combination Accrued Contingent Consideration [Member]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]

Beginning balance $ 56,308 44,911

Addition through acquisition transactions 1,262 9,301

Adjustment for prior year transactions 0 (283)

Change in accrued contingent consideration 505 4,884

Payments (3,968) (4,706)

Ending balance $ 54,107 $ 54,107

X

- Definition
Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Change In Contingent Consideration
+ References
No definition available.
+ Details

Name: ipcm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangeInContingentConsideration

Namespace Prefix: ipcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Changes In Initial Accounting Estimates
+ References
No definition available.
+ Details

Name: ipcm_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityChangesInInitialAccountingEstimates

Namespace Prefix: ipcm_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByLiabilityClassAxis=ipcm_BusinessCombinationAccruedContingentConsiderationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 48 R5.htm IDEA: XBRL DOCUMENT v3.2.0.727

Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
6 Months Ended

Jun. 30, 2015

Jun. 30, 2014

Operating activities

Net income $ 15,160 $ 20,883

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization 2,976 2,631

Stock-based compensation expense 3,688 4,024

Changes in assets and liabilities:

Accounts receivable 393 (9,710)

Prepaid expenses and other current assets 6,755 7,452

Accounts payable and accrued liabilities 1,667 3,400

Accrued compensation (3,363) (1,199)

Medical malpractice and self-insurance reserves, net 517 1,937

Accrued contingent consideration 4,884 (3,304)

Net cash provided by operating activities 32,677 26,114

Investing activities

Acquisitions of physician practices (45,831) (21,575)

Purchase of property and equipment (2,931) (2,485)

Net cash used in investing activities (48,762) (24,060)

Financing activities

Proceeds from long-term debt 35,000 0

Repayments of long-term debt (25,000) (5,000)

Net proceeds from issuance of common stock 2,526 3,648

Excess tax benefits from stock-based compensation 211 585

Net cash provided by (used in) financing activities 12,737 (767)

Net (decrease) increase in cash and cash equivalents (3,348) 1,287

Cash and cash equivalents, beginning of period 14,913 25,010

Cash and cash equivalents, end of period 11,565 26,297

Supplemental disclosure of cash flow information

Interest 548 693

Income taxes $ 7,809 $ 8,448

X

- Definition
Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration, Change In Liability For Current Year Acquisitions
+ References
No definition available.
+ Details

Name: ipcm_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationChangeInLiabilityForCurrentYearAcquisitions

Namespace Prefix: ipcm_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11374-113907

+ Details

Name: us-gaap_ExcessTaxBenefitFromShareBasedCompensationFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the period in accrued salaries.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedSalaries

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current liabilities, other noncurrent liabilities, or a combination of other current and noncurrent liabilities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period net of cash paid for interest that is capitalized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the additional capital contribution to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 49 R10.htm IDEA: XBRL DOCUMENT v3.2.0.727

Income Taxes
6 Months Ended

Jun. 30, 2015

Income Tax Disclosure [Abstract]

Income Taxes
Income Taxes
The following table sets forth our income tax provisions and effective tax rates for the three and six months ended June 30, 2015 and 2014 (dollars in thousands):

Three Months Ended June 30,

Six Months Ended June 30,

2015

2014

2015

2014
Income tax provision
$
5,364

$
6,586

$
9,291

$
12,963

Effective tax rate
38.0
%

38.3
%

38.0
%

38.3
%

The effective tax rates differ from the statutory U.S. federal income tax rate of 35.0% due primarily to state income taxes.
Our accounting policy is to include interest and penalties related to income tax liabilities in income tax expense. As of June 30, 2015, we did not have any estimated interest and penalties related to uncertain tax positions.
The tax years 2009 to 2013 remain open to examination by the major taxing jurisdictions to which we are subject. The statute of limitations for tax years 1999 to 2008 has expired, except that the tax year 1999 is subject to adjustment of net operating losses by the Internal Revenue Service. We are subject to taxation in the United States and various state jurisdictions. We are currently subject to one state tax examination for the tax year of 2009 and two federal tax examinations for the tax year of 2013. The outcome of the examinations cannot be predicted with certainty; however, we believe that the ultimate resolution will not have a material effect on our consolidated financial position, results of operations, or cash flows.
We make our best estimate of the tax rate expected to be applicable for the full fiscal year. The rate so determined is used to compute our income tax expense for an interim period.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R27.htm IDEA: XBRL DOCUMENT v3.2.0.727

Fair Value Measurement - Additional Information (Details) - Significant Unobservable Inputs (Level 3) [Member]
6 Months Ended

Jun. 30, 2015

Fair Value Inputs, Liabilities, Quantitative Information [Line Items]

Probability of achieving estimated projected earnings 100.00%

Minimum [Member]

Fair Value Inputs, Liabilities, Quantitative Information [Line Items]

Discount rates 1.27%

Probability of achieving certain other objectives 10.00%

Maximum [Member]

Fair Value Inputs, Liabilities, Quantitative Information [Line Items]

Discount rates 1.90%

Probability of achieving certain other objectives 80.00%

X

- Definition
Fair Value Inputs, Projected Probability Of Achieving Estimated Projected Earnings
+ References
No definition available.
+ Details

Name: ipcm_FairValueInputsProjectedProbabilityOfAchievingEstimatedProjectedEarnings

Namespace Prefix: ipcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair Value Inputs, Projected Probability Of Other Achievements
+ References
No definition available.
+ Details

Name: ipcm_FairValueInputsProjectedProbabilityOfOtherAchievements

Namespace Prefix: ipcm_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bbb)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueInputsDiscountRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.2.0.727 html 48 177 1 false 21 0 false 6 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.hospitalist.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Consolidated Balance Sheets Sheet http://www.hospitalist.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.hospitalist.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Consolidated Statements of Income Sheet http://www.hospitalist.com/role/ConsolidatedStatementsOfIncome Consolidated Statements of Income Statements 4 false false R5.htm 1003000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.hospitalist.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 5 false false R6.htm 2101100 - Disclosure - Basis of Presentation and Significant Accounting Policies Sheet http://www.hospitalist.com/role/BasisOfPresentationAndSignificantAccountingPolicies Basis of Presentation and Significant Accounting Policies Notes 6 false false R7.htm 2102100 - Disclosure - Business Acquisitions Sheet http://www.hospitalist.com/role/BusinessAcquisitions Business Acquisitions Notes 7 false false R8.htm 2103100 - Disclosure - Fair Value Measurement Sheet http://www.hospitalist.com/role/FairValueMeasurement Fair Value Measurement Notes 8 false false R9.htm 2104100 - Disclosure - Debt Sheet http://www.hospitalist.com/role/Debt Debt Notes 9 false false R10.htm 2105100 - Disclosure - Income Taxes Sheet http://www.hospitalist.com/role/IncomeTaxes Income Taxes Notes 10 false false R11.htm 2106100 - Disclosure - Stock-Based Compensation Sheet http://www.hospitalist.com/role/StockBasedCompensation Stock-Based Compensation Notes 11 false false R12.htm 2107100 - Disclosure - Earnings Per Share Sheet http://www.hospitalist.com/role/EarningsPerShare Earnings Per Share Notes 12 false false R13.htm 2108100 - Disclosure - Commitments and Contingencies Sheet http://www.hospitalist.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 2201201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://www.hospitalist.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies Basis of Presentation and Significant Accounting Policies (Policies) Policies http://www.hospitalist.com/role/BasisOfPresentationAndSignificantAccountingPolicies 14 false false R15.htm 2301302 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) Sheet http://www.hospitalist.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables Basis of Presentation and Significant Accounting Policies (Tables) Tables http://www.hospitalist.com/role/BasisOfPresentationAndSignificantAccountingPolicies 15 false false R16.htm 2302301 - Disclosure - Business Acquisitions (Tables) Sheet http://www.hospitalist.com/role/BusinessAcquisitionsTables Business Acquisitions (Tables) Tables http://www.hospitalist.com/role/BusinessAcquisitions 16 false false R17.htm 2303301 - Disclosure - Fair Value Measurement (Tables) Sheet http://www.hospitalist.com/role/FairValueMeasurementTables Fair Value Measurement (Tables) Tables http://www.hospitalist.com/role/FairValueMeasurement 17 false false R18.htm 2305301 - Disclosure - Income Taxes (Tables) Sheet http://www.hospitalist.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.hospitalist.com/role/IncomeTaxes 18 false false R19.htm 2306301 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.hospitalist.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.hospitalist.com/role/StockBasedCompensation 19 false false R20.htm 2307301 - Disclosure - Earnings Per Share (Tables) Sheet http://www.hospitalist.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.hospitalist.com/role/EarningsPerShare 20 false false R21.htm 2401403 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Changes in Carrying Amount of Goodwill (Details) Sheet http://www.hospitalist.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfChangesInCarryingAmountOfGoodwillDetails Basis of Presentation and Significant Accounting Policies - Schedule of Changes in Carrying Amount of Goodwill (Details) Details 21 false false R22.htm 2401404 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Total Accrued Medical Malpractice Reserves and Related Insurance Receivables (Details) Sheet http://www.hospitalist.com/role/BasisOfPresentationAndSignificantAccountingPoliciesScheduleOfTotalAccruedMedicalMalpracticeReservesAndRelatedInsuranceReceivablesDetails Basis of Presentation and Significant Accounting Policies - Schedule of Total Accrued Medical Malpractice Reserves and Related Insurance Receivables (Details) Details 22 false false R23.htm 2402402 - Disclosure - Business Acquisitions - Additional Information (Details) Sheet http://www.hospitalist.com/role/BusinessAcquisitionsAdditionalInformationDetails Business Acquisitions - Additional Information (Details) Details 23 false false R24.htm 2402403 - Disclosure - Business Acquisitions - Schedule of Acquisition of Hospitalist Practices (Details) Sheet http://www.hospitalist.com/role/BusinessAcquisitionsScheduleOfAcquisitionOfHospitalistPracticesDetails Business Acquisitions - Schedule of Acquisition of Hospitalist Practices (Details) Details 24 false false R25.htm 2403402 - Disclosure - Fair Value Measurement - Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.hospitalist.com/role/FairValueMeasurementLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurement - Liabilities Measured at Fair Value on Recurring Basis (Details) Details 25 false false R26.htm 2403403 - Disclosure - Fair Value Measurement - Rollforward for Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Details) Sheet http://www.hospitalist.com/role/FairValueMeasurementRollforwardForLiabilitiesMeasuredAtFairValueOnRecurringBasisUsingSignificantUnobservableInputsDetails Fair Value Measurement - Rollforward for Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Details) Details 26 false false R27.htm 2403404 - Disclosure - Fair Value Measurement - Additional Information (Details) Sheet http://www.hospitalist.com/role/FairValueMeasurementAdditionalInformationDetails Fair Value Measurement - Additional Information (Details) Details 27 false false R28.htm 2404401 - Disclosure - Debt (Details) Sheet http://www.hospitalist.com/role/DebtDetails Debt (Details) Details http://www.hospitalist.com/role/Debt 28 false false R29.htm 2405402 - Disclosure - Income Taxes (Details) Sheet http://www.hospitalist.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.hospitalist.com/role/IncomeTaxesTables 29 false false R30.htm 2406402 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.hospitalist.com/role/StockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 30 false false R31.htm 2406403 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized When Options, Restricted Stock Awards, Performance Stock Awards and Employee Stock Purchase Plan Shares Vested (Details) Sheet http://www.hospitalist.com/role/StockBasedCompensationScheduleOfStockBasedCompensationExpenseRecognizedWhenOptionsRestrictedStockAwardsPerformanceStockAwardsAndEmployeeStockPurchasePlanSharesVestedDetails Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized When Options, Restricted Stock Awards, Performance Stock Awards and Employee Stock Purchase Plan Shares Vested (Details) Details 31 false false R32.htm 2406404 - Disclosure - Stock-Based Compensation - Schedule of Unrecognized Compensation Costs Related to Non-Vested Stock-Based Compensation Arrangements Granted under Equity Plan and Weighted-Average Period of Years Expected to Recognize Those Costs (Details) Sheet http://www.hospitalist.com/role/StockBasedCompensationScheduleOfUnrecognizedCompensationCostsRelatedToNonVestedStockBasedCompensationArrangementsGrantedUnderEquityPlanAndWeightedAveragePeriodOfYearsExpectedToRecognizeThoseCostsDetails Stock-Based Compensation - Schedule of Unrecognized Compensation Costs Related to Non-Vested Stock-Based Compensation Arrangements Granted under Equity Plan and Weighted-Average Period of Years Expected to Recognize Those Costs (Details) Details 32 false false R33.htm 2406405 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activities in Equity Plan (Details) Sheet http://www.hospitalist.com/role/StockBasedCompensationSummaryOfStockOptionActivitiesInEquityPlanDetails Stock-Based Compensation - Summary of Stock Option Activities in Equity Plan (Details) Details 33 false false R34.htm 2406406 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Award and Performance Stock Award Activities in Equity Plan (Details) Sheet http://www.hospitalist.com/role/StockBasedCompensationSummaryOfRestrictedStockAwardAndPerformanceStockAwardActivitiesInEquityPlanDetails Stock-Based Compensation - Summary of Restricted Stock Award and Performance Stock Award Activities in Equity Plan (Details) Details 34 false false R35.htm 2407402 - Disclosure - Earnings Per Share (Details) Sheet http://www.hospitalist.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.hospitalist.com/role/EarningsPerShareTables 35 false false R36.htm 2408401 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.hospitalist.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.hospitalist.com/role/CommitmentsAndContingencies 36 false false All Reports Book All Reports In ''Consolidated Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''Consolidated Statements of Cash Flows'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression. ipcm-20150630.xml ipcm-20150630_cal.xml ipcm-20150630_def.xml ipcm-20150630_lab.xml ipcm-20150630_pre.xml ipcm-20150630.xsd true true XML 52 R20.htm IDEA: XBRL DOCUMENT v3.2.0.727

Earnings Per Share (Tables)
6 Months Ended

Jun. 30, 2015

Earnings Per Share [Abstract]

Schedule of basic and diluted net income per share
The calculations of basic and diluted net income per share for the three and six months ended June 30, 2015 and 2014 are as follows (dollars in thousands, except for per share data):

Three Months Ended
June 30,

Six Months Ended
June 30,

2015

2014

2015

2014
Basic:

Net income attributable to common stockholders
$
8,750

$
10,609

$
15,160

$
20,883

Weighted average number of common shares outstanding
17,388,646

17,123,840

17,345,822

17,089,410

Basic net income per share attributable to common stockholders
$
0.50

$
0.62

$
0.87

$
1.22

Diluted:

Net income attributable to common stockholders
$
8,750

$
10,609

$
15,160

$
20,883

Weighted average number of common shares outstanding
17,388,646

17,123,840

17,345,822

17,089,410

Weighted average number of dilutive common share equivalents from options to purchase common stock
487,076

392,098

476,568

467,535

Common shares and common share equivalents
17,875,722

17,515,938

17,822,390

17,556,945

Diluted net income per share
$
0.49

$
0.61

$
0.85

$
1.19

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Stock-Based Compensation - Summary of Stock Option Activities in Equity Plan (Details) - Jun. 30, 2015 - USD ($) $ / shares in Units, $ in Thousands	Total
Shares
Shares, Options outstanding as of beginning of period	1,234,530
Shares, Exercised	(46,980)
Shares, Canceled	(2,574)
Shares, Options outstanding as of end of period	1,184,976
Shares, Options exercisable as of end of period	1,120,916
Weighted- Average Exercise Price
Weighted-Average Exercise Price, Options outstanding as of beginning of period	$ 31.10
Weighted-Average Exercise Price, Exercised	33.07
Weighted-Average Exercise Price, Canceled	34.61
Weighted-Average Exercise Price, Options outstanding as of end of period	31.01
Weighted-Average Exercise Price, Options exercisable as of end of period	$ 30.40
Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value
Weighted-Average Remaining Contractual Term, Options outstanding as of end of period	4 years 8 months 10 days
Weighted-Average Remaining Contractual Term, Options exercisable as of end of period	4 years 7 months 9 days
Aggregate Intrinsic Value, Options outstanding as of end of period	$ 28,946
Aggregate Intrinsic Value, Options exercisable as of end of period	$ 28,068
Weighted- Average Fair Value
Weighted-Average Fair Value, Options outstanding as of beginning of period	$ 12.75
Weighted-Average Fair Value, Exercised	13.90
Weighted-Average Fair Value, Canceled	14.14
Weighted-Average Fair Value, Options outstanding as of end of period	12.70
Weighted-Average Fair Value, Options exercisable as of end of period	$ 12.55

Fair Value Measurement - Liabilities Measured at Fair Value on Recurring Basis (Details) $ in Thousands	Jun. 30, 2015 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)	$ 54,107
Quoted Price In Active Markets for Identical Instruments (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)	0
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)	0
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)	$ 54,107

Debt	6 Months Ended
Debt	Jun. 30, 2015
Debt Disclosure [Abstract]
Debt	Debt Our secured revolving credit agreement (Credit Facility) provides a revolving line of credit of $125.0 million and contains an “accordion” feature that allows an increase of up to $25.0 million to the Credit Facility with lender approval. The Credit Facility has a maturity date of August 4, 2016 and is available for working capital, practice acquisitions, capital expenditures and general business expenses. As of June 30, 2015, we had borrowings of $90.0 million and letters of credit of $0.3 million outstanding, and $34.7 million available under the Credit Facility. The revolving line of credit is limited by a formula based on a certain multiple times the trailing twelve months of earnings before interest, taxes, depreciation, amortization and certain non-cash items. Interest rate options for each borrowing under the Credit Facility, to be selected by us at the time of each borrowing, include either LIBOR plus 0.75% to 1.75%, or the lender’s prime rate plus 0% to 0.75%, both based on a leverage ratio. We pay an unused commitment fee equal to 0.25% per annum on the difference between the revolving line capacity and the average balance outstanding during the year. Outstanding amounts advanced to us under the revolving line of credit are repayable on or before the maturity date. The interest rate for our borrowings under the Credit Facility at June 30, 2015 was 0.9375% per annum. The Credit Facility is guaranteed by our subsidiaries and affiliated Professional Medical Corporations and limited liability companies, and is secured by substantially all of our and our guarantors’ tangible and intangible assets. The Credit Facility includes various customary financial covenants and restrictions, as well as customary remedies for our lenders following an event of default. As of June 30, 2015, we were in compliance with such financial covenants and restrictions.

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Tax Disclosure [Abstract]
Income tax provision	$ 5,364	$ 6,586	$ 9,291	$ 12,963
Effective tax rate	38.00%	38.30%	38.00%	38.30%
Statutory U.S. federal income tax rate	35.00%	35.00%	35.00%	35.00%

Debt (Details) - Jun. 30, 2015 - USD ($)	Total
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Revolving line of credit borrowing capacity	$ 125,000,000.0
Additional borrowing capacity under revolving line of credit facility	25,000,000.0
Amount provided by credit agreement	90,000,000
Remaining amount available under revolving line of credit facility	$ 34,700,000
Percentage of unused commitment fee, per annum	0.25%
Revolving line of credit interest rate, per annum	0.9375%
Revolving Credit Facility [Member] \| LIBOR [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Variable interest rate, percentage in addition to base rate	0.75%
Revolving Credit Facility [Member] \| LIBOR [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Variable interest rate, percentage in addition to base rate	1.75%
Revolving Credit Facility [Member] \| Prime Rate [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Variable interest rate, percentage in addition to base rate	0.00%
Revolving Credit Facility [Member] \| Prime Rate [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Variable interest rate, percentage in addition to base rate	0.75%
Letters of Credit [Member]
Line of Credit Facility [Line Items]
Amount provided by credit agreement	$ 300,000

Stock-Based Compensation - Additional Information (Details) - shares	6 Months Ended
	Jun. 30, 2015	Jun. 07, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares reserved for issuance under stock-based employee compensation program	4,943,170
Common stock available for issuance under Equity Plan	529,851	1,422,130
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, in years	4 years
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, in years	4 years
Performance Stock Awards [Member] \| Granted Prior to 2015 [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, in years	2 years
Performance Stock Awards [Member] \| Granted Prior to 2015 [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, in years	3 years
Performance Stock Awards [Member] \| Granted in 2015 [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, in years	3 years
Performance Stock Awards [Member] \| Granted in 2015 [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period, in years	4 years

Stock-Based Compensation - Schedule of Unrecognized Compensation Costs Related to Non-Vested Stock-Based Compensation Arrangements Granted under Equity Plan and Weighted-Average Period of Years Expected to Recognize Those Costs (Details) - Jun. 30, 2015 - USD ($) $ in Thousands	Total
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Unrecognized Compensation Cost	$ 903
Weighted -average Remaining Recognition Period	1 year 5 months 19 days
Restricted Stock And Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Unrecognized Compensation Cost	$ 11,916
Weighted -average Remaining Recognition Period	2 years 5 months 19 days

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 11,565	$ 14,913
Accounts receivable, net	121,699	122,092
Insurance receivable for malpractice claims, current portion	12,322	12,564
Prepaid expenses and other current assets	14,121	20,876
Total current assets	159,707	170,445
Property and equipment, net	8,960	8,798
Goodwill	458,494	408,988
Other intangible assets, net	4,924	4,957
Insurance receivable for malpractice claims, less current portion	22,999	21,574
Total assets	655,084	614,762
Current liabilities:
Accounts payable and accrued liabilities	7,829	8,388
Accrued compensation	37,544	40,907
Payable for practice acquisitions, current portion	49,611	35,411
Medical malpractice and self-insurance reserves, current portion	12,889	13,079
Deferred tax liabilities, current portion	584	584
Total current liabilities	108,457	98,369
Long-term debt	90,000	80,000
Medical malpractice and self-insurance reserves, less current portion	49,129	47,239
Payable for practice acquisitions, less current portion	4,496	9,500
Deferred tax liabilities, less current portion	13,622	11,737
Total liabilities	265,704	246,845
Stockholders’ equity:
Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued	0	0
Common stock. $0.001 par value, 50,000,000 shares authorized, 17,414,907 and 17,242,209 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively	17	17
Additional paid-in capital	188,144	181,841
Retained earnings	201,219	186,059
Total stockholders’ equity	389,380	367,917
Total liabilities and stockholders’ equity	$ 655,084	$ 614,762

Basis of Presentation and Significant Accounting Policies - Schedule of Total Accrued Medical Malpractice Reserves and Related Insurance Receivables (Details) - USD ($) $ in Thousands	Jun. 30, 2015	Dec. 31, 2014
Assets
Insurance receivable for malpractice claims, current portion	$ 12,322	$ 12,564
Insurance receivable for malpractice claims, long-term portion	22,999	21,574
Insurance receivable for malpractice claims, total	35,321	34,138
Liabilities
Medical malpractice and self-insurance reserves, current portion	12,889	13,079
Medical malpractice and self-insurance reserves, long-term portion	49,129	47,239
Medical malpractice and self-insurance reserves, total	62,018	60,318
Claims Reserve [Member]
Liabilities
Medical malpractice and self-insurance reserves, current portion	12,322	12,564
Medical malpractice and self-insurance reserves, long-term portion	22,999	21,574
Medical malpractice and self-insurance reserves, total	35,321	34,138
IBNR Reserve [Member]
Liabilities
Medical malpractice and self-insurance reserves, current portion	567	515
Medical malpractice and self-insurance reserves, long-term portion	26,130	25,665
Medical malpractice and self-insurance reserves, total	$ 26,697	$ 26,180

Commitments and Contingencies (Details)	6 Months Ended
Commitments and Contingencies (Details)	Jun. 30, 2015 defendant
Commitments and Contingencies Disclosure [Abstract]
Number of defendants	29

Business Acquisitions - Schedule of Acquisition of Hospitalist Practices (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Acquired assets, net of assumed liabilities – paid and accrued:
Goodwill - current year transactions	$ 49,789
Other intangible assets	630
Fixed assets	7
Total acquired assets - current year	50,426
Goodwill - adjustment for prior year transactions	(283)
Total acquired assets, net of assumed liabilities	50,143
Cash paid for acquisitions:
Current year transactions	(41,125)
Contingent consideration	(4,706)
Total cash paid for acquisitions	(45,831)
Change in accrued contingent consideration	4,884	$ (3,304)
Net change in payable for practice acquisitions	9,196
Payable for practice acquisitions, beginning of period	44,911
Payable for practice acquisitions, end of period	$ 54,107

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	15,000,000	15,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	17,414,907	17,242,209
Common stock, shares outstanding	17,414,907	17,242,209

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2015	Jul. 23, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	IPC Healthcare, Inc.
Entity Central Index Key	0001410471
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		17,415,207

Consolidated Statements of Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Consolidated Statements of Income - USD ($) $ in Thousands	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Net revenue	$ 184,026	$ 172,268	$ 364,797	$ 344,994
Operating expenses:
Cost of services—physician practice salaries, benefits and other	135,677	125,687	269,844	252,960
General and administrative	31,317	28,334	61,109	55,941
Net change in fair value of contingent consideration	1,174	(695)	5,858	(1,078)
Depreciation and amortization	1,461	1,366	2,976	2,631
Total operating expenses	169,629	154,692	339,787	310,454
Income from operations	14,397	17,576	25,010	34,540
Investment income	0	1	1	2
Interest expense	(283)	(382)	(560)	(696)
Income before income taxes	14,114	17,195	24,451	33,846
Income tax provision	5,364	6,586	9,291	12,963
Net income	$ 8,750	$ 10,609	$ 15,160	$ 20,883
Net income per share:
Basic	$ 0.50	$ 0.62	$ 0.87	$ 1.22
Diluted	$ 0.49	$ 0.61	$ 0.85	$ 1.19

Business Acquisitions - Additional Information (Details) - Jun. 30, 2015 - Hospitalist	Total	Total
Business Acquisition, Contingent Consideration [Line Items]
Number of hospitalist physician practices acquired	4	13
Period in which identifiable intangible assets amortized for tax purposes, years		15 years
Achievement of certain operating results [Member]
Business Acquisition, Contingent Consideration [Line Items]
Number of hospitalist physician practices acquired		10

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated clinicians. We may also become subject to other lawsuits, which could involve significant claims and/or significant defense costs. We believe, based upon our review of pending actions and proceedings that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, consolidated financial position, results of operations, or cash flows. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, consolidated financial position, results of operations, or cash flows in a future period. Government Claim On June 7, 2010, we received a civil investigative demand (CID) issued by the Department of Justice (DOJ), U.S. Attorney’s Office for the Northern District of Illinois. The CID requested information concerning claims that we have submitted to Medicare and Medicaid. The CID covered the period from January 1, 2003, through June 4, 2010, and requested production of a range of documents relating to our Medicare and Medicaid participation, physician arrangements, operations, billings and compliance programs. We believe we have a strong compliance focus, and that we operate with appropriate billing policies, procedures, provider training, and compliance programs and controls. We produced responsive documents and were in contact with representatives of the DOJ who informed us that the inquiry related to a qui tam whistleblower action filed under court seal in the U.S. District Court for the Northern District of Illinois (Chicago). We also were informed that several state attorneys general were examining our Medicaid claims in coordination with the DOJ. Though we cooperated with the government’s investigation and would welcome a resolution to this matter, we are now in active litigation with the federal government regarding this matter and intend to contest the case vigorously. On December 6, 2013, the U.S. District Court partially lifted the seal on the civil False Claims Act case related to this investigation. The unsealed portions of the Court docket at that time included the whistleblower’s Complaint, which contains allegations of improper billing to Medicare and Medicaid, a Notice of Election to Intervene filed by the federal government and a Notice of Election to Decline Intervention filed by the State of Illinois and 12 other states that participated in the investigation. On June 16, 2014, the federal government filed its Complaint in Intervention against IPC and several of its subsidiaries in the U.S. District Court. The Complaint in Intervention contains allegations of improper billing to Medicare, Medicaid and other federal healthcare programs from January 1, 2003 to the present, seeks to recover treble damages and civil penalties under the civil False Claims Act, and seeks to recover damages under the common law theories of payment by mistake and unjust enrichment. On August 13, 2014, IPC and the IPC subsidiary defendants filed a joint motion to dismiss the Complaint in Intervention or, in the alternative, to sever claims against the defendants. The federal government filed its response on September 18, 2014, to which the defendants replied on September 25, 2014. The court’s decision, which was filed on February 17, 2015, granted the motion to dismiss in part and denied it in part. The Court’s Opinion and Order dismissed the 29 IPC subsidiary and affiliate defendants without prejudice, but the Court denied the request to dismiss IPC, which remains the sole defendant in the lawsuit. The parties are engaged in active discovery. It is not possible to predict when this matter may be resolved, the time or resources that we will need to devote to this litigation, or what impact, if any, the outcome of this matter might have on our business, consolidated financial position, results of operations, or cash flows. Derivative Lawsuit Although the underlying government lawsuit is still in an early stage and no liability has been found by a court, on October 20 and 24, 2014, shareholder derivative lawsuits were filed in the Court of Chancery of the State of Delaware against certain of our current and former directors and officers. We are named as a nominal defendant in both suits. The actions both assert alleged breaches of fiduciary duties related to our billing practices, and incorporate allegations from the False Claims Act case. The lawsuits seek a variety of relief, including monetary damages and injunctive relief. On December 4, 2014, the derivative lawsuits were consolidated into one lawsuit. On April 15, 2015, we filed a motion to stay the consolidated derivative lawsuit, pending the resolution of the False Claims Act case. That motion remains pending. The litigation is in an early stage and it is not possible to predict when this matter may be resolved, the time or resources that we will need to devote to this litigation, or what impact, if any, the outcome of this matter might have on our business, consolidated financial position, results of operations, or cash flows.

Basis of Presentation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation IPC Healthcare, Inc. and its wholly-owned subsidiaries (the “Company,” “IPC,” “we,” “us,” and “our”) is a national physician group practice company that operates and manages full-time acute hospitalist and post-acute physician practices. We prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) on the same basis as our audited annual financial statements. The consolidated financial statements include all accounts of IPC Healthcare, Inc. and its wholly owned subsidiaries and consolidated professional medical corporations (Professional Medical Corporations) managed under long-term management agreements. Through the management agreements and our relationship with the stockholders of the Professional Medical Corporations, we have exclusive authority over all non-medical decision making related to the ongoing business operations of the Professional Medical Corporations. Further, our rights under the management agreements are unilaterally salable or transferable. Based on the provisions of the agreements, we have determined that the Professional Medical Corporations are variable interest entities (VIE’s), and that we are the primary beneficiary because we have control over the operations of these VIE’s, provide full financial and management support to them, and take all residual benefits and bear all residual losses from their operations. Consequently, we consolidate the revenue and expenses of the Professional Medical Corporations from the date of execution of the agreements. All intercompany balances and transactions have been eliminated in consolidation. In our opinion, these consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial information set forth therein. Certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to GAAP and SEC rules and regulations, which are applicable to interim financial statements. As a result, the following disclosures should be read in conjunction with our audited consolidated financial statements and notes thereto as of December 31, 2014 included in our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the SEC on February 23, 2015.
Revenue	Revenue Net revenue consists of fees for medical services provided by our affiliated hospitalists under fee-for-service, case rate and other professional fee arrangements with various payors including Medicare, Medicaid, managed care organizations, insurance companies and hospitals. Net revenue is reported in the period in which services are provided at amounts expected to be collected, which excludes contractual discounts and an estimate of uncollectible accounts.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions of the fair value of certain reported amounts of assets, liabilities, revenues and expenses at the date and for the periods that the financial statements are prepared. Significant estimates include the estimated net realizable value of accounts receivable, medical malpractice insurance receivable and payable for known claims, liabilities for claims incurred but not reported (IBNR) related to medical malpractice, fair value of contingent consideration related to business combinations and the analysis of goodwill for impairment. The process of estimating these assets and liabilities involves judgment, which is subject to an inherent degree of uncertainty. Actual results could differ from those estimates. The results of operations for the current interim period are not necessarily indicative of the results for the entire year ending December 31, 2015.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Our consolidated balance sheets as of June 30, 2015 and December 31, 2014 included the following financial instruments: cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, payable for practice acquisitions and long-term debt. We consider the carrying amounts of cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amount of our long-term debt borrowed from our line of credit approximated its fair value at June 30, 2015 and December 31, 2014. Pursuant to GAAP, we determine the fair value of our long-term borrowing using observable inputs, which are defined as Level 2 inputs under GAAP on fair value measures. See Note 3 for the definition of Level 2 inputs under GAAP. Our payable for practice acquisitions consisted of accrued contingent consideration for practice acquisitions. The accrued contingent consideration is carried at fair value largely determined using the income approach with unobservable inputs defined as Level 3 inputs under GAAP. See Note 3 for the definition of Level 3 inputs under GAAP and more information.
Medical Malpractice Liability Insurance	Medical Malpractice Liability Insurance We record our medical malpractice reserves, on an undiscounted basis, for claims incurred and reported and claims incurred but not reported (IBNR) during the policy period, based on actuarial loss projections using historical loss patterns. For claims incurred and reported, an insurance receivable from our carrier has been recorded pursuant to GAAP.
New Accounting Principles	New Accounting Principles In May 2014, the Financial Accounting Standards Board issued a GAAP update "Revenue from Contracts with Customers". This GAAP update requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. This GAAP update also requires more detailed disclosures to enable users of the financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The GAAP update is effective for fiscal years (and interim reporting periods within fiscal years) beginning after December 15, 2016, which is extended to December 15, 2017. We are currently evaluating the impact of the GAAP update on our consolidated financial position, results of operations and cash flows.

Stock-Based Compensation - Summary of Restricted Stock Award and Performance Stock Award Activities in Equity Plan (Details) - Jun. 30, 2015 - Restricted Stock And Performance Shares [Member] - USD ($) $ / shares in Units, $ in Thousands	Total
Shares
Shares, Restricted/performance stock awards outstanding as of beginning of period	265,219
Shares, Granted	198,893
Shares, Vested	(105,444)
Shares, Forfeited	(4,959)
Shares, Restricted/performance stock awards outstanding as of end of period	353,709
Weighted- Average Remaining Contractual Term
Weighted-Average Remaining Contractual Term, Restricted/performance stock awards outstanding as of end of period	1 year 9 months 20 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value, Restricted/performance stock awards outstanding as of end of period	$ 19,225
Weighted- Average Fair Value
Weighted-Average Fair Value, Restricted/performance stock awards outstanding as of beginning of period	$ 45.69
Weighted-Average Fair Value, Granted	44.43
Weighted-Average Fair Value, Vested	41.89
Weighted-Average Fair Value, Forfeited	46.10
Weighted-Average Fair Value, Restricted/performance stock awards outstanding as of end of period	$ 46.11

Basis of Presentation and Significant Accounting Policies - Schedule of Changes in Carrying Amount of Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2015 USD ($)
Goodwill [Roll Forward]
Goodwill - beginning balance	$ 408,988
Goodwill acquired during 2015	49,789
Adjustment for prior year transactions	(283)
Goodwill - ending balance	$ 458,494

Fair Value Measurement - Rollforward for Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Details) - Jun. 30, 2015 - USD ($) $ in Thousands	Total	Total
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Payments		$ (4,706)
Business Combination Accrued Contingent Consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 56,308	44,911
Addition through acquisition transactions	1,262	9,301
Adjustment for prior year transactions	0	(283)
Change in accrued contingent consideration	505	4,884
Payments	(3,968)	(4,706)
Ending balance	$ 54,107	$ 54,107

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Operating activities
Net income	$ 15,160	$ 20,883
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,976	2,631
Stock-based compensation expense	3,688	4,024
Changes in assets and liabilities:
Accounts receivable	393	(9,710)
Prepaid expenses and other current assets	6,755	7,452
Accounts payable and accrued liabilities	1,667	3,400
Accrued compensation	(3,363)	(1,199)
Medical malpractice and self-insurance reserves, net	517	1,937
Accrued contingent consideration	4,884	(3,304)
Net cash provided by operating activities	32,677	26,114
Investing activities
Acquisitions of physician practices	(45,831)	(21,575)
Purchase of property and equipment	(2,931)	(2,485)
Net cash used in investing activities	(48,762)	(24,060)
Financing activities
Proceeds from long-term debt	35,000	0
Repayments of long-term debt	(25,000)	(5,000)
Net proceeds from issuance of common stock	2,526	3,648
Excess tax benefits from stock-based compensation	211	585
Net cash provided by (used in) financing activities	12,737	(767)
Net (decrease) increase in cash and cash equivalents	(3,348)	1,287
Cash and cash equivalents, beginning of period	14,913	25,010
Cash and cash equivalents, end of period	11,565	26,297
Supplemental disclosure of cash flow information
Interest	548	693
Income taxes	$ 7,809	$ 8,448

Fair Value Measurement - Additional Information (Details) - Significant Unobservable Inputs (Level 3) [Member]	6 Months Ended
	Jun. 30, 2015
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Probability of achieving estimated projected earnings	100.00%
Minimum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Discount rates	1.27%
Probability of achieving certain other objectives	10.00%
Maximum [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Discount rates	1.90%
Probability of achieving certain other objectives	80.00%